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Abstract 
 
Prognostic factors (PFs) are patient characteristics (e.g. age, biomarker levels) that are 
associated with future clinical outcomes in patients with a disease or health condition. 
Evidence-based PF results are paramount, for which individual patient data (IPD) meta-
analysis is thought to be the ’gold-standard’ approach, as it synthesises the raw data across 
related studies (in contrast to an aggregate data meta-analysis, that just uses reported summary 
data). 
In this Ph.D. thesis, I investigate statistical issues and develop methodological 
recommendations for individual patient data meta-analysis of prognostic factor studies (IMPF) 
projects. First, I investigate the benefits and limitations of IPD meta-analyses of PF studies 
through a systematic review and in-depth evaluation of existing IPD meta-analyses of PFs; 48 
IMPF articles were found and an in-depth evaluation of a random sample of 20 IMPF articles 
was undertaken to identify how such projects are initiated, conducted, and reported, and to 
identify the benefits and challenges of the IPD approach. I found that although IMPF articles 
have many advantages, they still face a number of challenges and pitfalls such as different 
methods of measurements, ignoring clustering of patients across studies, missing data, and 
potential publication bias, unachieved linearity assumption of PFs, poor reporting, and 
potentially not protocol driven. To improve IMPF articles and projects guidelines were 
developed, and an array of methodological research questions identified. 
Secondly, I undertook an empirical study to compare between the IPD and aggregated data 
approach to assess PFs in breast cancer.  I showed that the IPD approach is preferable over 
aggregated data, as it allows one to adjust the PF by other confounding factors, examine PFs 
in subgroups of patients and assess the interaction between two PFs as an additional PF. It also 
allowed more studies and more patients to be included. However, the IPD approach still faced 
challenges, such as potential publication bias, missing data, and failed model assumptions in 
some studies.   
Thirdly, I developed eleven IPD meta-analysis models to investigate whether 
accounting for clustering of patients within studies should be undertaken and 
which approach is the best to use. The models differed by using either a one-step 
or two-step approach, and whether they accounted for parameter correlation and 
residual variation.  An IPD meta-analysis of 4 studies for age as a PF for 6 month 
mortality in traumatic brain injury was used as an applied example. Surprisingly, 
I found that there was no difference between the eleven models because there was 
little variation in baseline risk across studies. Thus, a simulation study was 
undertaken to examine which model is the best one-step or two-step, and whether 
accounting for the clustering of patients within studies is important. I found that 
the clustering across studies should be considered, and one-step model accounting 
for the clustering of patients within studies is the best fitted model as it yielded 
the lowest bias and the coverage was around 95%. Ignoring clustering can 
produce downward bias and too low a coverage; occasionally the two-step 
produces too high a coverage. 
Fourthly, I examined the linearity assumption for the relation between age and 
risk of 6 months mortality in the traumatic brain injury dataset. I found that the 
linear trend was not the best in all studies. Thus, I developed three non-linear 
fractional polynomial IPD meta-analysis models based on whether one-step or two-step 
approach and whether first or second order fractional polynomial functions are performed. I 
found that one-step fractional polynomial meta-analysis model that account for the clustering 
of patients within studies is again the best fitted model, as it easier to fit and force the IPD 
studies to have the same polynomial powers. This revealed age has a quadratic relationship 
with mortality risk. 
Fifth, I assessed whether small-study effects (i.e. potential publication bias) exists for 6 IPD 
prognostic factor articles by using different tools, such as contour funnel plot, cumulative 
meta-analysis, trim and fill method, and regression tests.  I found the small-study effects 
problem is not a major concern, in contrast to aggregated data meta-analysis of PFs. Only in 
the breast cancer data of Look et al. was there substantial evidence for small-study effects. 
However, adjusted results to account for this provided a smaller PF effect but suggested the 
original conclusions are unlikely to change.    
To sum up, this thesis highlights a number of challenges of IMPF projects and discusses 
possible approaches to dealing with some of them. However, numerous challenges remain for 
future work. 
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CHAPTER 1 
AIMS AND BACKGROUND FOR THE THESIS 
 
1.1 Introduction 
In healthcare, prognosis is the study of future health related events in patients with a particular 
disease or condition. Prognosis research studies can take a prospective or retrospective approach. 
In prospective studies, patients are recruited at the current date and followed for an adequate 
length of time to identify what outcomes are achieved. This allows baseline characteristics 
and outcomes to be recorded by the researcher.  On the other hand, retrospective studies utilise 
existing data (e.g. from cancer databases) about the baseline characteristics and outcome. Most 
prognosis studies are retrospective due to the ease and speed of using existing data. However 
they are restricted by the data collected (e.g. certain variables and outcomes may be missing)1. 
Prospective studies are preferred as they allow greater conduct on the data collected and the 
quality of the study (e.g. complete follow-up, less missing data). 
There are many different types and objectives of prognosis studies, but most usually have the 
aim to identify which factors measured at some baseline point (e.g. diagnosis of disease), are 
associated with the outcome, or predict the outcome. However, other types of prognosis studies 
might look to predict response to treatment, or ascertain the overall prognosis and survival 
rates in certain diseases. Such distinct objectives of prognosis research are not well understood2, 
and section 1.2.2 unpacks this further. 
Prognostic factors (PFs) are patient characteristics (e.g. age, biomarker levels) that are 
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associated with future clinical outcomes in patients with existing disease. PFs are important 
clinical tools because they help to identify patients with different risks of outcome (e.g. 
recurrence of disease) and thereby facilitate the most appropriate treatment strategies and aid 
patient counselling3, they are also used in the design and analysis of trials, and act as confounding 
factors in observational studies4. Evidence regarding PFs is therefore very important to both 
clinicians and their patients. However, primary PF studies have numerous problems such as poor 
reporting, analysis and design5-7. PF studies are subject to numerous biases, such as selective 
reporting7  and “optimal” choice of cut-points8. These severely limit meta-analysis of PF studies 
using aggregated data, where summary of results are combined across PF studies. Individual 
Patient Data Meta-analysis of PF studies (IMPF) have been proposed as the gold-standard 
approach9-11, because it utilises the raw patient data and thus does not rely on reported results. 
The aims of this thesis are to examine the feasibility of an IMPF articles and to tackle a number 
of statistical and methodological challenges when undertaking IMPF projects. I begin with a 
broad discussion on the different types of prognosis research and then introduce the 
fundamental concepts for primary PF studies and their analysis, and the rationale and basic 
methodology for meta-analysis of PF studies.  
1.2 Types of prognosis research 
There are four types of prognosis research: 
 1.2.1 Overall prognosis 
An often forgotten part of prognosis research is to establish the natural prognosis in a disease. 
For example, it is of interest to know survival rates at various time points following diagnosis of 
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breast cancer.  This may be sub-grouped further by characteristics (such as pre to post 
menopausal), prognostic factors (see below), and certain treatments. In some poor countries, it 
may unfortunately be possible to establish natural prognosis of patients with a disease, where 
no treatment is available. 
Figure 1.1: 0-10 year relative survival for breast cancer by stage, 
diagnosed in the West Midlands 1990-1994 followed up to the end of  
2004, as at December 200812 
 
The overall prognosis of a condition is important for looking at trends in, say, survival rates 
over time (Figure 1.1), planning and preparing for future healthcare demands in the population 
(e.g. if patients live longer with disease), and understanding ‘baseline risk’ so to help see if any 
new treatment and PFs modify it. For example, Figure 1.1 shows 0-10-year relative survival for 
breast cancer by stage, diagnosed in the West Midlands 1990-1994 followed up to the end of 
200412. 
1.2.2 Prognostic Factors 
Prognostic factors (PFs) are patient characteristics or measurements (e.g. age, biomarker levels) 
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that are associated with future clinical outcomes in patients with existing disease13. For 
example, Figure 1.1 shows that stage of disease is a PF, as the survival curve is 
different for different stages. PF studies investigate the prognostic value of one or more 
particular variables; for example, in breast cancer Look et al.14 Investigate whether Urokinase 
type Plasminogen Activator (uPA) and its inhibitor PAI-1 were associated with overall and 
disease free survival. PF studies are the most common type of prognosis study. Hundreds of 
papers are published each year in oncology alone15. 
PFs have many uses; for example, they are the building block for prognostic models (see 
below), and are potential confounding factors in observational studies and randomised trials to 
be adjusted for. They can also be incorporated in the design and analysis of randomised trials, 
to ensure treatment groups are balanced (via stratified sampling) and to increase power (by 
including them as covariates in the analysis). 
As a detailed example of a PF study consider Braun et al.16, whose primary objective was to detect 
whether there is an association between the presence of micro-metastasis at diagnosis in the bone 
marrow with survival or recurrence of disease in breast cancer patients; i.e. whether micro-
metastasis is a PF in  breast cancer at diagnosis.  The authors adjusted for other PFs ( e.g. age, 
menopausal status, tumour size, tumour grade) to see whether the presence of micro-metastasis 
in the bone marrow was still a significant independent PF after accounting for these other 
factors. They also assessed micro-metastasis as a PF in sub-groups of patients according to those 
who received endocrine treatment alone or chemotherapy alone; they found that it is still a PF. 
In this thesis the focus is on using meta-analysis to identify PFs by combining across multiple 
PF studies like Braun et al.16 
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1.2.3 Prognostic Models 
Prognostic models, also called prediction models, risk scores or prognostic scores, evaluate many 
variables simultaneously to determine a model that predicts the outcome for the individual patient, 
based on the final set of included variables. A prognostic model is crucially different to a PF; 
PFs may be associated with the outcome, but the predictive ability of each PF for the 
individual patient may be poor. A well-known example for prognostic model is the Nottingham 
Prognostic Index (NPI), which is used to predict mortality risk in an individual patient with breast 
cancer based on a set of factors such as tumour size and tumour grade17. 
Figure 1.2 and 1.3 shows why a PF is usually not an accurate predictor of absolute risk for the 
individual patient18. In particular, Figure 1.2 shows Kaplan-Meier survival curves for each of 
three groups of patients defined by “low”, “medium” and “high” levels of a PF; the distinct 
curves show that this factor is prognostic as it is associated with differential risks of outcome. 
  
 
 
Figure 1.3 shows the distribution of survival times for the same patients in the same study 
amongst individual patients in each group defined by three levels of a PF. There is wide overlap of 
Figure 1.2: Kaplan-Meier survival curves for each of 
three groups of patients defined by 'low', 'medium', and 
'high' levels of a prognostic factor18 
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the distributions, emphasizing that levels of the PF do not accurately predict survival times for 
the individual patient. 
Figure 1.3: The distribution of survival times, from the same 
patients in the same study is shown amongst individual patients in 
each group defined by three levels of a prognostic factor18 
 
 
Thus, prognostic models are concerned with individual predictive accuracy, which is usually 
improved by using multiple PFs together. This difference between PFs and prognostic models 
is often not understood, and in particular researchers often interpret a PF as if it can be used for 
making individual predictions, when this has actually not been evaluated. Note that prognostic 
models are not the focus in this thesis.  
1.2.4 Predictive Factors 
Predictive factor studies are concerned about identifying variables that predict treatment 
response; in cancer these are known as predictive markers, though this terminology is not 
wide-spread outside the cancer field.  For example, breast cancer studies often investigate what 
variables modify response to adjuvant hormone therapy or polychemotherapy2. Predictive factor 
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studies essentially look to detect treatment covariate interactions or treatment effects in 
subgroups, often within a randomized trial design. For instance, oestrogen receptor status in 
breast cancer is a predictor of responsiveness to treatment of hormonal therapy, but it contributes 
little information on prognosis otherwise (i.e. it is not a PF). While progesterone receptor 
status is a PF but it does not influence treatment response2. So clearly not all predictive factors 
are PFs. Predictive factors will not be discussed further in this thesis.  
1.3  Prognosis Research - A Turbulent Time 
Although there is continuously a large amount of research activity,  very few prognosis studies seem to 
impact upon clinical practice because PF studies still have problems such as missing data, 
different methods of measurements, publication bias and availability bias. Further, increasing 
evidence suggests that prognosis research is often poorly designed, poorly reported, and 
subject to numerous biases such as selective reporting and publication bias.  Hemingway et al.2 
outline many challenges required to improve quality and impact of prognosis research which 
are now summarized below. 
Purpose of the studies 
Often the goals of prognosis research studies are not clear.  In particular researchers often 
perform a PF study and conclude it can be used to decide treatment strategies or predict 
likely outcomes for the individual patients, when this has not actually been investigated. Thus 
the awareness of the main goals of prognosis research and the distinction between them needs to be 
better understood by prognosis researchers.  There is a need to firmly establish taxonomy of the 
goals and types of prognosis research.  The PROGRESS initiative (a UK initiative to improve 
Prognosis research) has been formed to tackle this problem, and currently distinguishes the 
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four types of study as outlined in section 1.2. 
Funding 
There is a lack of strategic framework for funding prognosis research2; as a result many 
prognosis studies have a “what’s in the freezer?” approach where existing data, often of poor 
quality, is given to a junior (who may have no training in prognosis research) to data dredge for 
prognostic results. This causes many problems, not least publication bias and selective outcome 
reporting.  Thus, there is a challenge here to guide funders to set up a strategic framework for 
investment toward different types of high-quality prognosis research. This undoubtedly 
requires the goals and impact of prognosis research to be better exemplified, so that funders can 
clearly see the benefits. 
Protocol 
Protocols are a very important first step in any healthcare research project. Yet, in many 
current prognosis research studies there is no protocol5. At the study onset the protocol should 
mention the research aims, inclusion, and exclusion criteria of patients, outcomes assessed and 
the statistical analysis plan.  Yet, this is often not done, highlighting again the “what’s in the 
freezer approach2 ”. Thus, encouraging protocols for prognosis research should be seen as a high 
priority. 
Methods 
Current evidence highlights poor quality in the methodology of prognosis research2 19. 
Methodology can be improved by developing and using appropriate methods in study 
design, statistical analysis, and reporting20.  In the study design the research should begin with 
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a clear and well-defined research question so that their study can be designed and targeted 
appropriately19; in particular prospective protocol driven studies are desired with large sample 
size and adequate power.  In Holländer et al.6 the authors showed that the choice of the 
statistical methods has strong influence on the results and on the interpretation of PF studies.  
So it is important to use the most reliable methods. This thesis will consider statistical 
methods at the meta-analysis level. 
Reportingly, there is currently a lack of sufficient information in PF study reporting15 21. For 
example, many important statistics are not reported15 22 (e.g. the number of patients in each 
group, the number of events in each group, hazard ratios, confidence intervals, P-values) , which 
makes it hard to reliably interpret PF studies and include them in a meta-analysis (see later). 
For improvement, developing generic reporting guidelines is important.  A good start toward 
this goal are the REMARK guidelines23. These are aimed at prognostic tumour marker studies 
in cancer, but are generally applicable to all PF studies in other disease, see Altman et al24  and 
Riley et al.22, for other reporting guidelines for prognosis and survival studies. 
A particular problem is that researchers often look at a wide range of PFs and outcomes, but 
selectively only report significant outcomes and factors8.  Thus the researchers should have 
to pre-specified PFs and outcomes for the project before starting the study; this again relates to 
the need for a protocol. 
1.4 Prognostic Factor Research 
Section 1.2 outlined four key areas of prognostic research.  From now on this thesis focuses on 
the research and analysis of PFs.  
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PF studies are perhaps the most common prognosis study, and they are desperately in need of 
improved research standards. Current evidence shows that PF studies are generally poorly 
designed, use small sample sizes, are poorly analyzed and reported, and are subject to 
numerous biases including publication bias, selective reporting and biased choice of cut-off 
level22 23 25 . 
As briefly mentioned in section 1.2, there are many reasons why PFs are important. They can 
help to: (i) identify the causal pathway (e.g. what factors are causally associated with poor 
outcome); if such factor are modifiable (e.g. smoking, obesity), then clinicians can help 
prevent poor outcome; (ii) identify variables to consider within prognostic models; (iii) 
identify factors that may confound results in observational study and (unbalanced) randomized 
trials; (iv) identify factors to consider in the design of randomized clinical trials (e.g. 
standardized randomization) and analysis (e.g. to increase power by adjusting for PFs); (v) 
inform what subgroups to look at within overall prognosis studies (e.g. age is a PF in traumatic 
brain injury, so producing survival by age groups can aid patient and family counselling). 
1.4.1 Types of  Prognostic  Factor  Studies 
Hayden et al.26 suggest PF studies can also be called ‘explanatory studies’ as they look to find 
factors associated with explaining outcomes. Hayden outlines three phases of PF studies (Phase I, 
Phase II, and Phase III). 
In Phase I, studies identify the association between a number of potential factors and 
outcomes. For example, in lung cancer, a Phase I study might assess smoking status as a PF 
alongside many other PFs such as age, gender, biomarker level...etc. Thus Phase I studies do not 
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study one specific PF but look at many PFs of interest to explore which appear associated with 
outcome. 
In Phase II, studies test the independent PF value of a small number of PFs identified in Phase I 
research.  In other words, these studies aim to measure the independent effect of a particular 
PF (or a small number of PFs) while controlling for other PFs.  For example in Look et al.14 
the authors aimed to measure the independent prognostic effect for uPA and PAI1 after adjusted 
by existing PFs (e.g. hormone receptor, lymph nodes, age) in relation to overall survival, see 
Figure 1.4. 
Figure 1.4: Phase II- testing the independent association of PF 
adjusted by other variables 
 
Hayden (2007) et al.26 suggest Phase III as studies are “those that attempt to describe the 
complexity of the prognostic pathways or processes.  These studies apply knowledge from the 
previous phases of study on independent associations and incorporate other knowledge from the 
field of study”.  These studies include the PF of interest, existing PFs, and other variables that 
are thought to be intermediate in the pathway toward the outcome, and the outcome of interest.  
Thus, Phase III studies essentially look at the role of PFs on the causal pathway to disease 
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outcome. Note that the focus in this thesis is on Phase I and Phase II PF studies. These are the 
most common published PF papers in the medical literature, and look to establish whether one 
or more factors are prognostic, but are not concerned with understanding the causal pathway or 
whether a PF is indeed causal. Most PFs, such as age, are not actually causal themselves, but 
associated with other (unknown) factors or underlying causal pathways. 
1.4.2  Types of Data  in Prognostic  Factor  Studies 
PF data are either continuous or binary. For example, in breast cancer markers uPA and PAI-1 
are continuous variables and hormone receptor is a binary variable.  However continuous PF 
variables are often dichotomized into a ’low’ and ’high’ group (e.g. uPA is often dichotomized 
by choosing a cut-off point)8 27. This is not recommended because it does not maintain the 
whole information of the variable, reduces power and leads to inaccurate  results28 29. Note 
that other types of data are possible for PFs and outcomes (e.g. ordinal), but the focus in this 
thesis is only on continuous or binary PF data, and time until the event occur and binary data for 
outcome(s).   
Binary Outcome Data 
Outcomes in PF studies are often binary, with two possible values (one and zero) representing 
whether the outcome occurred or not (e.g. dead =1, alive = 0).  For example, in 
Hukkelhoven et al.30 the authors assess the association between age (per 10 years) and 6 month 
mortality (dead = 1, alive = 0) in patients with severe traumatic brain injury (TBI) using data 
from 4 trials. Table 1.1 details the IPD available within Hukkelhoven et al.30 with each patient in 
each study providing their age (defined as age in years divided by 10) and whether they were 
dead or alive at six months.  This database has been kindly provided by E. Steyerberg31 for use 
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in this thesis. 
(N.B. a set of IPD from multiple studies often contains thousands of patients.  This is the case 
in Table 1.1, so for brevity I do not show all the rows of data here. Rather I use four horizontal 
dashes to indicate where non-displayed rows of data occur, and these follow in a similar manner 
to the displayed rows above them). 
Table 1.1:  IPD from 4 trials that assess whether age is a PF for six 
month mortality on TBI, from Hukkelhoven et al.30 
Study id Patient Age (years/10) Event(dead = 1, alive = 0) 
1 1 1.9 0 
1 2 2.5 0 
1 3 2.7 0 
- - - - 
- - - - 
- - - - 
1 825 3 1 
2 1 1.6 0 
2 2 2.7 0 
2 3 2.1 0 
- - - - 
- - - - 
- - - - 
2 959 5.3 0 
3 1 2.5 1 
3 2 8.9 1 
3 3 6.1 1 
- - - - 
- - - - 
- - - - 
3 466 2.2 1 
4 1 2.3 1 
4 2 2.2 1 
4 3 5.9 0 
- - - - 
- - - - 
- - - - 
4 409 4 1 
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Survival Data 
Another common type of outcome data in PF studies is time to event or survival data. Survival 
data is the time it takes for a certain event to occur (time to event), (e.g. time to death or time to 
recover from a certain disease).  In the breast cancer study of Look et al.14 the authors 
assessed whether uPA and its inhibitor (PAI-1) are PFs.  The study included 18 IPD datasets 
provided by member of the European Organization for Research and Treatment of Cancer 
Receptor and Bio-marker Group (EORTC-RBG), including 8837 breast cancer patients.  The 
association of many potential PFs (including Lymph nodes status, hormone receptor status, 
menopausal status, age, uPA, PAI1) with overall survival (OS) and relapse free survival (RFS) 
were assessed. The IPD from 15 studies have been kindly provided for use in this thesis by 
Look et al.14 Data are listed in Table 1.2 for some selected PFs for the 15 studies. 
PF studies are often time to event studies, as they follow patients from a baseline point (where 
PFs are measured) over time until an event occurs or the study ends or the patients leave the 
study, which I illustrate in Figure 1.5. 
  Figure 1.5: Time until the events occurs 
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Table 1.2: Survival data for IPD from 15 studies,  assessing PFs in breast cancer, Look et al14. 2002 
Study No. Study Name Patient id OS Event(dead = 1, alive = 0) uPA PAI-1 Hormone  Receptor Lymph nodes status 
1    Rdam 1 13.73 0 0.81 53.85 1 1 
1 Rdam 2 120.00 0 0.59 14.46 1 1 
-    - - - - - - - - 
-    - - - - - - - - 
-    - - - - - - - - 
1 Rdam 2722 69.78 0 0 5.43 1 1 
2 Utr 1 78.69 0 0.02 0 1 0 
2 Utr 2 93.80 0 2.93 6.23 0 0 
-                - - - - - - - - 
-   - - - - - - - - 
-   - - - - - - - - 
2 Utr 199 78.85 0 0.10 0 1 1 
-   - - - - - - - - 
-   - - - - - - - - 
-   - - - - - - - - 
-   - - - - - - - - 
-   - - - - - - - - 
-   - - - - - - - - 
15 Swiss 1 31.97 0 0.65 6.90 1 0 
15 Swiss 2 39.56 0 0.35 2.10 0 0 
-    - - - - - - - - 
-    - - - - - - - - 
-    - - - - - - - - 
15 Swiss 663 55.33 0 0.58 4.50 1 1 
      Note that: OS is Overall Survival; uPA is Urokinase type Plasminogen activator and its inhibitor PAI-1
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The length of time from baseline to the event is called the survival time. Patients who do not 
experience the event have a censored survival time. The type of censoring shown here is called 
right censoring, where the true event occurs after (to the right of) the censoring time. Other forms 
of censoring can occur, such as left censoring32, but in this thesis the focus is on the right 
censoring data, as this is the most common for PF studies. 
Figure 1.6 Example of censored and uncensored data for 6 patients 
followed over time 
 
 
Figure 1.6 illustrates the experience for 6 patients followed over time. The horizontal axis 
represents time since the start of the study in months and the vertical axis represents patients. X 
refers to the event (death). Both Patient A and Patient C are uncensored observations, as the time 
of occurrence the event (death) is known. On the other hand, Patients B, D, E, and F are 
censored, as the time of the occurrence of the event (death) is unknown. For example, Patient B 
was recruited at month 4 but by the end of the study the event had not occurred. Patient D started 
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at month 4 but he was lost to follow up after 3 months. Usually, the time of entry into the study 
is not important, and so all patients are set to a 	 = 	0 baseline point and their survival times 
give the time from zero to their event or censoring.  
 
1.5 Logistic Regression Analysis in a Single Study 
Researchers of PF studies must analyse data using the most appropriate statistical methods. The 
choice of statistical model depends firstly on the type of outcome, which for PF studies is 
usually binary (e.g. dead / alive) or time to event (time to death or censoring) as discussed, and 
this thesis focuses on these two outcome types. In the next section, I briefly consider basic 
statistical models for binary data and time to event data, to set the foundation for subsequent 
chapters. Note I consider here a single PF study; meta-analysis of multiple PF studies is 
considered in section 1.7.2. 
1.5.1 Odds Ratio 
 
In a simple situation of a binary outcome (e.g. dead / alive), and a binary PF (e.g. Hormone 
receptor), a two by two table can be constructed to look at the PF effect on outcome. 
          Table 1. 3: Two by two table for prognostic factor and outcome 
                                                                        Outcome 
PF                 Dead         Alive 
Positive hormone receptor                                   A            b 
Negative hormone receptor                    C            d 
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For example, one can calculate an estimate of the odds ratio (OR) and its confidence interval 
As   follows: 
 
                                     Odds ratio =  																																																																							(1.1) 
This gives the odds of death in the positive group versus the odds of death in the negative group, 
with OR value greater than one indicating a higher odds for positive patients. 
The 95% confidence interval is 
                                                    () ± 1.96"	# + # + # + # 																																											(1.2) 
	
However, to assess a continuous PF or to allow multiple PFs to be examined together a more 
advanced method such as logistic regression is needed. 
1.5.2 Logistic Regression 
Logistic regression is a frequently used generalized linear model33, which can be used to describe 
the relationship between a set of variables and the probability of a binary dependent variable. 
Specifically, it models the probability transformed by the logistic function as follows: 
 
 
																																																																&(')
= 	  + (' 																																																																											(. )															
 
Where )	(*) is between zero and one; it is equal to zero when *	 =	−∞, and equal to one 
when		*	 = 	∞. The logistic function allows an S-shape such that the influence of	* on the 
probability ) is minimal for  low values until some threshold is reached. Then, probability )  
increase over a certain range of intermediate * values, until it increases rapidly toward one 
[19] 
 
i
once * gets large enough.  Then, )  remains extremely close to one, see Figure 1.7. The model 
is useful for assessing PFs because * can be replaced by a linear function of (unknown) 
parameters relating to the PFs under consideration as follows: 
                                        Figure 1.7: S-shape for various values of z 
 
 
																																																	) = 	 11 +	-∝.∑ 01		213145 																																																							(1.4) 
Or equivalently, 
																																														 7 81 − 89 =∝ +:;<	=<
>
<?#
																																																		(1.5) 
Where =A refers to the set of	A	 = 	1	BC	D			PFs under considerations;  E and ;A are unknown 
parameters to be estimated. E denotes the ln-odds of outcome probability for patients with all 
PFs equal to zero, where odds is defined byF G#(GH. βi gives the ln-odds ratio between two 
patients who differ in patients =´A by one unit, with all other =A values 	 (A	 ≠ 	A´) the same; 
the odds ratio is thus -J8(;A	).  So, for a binary PF such as hormone receptor (positive = 1, 
negative = 0) in breast cancer, the odds ratio gives the odds of the outcome for the positive 
hormone receptor relative to the odds for patients with negative hormone receptor after 
adjusting for other PFs in the model. For a continuous PF such as age, the odds ratio gives the 
ratio of odds for two patients who differ in age by a value of 1 unit. 
[20] 
 
1.5.3  Application of Logistic Regression 
As an illustrated example, I now apply logistic regression to one study (study 1), within IPD 
provided by Hukkelhoven et al.30 in order to assess the association between age and 6 month 
mortality in patients with severe traumatic brain injury [Table 1.1]. Six month mortality is coded 
as 1 if a patient died and 0 if the patient was still alive at six months. Age is the one PF of interest 
here, denoted by X and it is a continuous variable. As the effect of a one year increase in age is 
likely to be small, in accordance with the original authors, I coded age in years dividing by 10, 
so to model the effect of a 10 year increase in age. The study includes 825 patients and 199 
died. The logistic regression model can be written as follows: 
 																																																			 7 8>1 − 8>9 =∝ +;	=>																																																										(1.6)				 
 
Where  8 is the probability of death at 6 months for patient	D. The model was fitted by using 
maximum likelihood method for estimating the unknown parameters, within the STATA 
package, and the results are shown in Table 1.4. 
Table 1. 4: The estimation result for the age and traumatic brain injury after 6 month 
for binary data 
Parameters Parameter  Standard   
error 
Confidence Interval P-value 
Lower Upper 
E -2.20 0.24 -2.67 -1.73 <0.001 ; 
 
0.31       0.06 
 
 0.19 
 
 0.45 
 
<0.001 
KKL	MNBAC= exp	(;) 1.36 --  1.20  1.55 <0.001 
  
[21] 
 
Table 1.4 shows that increasing age significantly increases the probability of mortality by 6 
months. The odds ratio for two patients who differ in age by 10 years is estimated 
as		-J8(0.31) 	= 	1.36; which indicates that the odds of mortality increase by 36%, for a 10 
years increase in age, with a 95% confidence interval of 1.20 to 1.55.  Thus we conclude from 
this analysis that age is associated with 6 month mortality, and thus age is a PF in traumatic 
brain injury patients.  This is a simple illustrate analysis.  Extensions to nonlinear trends and 
adjustment for other PFs will be considered in later chapters, within a meta-analysis setting. 
1.6 Survival Analysis of Prognostic Factor in a Single Study 
1.6.1 The Survival Function 
 
The analysis of time to event data assesses the survival function, denoted as S(t), where 
 
 																																														S(B) = 	)	(	 > 	B)																																																		(1.7) 
 
 
With ) meaning probability and  is the random variable for a patient’s survival time.  can be 
any number greater than or equal to zero. S(B)		is the probability that the patient survives 
longer than a specified time	B. For example, if B	 = 	2	years, then the survival function will be 
S(2) 		= 	)(	 > 	2) which means the probability a patient survives longer than two years 
after the baseline point (usually diagnosis of disease). In relation to this thesis, it is of interest 
to identify PFs that modify	S(B). 
1.6.2  The Hazard Function 
 
The hazard function is denoted as V(B) which can be defined as the instantaneous probability at 
time B	for having the event at that time. It can be written mathematically as follows: 
																														V(B) = limZ→\)(B ≤  ≤ (B + ^B)| ≥ B)^B 																																																				(1.8) 
[22] 
 
 
 
 
In other words, hazard function is defined as the conditional probability that the patient’s event 
time  will lay in the time interval between B and	B	 + 	^B, given that the event does not occur 
before time	B. The hazard function is nonnegative, taking any value from 0 to ∞ and can start 
from any value and increase or decrease over time. 
 
 The relationship between hazard function and survival function is given as follows: 
																																				S(B) = -J8 b−c V(J)KJ	d\ e																																																																	(1.9) 
 
																																																				V(B) = − bSf(B)S(B) e																																																																			(1.10) 
 
 
 
If the survival function is known; it is easy to determine hazard function and vice versa, for 
more details see Lee et al.34 and Hosmer35. 
1.6.3 Kaplan-Meier Survival Curves and the Log Rank Test 
 
To estimate and plot survival curves and to compare two or more survival curves defined by PFs, 
a common approach is the Kaplan- Meier (KM) method followed by a log rank test. 
Kaplan-Meier Method 
The Kaplan-Meier estimator32 35 36 (also known as the product limit estimator) obtains a non-
parametric estimate of the survival function from the data.  Suppose that a sample of   
patients are obtained from a population with survival function S(B) and B1		< 	B2		 < ⋯	<
	BD		are the observed event times (e.g. death) where	D	 ≤ 	, as some patients may be censored. 
[23] 
 
Let A  be the number of observations at risk at the time prior to BA	.	  let  KA	 be the number of 
events occurs at time  BA . The survival function S(B) can be estimated by using Kaplan-Meier 
formula which can be written as follows: 
 
																																																						Si(B) = 	j7< −	K<K< 	9																																																								(1.11)d1kl  
 
As an example consider the ’Utr’ study selected from the IPD of Look et al.14 , see Table 1.2; 
this study has 199 subjects and 42 died.  This dataset is divided into two groups defined by a 
potential PF called Lymph node status that is either positive or negative; the aim is to assess 
whether the Lymph node status has influence on the breast cancer patients. 
The Kaplan-Meier graph shown in Figure 1.8 is obtained from survival estimates from 
applying to equation 1.11 to the data in Table 1.2. In Figure 1.8 the estimated survival function 
for the patients with negative lymph node lies completely above that for the patients with 
positive lymph node, which indicates that the patients who have negative lymph node have a 
more favourable survival experience (live longer). To test if there is a statistically significant 
difference between the two groups, the log rank test can be used. 
[24] 
 
      Figure 1.8 Kaplan Meier curve for the positive lymph node group 
 
The log rank test is a large sample chi-square test, and tests the null hypothesis that the curves are 
equal.  It calculates the expected and observed numbers of events at each event time for each 
group. For more details, see Collett 37. The results of the log rank test for the lymph node 
status are illustrated in Table 1.5. It gives a P-value of	< 0.01. This indicates statistically 
significant evidence that there is a difference between the survival curve for positive and 
negative Lymph node status, thus lymph node status appears to be a PF in breast cancer. 
Table 1. 5: Log rank test results and P-value for the equality of positive 
and negative lymph node status for all Utr study 
Lymph node status Observed deaths Expected death 
Negative lymph node      15.00        25.44 
Positive lymph node      27.00       16.56 
Total      42.00       42.00 
                                                                       P-value <0.001 
                                                                       chi2(1)=10.91 
 
  
[25] 
 
  
As a log rank test is a hypothesis test, it does not estimate the difference in survival or the 
difference in event risk between groups, but this can be addressed by calculating a hazard 
ratio and using Cox proportional hazard models, as now described. 
1.6.4  Hazard Ratio 
The hazard ratio is the effect of an explanatory variable (PF) on the hazard or risk of an event. It 
compares the (instantaneous) risk of an event in one group relative to the risk in another group38 
39
. An estimate of the hazard ratio can be obtained from the log rank test as follows: 
 
																																																								m = #/o#p/op 																																																																															(1.12)					 
 
 
 Where  1  and 2  are the observed number of the event in each group;  o1  and o2  are the 
expected number of events. Applying to our example, the hazard ratio can be calculated from 
Table 1.5 as follows 
 
 
																											m = 15/25.4427/16.56 	= 0.58961.6304 = 0.361																																																				(1.13) 
The hazard ratio of 0.361 indicates that the risk of death into negative lymph node group is 
0.361 times (36% of the risk in the positive lymph node group). 
The confidence interval for the hazard ratio can be calculated as follows: 
 																					expqln(m) ± 1.96 × L. -. (ln	(m))t																																																									(1.14) 
 
[26] 
 
where: 
 
																																L. -. ln(m) = u 1o# + 1op 																																																																											(1.15)						 
 
 
Applying to our example the confidence interval for hazard ratio is calculated as follows: 
 
														L. -. ln(m) = 	u 125.44 + 116.56 = √0.099 = 0.315																																					(1.16) 
 
 
 
 																										-J8qln(0.361) ± 1.96× (0.315)t																																																																	(1.17)				 
 
 
So we are 95% confident that the hazard ratio lies between 0.20 and 0.67, which does not 
include the null value of 1 which confirms the significant result that we obtained from the log 
rank test. 
1.6.5  Cox Proportional Hazards Model 
 
A more flexible way to estimate the hazard ratio (HR) that allows continuous multiple PFs to 
be considered is a Cox proportional hazard model, which is the most commonly model for 
analysing survival data. It is expressed as follows: 
																																								V(B) = V\	(B)	-∑ 0	1		w13145 																																																																								(1.18)				 
Where V(B) the hazard is at time B, JA  is an explanatory variable (i.e. a PF), D indicates the 
number of the variables, and V0	(B) is the baseline hazard for patients with JA  values equal to 
zero. 
[27] 
 
The Cox proportional hazard model and indeed the log-rank test assume that the hazard ratio is 
constant over time. In other words, suppose that there are two hazards for two patients who differ 
in just		J# by one unit, and then the hazard ratio can be calculated as: 
 
 
					mx 	= 	 V(B, =# + 1)V(B, =#) = 	 V\			(B)-J8y;
i#(=#	 + 1)zV\(B)-J8y;i#			=#z = -J8	q;i#	t																																					(1.19)	 
 
From the previous equation, it can be seen that the baseline hazard function for the two patients 
is cancelled out of the formula and the net result does not contain	B, thus the hazard ratio is a 
constant over time. 
The Cox proportional hazard model is a semi-parametric model, this means that the 	V0(B)	is an 
unknown function and is left unspecified. The model can be estimated by using maximum 
likelihood estimation of the partial likelihood to give parameter estimates denoted as	;{ <  , see 
Hosmer et al35. The partial likelihood is given as: 
																																	|G		(;) = 	jb expq=<f	;it∑ expq=<f	;it}∈(d1) e	

<?#
1 																																																							(1.20) 
where the summation in the denominator is over all subjects in the risk set at time BA , denoted 
by (BA	), A	 = 	1 for uncensored observations, A	 = 	0 for censored observations, D is the 
number of PF’s for subject A denoted by the vector =´A		=	(JA1, JA2	, JA3, . . . . . , JAD	).		This vector 
could
 include any types of PF’s (e.g. continuous PF, dichotomized PF). By taking the 
logarithm for equation 1.20, the value of ;	can be found by taking the first derivative with 
respect to 	;, equalling the equation to 0 and solving it; the variance of the ;	 can be calculated by 
the same manner, by taking the inverse of the negative of the second derivative of the log partial 
[28] 
 
likelihood with respect to ; and equalling the equation with 0 and solving  it, for more detail see 
Homser  et al.35 
1.6.6 Test of Proportional Hazard Assumption 
The assumption of Cox proportional hazard model is that the hazard ratio is constant overtime. 
There are many methods to test the assumption of Cox proportional hazard model34. The two 
common of these methods are as follows: 
 	−	 −   Survival Curve 
This is a graphical technique which allows comparing estimated (−|(−|)) survivor curves 
over different categories of PFs. Parallel curves, say comparing positive with negative lymph 
nodes status, indicate that the Cox proportional hazard assumption is satisfied, for more de- 
tails, see Kleinbaum et al.40. Applying to our example for ‘Utr’ study, the (−|(−|))  
survival curve for positive and negative lymph nodes for 199 patients is shown as follows: 
 
Figure 1.9: −(−) survival curve for lymph node 
status for all subjects in Utr study 
 
 
It can be seen from Figure 1.9 that the assumption of Cox proportional hazard model 
appears reasonable because the two curves are parallel. Note that −|(−|) survival curve is only 
[29] 
 
valid to check the Cox regression assumption for the categorized PF; in particular, it cannot be 
applied with continuous scale PF. The approach of goodness of fit test (e.g.  Schoenfeld 
residuals) can be used to check the proportional hazard assumptions for the continuous PF (see 
below). 
The Goodness of Fit Test Approach 
The most common test uses Schoenfeld residuals, which is proposed by Shoenfeld41. For each 
PF in the model, Schoenfeld residuals are defined for every subject who has an event. The 
estimator of the Schoenfeld residuals for the ABℎ subject on the DBℎ  PF is given as 
 
                                        M> 		= <	(J<> − J̅13)                                                              (1.21) 
where 
                	J13 =		∑ w3			 q 	{t∈(l1)∑ q20{ t∈(l1) 																									                               (1.22) 
Grambsh and Therneau42 suggest scaling the Schoenfeld residuals by an estimator of the 
covariance matrix of the estimated coefficients by the number of events (i.e. the observed 
number of uncensored survival times ), yields residuals with greater diagnostic power than the 
unscaled residuals.  Thus, the approximate scaled Schoenfeld residuals43 are given as : 
                                        	M<>∗ = 	Var	(;i)M̂<>                                                                             (1.23) 
where M̂<> can be obtained from equations 1.21 and Var(β) can be calculated from equation 1.20 
as mentioned before. 
Consider a Cox proportional hazard model with two PFs: uPA and lymph node status. Then, 
there are two Schoenfeld residuals defined for each subject who has an event, one for each of the 
two PFs. If the proportional hazard assumption holds for a particular PF, then the Schoenfeld 
residuals for that PF will not be related to survival time. The P-value is used to decide whether 
[30] 
 
the proportional hazard assumption holds. If the P-value is less than certain values (say 0.10), 
this provides evidence that the proportional hazard assumption does not hold. Furthermore, the 
graphs of Schoenfeld residuals against survival time can be used to check the adequacy of the 
proportional hazards model. The presence of certain patterns in these graphs may indicate 
departures from the proportional hazards assumption, while extreme departures from the main 
cluster indicate possible outliers or potential stability problems of the model (see below). 
1.6.7  Example of Cox Regression Analysis with Multiple PFs 
To illustrate the use of Cox regression model for multiple PFs, two PFs within Look et al.14 were 
selected from the ‘Utr’ study (uPA and lymph node status) as mentioned before; uPA is a 
continuous variable and lymph node status is a dichotomous variable (positive hormone receptor 
=1 and negative hormone receptor = 0). A Cox proportional hazard model is fitted as follows: 
        								V(B) = V0(B)-J8q;1 ⋅ uPA + ;2 ⋅ lymphnodet                                    (1.24) 
The goodness of fit test using Schoenfeld residuals was used to check the assumption of the 
proportional hazard model which gave P-value of 0.32 and 0.95 for the uPA and lymph node 
factors respectively. Note that each of those P-values test the assumption for one variable given 
that the other PFs are included in the model. For example, the P-value for uPA (0.32) assesses 
the proportional hazard assumption for uPA, assuming the proportional hazard assumption is 
satisfied for lymphnode status. As the P-value for the two PFs is greater than a  certain value 
(0.10), this indicates no significant evidence against the proportional hazard model assumptions. 
Figure 1.10  and Figure 1.11 illustrate the scaled Schoenfeld residuals for uPA and lymph nodes 
PFs as follows:  
[31] 
 
                    Figure 1.10:  The scaled Schoenfeld residuals for the uPA 
 
It can be seen from Figure 1.10 that the horizontal axis represents the time and the vertical axis 
represents the scale Schoenfeld residuals for uPA. The assumption of the Cox proportional 
hazard model is acheived for the uPA as a continuous variable; this is because there is no a 
strong trend between the Schonfield residuals and the original time.   
Figure 1.11: The scaled Schoenfeld residuals for the lymph node 
 
Figure 1.11 shows the scaled Schoenfeld residuals for the lymph node status as a binary PF.  
There are two bands of residuals for the dichotomous lymph node PF. The upper band 
corresponds to subjects with positive lymph node (np=1) and the bottom one to those with 
negative lymph node (np=0).  As can be seen from the graph, there is no a strong trend between 
[32] 
 
the scaled schonfeld for the lymph node status as a PF and the original time, whether when the 
lymph node status is positive or negitave.                                     
After verifying the proportional hazard model assumption, the Cox proportional hazard model 
estimates are shown in Table 1.6. Both uPA and lymph node appear to be PFs. For example, the 
hazard ratio for lymph node status means that the patients with positive lymph node have a 2.23 
times higher death risk than those with negative lymph node status throughout the study period. 
Also, the confidence interval for the hazard ratio for lymph node PF does not include one which 
means that the hazard ratio is statistically significant and  this is confirmed by the P-value which 
is 0.006. 
     Table 1. 6: Cox proportional hazard estimates for all subjects in Utr study 
 Variables  uPA Positive Lymph nodes 
 Hazard Ratio (HR) 1.21 2.23 
 Standard Error of ln(HR) 0.12 0.65 
Confidence Interval (95%) 1.01-1.46 1.27-3.94 
 P-value 0.05 0.006 
1.7  Systematic Reviews and Meta-analysis of Prognostic Factor 
Studies 
1.7.1  Systematic Reviews 
Systematic reviews are considered as an essential tool in health care research because they 
greatly facilitate evidence-based clinical practice and healthcare policies. Systematic reviews 
seek to identify, collate and appropriately summarise the existing evidence on a particular topic 
from published and unpublished existing research studies. The whole process is done 
systematically, so that the review process is transparent and reproducible. The review allows 
overall evidence-based conclusions to be formed and helps to identify the questions to be 
[33] 
 
addressed in future primary studies. They are practically crucial for identifying PFs, as numerous 
research studies exist for each PF and many have conflicting results. Evidence based guidelines 
for each PF are highly desirable, and indeed essential.  
Numerous systematic reviews of PFs exist. For example, in Falagas  et al.44 the authors did a 
systematic review by searching in Medline and PsycINFO database to examine the effect of 
psychosocial factors (e.g. social support, marriage, depression and constraint emotions) on the 
survival of breast cancer patients. They identified 31 studies examining the association of 
various psychosocial parameters with overall breast cancer survival. They found 25 of the 31 
studies showed a statistically significant association between at least one psychosocial variable 
and disease outcome and 6 studies examining whether psychological intervention influences the 
disease outcome. In particular, they found that social support, marriage have a positive effect on 
breast cancer patients; while depression and constraint of emotions have a negative effect on the 
breast cancer survival. 
1.7.2  Meta-Analysis using Aggregate Data  
Meta-analysis is a statistical analysis that combines results from multiple individual studies on 
the same topic. It is often applied as part of  the systematic review to provide a quantitative 
summary of the evidence45. Typically meta-analysis seeks to estimate the average value of an 
effect of interest across studies, such as the prognostic effect of a particular factor. To do this, it 
is common to extract and combine relevant aggregated data from the identified studies. For a 
meta-analysis of PFs the choice of aggregated data are usually the odds ratio or the hazard ratio, 
alongside some measure of their uncertainty (e.g. standard error or confidence interval). These 
are  combined across studies, using an appropriate meta-analysis model, to estimate the average 
effect size across studies. 
[34] 
 
Fixed-effect Approach 
A fixed-effect meta-analysis assumes that there is no heterogeneity in the effect size across 
studies46. In other words, it means that the true effect size in all studies is the same. For PF 
studies this means the true PF effect (i.e. hazard ratio or odds ratio) is the same in each study. 
The fixed-effect model can be written mathematically as follows:                                                                       
 ;i< = ; + -< 
  -<~©(0, S<p) 
where ;i< is the effect estimate in study A (e.g. log hazard ratio), S<p is the known variance of ;i< 
(assumed known), ; is the fixed effect size, -< represents the sampling error for each study and 
A = 1,2, . . . . , D represents the number of studies to be combined. The main goal of the meta-
analysis is estimating the fixed-effect size ;. One method to achieve this is the inverse variance 
method, where each study estimate is given a weight inversely proportional to S<p. Thus, the 
parameter ; which represents the pooled effect size of the studies, is estimated as: 
 
                                                             ;{ = ∑ 1 0{13145∑ 13145                                                                        (1.25) 
Where ª< = #«1¬  refers to the weight for each study. This is the maximum likelihood estimate 
which minimizes the variance of ;. The variance of ;i  is found by (Borenstein et al.46): 
                                        ­NM(;i) = #∑  3145 1                                                                  (1.26) 
The confidence interval for ;i  can be written as:  
                                           ;{ ± 1.96 × "­NM(;i)                                                        (1.27)                                                 
[35] 
 
For  ratio measures such as the hazard or odds, it is best to apply the meta-analysis on the natural 
log scale as this will be more symmetric and approximately normal; to convert back to the 
original scale one can take exponential of ;i  and the exponential of the confidence interval in 
1.25 and 1.27. 
Random-effects Approach 
In the medical literature, often there is no heterogeneity among studies. Studies often differ in 
their design, clinical and patients characteristics, methods, analysis...etc. This may cause the 
effect of interest to vary across studies. As a result a random-effects meta-analysis method will 
be more approachable, as this estimate show the true effect size vary across studies. Let the 
notation be as before, with additionally Θ< the true effect size in the Ad® study. The random-
effects model can be written as follows 
;i< = Θ< + -< 
                                      																					= ; + ¯< + -<                                                (1.28) 
where ¯<~©(0, °p) and -<~©(0, S<p). In particular, ¯< represents the difference between the 
study specific effect size Θ< and the average study effect size ;; -< is the sampling error in each 
study, with known variance S<p, and °p is the between study variance. For more clarification, the 
total variance of each ;i< around ;	can be written as: 
                                                         ­NM(;i<) = °p + S<p                                          (1.29) 
It can be seen from equation (1.29) if the between study variance is zero, then the random-effects 
model will reduce to the fixed-effect  model. 
There are a number of different methods to estimate the random-effects model, for which both ; 
and °p must be estimated. For example, restricted maximum likelihood can be used to iteratively 
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estimate both °p and ; simultaneously. Else a method of moment estimate of °p can be obtained, 
using the Dersimonian and Laird method46 : 
                                                         °̂p = ±((>(#)²                                           (1.30)                                                    
where ³ is the value of heterogeneity test statistic, calculated as ³ = ∑ 	><?# ª<;<p − (∑ 	31451´µ)¬∑ 	31451 , D 
is the number of studies, ¶ = (D − 1)(ª − «·¬> ), where ª  and Sp  are the mean and variance of 
the weights from the D studies respectively, ª = ∑ 	<?# 1>  and Sp = #>(# (∑ 	><?# ª<p − Dª p), then 
the pooled value  ;i  and its variance can then be estimated  
by  
                                                             ;i = ∑ 0{11∗3145∑ 1∗3145                                                   (1.31) 
The maximum likelihood solution with the study weights ª<∗ = #«1¬.¸¬ 
The variance is estimated as ­NM(;i) = #∑ 	31451∗ and confidence interval as in equation 1.27. The 
random-effects confidence interval will be wider than the confidence interval for the fixed-effect 
method because the between study variance is accounted for if °p > 0. 
The random-effects method is usually more preferable for PFs studies, as heterogeneity usually 
exists. PF studies often differ in quality, types of participants, methods of measurement, and 
choice of statistical techniques (e.g. cut offs, analysis methods, length of follow up, adjustment 
factors) amongst other factors that create heterogeneity. 
The ¹p  statistic is a tool for measuring heterogeneity. The ¹p statistic assess the extent of 
heterogeneity in a meta-analysis. Higgins et al.47 interpreted ¹p, as percentage of the total 
variability in a set of effect sizes due to between study heterogeneity. For example ¹p = 50% 
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means that half of the total variability among effect sizes is caused by between study 
heterogeneity . 
Higgins and Thompson 47 tentatively proposed a guideline for interpertating the magnitude of ¹p 
as 25% means low heterogeneity, 50% means medium heterogeneity, and 75% means high 
heterogeneity. 
Note that under the fixed-effect model, as mentioned before, the true effect size for all studies is 
assumed to be identical, and the only source of uncertainty is the within study error (sampling 
error). By contrast, under the random-effects model, the true effect size across studies is 
different, because there are two sources of variation. So, in a random-effects model of PFs, ; 
gives the mean effect size from the distribution of effect sizes across studies. Traditionally, 
random-effects meta-analysis focuses on the summary effect size ; and its confidence interval. 
But this says nothing about how the true effects in each study are distributed about the mean 
effect. To address this,  Higgins et al.47 suggest calculating a 95% prediction interval for the 
effect in new study as follows:  
                               ;i ± 1.96"°̂p + ­NM(;i)                                                    (1.32) 
where ;i , as mentioned before, is the mean effect size, °̂p is the estimate of the variance of the 
true effect sizes, and ­NM(;i) is the variance of ;i . 
1.7.3  Meta-Analysis Examples 
As mentioned, Hukkelhoven et al.30 assess the effect of age as a PF for severe traumatic brain 
injury and they obtained IPD data for four trials. 
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Table 1. 7:  Odds ratio and standard error estimates for logistic regression for the four 
trials 
Trial  
number 
Odds ratio Coefficient  
(Ln (Odds ratio)) 
Standard error of ln 
(Odds ratio) 
Trial 1 1.364           0.310 0.064 
Trial 2 1.302           0.262 0.050 
Trial 3 1.456           0.375 0.053 
Trial 4 1.388           0.328 0.085 
Table 1.7 gives the odds ratio estimates for each study, for two patients who differ in age by 10 
years and the standard error of the ln (odds ratio) as obtained from a logistic regression model 
including age as a linear prognostic effect in each study separately (see equation 1.6). 
 Table 1. 8: Meta-analysis estimates for fixed-effect and random-effects meta-analysis applied to 
the TBI data of Hukkelhaven et al. assessing whether age is a PF of 6 month mortality 
 Ln odds ratio (OR)  95% CI for  
  (Ln OR) 
 OR   95% CI for OR 
Fixed-effect     0.32  
 0.26 − 0.37 1.37  1.29 − 1.45  
Random-effects     0.32 
 0.26 − 0.37 1.37  1.29 − 1.45 
 
8 < 0.01 (for the model) 
¹p = 0 and 8 = 0.492 ( from Q test for heterogeneity) 
Table 1.8 gives the parameter estimates when fitting a fixed and random-effects model, using 
maximum likelihood estimator using the STATA 'metan' command48 49. As there is no 
heterogeneity between studies (¹p = 0%), the fixed-effect estimate is the same as random-
effects estimate (1.37), which means that the odds of mortality by 6-months increases by 1.37 
times as a result of increasing age by 10 years. The confidence interval does not include one, 
which indicates that there is a significant relationship between age and outcome (6 month 
mortality), i.e. age is a PF. 
[39] 
 
Figure 1.12: The forest plot for fixed-effect of meta-analysis of the four TBI 
studies 
 
 
Figure 1.12 gives the forest plot for this meta-analysis. The black dots represent the study effect 
estimates and the horizontal line represent their associated 95% confidence interval. The centre 
and width of the diamond give the estimate and 95% confidence interval of the odds ratio 
respectively. The homogeneity in this example is unusual for PF meta-analysis, but perhaps 
arises from the four TBI studies all being trials. Usually, PF studies are observational studies that 
are less well designed and will have heterogeneity. An example of this for the Look et al.14 is 
shown in detail in chapter 3. 
1.7.4 The Problems of Meta-analysis of Prognostic Factor Studies using 
Aggregate Data 
Though meta-analysis of PF studies are clearly desirable, unfortunately there are many problems 
for the approach, which are briefly described below 
Difficulty of Identifying Relevant Publications 
 Due to a lack of taxonomy, it is difficult to search for PF studies. PFs are termed prognostic 
markers, predictive markers, and  prognostic variables, amongst many other names45. Further, 
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individual PFs often have multiple names themselves, like NMYCN, N-MYC, MYCN in 
neurosblastoma50. There are currently no standards for conducting a literature review and search 
of PF studies. 
Publication Bias and Other Sources of Bias 
Publication bias is considered as one of the biggest problems in PF studies. It occurs when the 
results of PF studies do not give statistically significant or clinically valuable findings, and so are 
not published. Furthermore, other dissemination bias problems may exist such as: (i) non-
statistically significant or negative results may not be reported in as much detail as significant 
results51; (ii) there may be outcome and sub-group reporting bias22; (iii) language bias, where 
non-english studies are only written-up in English if they are significant22 and (iv) the biased 
choice of optimum cutoff point (for dichotomizing continuous PFs) which researchers often 
choose to produce the most significant result8. 
Poor Primary Study Design 
Currently, many published primary studies do not have a protocol, are not designed properly, and 
are of poor quality. For instance, there is no prior specification of the PFs to be investigated; no 
sample size calculation; and no adjustment for other PFs. Also, due to poor reporting; it is often 
hard to distinguish good quality and bad quality PF studies25. 
Inadequate Reporting of the Methods 
The general standard of reporting primary PF studies are inadequate52 53. For example, there is 
often insufficient information reported about the statistical analysis (e.g. what is the statistical 
model that used, how the assumptions were checked); basic information such as the number of 
patients and events in the groups defined by marker level are often not provided; the inclusion 
and exclusion criteria may not be clear or given and results such as hazard ratio, confidence 
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interval and P-value are often missing or partially reported. As a consequence, not all of the 
available PF studies can be incorporate in a meta-analysis of aggregate data, which may cause 
bias and inefficiency. 
Heterogeneity 
Heterogeneity is one of the most common problems in meta-analysis of PF studies. For example, 
there is often great diversity in the choice of the cut-off points that used to dichotomize the 
continuous PFs (e.g. age) across studies; the choice of adjustment factors; the stage of disease; 
the type of treatments; the methods of measurement; among many other factors. Heterogeneity 
across studies can limit the interpretation of meta-analysis results, especially when the direction 
of PF effect appears inconsistent across studies46. 
For such reasons the aggregate data approach to meta-analysis of PFs has been criticized and 
often only serves to show problems. This has been shown in numerous existing reviews of PFs 
54and discussed in many commentaries55. To help overcome the issues, an alternative IPD 
approach has been championed56-59. 
1.8 Individual Patient Data versus Aggregated Data 
An IPD approach to meta-analysis utilizes the raw data for each individual study, rather than the 
available aggregated data. Example IPD for PF meta-analysis was shown in Table (1.1) and 
(1.2). IPD can potentially overcome many of the problems discussed in section 1.7.4; for 
example, it allows one to11 56 60-63. 
• Use consistent inclusion and exclusion criteria across studies, and if appropriate reinstate 
individuals into the analysis who were originally excluded. For example in Look et al. 
dataset one could study uPA after adjusted or grouped by hormone receptor for all 15 
studies.  
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• Observe and account for missing data at the individual-level.  
•  Verify results presented in the original study publications (assuming IPD provided can be 
matched to that IPD used in the original analyses).  
•  Use up-to-date follow-up information, which is potentially longer than that used in the 
original study publications.  
•  Identify those studies which contain the same or overlapping sets of participants.  
•  Calculate and incorporate results for those missing or poorly reported outcomes and 
summary statistics across published studies; it may thus reduce the problem of selective 
within-study reporting.  
•  Calculate and incorporate results for unpublished studies; it may thus reduce the problem of 
publication bias.  
•  Standardize the strategy of statistical analysis across studies (e.g. the analysis method, how 
continuous variables are analysed, the time-points assessed etc) and use more 
appropriate/advanced methods where necessary.  
•  Assess model assumptions in each study, such as proportional hazards in Cox regression 
models, and model complex relationships like time-dependent effects. 
•  Produce estimates adjusted for existing PF, where previously only unadjusted estimates 
were available; this may increase statistical power and allow the independent prognostic 
ability of a factor to be identified.  
•  Adjust for a consistent set of PFs across studies.  
• Obtain meta-analysis results for specific subgroups of participants across studies (e.g. those 
receiving a particular treatment, those with a particular stage of disease), and assess 
differential PF effects across individuals; this facilitates individualized or stratified 
estimates, and can help reduce observed between-study heterogeneity. 
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An IPD meta-analysis is not without its disadvantages11 55 64. In particular, it is known to be 
resource intensive, as substantial time and costs are required to contact study authors; obtain 
their IPD; input and 'clean' the provided IPD; resolve any data issues through dialog with the 
data providers; and generate a consistent IPD format across studies. For example, in 2002 the 
IPD meta-analysis of Ioannidis et al.65 required 2,088 hours for data management, with 1000 e-
mails exchanged between study collaborators and the data managers. The required cost and time 
will clearly vary depending on the complexity and number of studies involved10. But such factors 
need serious consideration before embarking on an IPD meta-analysis or when applying for grant 
income. In particular, resource requirements must be considered for both the team conducting the 
IPD meta-analysis and the original study authors themselves; the latter are often neglected but 
they are crucial to the success of the project and will often commit many hours 'cleaning' and 
updating their data, and resolving ongoing queries. 
1.9 Statistical Methods for IPD Meta-Analysis 
As for any meta-analysis, an IPD meta-analysis aims to summarise the evidence from multiple 
related studies regarding a particular clinical question, such as whether a factor is prognostic. It 
seems sensible the statistical implementation of an IPD meta-analysis to preserve the clustering 
of patients within studies, and not analyse the IPD as if all coming from a single study (although 
this has not been explicitly shown, see chapter 4 and 5). This can be achieved using a 'one-step' 
or a 'two-step' approach10. In the 'two-step' approach, the IPD are first analysed separately in 
each study using an appropriate statistical method for the type of data being analysed; for 
example, for binary outcome a logistic regression model might be fitted, or for time-to-event 
data a Cox regression might be applied. This produces aggregate data for each study, such as the 
PF effect estimate and its standard error; these are then synthesized in the second step using a 
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suitable model for meta-analysis of aggregate data, such as one weighting by the inverse of the 
variance whilst assuming fixed or random PF effects across studies (see section 1.7). 
In the 'one-step' approach, the IPD from all studies are modeled simultaneously whilst 
accounting for the clustering of participants within studies; this again requires a model specific 
to the type of data being synthesized, alongside appropriate specification of the meta-analysis 
assumptions (e.g. fixed or random-effects across studies). Detailed statistical articles regarding 
the implementation and merits of 'one-step' and 'two-step' IPD meta-analysis methods are 
available; for example, see Turner et al. 66, Higgins et al.67  and Whitehead et al.68 . The 
approaches have been shown to give very similar results, particularly when interest lies in a 
single treatment effect estimate69, though this has not been considered in much details for PFs 
(see chapter 4 and 5). 
One-step IPD meta-analyses more conveniently require only a single model to be specified, but 
this may increase complexity for non-statisticians and requires careful separation of within-study 
and between-study variability60. Two-step IPD meta-analyses are clearly more laborious, but in 
the second-step they allow traditional, well-known meta-analysis techniques such as those used 
by the Cochrane Collaboration (e.g. inverse-variance fixed-effect or random-effects approach; 
Mantel-Haenszel method). Importantly both 'one-step' and 'two-step' IPD meta-analysis 
approaches produce results to inform evidence-based practice, such as the pooled PF effect 
across studies and how the PF effect is modified by study-level characteristics (e.g. treatment, 
study location) and patient-level characteristics (e.g. age, stage of disease). IPD meta-analysis 
models ('one-step' and 'two-step') will be considered in details in chapters (4), (5) and (6). 
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1.10  Aims and Outlines of the Thesis 
 An IPD meta-analysis is clearly a desired approach to evidence synthesis of PF studies and 
considered the best way to facilitate evidence-based use of PFs in health care. As mentioned, in 
this thesis I have two large IPD meta-analysis datasets available, which I will use to explore 
these advantages further. However, IPD does not necessarily overcome all the problems of PF 
meta-analysis such as poorly designed studies, missing patient data, and different methods of 
measurements. There has also been little methodological or empirical research of how to conduct 
an IPD meta-analysis of PFs, and this thesis aims to address this. 
My research in this thesis begins in chapter (2) with a systematic review to collate existing IMPF 
articles and examine a sample of these in detail to identify the current advantages and problems 
of the IPD approach. This allows me to form an appropriate research agenda to motivate the 
subsequent research in this thesis to overcome the problems identified. In chapter (3) I then show 
some real examples of why the IPD approach is preferred to an aggregated data approach from 
the statistical prospective, using the provided IPD in breast cancer. At the same time, this allows 
me to illustrate some of the problems identified in chapter (2) that need to be addressed by 
further research. In chapter (4) I develop possible IPD meta-analysis models according to 
whether  a one-step or two-step meta-analysis approach is used; whether the model accounts for 
the clustering of patients within studies; and whether the model accounts for the residual 
variation for the same values of a PF in each study. In Chapter (5) I then use a simulation study 
to investigate further three models of IPD meta-analysis that have been developed in chapter (4), 
to investigate and examine whether we should ignore the clustering of patients within-studies 
and which is the best approach (one-step or two-step). In Chapter (6) I investigate what we 
should do when the continuous PF does not exhibit a linear prognostic effects; in particular I use 
a  fractional polynomial approach to overcome this problem and fit possible fractional 
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polynomial IPD meta-analysis logistic regression models by using one-step and two-step 
approaches. In chapter (7) I consider the potential problem of small-study effects and availability 
bias that may arises in IMPF; in particular, I review IMPF articles and extract forest plot 
statistics to allows small-study effects to be examined using funnel plots, cumulative meta-
analysis, statistical tests and adjustment methods. Finally, in chapter 8 I conclude with a 
summary and discussion of the key findings of this thesis with suggestions for further research.  
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CHAPTER 2 
A REVIEW OF EXISTING META-ANALYSIS OF 
PROGNOSTIC FACTOR STUDIES USING IPD  
2.1  Introduction 
As discussed at the end of chapter 1, an IMPF has many potential advantages over the aggregate 
data approach, but it will have its own challenges and potential pitfalls, and may not solve all the 
problems of conducting meta-analysis of PFs. In this chapter I will undertake a systematic 
review to identify IMPF articles in the published medical literature. The aim of this review is to 
identify how common the IPD approach is; to assess the trend in it application over time; and to 
critically examine a random sample of IMPF studies; in particular, to examine how an IMPF is 
conducted (e.g. how IPD are obtained, how statistical analyses are performed etc.) and to 
evaluate how IMPF projects are reported. The latter is particulary important to establish the 
current state of the field and to identify common challenges and problems to motivate the 
remainder of the thesis. The methods and results of the systematic review are described in the 
next two sections followed by some discussion and the rationale for remaining chapters. 
2.2  Methods of the Review 
2.2.1  Identification of General IPD Meta-analysis Articles 
It was deemed very difficult to identify IMPF articles directly60, due to the huge variety of 
disease fields, inconsistent nomenclature (e.g. 'predictive', 'prognostic'), and numerous types of 
PFs (e.g. genes, tumor markers, chromosomes, biomarkers, clinical characteristics etc). So, to 
identify IMPF studies, a wider search was initially undertaken for any type of IPD meta-analysis 
articles (i.e. IPD meta-analysis articles in PF and non-PF settings). 
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An existing database of IPD meta-analysis articles were available from Riley et al.54; this 
contained 199 articles identified from January 1992 to the week 24 of 2005, and these were 
included in my database. To update this database, I also searched Medline, Embase and the 
Cochrane Library from the st1  Jan 2005 to March 2009 using the same search strategy as Riley et 
al.54 see Table (2.1). I also searched Google crudely using 'Individual Patient Data Meta-
analysis', to check for any omissions (Figure 2.2). 
Articles must have reported an IPD meta-analysis to be included in my database, that synthesized 
IPD across multiple studies or collaborative groups. Note that these articles did not need to be 
part of a systematic review, as often IPD meta-analysis is done on a 'convenient' set of IPD 
available from collaborators. There was also no restriction on included articles according to type 
of studies being synthesized (e.g. randomized trials, observational studies,...etc). However, 
methodological articles that reported an IPD meta-analysis to demonstrate their methods were 
excluded, as were articles reporting single multi-centre trials. The abstracts of all articles 
identified by the search were read by me and then classified as either 'yes', 'unsure', or 'no'. 
Richard Riley double checked for all articles which I classified as 'yes' or 'unsure', and checked 
10% of the ‘no’ articles. Any discrepancies were resolved by discussion. A final decision on the 
'no abstract' articles was made after obtaining the full paper. 
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Table 2. 1: The search strategy used to identify articles in Medline, Embase, and the Cochrane 
Library 
1.(individual patient $ adj6 data.ti.ab.) 
2.(individual patient $ adj6 report$.ti.ab.) 
3.(individual patient $ adj6 outcomes$.ti.ab.) 
4.(individual patient $ adj6 levels$.ti.ab.) 
5.(individual patient data.ti.ab.) 
6.(ipd.ti.ab.) 
7.(individual subject$ adj6 data.ti.ab.) 
8.(individual subject $ adj6 report$.ti.ab.) 
9.(individual subject $ adj6 outcomes$.ti.ab.) 
10.(individual subject $ adj6 levels$.ti.ab.) 
11.(raw patient $ adj6 data.ti.ab.) 
12.(raw patient $ adj6 report$.ti.ab.) 
13.(raw patient $ adj6 outcomes$.ti.ab.) 
14.(raw patient $ adj6 levels$.ti.ab.) 
15.(raw subject$ adj6 data.ti.ab.) 
16.(raw subject $ adj6 report$.ti.ab.) 
17.(raw subject $ adj6 outcomes$.ti.ab.) 
18.(raw subject $ adj6 levels$.ti.ab.) 
19.idiopathic.ti.ab. 
20.(immediate pigment darkening).ti.ab. 
21.(intermittent peritoneal dialysis).ti.ab. 
22.(invasive pneumococcal disease).ti.ab. 
23.(indirect photometric detection).ti.ab. 
24.(interaural phase disparity).ti.ab. 
25.or 18/1−  
26. or/ 2419−  
27.25 not 26 
2.2.2 Identification of IPD Meta-analysis of Prognostic Factors (IMPF) 
Articles 
Using the database of all IPD meta-analysis articles, I then read each one to classify articles as 
IMPF,  not  IMPF or 'unsure'. Double checking of all classification was again done by Richard 
Riley, and any discrepancy resolved via discussion. 
Recall that - as outlined in chapter 1 - in this thesis I define a PF study to be an assessment of 
whether one or more factors measured at some point from diagnosis of disease (or onset of some 
health condition) are associated with some future outcome. Thus, to be relevant in this review, 
the IPD meta-analysis article must relate to a synthesis of such studies. I call such articles IMPF 
articles, other IPD articles that were not mainly focused on evaluating PFs were not deemed 
relevant. For example, studies with a primary objective to assess a treatment effect were 
excluded, even if they adjusted for PFs. Similarly, so-called predictive factor studies, which 
mainly focus on identifying factors that predict response of treatment, were also excluded. 
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Studies that sought only to develop a prognostic model (and not to evaluate PFs themselves but 
rather the performance of the model) were also excluded. If studies sought to establish the 
prognostic effect of one or more factors, and also later developed a prognostic model, they were 
included. Note that PF studies relate to outcomes in patients with an existing disease, or health 
condition, (see Hemingway et al.2) whereas aetiological studies start with patients without 
disease and look to identify risk factors for onset of disease. IPD meta-analysis of such 
aetiological studies were excluded, though a record kept of how many such articles existed. 
2.2.3  In-depth Evaluation of Recent IMPF 
Following the identification of IMPF articles, I performed an in-depth evaluation of those IMPF 
articles published from 2006 to 2009 inclusive. A data extraction form was developed, which 
included 58 questions covering five aspects of the rationale, conduct, analysis, design and 
reporting on the IMPF. Figure (2.1) gives a brief summary of these questions, for the full list of 
the questions, see Appendix A. 
I also catalogued all the issues noted within each article that hindered the IMPF to generate 
priority research ideas for the rest of this thesis. 
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Figure 2.1: Summary of the data extraction from involving 58 questions, which was used 
to extract information about the 20 IMPF articles examined in details 
Aims and initiation: This section investigates the aims for the IMPF articles, the 
location for the first author and whether there was mention of a project protocol and 
ethics approval. 
Process of obtaining IPD: This section examines how researchers identified relevant 
primary studies (e.g. systematic review, coalition of research groups); how they 
decided which studies to seek IPD from; the process of obtaining IPD; and problems 
encountered. 
Details of IPD obtained: this section points out to the proportion of studies providing 
IPD; the total number of patients in the IPD; whether the number of patients and 
events were reported for each IPD study; whether there was any missing data 
problems; and whether there was variability in how prognostic factors were measured. 
Type and quality of IPD studies: this section highlights the  information about the 
design (e.g. cohort, randomised trials) of studies providing IPD; whether they were 
published or unpublished; and whether they were assessed for their quality and, if so, 
how. 
Statistical methods used: this section examines whether a statistical methods section 
was provided; the statistical models used in the meta-analysis (e.g. Cox regression, 
logistic regression); and how some specific statistical issues were addressed (such as 
clustering of patients within studies; between-study heterogeneity in PF effects; and 
the analysis of continuous PFs). 
Assessment of publication bias and availability bias: this section highlights if and 
how researchers examined the potential impact of publication bias (studies 
unpublished due to non-significant prognostic results) or availability bias (studies 
providing IPD are a biased portion of the studies from which IPD was desired) in their 
meta-analysis.  
Adherence to reporting guidelines: As a crude measure of adherence to reporting 
guidelines for meta-analysis, we recorded how many of the articles referenced the 
reporting guidelines of either MOOSE70 or QUORUM71. 
Limitations and challenges of an IMPF: We catalogued all the problems that 
hindered the IMPF approach as reported by the researchers 
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2.3  Results 
This section documents the findings of the review in three stages: the first stage summarizes the 
classification of any type of IPD meta-analysis and looks at their trend over time; the second 
stage summarizes the classification of IMPF articles and assesses their trend over time; and the 
third stage describes the findings from the in-depth examination of IMPF articles from 2006 to 
2009. 
2.3.1  IPD Meta-analysis Articles 
 After duplicates were removed, the literature search identified 1420 potential IPD meta-analysis 
found from st1  Jan 2005 to March 2009. I read the abstract of these articles. These were 
classified and double checked, see Figure (2.2), resulting in 203 deemed an IPD meta-analysis. 
There were added to those 199 from Riley et al., 54 with 20 further duplicates then removed; 
followed by adding another 2 articles after checking references. Finally a further one article was 
identified from the Google search, giving a final total of 385 IPD meta-analysis articles 
published between 1991 and March 2009. 
Figure 2.3 shows the number of applied IPD meta-analysis articles published per year. It can be 
seen from the graph that it covers the years from 1991 to 2008 and the number of applied IPD 
meta-analysis articles per year is generally increasing over time. There are just a few articles per 
year in the early 1990’s, but about 50 per year by 2009. This show the IPD approach is 
achievable and increasingly common.  
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Figure 2.2: Details of the search and classification of IPD articles 
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Figure 2.3: Graph showing the number of district, applied IPD meta-analysis articles 
published over time (6 articles were also identified in 2009, up to 5 th March when the 
review was conducted), as identified by my systematic review. 
 
2.3.2   IPD Meta-analysis of Prognostic Factor Studies 
 The 385 IPD meta-analysis articles were classified and double checked in regards whether they 
focused on evaluating a PF (Figure 2.4). Ninety articles were identified that assessed an 
association between one or more factors and an outcome. I then distinguished between PF 
articles (where at baseline patients have disease or some health condition and aetiological articles 
(where at baseline patients are healthy).  
Forty-eight of ninety articles were classified as IMPF. Figure 2.5 shows the trend of these studies 
over time. It can be seen from the graph that there are no studies available in 1991, 1992, 1995 
and from 1997 to 1999 (also none published in 2009 up to March where the review included) . 
There are fluctuations of the number of PF studies over time, however, it is noticeable that these 
studies tend to rise from 2000 to 2008, and it appears to be an increasingly active research area. 
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Figure 2.4: Description and results of the search and classification of IPD meta-analysis of PF 
articles 
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Figure 2.5: Number of published IMPF articles over time  (NB no articles were identified in 
2009 up to the start of March, when my review was conducted); the spike in 2007 is due to 
eight articles from the IMPACT collaboration being published simulaneously within the 
Journal of Neurotrauma 
 
2.4  In-depth Evaluation of the 20 Most Recent IMPF Articles 
In-depth evaluation was performed on a sample of 20 IMPF articles published from 2006 to 
200872-91.  Twenty was chosen to give a manageable number of articles to review in the time 
available. These include: 
• Six studies from IMPACT collaboration74-79 entitled 'International Mission for Prognosis 
and Analysis of Clinical Trials in traumatic brain injury'. 'IMPACT' articles utilize a 
database of 11 studies ( 8 randomised trials and 3 observational studies) provided by 
'IMPACT' collaborators; however I considered each IMPACT article independently and 
so did not, for example, assume consistent methodology in all IMPACT papers, or 
assume the information presented in one IMPACT paper was transferable to another 
IMPACT paper containing missing details. 
• Nine 'literature review' articles; 'Literature review' articles sought IPD by first identifying 
relevant studies using a literature review (e.g. using Medline, Embase ) and then 
contacting authors of all identified articles to ask for their IPD.  
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• Five articles classified under the name of  'Others' articles; the ‘Others’ articles are non-
IMPACT articles that obtained IPD via existing personal articles without a literature 
review. 
 I now summarise the key findings in relation to the eight questionnaire categories defined in 
Figure 2.1. 
2.4.1 Aims and Initiations 
Table 2.2 summarises basic information about the 20 IMPF articles; including the location for 
the first author, the PF, the outcome of interest and whether it is a protocol driven. A common 
aim for the IMPF projects was to increase statistical power compared to individual studies alone, 
and to resolve disagreements in the field; for example, the aim for Lanterna et al. 83 was that 
'emerging evidence suggests that the APOE4 allele may increase the risk of a negative outcome 
in patients with aneurysmal subarachnoid hemorrhage, but the results are conflicting.' Another 
common objective was to identify whether a PF was still an independent PF after adjusting by 
some other confounding factors. For example, Trivella et al.72 assess whether microvessel-
density has prognostic value in non-small-cell lung carcinoma when adjusting for other variables 
including age and stage of disease.  
The location of the first author for the most often the Netherlands (7) due to their leading 
involvement in the 'IMPACT' initiative followed by United kingdom (4). Age and gender were 
the most common PFs of interest in the 20's IMPF articles, and there were evaluated alongside 
with disease specific factors (e.g. Micro vessel-density counts in lung cancer, Palliative 
performance scale in heart failure). All of the 'IMPACT' studies focus on the traumatic brain 
injury as a disease and usually 6 month outcome in terms of Glasgow outcome scale.  
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Table 2. 2: Summary of the general information of the review of the random sample of IMPF studies 
  No.   First Author  Type of 
study  
 Year of Publication   Location of 
first author  
 Disease or 
condition at 
baseline  
 Main PFs of interest   Outcomes of interest   Was it stated 
that the IPD 
project was 
funded?  
 Was a 
protocol 
explicitly 
mentioned for 
the IPD 
project?  
 Was mention 
that ethics 
approval was 
given for the 
IPD project?  
 Was a 
prognostic 
model ('risk 
score') also 
developed in 
the article? 
 1   Butcher   IMPACT   2007   United 
Kingdom  
 TBI*   Systolic and mean arterial 
blood pressure  
 Analysis for various 
Glasgow Outcome Scale 
categories.  
 Yes   No   No   No 
 2   McHugh   IMPACT   2007   United 
Kingdom  
 TBI   Hypoxia, hypotension, and 
hypothermia  
 Glasgow Outcome Scale   Yes   No   No   No 
 3   Murray  IMPACT   2007   United 
Kingdom  
 TBI   Age, Glasgow Coma Scale, 
motor score, pupil response, 
computerized tomography 
(CT) characteristics, 
hypotension, hypoxia, etc.  
 Glasgow Outcome Scale 
at 6 months after injury  
 Yes   No   No   No 
 4   Maas   IMPACT   2007  Netherlands    TBI   CT classification and CT 
characteristics, and also 
other PFs as secondary 
analysis too  
 6-month outcome, 
assessed by the Glasgow 
Outcome Scale (GOS)  
 Yes   No   No   No 
 5  Mushkudiani  IMPACT   2007  Netherlands   TBI   Age , gender , race , and 
education  
 6 - month outcome, 
assessed by the Glasgow 
Outcome Scale after  
 Yes   No   No   No 
 6    Beek   IMPACT   2007  Netherlands    TBI   Laboratory parameters (e.g. 
glucose, sodium, 
haemoglobin etc)  
 6 months Glasgow 
Outcome Scale  
 Yes   No  No   No 
 7   Koopman  Literature 
review  
 2008   Netherlands  Acute otitis    
media  
 Age, sex, season, pain, 
fever, smoking, recurrent, 
etc  
 Middle ear effusion at 1 
month  
 Yes   No   No   Yes 
 8   Thakkinstian Literature 
review  
 2008   Thailand   Renal 
transplantation  
 Cytokinin gene 
polymorphism  
 Chronic allograft 
nephropathy, graft 
rejection, graft failure  
 No   No   No   No 
*Traumatic Brain Injury                                                                                                                                                                                                                                             Continued on next page 
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  No.   First Author  Type of study   Year of 
Publication 
 Location of 
first author  
 Disease or condition at 
baseline  
 Main PFs of interest   Outcomes of 
interest  
 Was it stated 
that the IPD 
project was 
funded?  
 Was a 
protocol 
explicitly 
mentioned for 
the IPD 
project?  
 Was It 
mentioned 
that ethics 
approval was 
given for the 
IPD project?  
 Was a 
prognostic 
model ('risk 
score') also 
developed in 
the article? 
 9  MeRGE1 Literature 
review  
  2008   New 
Zealand  
 Acute Myocardial 
Infraction  
Restrictive filling 
pattern(RFP) was the key 
interest; they also want to 
adjust for the other factors 
of LV systolic function, LV 
volumes, and Killip class 
(though they also adjust for 
age , gender and a few other 
variables in the full model) 
  Mortality   No   Yes   No   No 
10 
 
 
Noordzij 
 
Literature 
review 
 
2008 
 
Boston 
 
Monitoring for 
hypocalcemia 
after thyroidectomy 
 
Preoperative PTH 
 
Development of  
hypocalcemia 
    
   No 
 
No 
 
No 
 
Yes   
 11  Downing   Literature 
review  
   2007   Canada   AT baseline, all patients 
were having palliative 
care (i.e. care to reduce 
suffering and improve 
quality of life); it is not 
disease specific but they 
all have severe disease of 
some sort  
 Palliative Performance Scale    length of 
survival  
 Yes   Yes   Yes   No 
12 Rovers Literature 
review 
2007 Netherlands Acute otities media AOM Age, gender, smoking, 
recurrent AOM etc 
Pain and/or fever 
at 3 to 7 days 
Yes No No Yes 
13 Trivella Literature 
review 
2007 United 
Kingdom 
Non-metastatic surgically 
treated non-small-cell 
lung carcinoma 
Micro vessel-density counts Overall survival Yes No No No 
14 MeRGE2 Literature 
review 
2008 New 
Zealand. 
Heart  failure Left ventricular ejection 
fraction , age, gender, NYHA 
class and the presence of a 
RFP 
Mortality Yes Yes No No 
Continue on the next page
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No. First 
Author 
Type of 
study 
Year of 
Publicati
on 
Location 
of first 
author 
Disease or condition at 
baseline 
Main PFs of interest Outcomes of interest Was it 
stated 
that the 
IPD 
project 
was 
funded? 
Was a 
protocol 
explicitly 
mentioned 
for the IPD 
project? 
Was it 
mentioned 
that ethics 
approval was 
given for the 
IPD project? 
 Was a 
prognostic 
model ('risk 
score') also 
developed in 
the article? 
 15  Lanterna  Literature 
review  
 2007   Italia   Aneurysmal 
subarachnoid 
haemorrhage  
 APOE4 allele   The risk of a negative outcome in 
patients with aneurysmal 
subarachnoid hemorrhage and 
delayed ischemia, a major 
complication of SAH  
 No   No   No   No 
16  Yap  Others  2007  Malaysia   Myocardial infraction   Demographic information, medical history, 
smoke, Concomitant medication  
   Death   Yes   No   No   Yes 
 17   Schaich  Others  2007  Germany   Acute myeloid 
leukaemia (AML)  
 Trisomy 8 (+8), either on its own or with one 
additional aberration in addition other PFs 
also of interest from clinical, cytogenetic and 
laboratory data  
 Overall survival, relapse-free 
survival, complete remission  
 Yes   No   No   Yes 
 18   Sylaja   Others   2007   Canada   Acute ischemic stroke   Aged 70>  years, severe stroke 
 (NIHSS 20> ), diabetics, history of CHF, and 
Hispanic ethnicity  
Two outcomes of interest: SICH 
(symptomatic intracerebral 
haemorrhage) a favourable 
outcome (defined by a favourable 
function recovery score of 
1)<=mRS   
 No   No   No   No 
 19  Warkentin   Others   2006   Canada   Any medical or surgical 
patients being treated 
with heparin (either 
unfractionated heparin 
(UFH) and low 
molecular- weight 
heparin  
 Gender, type of heparin  
(UFH vs. LMWH) and type of patient (Surgical 
vs. medical) and the interaction between 
them.  
 Heparin-induced 
thrombocytopenia (HIT)  
 Yes   No   No   No 
 20   Goetz   Others   2008   Chicago   Parkinson's Disease   Patient-based factors (e.g. gender, 
age...etc),Study-dependent factors included 
medical vs. surgical interventions, likelihood 
of placebo assignment 50% vs. 50%, and 
disease severity inclusion criteria   
 50% improvement in total Unified 
Parkinson's Disease Rating Scale 
motor score or a decrease by 2 
points on at least two UPDRSm 
items compared to baseline  
 Yes   No   No   No 
End of Table (2.2) 
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Note that each 'IMPACT' article focused on a different PF. In the 'literature review' articles and 
'Others' articles, acute otitis media and cardiovascular disease were the most common disease; 
whilst survival is the most common outcome. 
Fifteen of the 20 articles mentioned that the project was funded. Only 3 articles88 92 93 directly 
stated there was a protocol for the project, and only one mentioned they had ethics approval85, 
see Table 2.2. 
2.4.2  Process of obtaining IPD 
Details about the process of obtaining IPD are summarized in Table 2.3.  Nine of the 20 IMPF 
articles used a literature review to identify primary studies for which IPD was desired. Six 
utilised those studies already providing IPD within the IMPACT database directly74-79; in the  
‘others’ articles, one utilised a set of known German trials88; one contacted colleagues in the 
field who had directed relevant trials with placebo arms89; one identified studies from a recent 
systematic review and ‘from our files’ 90; and two did not state how they identified relevant 
studies 80 91, see Table 2.3. 
In the nine articles that used 'literature reviews', just six reported the keywords used in 
searching, and  the most common database used for searching were PubMed, Embase, the 
Cochrane databases, Medline and Google Scholar. Only four of the nine articles explicity stated 
how authors were approached for their studies (three by E-mail and one by letter); four simply 
said authors ‘were asked’, and one article did not mention anything in this regard. Only one of 
the nine articles  reported a flowchart detailing the process of searching, classifying, and 
retreiving IPD studies81. 
Two of the twenty articles revealed some resource related issues for obtaining and managing 
the IPD. Thakkinstian et al. 81 state that ‘data cleaning and checking were performed separately 
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for each study’, whilst more strikingly Trivella et al.72 state that ‘checking, validation and 
standardisation of all datasets took nearly two years’. None of the 20 IMPF articles reported  
that any of the studies providing IPD held back some of their IPD. 
2.4.3. Details of IPD Obtained 
For the nine IMPF articles using a literature review to identify relevant IPD studies; none of 
these obtained IPD from all studies desired, see Figure (2.6).  Six of these articles explained why 
the IPD was not always available: reasons included non-response to e-mail, IPD no longer 
available, lack of resources to participate; For example Trivella et al.72 state that ‘nine centers 
had no data, one had no resources to participate and 10 did not reply’, while Rovers et al.87state 
that ‘inadequate randomization or lack of availability of information on the outcomes’,  see 
Table 2.3 
Figure 2.6: The number of IPD studies that was requested and obtained, in each 
of the nine IMPF articles, using a literature review to identify relevant studies 
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Table 2.3: Details about the process of obtaining IPD 
 No.  First Author   How were 
relevant 
IPD studies 
identified 
 If a 
literature 
review, was 
a list 
presented 
of 
keywords 
used for 
searching?  
If a literature review, 
what sources were 
searched? 
How were 
authors of 
relevant 
studies 
approached 
for obtaining 
their IPD?  
What 
resource-
related issues 
for obtaining 
IPD were 
mentioned? 
 How 
many 
studies 
were 
asked for 
their IPD?  
 How 
many 
studies 
provided 
their 
IPD?  
 What 
were the 
reasons for 
studies not 
providing 
IPD?  
Was it 
stated that 
any of the 
studies 
providing 
IPD held 
back some 
of their 
IPD?  
 Was it stated 
that the IPD 
provided 
were 
different to 
that used by 
the same 
study in a 
previous 
publication?  
Was a 
flowchart 
given showing 
the process of 
searching, 
classifying, 
retrieving and 
including IPD 
studies?  
Was it 
stated 
that 
unpublish
ed studies 
or 
published 
data were 
included 
in the IPD 
provided? 
1   Butcher   IMPACT 
database  
 Not 
relevant  
 Not relevant   Not relevant   None 
mentioned  
 Not 
relevant  
 9   Not 
relevant  
 No   No   No   No 
 2  McHugh   IMPACT 
database  
 Not 
relevant  
 Not relevant   Not relevant   None 
mentioned  
 Not 
relevant  
 11   Not 
relevant  
 No   No   No   No 
 3   Murray  IMPACT 
database  
 Not 
relevant  
 Not relevant   Not relevant   None 
mentioned  
 Not 
relevant  
 11   Not 
relevant  
 No   No   No   No 
 4   Maas   IMPACT 
database  
 Not 
relevant  
 Not relevant   Not relevant   None 
mentioned  
 Not 
relevant  
 11   Not 
relevant  
 No   No   No   No 
 5  Mushkudiani   IMPACT 
database  
 Not 
relevant  
 Not relevant   Not relevant   None 
mentioned  
 Not 
relevant 
 11   Not 
relevant  
 No   No   No   No 
 6   Beek   IMPACT 
database  
 Not 
relevant  
 Not relevant   Not relevant   None 
mentioned  
 Not 
relevant  
 7   Not 
relevant  
 No   No   No   No 
 7   Koopman   Literature 
review  
 No  PubMed,EMBASE, 
Cochrane databases, 
and the proceedings 
of international 
symposia on recent 
advances in otitis 
media  
 Unclear-they 
were asked 
 None 
mentioned  
 6   5  Data were 
not 
available  
 No   No   No   No 
 8   Thakkinstian   Literature 
review  
 Yes  Medline   E-mail  Data cleaning 
and checking 
were 
performed 
separately for 
each centre  
 13   5   No reasons 
given  
 No   No   Yes   No 
Continued on  next page 
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 No  First 
Author  
 How were 
relevant IPD 
studies 
identified 
 If a 
literature 
review, was 
a list 
presented 
of 
keywords 
used for 
searching?  
If a literature review, 
what sources were 
searched? 
How were 
authors of 
relevant 
studies 
approached 
for 
obtaining 
their IPD?  
What resource-
related issues 
for obtaining 
IPD were 
mentioned? 
 How 
many 
studies 
were 
asked 
for their 
IPD?  
 How 
many 
studies 
provide
d their 
IPD?  
 What were the 
reasons for 
studies not 
providing IPD?  
Was it 
stated 
that any 
of the 
studies 
providing 
IPD held 
back 
some of 
their IPD?  
 Was it stated 
that the IPD 
provided 
were 
different to 
that used by 
the same 
study in a 
previous 
publication?  
Was a 
flowchart 
given 
showing the 
process of 
searching, 
classifying, 
Retrieving 
and 
including 
IPD studies?  
Was it 
stated 
that 
unpublish
ed studies 
or 
published 
data were 
included 
in the IPD 
provided? 
 9   MeRGE2   Literature 
review  
 Yes   Biological Abstracts, 
Clinical Evidence, Current 
Contents, Embase, 
Medline, Medline In-
progress and PubMed. 
 Unclear-
they were 
asked  
 None 
mentioned  
 17   12   Some of them 
inaccessible  
 No   No   No   No 
 10   Yap   Others   No   Not stated   Not stated   Not mentioned   4   4   Not relevant   No   No   No   No 
11   Rovers  Literature 
review  
 no   PubMed, Embase,the 
proceedings of 
International Symposia 
on Recent Advances in 
Otitis Media, and the 
Cochrane  
 Unclear-
they were 
asked  
 None 
mentioned  
 19   6   Inadequate 
randomization 
or lack of 
availability of 
information on 
the outcomes  
 No   No   No   No 
 12   Trivella  Literature 
review  
 Yes   Medline   Letter   High cost and 
time consuming 
(checking, 
validation, and 
standardization 
of all datasets 
took nearly 2 
years)  
 38   18   Nine centres 
had no relevant 
data;1 stated 
they had no 
resources to 
participate; 10 
did not reply  
 No   No   No   Yes 
13 MeRGE1 Literature 
review 
Yes Biological Abstracts, 
Clinical Evidence, Current 
Contents,Embase, 
Medline,Medline In-
progress and PubMed, 
Not 
mentioned 
Not mentioned 32 18 Not-accessible No No No Yes 
 14   Noordzij   Literature 
review  
 Yes  Pubmed   E-mail   None 
mentioned  
 15   9   No reason 
given  
 No   No   No   No 
Continued on  next page 
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Continued from previous page  
   NO.  First 
Author  
 How were relevant 
IPD studies 
identified 
 If a 
literature 
review, was 
a list 
presented of 
keywords 
used for 
searching?  
If a literature 
review, what 
sources were 
searched? 
How were 
authors of 
relevant 
studies 
approached 
for 
obtaining 
their IPD?  
What 
resource-
related 
issues for 
obtaining 
IPD were 
mentioned
? 
 How 
many 
studies 
were 
asked 
for their 
IPD?  
 How 
many 
studies 
provided 
their IPD?  
 What were the 
reasons for studies 
not providing IPD?  
Was it 
stated that 
any of the 
studies 
providing 
IPD held 
back some 
of their IPD? 
 Was it stated 
that the IPD 
provided were 
different to that 
used by the same 
study in a 
previous 
publication?  
Was a flowchart 
given showing 
the process of 
searching, 
classifying, 
Retrieving and 
including IPD 
studies?  
Was it 
stated that 
unpublishe
d studies 
or 
published 
data were 
included in 
the IPD 
 15  Lanterna  Literature review   Yes  M EDLINE, 
EMBASE,the 
Cochrane 
Library,CINHAL, 
and LILACS  
 Unclear-
'they were 
asked'  
 None 
mentioned 
 8   7   No reason given   No   No   No   No 
16  Downing  Literature review   No  Medline database, 
Web of science 
and Google 
scholar 
 E-mail   Not 
mentioned 
 6   3*  Yes-2 'did not 
reply' and 1 did not 
have access to the 
original data 
anymore  
 No  No   No   No 
 17   Warkentin  'Others'-Studies 
already identified 
from recent 
systematic reviews 
and from our files  
 Not relevant Not relevant   Unclear   None 
mentioned 
 8   7   They omitted one 
study because it 
has not gender 
information which 
considered the 
main factor in this 
study  
 No   No   No   No 
18  Sylaja  Others   -   -   Not 
mentioned  
 None 
mentioned 
 Unclear   4   None mentioned   No   No   No   No 
19   Schaich 'Others'- Known 
German trials 
involving acute 
myeloid leukaemia 
patients between 
April 1993 and 
December 2002  
 Not relevant Not relevant   Not 
mentioned  
 None 
mentioned 
 8   8   Not relevant   No   No   No     No 
 20   Goetz   'Others'-contacting 
colleagues who had 
directed relevant 
clinical trials with 
placebo arms  
 Not relevant Not relevant   Unclear, 
they were 
'contacted'  
 Not 
mentioned 
 Unclear   11   Not mentioned   No   No   No   No 
• Four researchers response to provide their IPD, but only three  provide the IPD studies                                                                                                           End of Table 2.3
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The percentage of studies providing IPD ranged from 32% to 88%, and five of the nine 
articles obtained IPD from 60% or less of the requested studies. The shortfall appeared larger 
in those IMPF articles requesting IPD from 10 or more studies see Figure 2.6. 
In the ‘others’  five IMPF articles, one article obtained IPD from all studies desired88, and  only  
one of these five articles reported the reason for not providing all IPD studies90. 
Table 2.3 gives details about included IPD studies for the 20 IMPF articles. All of the 20 articles 
provided the number of patients included in their available IPD (Figure 2.7); this ranged from 
131 to 8721, indeed, IMPACT studies have the highest number of patients included in their 
availability IPD, this range between 5672 and 8721.  Sixteen articles also reported the number 
of patients separately for each included IPD study, but only 4 articles reported the number of 
outcome events separately for each IPD study. 
Figure 2.7: The number of patients included in IPD studies for the 20 IMPF articles 
 
[67] 
 
Table 2. 4: Details about included IPD studies for the 20 IPFM articles 
Study ID   First Author   Type of the 
study 
How 
many 
studies 
provided 
their IPD?  
 What types of studies were they (how 
many of each)?  
 Across all the IPD 
studies, How 
many patients 
were included in 
the IPD provided?  
Was the 
number of 
patients 
reported 
for each 
IPD study 
separately
?  
 Was the 
number of 
events 
reported for 
each IPD 
study 
separately?  
 What problems of 
missing data were 
there in the IPD 
database?  
 Was a quality 
assessment done for 
each included study 
providing IPD (e.g. to 
check the quality of 
the study design, the 
process used to 
follow-up and collate 
data, etc)  
 1   Butcher   IMPACT 9   8 RCTs, 1 observational Study   6801   Yes   No   Missing data and 
missing outcomes  
 No 
 2  McHugh   IMPACT 11   8 RCTs and 3 observational studies   8721   Yes   No   Missing data and 
missing outcomes  
 No 
3   Murray   IMPACT 11   There are 3 observational studies and 8 
RCTs  
 8686   No   No   Missing values   No 
 4  Maas   IMPACT 11   11- but it doesn't state in this paper 
whether they are RCTs or what (in a related 
paper no.14 it tell us they are 8 RCTs and 3 
observational  studies, but it never 
mentioned that here)  
 8721   Yes   No   Missing data and 
missing variables  
 No 
 5   
Mushkudiani  
 IMPACT 11   Eight therapeutic Phase III randomized 
clinical trials and three surveys in moderate 
or severe TBI  
 8721   Yes   No   Missing variables 
and missing 
outcomes  
 No 
 6   Beek   IMPACT 7   6 Randomized trials and 1 observed   5672   Yes   No   Missing values, 
missing variables and 
missing outcomes.  
 No 
 7   Koopman   Literature 
review  
5   All randomized trials   1328   Yes   No   Missing variables, 
missing values and 
missing outcomes  
 No 
 8   Thakkinstian   Literature 
review  
5   'Human population-based association 
studies'  
 1087   Yes   No   Missing variables 
and missing 
outcomes  
 The Hardy-Weinberg 
equilibrium (HWE) was 
assessed in each study 
providing IPD, only 
studies that observed 
HWE were included in 
the analysis 
 9   MeRGE 2  Literature 
review  
 12   12 prospective studies including 5 clinical 
trials  
 3396   No   No   Missing values   No 
Continue on next page 
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Study ID   First 
Author  
 Type of 
the study 
How 
many 
studies 
provided 
their 
IPD?  
 What types of studies were they 
(how many of each)?  
 Across all the 
IPD studies, 
How many 
patients were 
included in the 
IPD provided?  
Was the 
number of 
patients 
reported 
for each 
IPD study 
separately?  
 Was the 
number of 
events 
reported for 
each IPD 
study 
separately?  
 What problems 
of missing data 
were there in the 
IPD database?  
 Was a quality 
assessment done for 
each included study 
providing IPD (e.g. to 
check the quality of the 
study design, the 
process used to follow-
up and collate data, etc)  
 10   Yap  Others   4   All of the Randomized trials  2707   Yes   Yes   Missing data and 
missing variables  
 No 
 11   Rovers   Literature 
review  
 6   All of the randomized trials   824   No   No   Missing data, 
missing values 
and missing 
variables  
 No 
 12   Trivella   Literature 
review  
 18   Not relevant - data provided by 
collaborating centres rather than 
specific studies  
 3200   Yes   No   Missing variables   No 
 13   MeRGE1  Literature 
review  
18   Of these 18 studies, it is not clear 
what type there were, other than 
that they were 'prospective'  
 3540   No   No   Missing data   No 
 14   Noordzij   Literature 
review  
9   Observational studies   457   Yes   No   Missing variables   No 
 15   Lanterna  Literature 
review  
 7   Not clear some prospective and 
some retrospective studies.  
 796   Yes   Yes  Missing data and 
missing outcomes  
 No 
 16   Downing   Literature 
review  
4   Cohort studies   1808   Yes   No  Missing variables, 
but they did focus 
on the available 
variables.  
 Yes, using quality 
assessment criteria 
proposed by McKibbon in 
1998, and Altman in 
2001  
 17   Sylaja   Others  4   All cohort studies   1966   Yes   No   Missing outcome   No 
 18  Schaich  Others   8   All are randomized trials   131   Yes   No   Missing values   No 
 19   Warkentin   Others   7   7 ; 2 randomized trials and 5 
prospective cohort studies  
 5810   Yes   Yes   Missing data and 
missing variables  
 No 
 20   Goetz   Others   11   All of the randomized trials   858   Yes   Yes   Missing data   No 
End of Table 2.4 
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Missing data was a major problem within the IPD obtained both at the patient-level and at 
the study-level. All of the 20 IMPF articles reported at least one of  missing data problem  [ 
Table 2.4]; in particular, missing values of PFs and  adjustment factors for some patients 
within a study (e.g. Murray et al.74); missing outcome data for some patients within a study 
(e.g. Sylaja et al.91) ; and some PFs or outcome missing completely in some studies 
(e.g.Trivella et al.72, Lanterna et al.83 ); only 9 of the 20 IMPF articles reported use of one of 
the statistical models (e.g. imputation analysis) to limit the missing data problem. 
2.4.4 Type and quality of IPD studies 
Over all of the 20 IMPF articles, 3 articles did not report directly what type of IPD studies 
was included (e.g. randomised trials, observational studies etc.). For example, Lanterna et 
al.83 stated that ‘There were some prospective studies and retrospective studies’ but the 
author did not go into specific details. Seventeen articles reported the type of IPD studies 
included; six of them were IMPACT articles that utilised IPD from 8 randomised trials and 
3 observational studies. Five articles utilised IPD from randomised trial only (for example 
Yap et al.80 utilised IPD from just the placebo arm of randomised trials); two articles utilised 
IPD from randomised and prospective studies; two articles utilised IPD from cohort studies; 
one article utilised IPD from observational studies86 and one article utilised IPD from 
human population- based association studies81,  see Table 2.4. 
Only two of the twenty articles mentioned that some of their IPD studies were unpublished 
72
 
74
 , and only two studies reported a quality assessment for each included study providing 
IPD; for example, Thakkinstian et al. 81  assessed the Handy-Weinberg Equilibrium (HWE) 
in each study providing IPD, and only the studies that observed HWE were ultimately 
included in the project. Downing et al.85 used quality assessment criteria proposed by 
Mckibbon66 in 1998 and Altman72 in 2001. 
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2.4.5  Statistical Methods Used 
All of the 20 articles provided a statistical analysis description in their methods section, see 
Table 2.5. 
Statistical Models for the Patient-level Data 
Logistic regression and Cox proportional hazard model were the most common statistical 
models used to analyze the patient level data; in particular 6 of them used Cox proportional 
hazard model, 10  articles used  either logistic or proportion odds regression and one article 
used both Cox regression and logistic regression89, see Table 2.5. Two of the twenty articles 
did not use any model, for example in sylaja et al.91 the authors did direct calculations of 
proportions in each group defined by the PF. Only three of the 20 articles reported checking 
model assumptions, all in regard the proportional hazards assumption in Cox regression. In 
two of these three articles85 92, it was explicitly stated that model assumptions were checked 
separately in each study included in the meta-analysis. 
Meta-analysis Framework 
For meta-analysis, seven articles used a two-step approach where the IPD was firstly 
analysed in each study separately, and then in the second step the summary data obtained 
(e.g. hazard ratios, odds ratios) were synthesised using a traditional model for meta-analysis 
of aggregate data (see chapter 1.7). Ten articles used a one-step approach, where the IPD 
across all studies were analysed together simultaneously; one article considered both one-
step and two step methods89. In the two remaining articles the choice of one-step or two-step 
method was not clear.  
In the one-step method, there are two approaches for estimating the effect size of the PF; the 
first approach accounts for the clustering of patients within studies by either including a 
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dummy variable for the study or by using multilevel modelling66 94; the second approach 
does not account for the clustering across studies by assuming all of the IPD studies came 
from one study. In contrast, the two-step method accounts naturally for clustering of patients 
within studies (see chapter 4). In five of the ten articles that used a one-step method, the 
authors explicitly reported that they accounted for the clustering of patients within studies 
(Table 2.5). The other 5 may have analysed the IPD as it came from one study, although this 
was not stated explicitly. 
Assessing and Accounting for Heterogeneity 
Details of methods for assessing and accounting for heterogenity in PF effect are 
summarized in Table 2.5. Between-study heterogeneity in prognostic effects (e.g. hazard 
ratios, odds ratios) was examined in 14 of the 20 articles, typically using the I2 statistic 95 or 
the Q-statistic (chi-square test for heterogeneity)96. Of the 20 articles, 8 accounted for 
heterogeneity by including random-effects; seven did not account for heterogeneity and 
justified why, for example as it was negligible (e.g. Koopman et al.82 noted small values of 
I2 < 25%) or the chi-square test was non-significant (e.g. Thakkinstian et al.81 noted the test 
gave p > 0.1), see Table 2.5; five articles did not account for heterogeneity in their meta-
analysis and did not explain why; and in the remaining article heterogeneity was examined 
but it was unclear whether it was accounted for in the meta-analysis . Three articles 72 83 90 
examined potential causes of between-study heterogeneity; for example, Trivella et al.72 
perform subgroup analyses according to the method of measuring microvessel density; 
Lanterna et al.83 used random-effects meta-regression; and Warkentin et al.90 looked at 
excluding a ‘before and after’ prospective cohort study that they believe is causing the 
heterogeneity. 
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Table 2. 5: Details about the summary of the statistical methods over the 20 IMPF articles 
Study 
ID  
 First Author   Was a 
statistical 
analysis 
description 
provided in 
the 
Methods 
section?  
 Did they 
state that 
their meta-
analysis 
method 
accounted for 
clustering of 
patients 
within 
studies?  
 What general 
structure was 
used for the 
meta-analysis 
(i.e. 'one-step' 
ignoring 
clustering; 'one-
step' 
accounting for 
clustering; 'two-
step')?  
 What statistical 
models were used 
at the patient-level 
in the meta-
analysis?  
 What model 
assumptions 
were checked in 
relation to these 
models? [Note if 
they were done 
in each study 
separately. Or at 
the synthesis 
level]? 
 Was between-study 
heterogeneity in the 
PF effect assessed? If 
yes, how?  
 Was between-study 
heterogeneity in the 
prognostic effect accounted 
for in the meta-analysis? If 
yes - how? If no, why not?  
 Were causes of 
between-study 
heterogeneity 
examined, and if so, 
how?  
 Did the meta-
analysis consider 
the quality of 
available IPD 
studies (e.g. 
sensitivity analysis 
excluding low 
quality studies)? 
 1   Butcher   Yes   Yes   'Two -step'   Proportional odds 
and logistic 
regression models 
 None checked No assessment of 
heterogeneity 
‘No because they state 
prognostic  effects 
‘demonstrated considerable 
consistency from study to 
study’ 
No Not relevant 
 2   McHugh   Yes   Yes   'Two-step'   Binary and 
proportional odds 
regression models 
 None checked Yes but they did not 
say how 
Yes random effect pooled No-presumably as 
consistent effect 
across studies 
Not relevant 
3   Murray   Yes   Yes   'Two-step'   Multiple logistic 
regression models,  
 None checked   No assessment of 
heterogeneity  
 Yes, using a random-effects 
model  
 Not relevant as 
there is no 
heterogeneity  
 Not relevant as no 
quality criteria 
applied 
 4   Maas   Yes   Yes   'Two-step'   Binary logistic and 
proportional odds 
regression model 
None checked Yes, by unnamed test 
of heterogeneity 
Yes, using a random-effects 
model 
No Not relevant as 
not quality criteria 
applied 
 5  Mushkudiani   Yes   Yes   'Not clear'   Logistic regression 
and proportional 
odds regression 
None checked No assessment of 
heterogeneity 
Yes, using a random-effects 
model 
No Not relevant as no 
quality criteria 
applied 
 6    Beek   Yes   No   'Not clear'   Logistic and 
proportion odds 
regression 
None checked Yes,they present a p-
value from an 
unnamed test for 
heterogeneity 
‘Not clear’ No Not relevant as no 
quality criteria 
applied 
 7   Koopman   Yes   No   'One-step'   Logistic regression   None checked   Yes, by using 2I    No, because 2I  25< %   Not relevant, as 
heterogeneity was 
considered small  
 No 
 8   Thakkinstian   Yes   Yes   'One-step'   Logistic regression   None checked   Yes, by using a chi-
square test  
 No, because p-value from 
chi-square test 0.1>   
 Not relevant, as 
heterogeneity was 
considered small  
 Yes-studies failing 
the Hardy-
Weinberg 
equilibrium were 
excluded 
 9   MeRGE 2  Yes   Yes   'One-step'   Cox PH model   None checked   Yes, by using 2I  
 and chi-square test  
 No, because 0.042=2I  and p-
value from chi-square test is  
0.06, which they deem to 
indicate little heterogeneity*  
 Not relevant as 
heterogeneity 
considered small’ 
 Not relevant as 
studies were not 
classed as low or 
high quality 
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  Study 
ID  
 First Author  Was a 
statistical 
analysis 
description 
provided in 
the Methods 
section?  
 Did they 
state that 
their meta-
analysis 
method 
accounted 
for 
clustering of 
patients 
within 
studies  
 What general 
structure was used 
for the meta-
analysis (i.e. 'one-
step' ignoring 
clustering; 'one-
step' accounting for 
clustering; 'two-
step')?  
 What statistical 
models were 
used at the 
patient-level in 
the meta-
analysis? 
 What model 
assumptions were 
checked in relation to 
these models? [Note 
if they were done in 
each study 
separately. Or at the 
synthesis level]? 
 Was between-study 
heterogeneity in the 
PF effect assessed? If 
yes, how?  
 Was between-study 
heterogeneity in the 
prognostic effect 
accounted for in the 
meta-analysis? If yes - 
how? If no, why not?  
 Were causes of 
between-study 
heterogeneity 
examined, and if 
so, how?  
 Did the meta-
analysis consider 
the quality of 
available IPD 
studies (e.g. 
sensitivity 
analysis 
excluding low 
quality studies)? 
 10   Yap   Yes   Yes   'One-step'   Multiple Cox PH 
model  
 Proportional hazards 
assumptions checked; 
not clear if this was 
done for each study 
though  
 Yes, by looking at the 
interaction between 
the prognostic effect 
and study in the 
model  
 Yes they looked at 
interaction between 
effect and studies, but it 
was usually not important 
 Not relevant, as 
heterogeneity was 
considered small  
 Not relevant as 
studies were not 
classed as low or 
high quality 
 11   Rovers   Yes   No   'One-step'   Logistic 
regression  
 None checked   Yes , by using 2I   No, as they identify low 
heterogeneity  
 Not relevant as 
low heterogeneity  
 Not relevant as 
no quality 
criteria applied 
 12   Trivella   Yes   Yes   'Two-step'   Cox regression   None checked   Yes, by using 2I    Yes, random-effects 
inverse-variance meta 
analysis.  
 They split the 
analysis by the two 
different methods 
to measure the 
main variable  
 Not relevant as 
no quality 
criteria applied 
13   MeRGE1   Yes   No   'One-step'   Cox PH model   The assumption of 
proportionality of 
hazards for RFP was 
assessed using 
Schoenfeld residuals 
and considered 
acceptable  
 Yes by using chi-
square test and 
2I  
 No, because 0=2I    Not relevant as 
there is no 
heterogeneity  
 Not relevant as 
no quality 
criteria applied 
 14   Noordzij   Yes   No   'One-step'   Linear 
regression 
(analysis of 
variance)  
 None checked   No assessment of 
heterogeneity  
 No   Not relevant as 
there is no 
heterogeneity  
 Not relevant as 
no quality 
criteria applied 
 15   Lanterna   Yes   Yes   'Two-step'   No models 
used; just direct 
calculation of 
tests  
 Not relevant  Yes, by Q statistic  
and 2I  tests  
Yes 50%>( 2whenI  or  p-value for Q statistic 
 0.1< ), using random-
effects model  
 Random-effect 
meta-regression  
 Not relevant as 
no quality 
criteria applied 
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  study ID   First 
Author  
 Was a 
statistical 
analysis 
description 
provided 
in the 
Methods 
section?  
 Did they 
state that 
their meta-
analysis 
method 
accounted 
for 
clustering of 
patients 
within 
studies? 
 What general 
structure was 
used for the 
meta-analysis 
(i.e. 'one-step' 
ignoring 
clustering; 
'one-step' 
accounting for 
clustering; 
'two-step')?  
 What statistical 
models were 
used at the 
patient-level in 
the meta-
analysis? 
 What model 
assumptions 
were checked 
in relation to 
these models? 
[Note if they 
were done in 
each study 
separately. Or 
at the 
synthesis 
level]? 
 Was between-
study 
heterogeneity 
in the PF effect 
assessed? If 
yes, how?  
 Was between-
study 
heterogeneity 
in the 
prognostic 
effect 
accounted for 
in the meta-
analysis? If yes 
- how? If no, 
why not?  
 Were causes of 
between-study 
heterogeneity 
examined, and if 
so, how?  
Did the meta-
analysis 
consider the 
quality of 
available IPD 
studies (e.g. 
sensitivity 
analysis 
excluding low 
quality 
studies)? 
 15   Lanterna   Yes   Yes   'Two-step'   No models used; 
just direct 
calculation of 
tests  
 Not relevant  Yes, by Q 
statistic and 2I  
tests  
Yes 
50%>( 2whenI
or p-value for Q 
statistic 0.1< ), 
using random-
effects model  
 Random-effect 
meta-regression  
 Not relevant as 
no quality 
criteria applied 
16   Downing   Yes   Yes   'One-step'   Cox PH model   Yes, by using 
martingale, 
schoenfeld, 
and deviance 
statistic within 
each study  
 Yes, they 
visually assess 
whether 
between-study 
heterogeneity 
exists  
 No, because 
no evidence of 
heterogeneity  
 Not relevant   Not relevant as 
no quality 
criteria applied 
 17   Sylaja  Yes   No   'One-step'   No models used; 
just direct 
calculations of 
proportions in 
each group 
defined by the 
prognostic factor  
 Not relevant   No assessment 
of 
heterogeneity  
 No   Not relevant 
because 
heterogeneity was 
not assessed  
 Not relevant as 
no quality 
criteria applied 
 18   Schaich  Yes   Yes   'One-step'   Cox regression 
and logistic 
regression  
 None checked   No assessment 
of 
heterogeneity  
 No   Not relevant as 
heterogeneity not 
assessed’ 
 
 Not relevant as 
no quality 
criteria applied 
 19   Warkentin   Yes   Yes   'Two-step'   Random-effects 
logistic model  
 None checked   Breslow- day 
statistic  
 Yes, using 
random-effects 
model if p< 
0.05 for the 
test of 
heterogeneity  
 They look at 
excluding a 
'before-and-after' 
prospective cohort 
study that they 
believe is causing 
it  
 Not relevant as 
no quality 
criteria applied 
 20   Goetz   Yes   Yes   'One-step' in 
some analysis, 
'two-step' in 
other analysis  
 Generalized 
estimating 
equations (GEE) 
for binary 
repeated 
measures  
 None checked   No assessment 
of 
heterogeneity  
 No   Not relevant as 
heterogeneity 
does not assessed  
 Not relevant, as 
no quality 
assessment 
done 
                                                                                                                                                                                                                                                                                                                     End of table 2.5 
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Analysis of Continuous Factors 
Details about the examination of continuous PFs for the 20 IMPF articles are summarized in 
Table 2.6. Nineteen of the 20 articles investigated one or more factors measured on a 
continuous scale. Of these, eight categorized the continuous factors for the analysis; five 
analysed the continuous factors on a continuous scale; and six used a continuous scale in 
some analyses (or for some factors) and used categorise in other analyses (or for other 
factors).  
Of the eleven articles that used continuous scales, seven of them transformed the scale for the 
PF before analysis, because of different methods of measurements across studies which limit 
using the data for analysis, and skewness in the PF which hinder the linearity assumptions. 
For example  Beek et al.76 stated that ‘for continuous PFs with a linear relation to outcome, 
the odds ratios were scaled so that they correspond to changing from the 25 th percentile of 
that PF to the 75 th percentile. This was done to allow a direct comparison of different PFs, 
which are recorded in different units or on different scales’; and Yap et al.80 stated that 
‘variables with skewed distribution were log-transformed’, see Table 2.6. Six of these eleven 
articles considered non-linear trend in their analysis; the most common non-linear model was 
spline model used in four articles, one article used a polynomial term and one article used a 
quadratic term (Table 2.6). 
. 
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Table 2. 6: Details about treatment the continuous variables over the 20 IMPF articles 
 Study 
ID  
 First Author   Were 
continuou
s PFs 
assessed?  
 If yes, were 
they examined 
on a continuous 
scale or on a 
categorised 
scale (e.g. 
dichotomized)? 
 If on a continuous scale, was a 
transformed scale used and if so why? 
 If on a 
continuous 
scale, were 
non linear 
trends 
considered 
and, if so, 
how?  
 If on a categorized 
scale, were 
categories (i.e. cut-
points) justified? If 
yes, give details on 
the justification? 
 Was the 
independent value 
of PFs assessed; i.e. 
were multivariable 
analyses done that 
examine the PF of 
interest adjusting 
for other know 
prognostic factors? 
 If yes multivariable 
analysis were used, 
were set criteria used 
to determine whether 
a PF remained 
important even after 
adjusting for other 
variables? If yes, what 
were they?  
 In 
multivariable 
analysis, were 
full results 
shown for the 
PFs of interest 
regardless of 
their statistical 
significance?  
 Was the 
interaction 
between 
two or 
more PF 
considered 
as a 
prognostic 
variable?  
 1   Butcher   yes   Categorized and 
continuous 
scales both used  
 No   Yes, using 
spline 
functions  
 Yes, as indicated by 
the spline function  
 Yes   No criteria used; all 
significant and non-
significant factors 
remained in the model  
 Yes   No 
 2   McHugh   yes   Categorized 
scale  
 Not relevant   Not relevant   Unclear, but 
authors mention 
they were restricted 
by the definitions 
used in the original 
studies  
 Yes   No criteria mentioned   Not relevant, 
as all variables 
are significant 
 Yes 
 3   Murray   Yes   Categorized 
scale for some, 
continuous scale 
for others  
Yes; for continuous PFs with a linear 
relation to outcome, the odds ratios 
were scaled so that they correspond 
to changing from the 25 
th
 percentile 
of that PF to the 75 
th
 percentile. This 
was done to allow a direct comparison 
of different PFs, which are recorded in 
different units or on different scales. 
No, as they 
note 
relationship 
was linear  
 Yes, to allow a 
direct comparison of 
different PFs, which 
are recorded in 
different units or on 
different scales.  
 Yes   No; p 0.01<  used for 
significance, but all 
variables remained in 
the model  
 Yes   No 
 4   Maas   Yes   Categorized 
scale and 
continuous scale  
 No   Yes, using 
spline 
functions  
 No   Yes   No criteria used; all 
significant and non-
significant factors 
remained in the model  
 Not relevant, 
as all variables 
are significant 
 No 
5  Mushkudiani   Yes   Continuous 
scale  
 No   Yes, using 
spline 
functions  
 Not relevant   Yes   No criteria used; all 
significant and non-
significant factors 
remained in the model  
 Yes   Yes 
 6    Beek   Yes   Continuous 
scale  
 Yes; for continuous PFs with a linear 
relation to outcome, the odds ratios 
were scaled so that they correspond 
to changing from the 25 th percentile 
of that PF to the 75 th percentile. This 
was done to allow a direct comparison 
of different PFs, which are recorded in 
different units or on different scales.  
 Yes, using 
spline 
functions  
 Not relevant   Yes   No criteria used; all 
significant and non-
significant factors 
remained in the model  
 Yes   No 
                                                                                                                                                                                                                                                                           Continue on next page 
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Continue from the previous page 
 Study 
ID  
 First Author   Were 
continuo
us PFs 
assessed
?  
 If yes, were they 
examined on a 
continuous scale or 
on a categorised 
scale (e.g. 
dichotomized)  
 If on a continuous 
scale, was a 
transformed scale used 
and if so why?  
 If on a 
continuous 
scale, were 
non linear 
trends 
considered 
and, if so, 
how?  
 If on a categorized scale, 
were categories (i.e. cut-
points) justified? If yes, give 
details on the justification  
 Was the independent 
value of PFs assessed; 
i.e. were multivariable 
analysis done that 
examine the PF of 
interest adjusting for 
other know prognostic 
factors  
 If yes multivariable 
analysis were used, 
were set criteria used 
to determine whether 
a PF remained 
important even after 
adjusting for other 
variables? If yes, what 
were they?  
 In multivariable 
analysis, were 
full results 
shown for the 
PFs of interest 
regardless of 
their statistical 
significance?  
 Was the 
interaction 
between two 
or more PF 
considered as 
a prognostic 
variable?  
7   Koopman   Yes   Categorized scale   Not relevant   Not relevant   No   Yes   P-value 0.05<=  
meant the PF was kept 
in the model  
 No   No 
 8   Thakkinstian   Yes   Categorized scale   Not relevant   Not relevant   No   Yes   P-value 0.05<= meant 
the PF was kept in the 
model  
 Yes   No 
 9   MeRGE 2  Yes   Categorized scale for 
one continuous 
variable, and 
continuous scale for 
another continuous 
variable (age)  
 Age treated per 10 
years increase  
 No   Yes, cut-points chosen to 
make results 'clinically 
applicable'  
 Yes   P-value 0.1<  meant 
that the PF was 
included  
 No   Yes 
 10   Yap   Yes   Continuous scale   Yes, variables with 
skewed distributions 
were log-
transformed.  
 Yes, by 
adding 
polynomial 
terms  
 Not relevant   Yes   P-value < 0.05 meant 
the PF was kept in the 
model  
 No   No 
 11   Rovers  Yes   Categorized scale   Not relevant   Not relevant   Yes, based on previous 
clinical information - note 
that that the categorised scale 
was imposed on them as some 
studies only provided 
prognostic factors dichotomised 
and not on their original scale 
 Yes   P-value <= 0.05 meant 
the prognostic factor 
was kept in the model  
 Yes for some 
but not all  
 Yes 
 12   Trivella  Yes  Categorised scale and 
continuous scale  
 Sometimes the 
prognostic factor 
effect was expressed 
per 10 unit increase 
 Yes, using 
quadratic 
terms 
 Yes, by noting that this was 
to enable a comparison with 
the analysis leaving the 
factor in the continuous 
scale and noting the choice 
of -point is different across 
previous studies 
 Yes Not criteria used Yes No 
 13  MeRGE1  Yes   Categorized scale   Not relevant   Not relevant   Yes, so that 'relevant' 
hazard ratios can be 
calculated  
 Yes   No criteria used; all 
significant and non-
significant factors 
remained in the model 
 Yes   Yes 
                                                                                                                                                                                                                                                                Continue  on   next  page 
 
[78] 
 
 Study 
ID  
 First 
Author  
 Were 
continuous 
PFs 
assessed?  
 If yes, were 
they examined 
on a continuous 
scale or on a 
categorised 
scale (e.g. 
dichotomized)? 
 If on a continuous scale, was a 
transformed scale used and if so 
why?  
 If on a 
continuous 
scale, were 
non linear 
trends 
considered 
and, if so, 
how?  
 If on a categorized 
scale, were 
categories (i.e. cut-
points) justified? If 
yes, give details on 
the justification?  
 Was the 
independent value 
of PFs assessed; i.e. 
were multivariable 
analyses done that 
examine the PF of 
interest adjusting 
for other know 
prognostic factors?  
 If yes multivariable 
analysis were used, were 
set criteria used to 
determine whether a PF 
remained important even 
after adjusting for other 
variables? If yes, what 
were they?  
 In 
multivariable 
analysis, were 
full results 
shown for the 
PFs of interest 
regardless of 
their statistical 
significance?  
 Was the 
interaction 
between 
two or 
more PF 
considered 
as a 
prognostic 
variable?  
 14   Noordzij   Yes   Continuous 
scale  
 Yes, they changed to a 
percentage scale when 
modelling the percentage 
change from baseline, to 
overcome different methods of 
measurement across studies 
No Not relevant No Not relevant Not relevant Not 
relevant as 
only one 
factor 
considered 
 15   Lanterna   Yes   Categorized 
scale  
 Not relevant   Not relevant   No   No   Not relevant as no 
multivariable model used  
 Not relevant   No 
 16   Downing   Yes   Categorized 
scale  
 Not relevant   Not relevant   Yes, categories 
chosen based on 
those determined in 
a previous report  
 Yes   No criteria used; all 
significant and non-
significant factors 
remained in the model  
 Yes   Yes 
 17   Sylaja   Yes   Categorized 
scale  
 Not relevant   Not relevant   Yes, but 
contradictory 
argument: they 
used a cut-off of 70 
years due to other 
studies showing 
advancing age 
increases risk in a 
continuous fashion  
 No   Not relevant, as no multi-
variable model used  
 Not relevant   No 
 18   Schaich  Yes   Categorized 
scale and 
continuous 
scale  
 No   No   Yes, as the cut-
points gave a 
significant result in 
the analysis 
hierarchical cluster 
analysis  
 Yes   Non-significant' variables 
were excluded  
 No   No 
 19   Warkentin   No   Not relevant   Not relevant   Not relevant   Not relevant   Yes   No criteria used; all 
significant and non-
significant factors 
remained in the model  
 Yes   Yes 
 20   Goetz   Yes   Continuous 
scale  
 Yes, e.g. age treated per 10 
years increase; some other 
variables also transformed 
similarly  
 No   Not relevant   No   Not relevant as no multi-
variable model fit  
 Not relevant   No 
End of Table 2.6 
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Of the 14 articles that used categorised scales,  nine articles used justification for their cut-off 
points; justifications were (i)  to make results clinically applicable82; (ii) to allow a direct 
comparison of different PFs, which are recorded in different units or on different scales74, (iii) 
based on previous clinical information85 87. For example, Rovers et al.87 stated that ‘some 
predictor and outcome variables (e.g. fever and pain) might have been more informative if 
analyzed on a continuous scale. Some trials did measure these items on a continuous scale but, 
because others did not, we needed to recode these items as dichotomous variables’. In contrast, 
four of these 14 articles did not justify their choice of categories, and one article was not clear.  
Assessment of Independent Prognostic Value 
Sixteen of the 20 articles reported a multivariable analysis to examine the independent 
prognostic value of one or more factors after adjusting for others (Table 2.6).  Seven out of these 
16 articles defined the criteria that used to judge whether the primary PF was still an 
independent PF even after adjusting by other confounding factors. In particular the P- value was 
used to decide whether the PF and the confounding factors are significant or not; for example in 
Koopman et al.82 a criteria of 8	 < 	0.05 was used for statistical significance in the multivariable 
model and thus evidence of independent prognostic value.  Whilst 9 of the 16 articles did not 
define the criteria  to decide whether the PF still independent or significant even after adding 
other confounding factors; for instance, in Mass et al.77 all significant and non-significant factors 
remained in the model. Nine of the sixteen articles reported the results in full (whether the PF is 
still significant factor after adjusting by other confounding factors, i.e. by using P-value); in two 
articles of these 16 articles, all of the factors are significant (Table 2.6.); and five articles did not 
report the results in full (i.e. adjusted effect estimate with uncertainty or p-value) for those 
factors deemed not to have independent prognostic value. 
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Assessment of Interactions between Prognostic Factors  
Of the sixteen articles that reported a multivariable analysis to examine the independent 
prognostic value of one or more factors after adjusting for others; seven of these articles 
considered a possible interaction between two or more factors in their multivariable model 
(Table 2.6). For example, McHugh et al. 79 consider whether the interaction between hypoxia 
and hypotension is prognostic for 6-month outcome in patients with traumatic brain injury. 
2.4.6  Assessment of Publication and Availability Biases 
Details about if and how IMPF articles asses publication and availability bias, and whether 
including non-IPD studies in the meta-analysis significantly  changed conclusion about a PF, are 
shown in Table 2.7.   
Two of the twenty articles formal assessed whether publication bias or small-study effects (i.e. 
the tendency for small studies in the meta-analysis to give more favourable prognostic effects 
than the larger studies) may be affecting their meta-analysis. For example; Lanterna et al.83 
used funnel plot for asymmetry alongside a regression asymmetry test, the funnel plot showed 
no asymmetry, whilst in MeRGE1 collaboration92  the authors used a funnel plot and the 
authors stated that ’The present result may be subject to publication bias. However, inspection 
of the funnel plot of the individual hazard ratios for each included study failed to identify 
important heterogeneity (¹p = 0.042	, ) = 0.06)’ 
Availability bias 
Ignoring  the six 'IMPACT' studies (which utilised an existing IPD database), 10 of the 
remaining 14 articles did not obtain IPD from all desired studies (Table 2.7), although two 
articles  did not mention whether all desired IPD studies were obtained or not89 91. 
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Of the 10 articles that stated they did not obtain all the IPD desired, four  studies gave the 
number of patients in the non-IPD studies, and only one article provided the number of events in 
the non-IPD studies83;  three articles reported some consideration about the robustness of meta-
analysis results after including or excluding non-IPD studies (e.g. whether the estimate effect of 
the PF is changed after including non-IPD studies81). Rovers et al.87 stated that ‘six out of ten 
studies were included in the meta-analysis, and the four excluded trials would have not changed 
the results of meta-anlayses’. Only one study combined IPD and non-IPD studies to see the 
effect on the PF; for instance Thakkinstin et al.81 stated that ‘IPD was partially reconstructed 
using summary data in three non-IPD studies, and pooled with IPD studies using logistic 
regression’. 
2.4.7 Limitations and Challenges of an IMPF  
Whilst reading the 20 IMPF articles, I recorded any pitfalls or challenges reported by the 
authors about the process of conducting IMPF projects (Figure 2.8); the three most common 
problems reported were: (i) unavailability of IPD for some studies (this may lead to the 
problem of publication and availability bias (see section 2.4.6 and chapter 7), (ii) different 
methods of measurement of the PF across studies and (iii) missing data. 
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Table 2. 7: Details about considering non-IPD studies and selection bias 
  Study 
ID  
 First Author   Was there a formal 
assessment of 
whether the 
included/selected 
IPD studies were a 
potential biased set 
of all available 
studies (akin to 
publication bias)? 
 If yes, what 
methods were 
used and what 
was concluded? 
 How many 
studies 
were asked 
for their 
IPD?  
 How many 
studies 
provided 
their IPD?  
 Was IPD 
obtained 
from all 
studies 
desired?  
 If no (or 
unclear): was 
the number 
of patients in 
the non-IPD 
studies given 
(or % 
missing)?  
 Were the 
number of 
events in 
the non-IPD 
studies 
given (or % 
missing)?  
 Were details 
given as to the 
robustness of 
meta-analysis 
results to the 
inclusion/exclusi
on of non-IPD 
studies? If yes, 
briefly state 
what was said? 
 Was a method 
used to 
combine IPD 
and non-IPD 
studies? If so, 
what was it?  
 1   Butcher   No   Not relevant   Not 
relevant  
 9   Not relevant   Not relevant   Not 
relevant  
 Not relevant   Not relevant 
 2   McHugh   No   Not relevant   Not 
relevant  
 11   Not relevant   Not relevant   Not 
relevant  
 Not relevant   Not relevant 
 3   Murray   No   Not relevant   Not 
relevant  
 11   Not relevant   Not relevant   Not 
relevant  
 Not relevant   Not relevant 
 4   Maas   No   Not relevant   Not 
relevant 
 11   Not relevant   Not relevant   Not 
relevant  
 Not relevant   Not relevant 
 5   
Mushkudiani  
 No   Not relevant  Not 
relevant 
 11  Not relevant  Not relevant   Not 
relevant  
 Not relevant   Not relevant 
 6   Van Beek   No   Not relevant   Not 
relevant  
 7   Not relevant   Not relevant   Not 
relevant  
 Not relevant   Not relevant 
 7   Koopman   No   Not relevant   6   5   No   No   No   No   No 
 8   Thakkinstian   No   Not relevant   13   5   No   No   No   Yes, but despite 
there were still 
no statistically 
significant effects  
 Yes, IPD was 
partially 
reconstructed 
using summary 
data in 3 non-
IPD studies, and 
pooled with IPD 
studies using 
logistic 
regression 
 9   MeRGE2  Yes   Inspecting 
funnel plot, and 
calculating the 
2I statistic and 
a test for 
heterogeneity  
 17   12   No   Yes   No   No   No 
 10   Yap   No   Not relevant   4   4   Yes   Not relevant   Not 
relevant  
 Not relevant   Not relevant 
Continue on the next page 
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Continue from previous page 
 Study 
ID  
 First 
Author  
 Was there a formal 
assessment of 
whether the 
included/selected 
IPD studies were a 
potential biased set 
of all available 
studies (akin to 
publication bias)  
 If yes, what 
methods were 
used and what 
was 
concluded? 
 How many 
studies 
were asked 
for their 
IPD?  
 How many 
studies 
provided 
their IPD?  
 Was IPD 
obtained 
from all 
studies 
desired? 
 If no (or 
unclear): was 
the number 
of patients in 
the non-IPD 
studies given 
(or % 
missing)?  
 Were the 
number of 
events in 
the non-
IPD studies 
given (or % 
missing)?  
 Were details 
given as to the 
robustness of 
meta-analysis 
results to the 
inclusion/exclusi
on of non-IPD 
studies? If yes, 
briefly state 
what was said? 
 Was a method 
used to 
combine IPD 
and non-IPD 
studies? If so, 
what was it  
 11   Rovers   No   Not relevant   19   6   No   No   No   Yes, 6 out of 10 
studies included 
in the meta 
analysis, and the 
4 excluded trials 
would have not 
changed the 
results of the 
meta-analysis.  
 No 
 12   Trivella   No   Not relevant   38   18   No   No   No   No   No 
 13  MeRGE1  No   Not relevant   32   18   No   Yes   No   No   No 
 14   Noordzij   No   Not relevant   15   9   No   No   No   No   No 
 15   Lanterna   Yes   Funnel plot for 
asymmetry and 
regression 
asymmetry test  
 8   7   No   Yes   Yes   No   No 
 16   Downing  No   Not relevant   6   4   No   Yes   No   Yes, they 
compare the 
meta-analysis 
result from the 4 
IPD studies with 
the published 
results from the 6 
studies  
 No 
 17   Sylaja   No   Not relevant   Unclear   4   Unclear   Not relevant   Not 
relevant  
 Not relevant   Not relevant 
 18  Schaich  No   Not relevant   8   8   Yes   No   No   No   No 
19   Warkentin  No   Not relevant   8   7   No   No   No   No   No 
 20   Goetz   No   Not relevant   Unclear   11   Unclear   Non-IPD 
studies not 
mentioned  
 Non-IPD 
studies not 
mentioned  
 Non-IPD studies 
not mentioned  
 Non-IPD 
studies not 
mentioned 
End of Table 2.7 
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Figure 2.8: Summary of the challenges facing researchers conducting an IMPF 
Identifying all relevant studies 
• Unavailability of IPD in some studies 
• Time-consuming and costly nature of obtaining, cleaning and analysing the IPD. 
Issues within individual studies 
• Dealing with skewed continuous variables and possible outliers. 
• Inability of IPD to overcome deficiencies of original studies, such as being retrospective rather 
than prospective, being too small for a multivariable analysis, missing important confounders, 
missing participant data or being of low methodological quality, etc. 
• How to assess the quality of studies identified 
• Dealing with the continuous variable if the linearity assumption is not achieved. 
Heterogeneity between studies 
• Different definitions of disease or outcome. 
• Different participant inclusion and exclusion criteria. 
• Different methods of measuring for the same prognostic factor.  
• For survival data different lengths of follow-up  
• Factors measured at different points in time or at different stages of disease across studies.   
• Different (or out-dated) treatments strategies, especially when a mixture of older and newer studies 
is combined. 
• Insufficient information about treatment for some of the studies.  
Statistical issues for meta-analysis 
• Missing data, including: missing factor values and outcome data for some participants within a 
study, and unavailable factors in some studies. 
• Inability to adjust prognostic effects for a consistent set of adjustment factors in each study 
• Imposed choice of cut-off levels when individual studies categorise their continuous variables 
and/or categorise their continuous outcomes in their provided IPD 
• Difficulty in using a continuous scale for continuous factors in meta-analysis when some studies 
give IPD give values on a continuous scale and others do not (e.g. see Rovers et al.97) 
• Considering whether it is sensible and/or possible to investigate differential prognostic effects in 
subgroups  
• Potential for study-level confounding when assessing whether study covariates (e.g. year of 
publication) modify the prognostic effect. 
• Difficulty of interpreting summary meta-analysis results in the presence of heterogeneity across 
studies. 
• When and how to account for clustering (‘one-step’, ‘two-step’ or just treat as all one study) 
• How to combine IPD and non-IPD studies.  
Assessment of potential biases  
• Potential for publication bias and availability bias 
• How to assess the robustness of IPD meta-analysis results to the inclusion/exclusion of studies 
only providing summary data; and how to combine IPD studies with summary data studies  
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Different Methods of Measurement 
If the PF has different units of measurement across studies, there is difficulty in combining 
the IPD studies for the PF. Of the 20 IMPF articles, seven articles reported the problem of 
different methods of measurement72 77 78 81 85 86 93; three of these seven articles explained the 
causes of different methods of measurement of the PF across their IPD studies and explained 
how they limit and cope with this problem72 78 86.  For example, Trivella et al.72 state that 
‘there are two main methods for measurement’ - so they do separate analyses for each one. 
Even when the same method was used to count microvessel density (i.e., Chalkley vs. all 
vessels), individual laboratories used very different procedures for measurement of 
microvessel density. Four of the seven articles that reported the problem of different 
methods of measurement did not attempt to limit or cope with this problem81 85 93. For 
instance, Thakkinstian et al.81 stated that “Since the IPD meta-analysis is a retrospective 
collaboration, it is difficult to get clinical variables that have been assessed and measured 
using similar methods across all studies”. So it seems they are aware of it, but haven't been 
able to address it. 
Missing Data 
Missing data occurs when no data are available in PF or outcomes; in particular  there are 
three types of missing data in IMPF articles; first, the missing variables occur when there is 
no data provided for a certain PF or confounding factors in some studies of the IPD studies 
provided. For example, in Look et al14. for the 15 IPD dataset, the PAi variable was not 
available in some of these IPD studies. Second, missing values occurs when some values are 
missing in a certain PF or confounding factors. For example, in Look et al14. across the 15 
IPD dataset,  there are 68 missing patients values for uPA across studies.  Third, missing 
outcomes occure when there is some missing values of the outcome for some patients in the 
[86] 
 
study. All of the twenty articles reported at least one of these  missing data problems. Nine 
of these twenty articles reported statistical methods to limit the problem of missing data; 
three of these nine articles directly mentioned to an ‘Imputation Analysis’, and gave a brief 
information about the methods of doing it74 77 83.   Three of nine articles report how they 
overcome missing data. One of them reported  ‘missing value analysis function’ whereby 
they imputed the missing data per trial using a linear regression method (e.g. Koopman et 
al.82) ; and in the remaining two articles the authors did not directly report to the statistical 
methods, they just reported that they imputed the data (e.g. missing outcomes, missing 
patient level) without any further information75 78 79. 
2.5 Discussion 
Meta-analysis of IPD is well-known to be the "gold-standard" approach to combining 
evidence across multiple studies. This review has shown that the number of IPD meta-
analysis articles have increased dramatically over time. Further, IMPF are also achievable 
and I identified 48 currently published. An in-depth evaluation of the 20 most recent IMPF 
revealed their methods and reporting are often sub-optimal, and there are numerous 
challenges for the IMPF approach, despite their numerous advantages over aggregated data. 
2.5.1  Review Limitations 
Though I used a systematic review that involved a wide search strategy to identify general 
IPD meta-analysis articles and IMPF articles, there is still possibility of missing some IPD 
articles and IMPF articles. Searching for and classifying IMPF articles was also not trivial; 
in particular, due to different types of prognosis studies, and the lack of taxonomy that 
exists in the field.  
Another limitation is that the information extracted from the 20 recent IMPF articles is 
dependent on reporting standards therein, and so apparent deficiencies within an IMPF 
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project may be confounded by poor reporting. For example, only 3 IMPF articles referred 
to a protocol for their project, but this does not necessarily mean a protocol did not exist in 
the other 17 articles. Thus apparent gaps in study conduct may simply relate to gaps in 
study reporting. This is particularly important given I only elicited information directly 
available in the published IMPF article, and did not utilise other reports (e.g. protocols, 
statistical analysis plan) or contact authors for information directly. However, it is unlikely 
that the aforementioned issues would alter the main findings about the trend in IPD articles 
over time; the often sub-optimal methods and reporting in IMPF and the main challenges 
facing those conducting IMPF. 
It is clear that IMPF articles still have many challenges. In this thesis, I tackle some of these 
challenges; at the end of the thesis (chapter 8), I provide recommendations for how IMPF 
projects can be improved.  
 2.5.2  Motivation for Further Research in this Thesis 
There are many challenges facing statisticians, working within an IMPF, as identified 
during the review in this chapter (Figure 2.8), and these motivate the rest of my thesis. 
Missing data (e.g. missing variables, missing values and missing outcomes) is one of the 
most common problems in IMPF articles. From the 20 IMPF articles, some authors deal 
with this problem by omitting the missing values and excluded the variables that are missed 
in some IPD studies; other authors limit this problem by using the imputation analysis to 
estimate the missing data. But a clear strategy for dealing with missing data in IPD meta-
analysis is not yet established. Another issue is that some of the IMPF articles did not 
account for clustering of patients within studies which might impact upon the accuracy of 
their results and this needs to be examined. Also is the choice between one-step and two-
step meta-analysis approaches important? 
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Handling different methods of measurement of PFs across studies is another substancial 
problem not currently solved, and the strategy for modeling continuous variables and 
dealing with non-linearity in meta-analysis is not established. Thus, there is an array of 
statistical problems that needs to be tackled to ensure IMPF produces reliable, evidence-
based results for PFs. 
In subsquent chapters I tackle some of these issues further; in particular chapter 4 and 5 
compares one-step versus two-step approaches, chapter 6 considers analysis of continuous 
PFs, and chapter 7 considers publication bias and availability bias. Before that I illustrate 
the issues using a real dataset in chapter 3. 
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CHAPTER 3 
IPD VERSUS AGGREGATED DATA: AN EXAMPLE 
OF THE ADVANTAGES AND PROBLEMS 
3.1 Introduction 
This chapter aims to show through simple analyses and empirical evidence why a meta-
analysis of aggregated data is limited severely for PF studies, and why an IPD meta-analysis 
is preferred. I will focus on the assessment of uPA as a PF in patients with breast cancer, see 
chapter 1, section 1.3, Table 1.2. First, I will highlight the problem of an aggregated data 
review as conducted by Look et al.98  using IPD from 15 studies. I will demonstrate how 
IPD allows more reliable and clinically meaningful answers. Finally, I will demonstrate that 
IPD does not solve all the problems of a meta-analysis of PFs by highlighting some of the 
issues for IMPF articles  identified in chapter 2. 
3.2  Aggregate Data of Meta-analysis of uPA in Breast Cancer 
The aggregate data approach to meta-analysis of PFs was introduced and exemplified in 
chapter 1, section 1.6, where the disadvantages of the approach were also noted. Some of 
the issues are apparent in an aggregate data meta-analysis of urokinase-types plasminogen 
activator system (uPA) in breast cancer by Look et al.98The uPA system comprises at least 
four proteins, urokinase-type plasminogen activator (uPA), its membrane-bound receptor 
(uPAR) and two plasminogen activator inhibitors (PAI-1 and PAI-2). These proteins have 
been suggested to be PFs in breast cancer. The balance between the expression levels of the 
various component of the uPA-system could determine whether active proteolysis and 
invasion takes place and whether cell migration will be affected by non-proteolytic or 
proteolytic mechanisms or by both. Look et al.14 reviewed the literature for the uPA system 
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and relapse-free survival in breast cancer patients, and clinical important subgroup therein. 
The authors identified 41 relevant studies from which aggregated data were extracted 
regarding the study results; in particular, the univariate and multivariate hazard ratio results 
regarding the prognostic effect of the uPA system. For simplicity, in this section the focus 
is on a relation between uPA as a PF and relapse-free survival in breast cancer patients. The 
other factors such as uPAR, PAI-1 and PAI-2 are excluded. 
Table 3.1 shows the aggregate data that could be extracted for uPA in those 7 studies 
reporting the relation between relapse-free survival and uPA for all patients. This table is 
taken from Look et al. 98  It can be seen from Table 3.1 that there are missing data for some 
studies such as the number of relapses during follow up, the univariate hazard ratio (i.e. the 
hazard ratio from a survival model just including uPA as a covariate) and the multivariable 
hazard ratio (i.e. the hazard ratio from a survival model including uPA and also other PFs). 
In addition, the variables included in the multivariable model differ from study to study, 
which is likely to cause heterogeneity in the adjusted uPA results across studies. 
Furthermore, there is a large difference in the choice of cut-off level among studies; for 
example, in one study the cut-off level for uPA is 0.62 and in another it is 4.45, which 
suggests no consistent strategy for determining the cut-off level and potentially different 
methods of measurements from study to study. 
Another limitation of an aggregate data approach is to examine the ability to look at uPA as a 
PF in subgroups of patients. For example, one may wish to look at the prognostic effect of 
uPA in those group defined by a negative and positive hormone receptors status. Only 3 
studies out of 41 considered this (Table 3.2), and only one of these provided the unadjusted  
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Table 3. 1: uPA and their relation with relapse-free survival in all patients98 
Study 
reference 
number 
Number of 
patients 
included 
 Cut-point Fraction of 
tumors with 
levels above the 
cut-point 
Number of 
Relapses 
during follow 
up 
Follow up 
in months 
 Unadjusted 
P-value  
 Unadjusted 
hazard ratio 
(uHR) 
Adjusted 
P-value 
 Adjusted hazard 
ratio( aHR(95% 
CI)) 
 Other PFs
1
 
uPA           
20  229   3.0      39 48 30   <0.0001  3.22  0.0002  3.0(1.7-5.5)  LN,PgR,PAI-1 
17  184  0.81      23 ?  83   0.0008    ?  0.003  2.3(1.3-4.0)  LN,ER  
42  688 0.62      33 173 42   0.0002    ?  0.004  1.8(1.2-2.8)  LN,TAM,S-phase,PgR 
46  429 4.45      50 201 61   0.0023    ?  0.17     ?  meno, LN, T, grade, PAI-1, 
HRS 
26  314 0.52      32 91 84   0.06    ?   ?     ?  Na 
45  226 0.3      50 50 60   0.014   2.04  0.044  1.89(1.01-3.50)  age,LN,ER,adjCT 
29  629 1.15      32 253  48    <0.0001    ?   0.01  1.46(1.1-1.95)  age/meno,LN,T,PAI-
1,ER,PgR,PS2,CD 
1 age/menopausal status: age and menopausal status, LN:Lymph-node status, T:tumor size, HRS:hormone-receptor status, TAM:adjuvant tamoxifen 
treatment, adjCT:adjuvant chemotherapy,CD:cathepsin D, ? Not shown, Na: not available. 
 
 
 
 
 
[92] 
 
Table 3.2: uPA and its relation with relapse-free survival in hormone receptor or ER -negative and positive patients98. 
Study reference number 
 
Number of 
patients 
included 
 
cut-point  Fraction of 
tumors with 
levels above 
the cut-point
Number of 
Relapses 
during 
follow up  
Follow up 
in 
months 
Unadjusted 
P-value 
 Unadjusted 
hazard  ratio 
    (uHR) 
Adjusted  
P-value 
aHR(95% CI)  Other PFs
 Negative Hormone-receptor             
20   59   3.0        ?    21    30        <0.21     1.79               ?                 ? na 
13   70  10       63    ?    64           ns       ?                   ?                     ?      na 
28   238  1.15       36    113    48            ?       ?               0.11         1.38(0.98-2.05) age/meno,L
N,T 
Positive Hormone-receptor  
20   170  3.0        ?    28    30      0.0002 3.72                  ?                    ?    na 
13   96  10       41    >14    64      <0.001  ?                  ?                    ?    na 
28   406  1.15       29   138    48         ?  ?        <0.0001       2.76(1.96-3.87) age/meno,L
N,T 
2   
age/menopausal status: age and menopausal status, LN:Lymph-node status, T:tumor size, HRS:hormone-receptor status, TAM:adjuvant tamoxifen treatment, 
adjCT:adjuvant chemotherapy,CD:cathepsin D, ? Not shown, Na: not applicable. 
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hazard ratio (uHR) and adjusted hazard ratio (aHR) for each group defined by hormone receptor.  
All these issues make a meta-analysis of aggregate data hard to justify here. There is much missing 
data, and interpretation is severely limited by heterogeneity. Thus, meta-analysis is unlikely to be 
reliable or clinically meaningful. One could try to utlise the methods of Parmar et al18, to obtain the 
estimates where currently missing, but Riley et al.22 and Kyzas et al7, show this is problematic for 
PF studies due to poor and selective reporting, and it would not solve most problems such as 
inconsistent cut-off and variable selection of adjustment factors. 
3.3 IPD Meta-analysis of uPA in Breast Cancer 
Look et al.14 seek to overcome the aggregate data problems described in section 3.2 by obtaining 
IPD from 18 collaborating centers in the field and they have kindly provided me with the IPD from 
15 of these centers. I will now use this to demonstrate the advantages of having the IPD over the 
aggregated data approach56 61 94 99.  An IPD meta-analysis of PFs can be tackled using a 'one-step' 
or 'two-step' approach66 94 100 101, but here I use the 'two-step' approach as this most closely reflects 
what the aggregate data approach is trying to achieve99.  In the 'two-step' approach, the IPD are 
first analysed separately in each study using an appropriate statistical method for the type of data 
being analysed. For example, for time until the events occur, the Cox proportional hazard model 
might be fitted. This produces aggregated data for each study, such as the PF effect estimate and its 
standard error; then a fixed-effect or random-effects meta-analysis method is used to pool the data 
across studies to estimate the summary hazard ratio (see section 1.7).  
3.3.1  Advantages of using the IPD Approach for uPA  
(1). Increased number of studies and events 
The number of the studies in my IPD breast cancer data was 15, comprising 7435 patients and 
2645 events. Though the total number of the studies in aggregate data review was 41 in Look et 
al.98 there were only 7 studies with 2699 patients and 816 events that provided aggregated data 
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PF results for uPA for the all breast cancer patients, and within these 7 studies there are missing 
estimates. This indicates that the number of studies, patients and events is larger in IPD 
compared to aggregated data approach.  Also, if  the data are classified according to confounding 
factor of hormone receptor, in the aggregated data approach for Look et al.98 only 3 studies with 
869 patients and 314 events (134 and 180 events for negative and positive hormone receptor 
respectively) were available. However, in the IPD approach, the whole 15 studies was available 
comprised 7435 patients with 2645 events (622 and 2023 events for negative and positive 
hormone receptor respectively). 
(2). Perform meta-analysis with uPA on original scale 
In the IPD, uPA was available on its original scale in each study69 102, so I chose to maintain this 
scale and not dichotomize, to maximise statistical power. This is not possible using the aggregate 
data approach, as aggregated data results are presented with uPA analysed on dichotomized scale 
with inconsistent cut-off points across studies. I thus applied a two-step IPD meta-analysis with 
uPA on its original scale. In the first step I fitted a Cox model to each study separately (A =
1	BC	15), which can be illustrated mathematically as follows: 
                                      
][exp)(=)( 0 uPAtt iii ⋅⋅ βλλ                                                  (3.1) 
where uPA is a continuous PF. In the second stage, I fitted a random-effects meta-analysis model  
to estimate the effect size of the PF, iβˆ , as follows: 
                                      ))ˆ(,(ˆ βββ varN ii ~                                                               (3.2) 
   
                                      ),( 2τββ Ni ~  
where β  is the average log hazard ratio across studies, and 2τ  is the between study 
heterogeneity in log hazard ratio. Figure 3.1 shows a forest plot of this IPD meta-analysis. It can 
be seen that there is large heterogeneity as 87.4=2I
 
% ; this means 87.4% of the total 
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variability among effect sizes is caused by between study heterogeneity. The pooled hazard ratio 
is 1.22 which means that the mean effect ( average of hazard rate) increases by 22% for every 
one unit increase in uPA; with 95% confidence interval for the average hazard ratio lies between  
1.15 and 1.31. Thus it does not include one, and indicates a statistical significant relationship 
between uPA and RFS on average. Thus, even despite the heterogeneity, there is still strong 
evidence that uPA has prognostic value in an individual study setting. The estimated between-
study variance of the true hazard ratio, 2τ ,  is 0.0085. 
Figure 3.1: A forest plot for uPA and RFS from the 15 IPD studies for the 
breast cancer patients. 
 
(3). Examine prognostic factors in subgroup of patients 
Another advantage of IPD is to look at the prognostic effect in specific subgroup of patients103. 
For example, one may wish to look at the effect of uPA in subgroup defined by hormone 
receptor status (e.g. negative or positive hormone receptor). This may lead to more specific 
recommendations about the role of uPA in individual patient, and help reduce between study 
NOTE: Weights are from random effects analysis
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heterogeneity. As discussed in section 3.2 this was very difficult using aggregate data, due to 
the poor reporting of subgroup results, see Table 3.2. 
In each study, I fitted Cox proportional hazard model for each hormone receptor group 
separately, the negative hormone receptor group model is as follows: 
                                        ][exp)(=)( 000 uPAtt iss ii ⋅⋅ βλλ                                             (3.3)  
where 0s  refers to the negative hormone receptor group. The positive hormone receptor model 
in each study is:  
                                      
][exp)(=)( 111 uPAtt iss ii ⋅⋅ βλλ                                               (3.4) 
where is1  here refers to the positive hormone receptor, for each study group separately. I then 
performed a random-effects meta-analysis of the i0ˆβ  or i1ˆβ
 
estimates , as in equation 3.2. 
Figure 3.2 shows the subgroup meta-analysis results obtained. In positive hormone receptor 
¹p = 78.1	%	,	which means that 78.1% of the total variability among effects sizes is due to 
between study heterogeneity. The estimated variance of the true effect size of the positive 
hormone receptor group	°p  is 0.0101. The estimated average hazard ratio for a 1-unit increase 
in uPA in the patients who had a positive hormone receptor is 1.21; this means that the hazard  
increases by 21% for every 1-unit increase in uPA for the patients with a positive hormone 
receptor. The 95% confidence interval is between 1.13 and 1.30; it does not include one 
indicating a statistically significant association between uPA and RFS for patients who have 
positive hormone receptor.  
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Figure  3.2: A forest plot for uPA and RFS from the 15 IPD studies for breast cancer patients 
after grouped by hormone receptor. 
 
In negative hormone receptor, 48.3%=2I , which indicates that there is still heterogeneity 
across studies, but the proportion of heterogeneity for negative hormone receptor patients is 
much less than for positive hormone receptor. The estimated variance of the true effect size for 
negative hormone receptor group °p is 0.0072. The estimated average hazard ratio is 1.14 
NOTE: Weights are from random effects analysis
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slightly less than the average hazard ratio estimate for positive hormone receptor, and the 95% 
confidence interval, for negative hormone receptor is between 1.06 and 1.24. 
The 95% confidence interval for the average hazard ratio is again entirely above 1. So, these 
analysis have shown that uPA is, at least on average, prognostic for RFS in both subgroup 
defined by hormone receptor status. A test of a subgroup effect (i.e. a difference in hazard ratio 
between hormone receptor groups), using a meta-analysis model was not significant. This can be 
seen by the largely overlapping confidence intervals for the  average of the meta-analysis 
results.  
 (4). Adjust analyses for a consistent set of other PFs 
Another advantage of IPD is to look at PFs whilst adjusting consistently for other variables. To 
demonstrate this, I will look at the effect of uPA in all patients after adjusted by age. First, in 
each study separately I fitted a Cox proportional hazard model for uPA in all patients after 
adjusting by age. The model is written below: 
                    
][exp)(=)( 210 ageuPAtt iiii ⋅+⋅⋅ ββλλ                                                   (3.5) 
Where ;#< and ;p< refer to the ln(HR) for a 1-unit increase in uPA and age respectively. Then I 
fitted a random-effects meta-analysis of the i1ˆβ  estimates obtained. 
Figure 3.3 shows the forest plot for this meta-analysis. The estimated between study variance of 
the 2τ  is 0.0088. The results again show that the uPA is an independent PF even after adjusting 
for age. Such a finding was not available without IPD. 
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Figure 3.3: A forest plot for uPA and RFS from the 15 IPD studies for 
breast cancer patients after adjusted by age 
 
(5). Assess the interaction between two PFs as an additional PF  
Another advantage of the IPD approach is to measure the effect of the interaction between two 
PFs. For example, I now assess whether the interaction between uPA and age is an independent PF 
itself, over  uPA and age themselves. I fitted the cox proportional hazard model as follows in each 
study:  
																V#<(B) = V\<(B). exp	q ;#< . ¯)» + ;p<. N¼- + β½<. (uPA ∗ age)																																				(3.6) 
 Then I fitted a random-effects meta-analysis to the i3ˆβ  estimates. 
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Figure 3.4: A forest plot for the interaction between uPA and age  after 
adjusted by uPA and age from 15 IPD studies for breast cancer patients 
 
It can be seen from Figure 3.4  that the hazard ratio is one which indicates that there is no 
significant effect for the interaction between uPA and age on risk of mortality (P-value > 0.05);  
and there is heterogenity across studies (65.8 %). Note that without the IPD, you are reliant on the 
studies themselves reporting the interaction estimates and their standard errors, but this rarely 
happens in practice and was not available in aggregated data approach here.  
The  five illustrated advantages show some of the key advantages of the IPD approach over the 
aggregate data approach, using more patients and events to consider PFs in subgroups and having 
adjusted for other factors. Other advantage exists, such as modeling non-linear trends (see chapter 
6). But, as identified in chapter 2, there are still numerous challenges for conducting the IPD 
approach. I now illustrate some of these: 
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(1). IPD not available for all studies 
Though the number of the IPD studies for Look et al.14 was 18 studies, only 15 IPD studies were 
provided to me. The other three studies were not provided to me as the original authors refused, 
as they also wanted to use their data for methodological research. This reflects sensitive issues 
around data sharing, and was seen in my review in Chapter 2, where many IMPF projects could 
not obtain all the IPD required. 
(2). Missing data 
There are missing data in the Look et al.14 IPD dataset. There are missing variables in some 
studies. For example, some PFs are entirely missed in some IPD studies (i.e. PAI-1), and some 
PFs have missing values for some patients in some  studies (e.g. in total there are 68 missing  
patients values for uPA across studies).  
(3). Different methods of measurements 
 Look et al.14 report that the uPA was measured using either an Enzyme-linked immunosorbent 
assay (ELISA) kit, a Luminometric Immuno Assay (LIA) kit, or a protein assay kit. Of the 
ELISA kits, there were 3 different varieties used across studies; of the LIA kits, there were at 
least 2 different varieties; and of the protein assay kits, there were 3 varieties. Look et al.14 note 
that this causes heterogeneity in uPA values across studies, causing the median and range of 
uPA values to vary from study to study. This will undoubtedly be contributing to the 
unexplained heterogeneity in my illustrated meta-analyses. Look et al.14 try to overcome the 
problem by transforming uPA values in each study onto a rank score, but I do not consider this 
here as their approach has not been validated in a methodological paper yet, and the 
transformation  does not aid clinical interpretability.  
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(4). Model assumptions 
Another advantage of having IPD is the ability to check model assumptions. But the issue arises 
about what to do if model assumptions fail in some studies? I checked the assumption of 
proportional hazards for each of the 15 IPD studies separately, and found that in 14 out of 15 
studies the assumption holds for RFS and OS, with a P-value for uPA from schoenfeld residuals 
test 0.10> . This generally confirms that Cox proportional hazard assumption is a suitable 
model. One could do a sensitivity analysis including and excluding the ‘fail’ study, and this does 
not change conclusions here. I also checked the Cox proportional hazrd assumption for uPA 
transformed in a rank score, whick look et al14. used to overcome different methods of 
measurement, I found that the proportional hazard assumption does not hold in  3 and 4 studies 
for RFS and OS respectively, which indicates that the Cox proportional hazard model is not 
suitable in this case, and so further reasons are to why the rank trandformation appears 
inappropriate.  
(5). Availability bias and publication bias 
Another concern for the IPD approach is that the set of available IPD studies may be influenced 
by publication bias or availability bias, where the studies providing IPD are a biased set of all 
studies14 22. One way to assess such bias is by funnel plot which is a graphical tool for displaying 
the relationship between study effect size and its precision104.  If there is no bias, the assumption 
is that the graph  display a funnel shape with more variability around the average value across 
studies with low precision than across studies with high precision; asymmetry in the plot may 
indicate availability or publication bias, though it is known that given heterogeneity asymmetry 
may also occur naturally105. 
Figure 3.4 shows the funnel plot for the ln(HR) estimates for the univariate uPA in the 15 IPD 
studies. It can be seen from the graph that there does appear to be asymmetry with more studies 
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to the right of centre, than the left. Availability and publication bias may be causing this Egger's 
test of asymmetry to be  highly significant (P=0.002), see Egger et al106. Thus, if availability or 
publication bias is causing the asymmetry, then the PF result is likely to be biased in favour of 
uPA being prognostic here. This issues is investigated again in chapter 7. Of course, the 
asymmetry may also be due to other reasons, such as the heterogenity covered by different 
methods of measurement 
Figure 3.4: Funnel plot for assessment of availability bias in the 15 IPD 
studies in breast cancer, in relation to the meta-analysis of uPA for RFS 
 
 
3.4  Discussion 
 In this chapter I have produced some very simple examples to demonstrate the problem of the 
aggregate data approach to meta-analysis of PFs and the advantages and the challenges of the 
IPD approach, in the context of whether uPA is a PF in breast cancer. The works builds on the 
review in chapter 2, that showed IMPF articles are increasingly common but that there are many 
challenges therein. 
In Jones et al.99 the authors compared between IPD and aggregated data meta-analysis 
approaches for repeated measurments models. The authors reported for two problems for meta-
analysis of aggregated data: (i) the lack of the information about the correlation coefficients; (ii) 
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the effect of the missing data at the patent-level. This generally confirms my results here that 
there is a lack for the information of the aggregated data across studies.  In Lyman et al.57the 
authors investigate the strengths and limitations on aggregated data. The authors concluded that 
IPD approach has many advantages over aggregated data. However IPD approach still have 
some limitations such as the cost and the time required to collect these data. This is again 
compatible with my conclusion.  Also, in Stewart et al.107 the authors investigated whether there 
is a difference between aggregated data and IPD data results, by applying on randomised trials of 
cisplatin-based therapy in ovarian cancer; the authors stated that ‘The results of a meta-analysis 
of the literature alone may be misleading. Whenever possible, a meta-analysis of updated 
individual patient data should be done because this provides the least biased and most reliable 
means of addressing questions that have not been satisfactorily resolved by individual clinical 
trials’.  
 In Berlin et al.108 the authors compared between IPD and aggregated data approach by applying 
on 5 randomized trials; in particular, they investigate the benefits of anti-lymphocyte antibody 
induction therapy among renal transplant patients; they also considered the subgroup analysis to 
see whether the treatment might be more effective with a certain group of patients.  The authors 
stated that ‘Although patient-level analyses are not always feasible, for reasons of time and cost, 
we suggest that such analyses be used whenever subgroup analyses are deemed important.’ 
Further in Smith et al.59 the authors concluded that when IPD are available, it improve the 
potential to investigate and explain heterogeneity across studies, and also the clustering across 
studies can be undertaken by using hierarchical model..  These two articles are consistent with 
my findings that the IPD data is better than aggregated data if subgroup analyses are required.  
In Williamson et al.109 the authors stated that ‘Methods of estimating log(HR) and its variance 
and constructing graphical displays using aggregate data extracted from published survival 
curves can only be approximate and will often be constrained by the quality of such Figures. The 
limitations of using survival curves to estimate the log (HR) include survival curve inter-reader 
[105] 
 
variability and the need to make some assumption about censoring’. And the authors also stated 
that ‘A significant discrepancy would indicate that the aggregate data meta-analysis is 
unreliable and individual patient data are needed’. This again indicates that the results from 
aggregated data are often unreliable, and IPD meta-analysis approach is in favour over 
aggregated meta-analysis approach.  
In conclusion, IPD approach have many advantages over the aggregated data approach, however 
it still have some challenges and pitfalls (e.g. missing data, publication bias, nonlinear trend). 
Solving some of these problems forms the motivation for the remainder of this Ph.D thesis. In 
particular, in  the next two chapters I develop one-step and two-step methods of meta-analysis 
and undertake a simulation study to investigate and generalize which  model is the best. In 
addition, in chapter 6 I will examine the effect of nonlinear trends by using fractional polynomial 
models within one-step and two-step approaches. Then, in chapter 7 I will examine the extent  of 
publication bias in IMPF articles.  
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CHAPTER 4  
STATISTICAL MODELS FOR FIXED-EFFECT IPD 
META-ANALYSIS OF A SINGLE PROGNOSTIC 
FACTOR WITH A BINARY OUTCOME 
4.1 Introduction 
Chapter 2 identified many issues  for an IMPF; one such issue is how best to perform meta-
analysis, and which statistical method is best to use. In particular should the meta-analysis 
account for the clustering of patients within studies, and is a one-step or two-step method more 
appropriate? Recall that through  my reviewing of the 20  IMPF articles in chapter 2,  14 of the 
20 articles mentioned they accounted for the clustering of patients within studies in their 
analysis. Five used a 'one-step' method80 81 85 88 93 with study as a covariate, seven used a 'two-
step' method72 74 75 77 79 83 90, one used both 'one-step' and 'two-step' approaches89; and one 
accounted for clustering but it was not clear whether a 'one-step' or 'two-step' was used78. In 
addition, five other articles used a 'one-step' method but did not account for clustering of patients 
within studies, essentially treating the IPD as if it is from one study. Indeed, it is clear that the 
statistical  differences between one-step and two-step method is still unclear, as there is not a 
common used approach, and even accounting for clustering is not always considered important.  
In this chapter, I develop a range of possible IPD meta-analysis models for examining a single 
PF for a binary outcome. These include one-step and two-step approaches, and those that do or 
do not account for clustering. Other studies have shown that non-linear models that do not 
account for important covariates produce estimates that are attenuated towards the null110 111. The 
4 IPD studies of the TBI dataset that investigate whether there is an association between age as a 
PF and probability of death by 6 months (see Table 1-2) is used to illustrate the methods. Note 
that in this chapter I do not consider methods that account for heterogeneity in PF effect across 
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studies as there is no heterogeneity for the TBI dataset (see section 1.7.3).  However, extension 
of the model to include random-effects is briefly considered. 
4.2 Overview of  Possible Fixed-effect IPD Meta-analysis Models for a 
single PF and Binary Outcome  
Assume that there are 1=i  to n  independent IPD studies that each assesses the binary outcome 
of interest for 
 in   patients. Let iky   be the binary outcome (1=dead, 0=alive) of patient k  in 
study i
 
and let ikx   be a PF, which could be continuous or binary112.  Each IPD study thus 
provides iky  and  ikx   for the in  patients in the study.  
A range of different models are potentially available to meta-analysis such IPD (see Table 4.1).  
The difference in the model structure arises from using a one-step or two-step approach; 
accounting for unexplained residual variation due to the included factor; whether clustering of 
patients within studies are accounting for, and whether the correlation between ∝< and ;i< was 
utilised in meta-analysis. I will explain these models in details in the following sections. The 
models adapt those proposed by Riley et al.112 for modelling baseline risk; here the focus is not on 
the baseline risk itself but on the PF effect.  
4.3 Possible Two- step Models 
 In the 'two-step' approach, the IPD are first analysed separately in each study using an 
appropriate statistical method for the type of data being analysed45 113-117; for example, for a 
binary outcome a logistic regression model might be fitted. This produces aggregate data for 
each study, such as the PF effect estimate and its standard error; these are then synthesized in the 
second step using a suitable model for meta-analysis of aggregate data55 60, such as one 
weighting by the inverse of the variance whilst assuming fixed or random PF effects across 
studies, see chapter 1. The two-step approach naturally accounts for clustering of patients within 
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studies by analysing each study seperately. For our situation the possible two-step models are 
given below, assuming a fixed-effect across studies. 
4.3.1 Model 1: Fully Two-step Model (not applicable) 
 Model (1) is written as follows: 
																																				¿AMLB	LB-8:															|C¼AB()<>) =	∝<+ ;<J<>+ Á<>  
Á<>		~©(0, Â<p) 
                  															S-CK	LB-8:																										;i< = ; + -<                                                                           (4.1)                                              
								-<~©Ã0, ­NM	(;i<)Ä 
;i = ∑ ª<	;i<><?#∑ ª<><?#  
∝< is the log-odds of event in study i  for patients withJ<>	 = 0; ;< represents the change in log-
odds of the event for one unit increase in J<> . Also, J<> is the PF for the patient k  in study i . In 
the second step the pooled PF effect size, β  across IPD studies is estimated by assuming a fixed-
effect method as discussed previously. Note that ª<  is the relative weight for each study A [See 
section 1.6]. 
In the first step  the  PF effect size,	;<, (i.e. log-odds ratio) is estimated by using a logistic 
regression model in each study separately; |C¼AB	()<>) specifies a separate log-odds for each 
patient in each  IPD study, Note that Á<>  has variance 2iσ , where 2iσ  represents the variance 
in		|C¼AB()<>);  Á<> 	is the residual error around	|C¼AB	()<>) for patient D in study A;  this is akin to 
a linear regression, where you have residuals for each patient around the fitted line. However	ÁAD	 
is impossible to estimate here because Á<> 	measures the within-study variance for each patient k  
in each study i , and the event for each patient just occurs once, so it is impossible to estimate the 
residual variance for each patient ( as you do not know their	|C¼AB	()<>)  value) and so 2iσ  is not 
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identifiable; model 1 is thus not estimable. Note that model 1 is estimable if the outcome is 
continuous, and I did not consider that in my thesis, as the focus here is on binary outcome.  
4.3.2. Model 2: Standard Two-step Model 
Model 2 below is similar to model 1, except that in this model I assume that there is no residual 
variation, and thus remove the Á<> 	as follows:  
                               	¿AMLB	LB-8:															|C¼AB()<>) =	∝<+ ;<J<> 
                              		S-CK	LB-8:																	;i< = ; + -<                                                                                                  																																																																								-<~	©	Ã0, ­NM	(;i<)Ä                                                                       (4.2) 
                                                                     	;{ = ∑ 1	0{13145∑ 13145  
The parameters in model 2 are as defined as in model 1. This is now estimable. 
4.3.3  Model 3: Advanced Two-step Model 
However, it is possible for an intermediate model between model 1 and 2112. In model 3, I 
specify a distinct error term, Á<(w13) ,	for each set of patients with the same value of J<>  in each 
IPD study. This allows for unexplained variation due to the covariate J<>  to be accounted for. 
Residual variation due to other unmeasured covariates is not considered; for the reasons outlined 
in section 4.3.1.  Model 3 is written as follows:  
																																			¿AMLB	LB-8:															|C¼AB()<>) =	∝<+ ;<J<>+ Á<(w13) 
Á<(w13)~©(0,ÂAÃÅ13Ä2 	) 
                  															S-CK	LB-8:																								;i< = ; + -<                                                                            (4.3)                          
		-<~©Ã0, ­NM	(;i<)Ä, 
	;{ = ∑ ª<	;i<><?#∑ ª<><?#  
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The parameters here have the same interpretation as in model 1. Â<ÃJADÄp  relates specifically to the 
remaining unexplained within-study variation in study i  caused  by the PF; in other words, it is 
the variance due to ikx  in study i  that is not explained by the specification of iki xβ  in the 
model112. For example, if ikx  should be included as a quadratic term in truth, but only iki xβ  is 
included then there will be residual variation. However, the approach only works when ikx   is a 
continuous covariate, with multiple patients with exactly the same ikx value as in the TBI example 
(it may also be possible for the categorical variable when the number of categorize need to be 
large); otherwise the residual variation is impossible to estimate as discussed in section 4.3.1. 
Note that Á<(w13) 	 denotes the within-study error in study i  for patients with the same PF value as 
patient	D. 
4.3.4 Model 4: Bivariate Fixed-effect Two-step Model 
Models 1 to 3 did not account for the correlation between αˆ  and βˆ in the second step model, so 
the question is raised; is it necessary to account for the correlation between αˆ  and βˆ  in the 
two-step meta-analysis? In other words does the correlation between αˆ  and βˆ  effect on the 
estimated pooled value of βˆ  in the two-step meta-analysis? Bivariate fixed-effect meta-analysis 
model (BFMA) is used to consider within-study correlation118-122, but before I explain the BFMA 
model I applied logistic regression model to one primary study of TBI dataset to see whether 
there is correlation between βα ˆˆ and  within a single study. I found that there was a large 
negative correlation (-0.938) between αˆ  and βˆ  (when the estimated value of the PF increase, 
the intercept decrease).  Thus this correlation can be accounted for by performing a BFMA 
model. 
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BFMA is a statistical model that synthesis ∝<  and ;i< together accounting for their correlation; 
model 4 can be written mathematically as follows: 
         																¿AMLB	LB-8:															|C¼AB()<>) =	∝<+ ;<J<>  
                  
																									S-CK	LB-8:																 Æ∝<;i<Ç~	© FE<	; , ^<H, 
                                                   ^< =	ÈÉNM(∝<	)																CÉ(∝<, ;i<)			CÉÃ∝<, ;i<Ä																		ÉNMÃ;i<Ä						 Ê,  
                                                                  ∝< ~	©(∝, °Ëp) 
Where iδ  is the within-study covariance matrix. αˆ  and βˆ  are estimated by using restricted 
maximum likelihood method121 123. Now CÉ(∝<, ;i<) = −ÉNM(EA 	)	 if ikx  is binary (see Appendix 
B1 for the proof of this). In this situation if °Ëp = 0 then  ;i  and ÉNM(;i) from the bivariate meta-
analysis of model 4 are equivalent to;i , and ÉNM(;)x from a standard univariate meta-analysis (as 
in step 2 of model 2), see appendix B2 for proof. This is perhaps why traditional meta-analysis 
methods do not worry about within-study correlation as where effect size relates to a binary 
covariate (e.g. a treatment), it makes no difference if the baseline risk (∝<) are simillar. However 
if °Ëp 	≠ 0 then ;i  can differ if correlation is ignored (model 2) or accounted (model 4). This will 
be shown in section 4.5.  Note that compared to previous models, model 4 makes an additional 
assumption that the ∝< are normally distributed about a mean∝. Note also that if  ikx  is 
continuous, ;i  and ÉNM	(;)x can also differ between a BFMA utilising correlation and a univariate 
model. 
4.3.5  Model 5:Bivariate Fixed-effect Advanced Two-step Model 
Model 5 below is similar to model 4, except that in this model, we assume that there is also 
remaining residual variation due toJ<>. Model 5 is written as follows: 
              
(4.4) 
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																																¿AMLB	LB-8:															|C¼AB()<>) =	∝<+ ;<J<>+ Á<(w13	)   
-<(Å13)~©(0,ÂAÃÅ13Ä2 	) 
                  													S-CK	LB-8:																 Æ∝<;i<Ç~	© FE< 	; , ^<H, 
                                                   ^< =	ÈÉNM(∝<	)																CÉ(∝<, ;i<)			CÉÃ∝<, ;i<Ä																		ÉNMÃ;{ 	Ä						 Ê, 
                                                                          ∝< ~	©(∝, °Ëp) 
The parameters in model 5 are as defined as in model 3 and 4.  
4.4 One-step Models  
In the 'one-step' approach, the IPD from all studies are modeled simultaneously whilst potentially 
accounting for the clustering of patients within studies; this again requires a model specific to the 
type of data being synthesized, alongside appropriate specification of the meta-analysis 
assumptions60 66 69 94 100 124 125 (e.g. fixed or random-effects across studies), see chapter (1). I now 
consider possible one-step models for meta-analysis of the prognostic effect of a covariate ikx
 
from IPD studies under a fixed- effects assumption. 
4.4.1 Model 6: Ignoring the Clustering of Patients within-studies  
 Model (6) fits a logistic regression, by pooling all of the data together without considering the 
clustering of patients within-studies (considering all patients as if they came from one study).  
																																																|C¼AB()<>) =∝ +;J<>																																																																														(4.6) 
This model specifies a single value for the intercept term (log-odds of the event for a patient 
withJ<> = 	0) for all of the patients in all studies, and thus ignores the clustering of patients 
within-studies entirely (essentially assuming a constant baseline risk in each study); β  indicates 
the change in log-odds of the event for one-unit increase inJ<>, and again this is assumed the 
              
(4.5) 
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same (fixed) in each study. Note this model does not have a two step counterpart, as the two-step 
method naturally assumes a different ∝<		in each study. 
4.4.2 Model 7: Ignoring the Clustering of Patients within-studies and 
Accounting for any Remaining within-study Error across Patients with 
the Same PF Values 
Model 7 is similar to model 6 in that it ignores clustering of patients within-studies, but it also 
accounts for any remaining within-study error across patients with the same ikx  values, that is 
not explained by the inclusion of ikxβ  in the model; in this sense it is similar to the first step of 
model 3 
                                            |C¼AB()<>) =∝ +;J<> + Áw13                                                                               (4.7)                                                              
                                                    Áw13~©(0,ÂJAD2 	) 
The parameters here have the same interpretation as in model (6), except that Áw13denotes the 
within-study error in all IPD studies  for patients with the same J<> values; normally distributed 
about a common mean of zero and variance	Âw13p 	.  As for model 3, Âw13p 	relates specifically to the 
remaining within-study variation due to J<> that is not explained by the specification of ikxβ  in 
the model.  
4.4.3 Model 8: Accounting for the Clustering of Patients Within-studies 
by using Indicator Variables  
While models 6 and 7 ignore the clustering of patients within studies, model (8) accounts for the 
clustering of patients within studies  by including study indicators, that allow a separate intercept 
term for each study126. This model estimates the effect size of the PF across IPD studies as 
follows: 
                                      |C¼AB()<>) =∝<+ ;J<>                                                                      (4.8) 
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Where iα   is   the log-odds of event in study i  when  0=ikx  and  β  is the fixed PF effect size; 
it indicates the change in log-odds for a one-unit increase in ikx . 
4.4.4 Model 9: Accounting for the Clustering of Patients within-studies by 
using Indicator Variables and Accounting for any Remaining within-
study Error across Patients with the Same PF Values 
Model 9 is an amalgam of models 7 and 8.  Model 9 is similar to  model 8 in that it  accounts for 
the clustering of patients within studies by using study  indicator variables, and similar to model 
7 in that it accounts for any remaining within-study error across patients with the same ikx  values 
for each IPD study 
|C¼AB()<>) =∝<+ ;J<> + Á<(w13) 
Á<(w13	)~	©(0, Â<ÃÅ13Äp ) 
The parameters here have the same interpretation as in model (8), with additionally Á<(w13	)	giving 
the within-study error in each study i   for patients with the same J<> value. 
4.4.5 Model 10: Accounting for the Clustering of Patients within-studies 
by Placing a Random-effects on the Intercept term (Different Intercepts 
in each Study) 
Model 10 is similar to model 8 in that it accounts for the clustering of patients within studies, but 
it achieves this differently. Whereas model 7 estimates a separate intercept for each study, model 
10 places a random-effects on the intercept term to allow it to vary across studies according to a 
normal distribution with mean ÌË and variance ÂËp 
                                                  |C¼AB()<>) =∝<+ ;J<>                                                          (4.10) 
                                                    			∝< ~	©(∝, °Ëp)                                         
     (4.9) 
[115] 
 
The parameters here have the same interpretation as in model 8. However, by assuming 
normality of the intercept value across studies, it makes a stronger assumption than Model 8 
which does not impose a normal distribution relationship for the ∝<.      
4.4.6. Model 11: Accounting for the Clustering of Patients within Studies 
by Placing a Random-effect on the Intercept Term and Accounting for 
any Remaining Within-study Error across Patients with the Same PF 
Values 
The final model, Model (11), is an extension of Model (10) to allow for residual variation across 
patients with the same value of ikx , similar to model 3, 5 and 9.  
                                                      |C¼AB()<>) =∝<+ ;J<> + ÁA(JAD) 																																																				(4.11) 
Á<(w13)~	©(0, ÂAÃJADÄ2 ) 
			∝< ~	©(∝, °Ëp)                                         
The parameters here have the same interpretation as in model 9, and Â<ÃÅ13Äp  are the remaining 
residual variation caused by ikx  that is not accounted for by the inclusion of ikxβ  in the model. 
For simplicity here, the covariance between Á<(w13) 	and 		∝< is assumed zero, but this can be 
relaxed if necessary. 
4.5 Summary of all of the possible IPD models by using two-step and 
one-step approach 
All of the possible models that explained in section 4.3 and 4.3 are summarized in Table 4.1. 
Again, the difference in the model structure arises from using a one-step or two-step approach; 
accounting for unexplained residual variation due to the included variable, whether the clustering 
of patients across studies are accounting for, and whether between ∝< and ;i< was utilized in 
meta-analysis. 
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Table 4.1: Summary of all of the possible IPD models by using two-step and one-step approach 
 
Model 
No. 
One-step or 
Two-step 
method 
Account for clustering  of patients 
within studies (if yes, how) 
Account for 
remaining 
residual 
variation due to 
the included 
PF? 
Accounting for 
correlation 
between ∝Íand {Í in the meta-
analysis? 
1 Two-step Yes -by using two-step method Yes ‘fully’ and 
n    not applicable 
No 
2 Two-step Yes -by using two-step method No No 
3 Two-step Yes -by using two-step method Yes ‘partial’ No 
4 Two-step Yes -by using two-step method No Yes 
5 Two-step Yes -by using two-step method Yes ‘partial’ Yes 
6 One-step No No Yes 
7 One-step No Yes ‘partial’ Yes 
8 One-step Yes-by using indicator variables of the 
studies 
No Yes 
9 One-step Yes-by using indicator variables of the 
studies 
Yes ‘partial’ Yes 
10 One-step Yes-by placing a random intercept term 
(different intercept in each study) 
No Yes 
11 One-step Yes-by placing a random intercept term 
(different intercept in each study) 
Yes ‘partial’ Yes 
 
4.5 Methods of Estimation 
Note here that all one-step models naturally account for correlation between ∝< and ; terms as 
they are estimated together. Model 2 and 4 (in two-step approach) and model 6, 8 and 10 (in one 
step approach) can be fitted classically by using maximum likelihood estimation. In contrast, 
model 3, 5 (two-step) and model 7, 9, 11 (one-step) are mixed models contain both fixed and 
random effects; the fixed effects are analogues to standard logistic regression coefficients and 
they can estimated directly by using maximum likelihood estimation. The random effects are not 
directly estimated but are summarized according to their estimated variances and covariances. 
The distribution of the random effects is assumed to be Gaussian, and an adaptive quadrative 
method is used to estimate the random effects for the model; this was undertaken by using the 
xtmelogit  procedure in STATA127 128.  
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4.6 Application to the TBI Data 
4.6.1 Application for Continuous PF 
I now apply models 2 to 11 to the TBI dataset to examine if age, ikx , is a continuous PF for risk 
of six month mortality. Table 4.2 gives the results and I now discuss this. 
Heterogeneity 
Recall as in Chapter 1.7.3 there is no heterogeneity across studies as	¹p = 0% in this dataset, 
thus the fixed-effect approach is appropriate here. Though the aforementioned models can be 
extended to allow for heterogeneity for in the PF effect, this can be considered as future work 
(see chapter 8). 
Two-step Models 
Odds Ratio 
As can be seen in Table 4.2, there is barely any difference in the pooled odds ratio estimate 
between models 2 to 5; as the pooled odds ratio is from 1.38 for the 4 models. All of the two-step 
models produce p-values <0.01, which indicate that there is a significant association between age 
and mortality rate (i.e. age is a PF). 
Standard Error and Confidence Interval for βˆ   
There is barely any difference for the confidence interval and standard error of βˆ  between 
models 2 to 5; however, the standard errors for models 3 and 5 are the highest standard errors122, 
as these models account for the residual variance for the same value(s) of the PF in each study. 
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Table 4. 2: Meta- analysis results from possible IPD meta-analysis models to the TBI data when age is continuous. 
Model  
type 
Model 
number 
Accounting 
for 
clustering 
Accounting for 
residual 
variation due 
to 	ÎÍÏ 
Accounting 
for 
correlation 
Odds ratio  95%  confidence 
interval for Odds 
ratio 
Ln (odds ratio) 
and s.e. 
95%  
confidence 
interval for Ln 
Odds ratio 
Within study 
variance 
2
iσ  
P-value for  
pooled 
effect-size, 
βˆ  
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       Model 2  
 
Yes No No 1.38 1.29- 1.45 0.32 (0.030) 
 
0.26   - 0.37 -------------- 
 
 
 
<0.01 
Model 3 
 
Yes Yes No 1.38 1.29-1.46 0.32(0.031) 
 
0.26-0.38 Study1= 6.30e-11    
Study 2= 0.026 
Study3= 0.008 
Study4=0.003 
<0.01 
Model 4 Yes No Yes 1.38 1.29-1.46 0.32 (0.030) 0.26-0.38 ---- <0.01 
Model 5 Yes Yes Yes 1.38 1.29-1.46 0.32 ( 0 .031) 0.26 - 0 .38 ---- <0.01 
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 Model 6 No No Yes 1.41 1.33-1.49 0.34(0.029) 0.29 - 0.40 ---- <0.01 
Model 7 No Yes Yes 1.42 1.33-1.51 0.35(0.032) 0.29-0 .41 0.013 <0.01 
Model 8 
 
Yes No Yes 1.37 1.30-1.45 0.32(0.029) 0.26 -0 .37 ----------- <0.01 
Model 9 Yes Yes Yes 1.38 1.29-1.46 
 
0.32 (0.031 ) 0.26- 0.38 Study1=  2.32 e-09   
Study2=0 .042 
Study3= 8.44e-13 
Study4= 0.001 
<0.01 
Model 10 Yes No Yes 1.38 1.29-1.46 0.32(0.030) 0.26- .38 0.196 <0.01 
Model 11 Yes Yes Yes 1.39 1.31-1.48 0.33(0.031) 0.27- 0 .39 Study1=  .003   
Study2= .049 
Study3= .011 
Study4= 3.56e-09 
<0.01 
N.B. all of results in this Table have been estimated by using  STATA software, and the stata modules to fit the two-step models are logit , xtmelogit and metan;  for 
one- step models, the models are  logit and  xtmelogit 
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, Model 4 and 5  are estimated by SAS, and the code was written by Richard Riley, for more details see 
Appendix C 
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One-step Models 
Odds Ratio 
As can be seen in Table 4.2, there is very little difference for the odds ratio between models 6 to 
11. The pooled effect size is slightly higher in models 6 and 7 which ignoring clustering of 
patients within studies, with odds ratio increasing from 1.37 to 1.41 and 1.42 respectively. All of 
the one-step models produce p-vaue <0.01, which indicate that there is a significant association 
between age and mortality rate, i.e. age is a PF. 
Standard Error and Confidence Interval for βˆ   
There is very little difference for the confidence interval and standard error between models 6 to 
11; however the standard error for model 7, 9 and 11 are slightly higher, as this model account 
for the residual variance for the same value(s) of the PF in each study.  
Two-step versus One-step Models 
Odds Ratio 
There is very little difference for the odds ratio between models 2 to 11 and thus little difference 
between two-step and one-step; however one-step models 6, and 7 increase the pooled log odds 
ratio slightly from 0.32 to 0.34 and 0.35; which equates to an increase of the odds ratio from 1.38 
to 1.41 and 1.42 respectively. This is due to model 6 and 7 ignoring the clustering of patients 
within studies. Also, it is clear that age is a PF as all of the one-step and two-step models yielded 
P-value < 0.01, and the confidence interval of the PF (e.g. age) for all models do not include one.  
This indicates that all of the one-step and two-step models have the same conclusion whether the 
meta-analysis models account for the correlation between parameters, taking into account the 
clustering of the patients across studies or consider the residual variation for the same values of 
the PF (e.g. age). 
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Standard Error and Confidence Interval for βˆ   
There is very little difference for the confidence interval, and standard error for the pooled log 
odds ratio between models 2 to 11; the smallest standard errors seem to occur when clustering is 
ignored (model 6), do not account for the residual variation and account for correlation between 
E< and ;i< (model 8). Also, the standard error for models 3, 7, 9, and 11 are slightly higher as 
these models account for the residual variance for the same value(s) of the PF in each study. 
However, one-step and two-step are giving very similar and often identical answers.  
To sum up, there are only minor differences between the results of one-step and two-step models 
for this data, as all of the estimated values of pooled effect size and its standard error are 
approximately the same.  It is difficult to decide the best model at this stage. Clearly, this is just 
one dataset, so a simulation study is needed to confirm these results (see chapter 5). Indeed, 
given that ignoring clustering and ignoring residual variation leads to lower standard errors, it is 
important that in other datasets this does not actually lead to overly-precise conclusions. 
4.6.2 Application for Binary  PF 
For illustration, I now consider how models 2 to 11 perform when the factor of interest is binary. 
Table 4.3 gives the results of the IPD meta-analysis models when age,	J<>, is made binary 
(i.e.	N¼-	 = 	1	AÐ	N¼- ≥ 	40	NK	N¼- = 0	AÐ	N¼-	 < 40). Note that the residual variation for the 
same values of the PF in each study can only be estimated when the PF is continuous, so these 
models (model 3, 5, 7, 9 and 11) are excluded. Thus, the focus is only on whether the IPD meta-
analyses models account for the clustering of patients across studies and whether they account 
for the correlation between parameters ∝ and  ;i . Note that the dichotomisation of age is merely 
for illustrative purpose. 
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Two–step Models 
Odds Ratio 
There is no difference in the pooled odds ratio estimate between models 2 and 4 as the pooled odds ratio 
is the same (2.45). Both models produce P-value <0.01, this again showed   that age is still a PF. 
Standard Error and Confidence Interval for {  
There are barely any differences in the standard error and confidence interval between model 2 
and 4. 
One-step Models 
 Odds Ratio 
Again, there is only slight difference for the odds ratio between models (Table 4.4). The odds 
ratio is slightly higher in model 6; this may be because it ignores the clustering of patients across 
studies. 
 Standard Error and Confidence Interval for { 
There is very little difference in the confidence interval and standard error between models. 
However the standard error for model 6 is slightly smaller potentially, due to the lack of 
clustering. 
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Table 4. 3: Meta-analysis results from two-step and one-step meta-analysis to the TBI data; 
when age is binary (1 if age >= 40, 0 if age < 40). 
Model 
type 
Model 
number 
Accounting 
for 
clustering 
Accounting 
for residual 
variation 
Accounting 
for 
correlation 
Odds 
ratio  
95%  
confidence 
interval for 
Odds ratio 
Ln 
(odds 
ratio) 
and s.e 
95%  
confidence 
interval for 
Ln Odds ratio 
P-value 
for  
pooled 
effect-
size, βˆ  
T
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s  
 
Model   2  
 
Yes No No 2.45 2.05 to 2.94 0.90 
(0.092) 
 
0.72 to 1.08 <0.01 
Model 4 Yes No Yes 2.45 2.05 to 2.94 0.90 
(0.091) 
0.72 to 1.08 <0.01 
O
n
e
-s
te
p
 
m
e
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-
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n
a
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s  
Model 6 No No Yes 2.59 2.18 to 3.10 0.95 
(0.090) 
0.78 to 1.13 <0.01 
Model 8 
 
Yes No Yes 2.46 2.05 to 2.95 0.90 
(0.091) 
0.72 to 1.08 <0.01 
Model 10 Yes No Yes 2.48 2.08 to 2.95 0.91 
(0.091) 
0.73 to 1.08 <0.01 
N.B. all of results in this Table have been estimated by using  STATA software, and the stata modules to fit the 
two-step models are logit, xtmelogit and metan;  for one- step models, the models are  logit and  
xtmelogit 
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Two-step versus One-step Models 
Odds Ratio 
There is a little difference between the odds ratio estimate for the five models; however, it is 
slightly higher in model 6 which ignores the clustering across studies. 
Standard Error and Confidence Interval for { 
There is barely difference of the standard error and confidence interval among the 5 models. 
However, the standard error of model 6 is slightly smaller (0.090), this again potentially due to 
the lack of clustering (Table 4.3). 
 To sum up, whether the PF is continuous or binary in this case, generally, there is barely 
difference between the results for one-step and two-step models. So it is difficult to decide which 
approach is the best (one-step or two-step); and whether ignoring clustering or residual model 
variation really matters. I undertake a simulation study to investigate and examine some of these 
models in the next chapter.  
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Heterogeneity in ∝ 
Now, I assess the heterogeneity for alpha to examine whether there is a substantial variation of 
patients across studies for the TBI dataset. I found that there is no heterogeneity across studies 
for the baseline of the disease (∝) as Ip = 0%  (see Figure 4.1). This might be the reason that 
there is no substantial difference between IPD meta-analysis models when they account for the 
clustering of patients across studies and when they ignore it (as there is no substantial variation 
across studies).  
Figure  4.1: The forest plot for the baseline of the disease (∝), in each IPD study 
for the TBI dataset 
 
4.7 Discussion and Limitation 
In this chapter I have proposed statistical models for meta-analysis binary outcome data in the 
presence of the one PF (age) for four IPD studies of TBI dataset. In particular, I show all 
possible two-step and one-step fixed-effect models for IPD studies that ignore or account for the 
clustering across studies and the residual variance for the patients who have the same value of 
the PF. In addition, I showed theoretically (see Appendix B) that correlation between parameters 
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(i.e. the intercept and the pooled effect size of PF ‘age’) does not effect on the pooled effect size 
of the binary PF when °Ë	p = 0. However, the correlation may effect on the pooled effect size of 
the PF when	°Ëp ≠ 0, whether the PF is binary or continuous (see end of chapter 5).  Application 
was made to 4 IPD studies of TBI examining the effect of age on six month mortality risk of 
death. The results show it is difficult to decide which model is the best at this stage because the 
results of pooled estimate of the PF, its standard error and confidence interval are all similar for 
most of the IPD models; for that reason, in chapter (5) a simulation study is made to decide 
which models are most accurate.  
In Riley et al.112 the authors developed IPD meta-analysis models for a binary outcome; in 
particular, they focused on the event-risk across studies and they considered residual variation. 
However, their focus was mainly on the event-risk across studies not on the effect size of the PF 
as undertaken in this chapter. In Goldstein et al.129 the authors focused on the one-step meta-
analysis by using multilevel models to consider the clustering across studies. However, they did 
not consider the two-step meta-analysis approach or even investigate whether there is difference 
in the results by following this approach. 
In Turner et al.66 the authors used multilevel model meta-analysis for a binary outcome, and they 
considered fixed and random effects. The authors stated that “we explore the potential of 
multilevel models for meta-analysis of trials with binary outcomes for both summary data, such 
as log-odds ratios, and individual patient data. Conventional fixed effects and random effects 
models are put into a multilevel model framework, which provides maximum likelihood or 
restricted maximum likelihood estimation”. They also stated that “If random trial effects are 
used the covariance between these and the random treatment effects should be included; the 
resulting model is equivalent to a bivariate approach to meta-analysis”. However, again the 
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authors did not consider the two-step approach and whether there is a difference between one-
step approach by using multilevel models and two-step approach, and which one is the best. 
In Mathew et al.130 the authors compared between one-step and two-step approaches. They found 
that both models are coincide, if they assumed the model with fixed treatment and fixed trial 
effects.  
There are a few limitations in this chapter, one of these limitations is that the IPD meta-analysis 
models are fitted and developed for one variable, and I used fixed-effect method to estimate the 
pooled effect size of the PF (as there is no heterogeneity across studies in TBI dataset). However, 
this work should be extended in other datasets later by considering random-effects for the pooled 
effect size of the PF and multivariable analyses. Also, Cox proportional hazard model may be 
considered if the outcome is time until the event occurs, rather than logistic regression. 
To sum up, by applying the 10 IPD meta-analysis models for TBI dataset, it yielded that there is 
no difference between one-step and two-step method. In particular, the IPD meta-analysis 
models yielded the same results whether they account for the clustering of patients within studies 
naturally in two-step models, or by including an indicator variable in one-step models. Also there 
is no difference between the results for IPD meta-analysis models if they account for the 
correlation between parameters naturally in one-step models, or by forcing the model to account 
for by using BFMA model in two-step models, or even if by including the residual variation for 
the same value of the PF that allows for unexplained variation due to the covariate,	J<> ,  to be 
accounted for.  The similar results that yielded from the 10 IPD meta-analysis models could be 
because there is a little variation across studies, as there is no heterogeneity across TBI studies 
for∝. In other datasets with more variation in ∝< , my findings may change.  Thus, a simulation 
study is undertaken in chapter 5 to examine whether there is generally a difference between one-
step and two-step approach, and I aim to find an approach to recommend. 
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CHAPTER 5 
A SIMULATION STUDY TO ASSESS WHETHER 
THE CLUSTERING OF PATIENTS WITHIN 
STUDIES CAN BE IGNORED IN IPD META-
ANALYSIS OF A SINGLE PROGNOSTIC FACTOR  
5.1 Introduction 
Clustered data arise frequently in medical research (e.g. clustering of patients within different 
hospitals, or different general practices, or even individual doctors themselves). In an IMPF, the 
IPD are synthesised from different studies with potentially different study design, study 
populations and study locations. Thus, there is clustering of patients within studies, and this 
hierarchical structure may represent an important source of variation. The question thus arises; 
‘what is the impact of ignoring the clustering of patients within studies?’  Hogan et al,131 states 
that ‘Ignoring important sources of variation in any analysis can lead to incorrect confidence 
intervals and P values’. However in chapter 2 I found that 6 of the 20 IMPF studies did not state 
whether they adjusted for clustering. Further in chapter 4 I analysed the TBI data and showed 
that conclusions and estimates were barely affected by whether clustering was accounted for or 
not. Although this was a single example shows that accounting for clustering may not always be 
necessary- but should this be the general advice? 
In this chapter I perform a simulation study to assess three of the IPD meta-analysis logistic 
regression models that I introduced in chapter 4, in order to formally assess whether the 
clustering within studies can be ignored. These models are the two-step approach model 2, that 
accounts for the clustering of patients within studies by applying two-step; the one-step approach 
that ignores the clustering of patients within studies (model 6); and the one-step approach that 
accounts for the clustering of patients within studies by using indicator variable (model 8). I 
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undertake my simulation for a single binary PF, and then a single continuous PF. The simulation 
also allows a more formal comparison of the one-step versus two-step framework. Not that, for 
simplicity and limited time I will not consider the models that account either for the residual 
variations for the PF, or the correlation between parameters across studies.  
5.2 Simulation for a Binary PF 
In this section I describe in detail the simulation procedure used to generate IPD from multiple 
studies to fit the meta-analysis models to the data, and to evaluate their performance. Initially, 
just a binary PF is considered, and a binary outcome (e.g. death). I want to emphasise here that 
all the simulations I perform in this thesis generate data at the patient-level. Further, the initiative 
STATA code for these simulations was written by Boliang Guo according to my specifications 
and design.  
5.2.1 The Simulation Procedure  
The procedure used in my simulation can be broken down in 7 steps as follows: 
Step 1: The number of studies in the meta-analyses is chosen as 5 and 10 respectively. Note that 
the number of studies was fixed in a simulation. 
Step 2: randomly sample the number of patients in each study from a uniform 
distribution	~	¶(N, Ò);  N = 30, Ò = 100	 for small sample size and N = 30 and	Ò = 1000 for 
large sample size, N	and Ò were fixed per simulation. 
Step 3:  For each patient in each trial, randomly sample a PF value using for a binary PF using a 
Bernoulli distribution, where  J<>	~	Ó-MMC¯||A(8M-É-|N-). The prevalence was 0.5 or 0.2. 
For a continuous PF a normal distribution is used to generate the data, where J<>	~	©(Ì, Âp) 
whereÌ = 4	NK	Â = 1.5.  Note that A refers to the number of studies, and D refers to the number 
of patient. 
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Step 4: Sample the binary outcome (Ô<>	ªℎ-M-	Ô<> = 1	ÐCM	K-NK	NK	Ô<> = 0		ÐCM	N|AÉ-	) for 
each patient according to a specified relationship between the outcome and the PF. Where Ô<> 
~Ó-MC¯||A	()<>),		log F Õ13#(Õ13H =	∝<+ ;	J<>, ∝< ~	©(∝, ÂËp),	where ; is the chosen PF effect 
(log odds ratio) and  ∝< could vary across the	A	studies according to a chosen ©(∝, ÂËp) 
distribution.	
Step 5: Fit each of the three different meta-analyses models to the data generated as follows: 
Model 2 (Two-step method) recall in chapter 4 - in the first step,  ;i<  is estimated for each IPD 
study separately and the pooled effect size is then estimated by using fixed-effect meta-analyses 
of the ;i<obtained: 
¿AMLB	LB-8:															|C¼AB()<>) =	∝<+ ;<J<> 
                                       S-CK	LB-8:													 ;i< = ; + -<                                                                                         
																																																																																			-<~	©	Ã0, ­NM	(;i<)Ä 
																							;i = ∑ ª<	;i<><?#∑ ª<><?#  
 Where	ª< = #Ö1¬, refers to the relative weight for each study A. 
Model 6  (One-step method ignoring clustering)  in this model the pooled value for ;i  is 
estimated by pooling all of the IPD data together without considering the clustering of patients 
within studies and the model is given as  
|C¼AB()<>) =∝ +;J<>			 
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Model 8 (One-step method accounting for clustering ) in this model the pooled value for ;i  is 
estimated in one step by accounting for the clustering of patients within studies by including 
study indicators, that allow a separate intercept term for each study, and the model is given as  
|C¼AB()<>) =∝<+ ;J<> 
Step 6: Repeat steps 1 to 5 a thousand times, keeping the chosen range of sample sizes, number 
of studies and parameter values as before in each step. This resulted in 1000 β values and 1000 
standard error of β values for each model. 
Step 7: Repeat step 1 to 6 for a different set of simulation criteria; that is choose again the 
number of studies, sample size distribution, x×Ø distribution and values, and the true α×, β, and	σÛp  
values in steps one to four, then fit the models to the generated data, and repeat 1000 times. 
For a binary PF, Table 5.1 shows the different permutations I chose according to different 
α×, β, σÛp   and prevelance of J<> = 1 values. Note that true ∝  here means the average log odds of 
the event (e.g. death) when the PF is zero, I chose this value according to the TBI data; ; means 
the true pooled effect size of the PF and again I chose the value of this parameter equals 0.90 
according to the TBI data then consider other situations by assuming ; = 0		CM		0.10, relating to 
no prognostic effect and small effect respectively. Also I chose ∝= −1.27  again according the 
TBI dataset and I allow different standard deviations (SD) for ∝ (i.e. SD=0 such that baseline 
risk is the same across studies; and ‘SD= 0.25 or 1.5’ which assumes a small and slightly larger 
baseline risk respectively). Note that when SD=1.5 of the baseline risk ∝, 95% range for the 
baseline |C¼	 F G#(GH across studies is between (-1.27±  2×1.5), and the rearranging gives a 95% 
range for the baseline probability from  0.014 and 0.849. So, there is a substantial variation for 
the baseline risk ∝ across studies. The standard deviation for ∝ here indicates clinically that the 
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variation in baseline risk, ∝ across studies might come from other factors such as the treatments 
being used in study, its location, measurement techniques etc.  
Table  5.1: The possible values considered for ∝ , standard deviation of ∝ , 	and prevalence of 
the binary PF in the simulation scenarios. 
Scenario no. True ∝ Standard deviation  for  ∝ True  
Prevalence of 
the true PF 
1 -1.27 0 0.90 0.5 
2 -1.27 0 0.10 0.5 
3 -1.27 0 0.00 0.5 
4 -1.27 0.25 0.90 0.5 
5 -1.27 0.25 0.10 0.5 
6 -1.27 0.25 0.00 0.5 
7 -1.27 0 0.90 0.2 
8 -1.27 0 0.10 0.2 
9 -1.27 0 0.00 0.2 
10 -1.27 0.25 0.90 0.2 
11 -1.27 0.25 0.10 0.2 
12 -1.27 0.25 0.00 0.2 
13 -1.27 1.5 0.90 0.2 
14 -1.27 1.5 0.10 0.2 
15 -1.27 1.5 0.00 0.2 
16 -1.27 1.5 0.90 0.5 
17 -1.27 1.5 0.10 0.5 
18 -1.27 1.5 0.00 0.5 
 
Each scenario was considered for 5 or 10 studies, and 30 to 100 (for small sample size) or 30 to 
1000 (for large sample size) patients.   
5.2.2 Evaluating the Performance of Statistical Models 
For each simulated scenario, 1000 ;i	 and their standard error were available for each model. The 
assessment of the three models was examined in terms of different criteria such as bias, mean 
square error (MSE), and coverage for all parameters estimates and their standard errors for all 
scenarios.  
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Assessment of Bias 
Bias is the deviation of the average of the pooled effect size estimates from the true value (;i̅– ;); 
the smaller the bias, the better the estimation method and on unbiased method would have zero 
bias132-134.  Percentage bias is another statistic to summarise bias; it is given as70{(00 9 ∗ 100.  
Larger percentage bias  indicates a worse estimation and if the percentage bias is greater than 
10% , this indicates that the bias is meaningful134. Note that with 95% confidence interval and 
1000 simulations studies, it yielded a small difference between the true bias and the estimated 
bias by using the following equation 
^ = (Ý#(ÃË pÞ Ä		Â)pÓ  
Where B is the number of simulation studies, Ý#((∝ pÞ )  is the  1 − ∝ 2Þ  quantile of the standard 
normal distribution, Âp   is the variance of the pooled effect size of the PF, and ^  is the specified 
level of accuracy of the pooled effect size of the PF (i.e. the accepted difference between the true 
values  ; ).  
Assessment of Accuracy 
Mean square error (MSE)135 is used to assess the overall accuracy of the statistical model and it 
is given as 
ßSo = (;i̅ − ;)p + (So(;i))p 
Where (;i̅ − ;)p refers to bias of the difference between the average pooled estimate,	;i̅, and the 
true pooled effect size,	;, for the 1000 estimates and (So(;i))p refers to the mean standard error 
of ;i  in one-step and two step meta-analyses. It is considered as a useful method for the 
assessment of estimation accuracy as it includes both of the bias and the variability. 
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Assessment of Coverage 
Burton et al.132 state that ‘The coverage of a confidence interval is the proportion of times that 
the obtained confidence interval contains the true specified parameter value’. The nominal 
coverage rate in this chapter is 95%, and a good estimation method will give an observed 
coverage in the simulation the same as the nominal coverage rate. If the observed coverage rate 
is above the nominal average rate, then the estimation method is too conservative, this means 
that too few samples will find significant results when the true effect is non-zero (i.e. the factor is 
prognostic);  thus this leads to a loss of the statistical power. If the coverage rate is lower than 
the nominal coverage rate; this leads to over-confidence and too many samples then will yield 
significant results when the true effect is zero (i.e. the factor is not prognostic); this leads to 
increased type I error and is anti-conservative. To check whether the coverage is suitable in the 
1000 simulations in each scenario, I expected coverage percentage should lie between  8	 ±
		1.96	L. -	(8) where	L. -	(8) = à8(1 − 8) 1000⁄ , and 8 = 0.95 assuming that the true coverage 
is 95%. The L. -(8) in my simulations equals 0.006892, so the observed coverage should lie 
between 0.936 and 0.964.  If the estimated coverage lies outside this interval, this indicates a 
problem. 
5.3 Simulation Results for the Binary PF 
In this section I describe the simulation results  when  J<> is a binary PF in relation to the three IPD meta-
analysis models for all of the 18 scenarios ( Table 5.1) given studies with a small sample size (30 to 100)  
or  large sample size (30 to 1000) , for a meta-anlysis of 5 studies or 10 studies or the prevelance of the 
PF is either 0.5 and 0.2.  
5.3.1 Simulation Results for Small Sample Size (30 to 100) and n=5 
Table 5.2 gives the simulation results for the three models when the prevalence=0.5 and standard 
deviation of ∝ =0 and 0.25 respectively for the first 6 scenarios (1 to 6).  For all of these 6 
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scenarios, all models give a bias almost zero, and the percentage bias is almost 6%. MSE and the 
mean of the standard error for the three models is approximately the same, and their coverage is 
always close to 95%. 
I changed the prevalence of  J<> to be 0.2 and repeated the above simulations; the results are 
shown in Table 5.3 (scenarios 7 to 12). In the first three scenarios (7, 8, and 9), the bias and 
percentage bias was again small for all models, and the MSE was approximately the same; 
however, the two-step models gave the highest percentage bias and in scenario 9 its coverage 
was slightly too large (and does not fall between 0.936 and 0.964), whilst the other models had 
coverage closer to 95%.  In the other three scenarios (10, 11 and 12) with standard deviation 
of	∝= 0.25; the bias is still small for both one-step models (0.03 or less), although their 
percentage bias is slightly above 10 % in scenario 11 where the true pooled value is 0.1. More 
concerning, the bias and percentage biases are large for two-step method. For example, in 
scenario 11 there is an upward bias of 0.11 and a percentage bias of 109%. 
Finally, I changed the standard deviation of ∝ to be 1.5 and repeated the simulation when the 
prevalence is 0.2 and 0.5 respectively. The results shows that in scenario 13 (where		; = 0.9) , 
model 6 (ignoring clustering) has a large downward bias of –0.21 with a percentage bias of -
23.5% and a low coverage of 87.6% (which does not fall between 0.936 and 0.964), reflecting a 
small mean standard error. Its percentage bias is similar in scenario 14. Clearly, when the 
standard error of ∝ is large, the one-step ignoring clustering (and thus assuming a fixed ∝ across 
studies) is inappropriate. The two-step method (in scenarios 13 to 15) continues to have a 
coverage somewhat greater than 95%, and in scenario 14 its upward bias is upward large again. 
In contrast the one-step accounting for clustering is approximately unbiased, and has suitable 
coverage. Also, when the prevalence is 0.5 (in scenarios 16 to 18), the two-step method yield no 
bias however it is still has a coverage somewhat greater than 95% because the estimated 
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confidence interval again falls between 0.936 and 0.964. The one-step method ignoring 
clustering still yields inaccurate results (downward bias and low coverage), see Table 5.4. 
Figure 5.1 shows the  pooled effect size of the PF and its standard error for the 1000 observations 
for the two-step model, one-step model accounting for the clustering and one-step model ignores 
the clustering of patients across studies, when the SD (∝) = 0.25	NK	1.5, and the true ; = 0.1 
and 0.9 respectively, for scenario 11 and 13 in Table 5.4. In particular, Figure 5.1a gives the 
scatter plot for the pooled effect size of the two-step model versus one-step accounting for the 
clustering for 1000 observations, when the SD (∝) = 0.25	, and the true ; = 0.1.  The estimated 
pooled effects size of the PF from two-step model generally lies above the line of equality, which 
reflect that the pooled effect size of PF in the two-step model is somewhat overestimated (large 
bias) compared to one-step model accounts for clustering.  Also, Figure 5.1b shows the standard 
errors for the same models, again the estimated values of the standard error in two-step model 
are generally slight above the line of equality. This again indicates that the standard error is 
slightly higher in two-step model compared to one-step model, if there is variation in the 
baseline risk (∝). 
Figure 5.1c gives the scatter plot for the pooled effect size of the one-step model  ignores the 
clustering versus one-step model accounts for the clustering for 1000 observations, when the SD 
(∝)=1.5	, and the true ;	 = 	0.9.  The estimated pooled effects size of the PF from one-step 
ignores clustering model lie below the line of equality, which reflect that the pooled effect size of 
PF in one-step ignoring clustering model is somewhat underestimated (downward bias) 
compared to one-step model accounts for clustering.  Also, Figure 5.1d shows the standard errors 
for the same models, again the estimated values of the standard errors in one-step ignores 
clustering model are slightly under the line of equality. This again indicates that the standard 
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error is slightly smaller in one-step ignores clustering model compared to one-step accounts for 
clustering model, if the variation for the baseline risk ∝= 1.5. 
Figure 5.1: The scatter plots for the pooled effect size and its standard error for two-step models, 
one-step model that accounts for clustering and the one-step model that ignore the clustering, in 
scenario 11 and 13 in Table 5.4 
Figure 5.1a: The scatter plot for the pooled effect-size 
of the two-step versus one-step model accounts for 
clustering, for scenario 11 with n=5, SD (∝) =
0.25,; = 0.1 and the sample size between 30 to 100 
for 1000 simulation  study. 
 
Figure 5.1c: The scatter plot for the pooled effect-
size of the one-step accounts for clustering versus 
one-step model ignore clustering, for scenario 13 
with n=5, SD (∝) = 1.5,; = 0.9, and the sample 
size between 30 to 100, for 1000 simulation study. 
 
Figure 5.1b: The scatter plot for the standard error for 
the two-step versus one-step model accounts for 
clustering, for scenario 11 with n=5, SD (∝) =
0.25,; = 0.1 and the sample size between 30 to 100 
for 1000 simulation study. 
 
Figure 5.1d: The scatter plot for the standard error 
for the one-step accounts for clustering versus one-
step model ignore clustering, for scenario 13 with 
n=5, SD(∝) = 1.5, ; = 0.9, and the sample size 
between 30 to 100, for 1000 simulation study. 
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Table 5. 2: Simulation results for the pooled effect size,{, for three models of IPD meta-analysis, two-step, one-step ignoring clustering and 
one-step including indicator variable, with prevalence =0.5and the sample size with-in each study is between 30 to 100 observations, with the 
number of studies n=5 and 1000 simulations, the true values of the pooled effect size,, is shown in the table; the standard error for ∝ is 0 and 
0.25. 
Scenarios No. of 
studies(
n) 
Model Meta-analysis 
model 
∝ 
(SD of ∝) 
 
prevalence  Mean  
of {  
 
Bias percentage 
bias* 
 
MSE of 
 
Percentage 
coverage 
Mean 
s.e. of 
{  
1 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.9 
0.9 
0.9 
0.91 
0.91 
0.92 
0.01 
0.01 
0.02 
0.99 
1.25 
1.83 
0.03 
0.03 
0.03 
94.90 
94.90 
94.70 
0.17 
0.16 
0.16 
2 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.10 
0.10 
0.10 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
2.67 
2.37 
3.36 
0.00 
0.00 
0.00 
95.60 
95.60 
95.60 
0.16 
0.16 
0.16 
3 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0 
0 
0 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
NA 
NA 
NA 
 
0.02 
0.02 
0.02 
95.00 
94.90 
94.90 
 
0.16 
0.16 
0.16 
4 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0.9 
0.9 
0.9 
0.90 
0.90 
0.91 
0.00 
0.00 
0.01 
 
0.35 
0.00 
1.58 
0.03 
0.03 
0.03 
95.80 
95.20 
95.30 
 
0.17 
0.17 
0.18 
5 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0.10 
0.10 
0.10 
0.09 
0.09 
0.10 
-0.01 
-0.01 
0.00 
-5.61 
-5.80 
-3.58 
0.04 
0.04 
0.04 
95.10 
94.60 
94.80 
 
0.19 
0.18 
0.19 
6 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0 
0 
0 
0.01 
0.01 
0.01 
0.01 
0.01 
0.01 
NA 
NA 
NA 
0.04 
0.04 
0.04 
95.50 
94.70 
94.50 
0.19 
0.19 
0.19 
*Note that all the results are shown to two decimal places but the calculations such as bias, percentage bias, ... etc are based on full results (more 
than two decimal places). Hint: in the first two rows are different even though the bias are identical for the decimal places/
[137] 
 
Table 5. 3: Simulation results for the pooled effect size,	{,, for three models of IPD meta-analyses (two-step, one-step ignoring clustering and 
one-step including indicator variable, with prevalence =0.2 and the sample size with-in each study is between 30 to 100 observations, with the 
number of studies n=5 and 1000 simulations, the true values of the pooled effect size,, is shown in the table; the standard error for ∝ is 0 and 
0.25. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(SD of ∝) 
 
Prevalence 
 
True 		 Mean  of {  
 
Bias percentage 
bias* 
 
MSE 
of  Percentage coverage Mean s.e. of {  
7 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2  
  0.9 
  0.9 
  0.9 
0.83 
0.90 
0.91 
-0.07 
0.00 
0.01 
-8.13 
0.02 
1.13 
0.10 
0.10 
0.10 
95.80 
94.90 
94.70 
0.32 
0.31 
0.31 
8 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2 
  0.10 
  0.10 
  0.10 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
-4.25 
-1.71 
0.40 
0.08 
0.08 
0.09 
96.40 
95.30 
95.40 
0.29 
0.28 
0.29 
9 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2 
   0 
   0 
   0 
0.01 
0.01 
0.01 
0.01 
0.01 
0.01 
  NA 
  NA 
  NA 
 
0.07 
0.08 
0.08 
97.00 
95.80 
95.80 
0.30 
0.28 
0.29 
10 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
  0.9 
  0.9 
  0.9 
0.94 
0.90 
0.92 
0.04 
0.00 
0.02 
 4.50 
-0.43 
 2.06 
0.09 
0.09 
0.10 
96.60 
95.10 
95.40 
0.32 
0.30 
0.31 
11 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
  0.1 
  0.1 
  0.1 
0.21 
0.08 
0.09 
0.11 
-0.02 
-0.01 
 109.64 
-16.18 
-14.91 
0.12 
0.12 
0.12 
95.60 
95.50 
94.90 
0.36 
0.34 
0.35 
12 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
   0 
   0 
   0 
0.11 
-0.03 
-0.03 
0.11 
-0.03 
-0.03 
  NA 
  NA 
  NA 
 
0.13 
0.12 
0.13 
95.20 
95.20 
95.10 
0.37 
0.35 
0.35 
* Note that all the results are shown to two decimal places but the calculations such as bias, percentage bias, ... etc are based on full results (more 
than two decimal places). 
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Table 5.4: Simulation results for the pooled effect size,	; ,  for three models of IPD meta-analyses (two-step, one-step ignoring clustering and 
one-step including indicator variable), with prevalence =0.2  and  0.5 and the sample size with-in each study is between 30 to 100 observations, 
with the number of studies n=5 and 1000 simulations, the standard error for ∝ is 1.5. 
Scenarios No. of 
studies 
(n) 
Model Meta-analysis 
model 
∝ 
(SD of ∝) 
 
Prevalence 
 
True 		 Mean  of 	{  
 
Bias percentage 
bias* 
 
MSE of  Percentage coverage Mean s.e. of {  
13 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2  
  0.9 
  0.9 
  0.9 
0.91 
0.69 
0.92 
0.01 
-0.21 
0.02 
  0.87 
-23.50 
  2.05 
0.13 
0.15 
0.14 
96.20 
87.60 
94.80 
0.38 
0.31 
0.36 
14 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2 
  0.1 
  0.1 
  0.1 
0.20 
0.07 
0.10 
0.10 
-0.03 
0.00 
  98.37 
-27.36 
-3.99 
0.16 
0.12 
0.17 
95.80 
95.70 
94.20 
0.41 
0.33 
0.38 
15 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2 
   0 
   0 
   0 
0.09 
-0.02 
0.00 
0.09 
-0.02 
0.00 
     NA 
     NA 
     NA 
 
0.28 
0.22 
0.26 
96.89 
94.00 
94.00 
0.41 
0.33 
0.38 
16 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
  0.9 
  0.9 
  0.9 
0.89 
0.70 
0.90 
0.01 
-0.20 
0.00 
 -1.11 
-22.22 
   0.00 
0.01 
0.04 
0.05 
95.40 
46.20 
94.90 
0.11 
0.09 
0.11 
17 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
  0.1 
  0.1 
  0.1 
0.10 
0.08 
0.10 
0.00 
-0.02 
0.00 
   0.00 
 -20.00 
   0.00 
0.01 
0.04 
0.05 
95.00 
93.90 
94.80 
0.11 
0.09 
0.11 
18 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
   0 
   0 
   0 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
    NA 
    NA 
    NA 
0.01 
0.04 
0.05 
95.10 
94.90 
94.70 
0.11 
0.09 
0..11 
* Note that all the results are shown to two decimal places but the calculations such as bias, percentage bias, ... etc are based on full results (more than two 
decimal places). 
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5.3.2 Simulation Results for Large Sample Size (30 to 1000) and  n=5 
Table 5.6 to 5.8 gives simulation results when the sample size is from 30 to 1000, for 
scenarios 1 to 18. The results are similar to the simulation results for small sample size (30 to 
100) as just discussed. In particular, model 8 (one-step accounting for clustering) performs 
consistently well with little bias and adequate coverage as it nearly always falls between 0.936 
and 0.964. However, in Table 5.7 model 6 (one-step ignoring clustering) again has a low 
coverage when ;  is large (55.8%), which does not fall between 0.936 and 0.964, and a 
significant downward bias of -0.2 (scenario 13). Further, the two-step model performs better 
here than when the sample size was 30 to 100. Indeed, there is very little bias anymore and the 
coverage is adequate except in scenario 8 for two-step and one-step methods as the estimated 
confidence interval does not fall between 0.936 and 0.964. Thus, the two-step and one-step 
accounting for clustering methods appear very similar here. 
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Table 5. 5 Simulation results for the pooled effect size,	{, for the three modelsof IPD meta-analysis,( two-step, one-step ignoring clustering and 
one-step including indicator varable), with prevelance= 0.50 and the sample size with-in each study is between 30 to 1000 observations, with the 
number of studies n=5 and 1000 simulation, the true values of the pooled effect size, , is shown on the table, the standard error for ∝ is 0 and 
0.25 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(SD of ∝) 
 
prevalence  Mean  
of {  
 
Bias percentage 
bias* 
 
MSE of  Percentage coverage Mean s.e. of {  
1 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.9 
0.9 
0.9 
0.90 
0.90 
0.90 
0.00 
0.00 
0.00 
-0.36 
-0.32 
-0.14 
0.01 
0.01 
0.01 
95.10 
95.20 
95.40 
0.09 
0.09 
0.09 
2 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.10 
0.10 
0.10 
0.1 
0.1 
0.1 
-0.01 
-0.01 
-0.01 
-6.87 
-6.74 
-6.69 
0.01 
0.01 
0.01 
94.00 
94.00 
94.00 
 
0.08 
0.08 
0.08 
3 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0 
0 
0 
0 
0 
0 
0.00 
0.00 
0.00 
NA 
NA 
NA 
 
0.01 
0.01 
0.01 
94.90 
94.90 
94.90 
0.08 
0.08 
0.08 
4 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0.9 
0.9 
0.9 
0.90 
0.89 
0.90 
0.00 
-0.01 
0.00 
0.05 
-0.67 
0.38 
0.01 
0.01 
0.01 
95.20 
94.50 
95.00 
0.09 
0.09 
0.09 
5 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0.10 
0.10 
0.10 
0.1 
0.1 
0.1 
0.00 
0.00 
0.00 
 
-1.84 
-1.86 
-1.38 
0.01 
0.01 
0.01 
 
95.10 
95.00 
95.00 
0.10 
0.10 
0.10 
6 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0 
0 
0 
-0.01 
-0.01 
-0.01 
-0.01 
-0.01 
-0.01 
NA 
NA 
NA 
 
0.01 
0.01 
0.01 
 
95.60 
96.00 
95.60 
0.10 
0.10 
0.10 
* Note that all the results are shown to two decimal places but the calculations such as bias, percentage bias, ... etc are based on full results (more than two 
decimal places). 
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Table 5. 6 Simulation results for the pooled effect size,	;i , for three models of IPD meta-analyses (two-step, one-step ignoring clustering and 
one-step including indicator variable), with prevalence=0.2 and the sample size with-in each study is between 30 to 1000 observations, with the 
number of studies n=5 and 1000 simulations, the true values of the pooled effect size,;, is shown in the table; the standard error for ∝ is 0 and 
0.25. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(SD of ∝) 
 
Prevalence 
 
True 		 Mean  of {  
 
Bias percentage 
bias* 
 
MSE 
of  Percentage coverage Mean s.e. of {  
7 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2  
0.9 
0.9 
0.9 
0.90 
0.90 
0.90 
0.00 
0.00 
0.00 
 -0.46 
  0.21 
  0.39 
0.01 
0.01 
0.01 
95.80 
95.70 
95.90 
0.11 
0.11 
0.11 
8 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2 
 0.1 
 0.1 
 0.1 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
  2.14 
  2.71 
  2.84 
0.01 
0.01 
0.01 
96.80 
96.60 
96.70 
0.10 
0.10 
0.10 
9 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2 
0 
0 
0 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
   NA 
   NA 
   NA 
 
0.01 
0.01 
0.01 
94.80 
94.60 
94.60 
0.10 
0.10 
0.10 
10 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0.9 
0.9 
0.9 
0.90 
0.89 
0.90 
0.00 
0.01 
0.00 
0.35 
-0.91 
0.16 
 
0.01 
0.01 
0.01 
96.00 
95.60 
95.80 
0.11 
0.11 
0.11 
11 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0.1 
0.1 
0.1 
0.11 
0.10 
0.10 
0.01 
0.00 
0.00 
  5.65 
 -5.13 
 -4.32 
0.02 
0.02 
0.02 
94.40 
94.80 
94.50 
0.12 
0.12 
0.12 
10 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0 
0 
0 
0.01 
0.00 
0.00 
0.01 
0.00 
0.00 
   NA 
   NA 
   NA 
 
0.02 
0.02 
0.02 
94.80 
95.40 
94.80 
0.12 
0.12 
0.12 
* Note that all the results are shown to two decimal places but the calculations such as bias, percentage bias, ... etc are based on full results (more than two 
decimal places). 
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Table 5. 7: Simulation results for the pooled effect size,	; ,  for three models of IPD meta-analyses (two-step, one-step ignoring clustering and 
one-step including indicator variable), with prevalence =0.2 and the sample size with-in each study is between 30 to 1000 observations, with 
the number of studies n=5 and 1000 simulations, the standard error for ∝ is 1.5. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(SD of ∝) 
 
Prevalence 
 
True 		 Mean  of 	{  
 
Bias percentage 
bias* 
 
MSE of  Percentage coverage Mean s.e. of {  
13 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2  
0.9 
0.9 
0.9 
0.90 
0.70 
0.90 
0.00 
-0.20 
0.00 
-0.43 
-22.19 
-0.38 
0.02 
0.07 
0.02 
95.50 
55.80 
95.30 
0.13 
0.11 
0.13 
14 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2 
0.1 
0.1 
0.1 
0.10 
0.07 
0.10 
0.00 
-0.03 
-0.01 
2.98 
-28.96 
-8.08 
0.02 
0.02 
0.02 
95.20 
94.30 
94.90 
 
0.14 
0.12 
0.14 
15 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2 
0 
0 
0 
0.01 
0.00 
0.00 
0.01 
0.00 
0.00 
NA 
NA 
NA 
 
0.02 
0.02 
0.02 
95.70 
95.20 
95.80 
0.14 
0.12 
0.14 
16 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5  
0.9 
0.9 
0.9 
0.86 
0.67 
0.91 
-0.04 
-0.23 
0.01 
-4.44 
-25.56 
1.11 
0.09 
0.13 
0.10 
96.00 
82.80 
95.00 
0.31 
0.25 
0.30 
17 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
0.1 
0.1 
0.1 
0.10 
0.07 
0.10 
0.00 
-0.03 
0.00 
0.00 
-30.00 
0.00 
0.09 
0.07 
0.10 
96.40 
94.80 
94.70 
0.31 
0.26 
0.30 
18 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
0 
0 
0 
-0.01 
 0.00 
-0.01 
-0.01 
 0.00 
-0.01 
NA 
NA 
NA 
 
0.09 
0.07 
0.10 
96.5 
95.7 
95.2 
0.22 
0.18 
0.21 
* Note that all the results are shown to two decimal places but the calculations such as bias, percentage bias, 
... etc are based on full results (more than two decimal places).
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5.3.3 Simulation Results for n=10 Studies 
I repeated scenarios 1 to 18 for n=10 studies, and considered 30 to 100 and 30 to 1000 sample size . The 
results are shown in Appendix D. Conclusions are generally the same as before. The one-step accounting 
for clustering performs consistently well, with little bias and coverage close to 95%. The two-step is  
comparable to this method, and the upward  bias previously seen in the n=5 simulations for scenario 11, 
and for 30 to 100 patients is almost gone. However, the one-step ignoring clustering continues to perform 
poorly when standard deviation of ∝	 is large, with downward bias in the PF effect and too low coverage 
and too small standard error when  ; = 0.9.  
5.4 Simulation Results for a Continuous PF 
I repeated step 1 to 7 of the simulation procedure described in section 5.2.1, but now for a 
continuous PF sampled for each patient from a normal distribution	©~	(Ì, Âp	). I assumed 
that	Ì = 4, and standard error =1.5, this is similar to the values that I found in TBI data when 
looking at the distribution of age per 10 years. 
Six different scenarios were considered as shown in Table 5.8. ;  now relates to the effect of a 
one-unit increase on the log-odds of death, and is specifying a true linear trend between J<> 
and	log F Õ13#(Õ13H. The scenario used ∝= −2.10,	 and	; = 	0.3, which is again similar to the 
estimated values from the TBI data, and also a small value of	;, say of 0.1 and no effect of 0. 
The standard error of ∝ was either small (0.2) or large (1.5). The scenarios were considered 
for 5 and 10 studies, and 30 to 100 or 30 to 1000   patients. 
Table 5. 8 The possible scenarios of ∝ and   for the continuous PF 
Scenario no. True ∝ SD for  ∝ True  
1 -2.10 0.2 0.3 
2 -2.10 0.2 0.1 
3 -2.10 0.2 0 
4 -2.10 1.5 0.3 
5 -2.10 1.5 0.1 
6 -2.10 1.5 0 
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5.4.1 Simulation Results for the Number of Studies n=5.  
Simulation Results for Small Sample Size (30 to 100) 
Table 5.9 gives the simulation results for scenario 1 to 6 for each of model 2, 6 and 8, for n=5 
studies and 30 to 100 patients per study. For the first three scenarios, when the standard error 
of	∝	= 0.20, there is a little difference among the three models. In particular, all models give 
little bias and a percentage bias less than 10 %. MSE is approximately the same in all models 
and the coverage is approximately the same, generally slightly over 95%. For scenarios 4 and 
5 when standard deviation of	∝= 1.5, there is a downward bias for model 6 (ignoring 
clustering) and the percentage bias is greater than 10%.  The coverage is much lower than 95% 
in model 6 when ; is large (scenario 5). In scenarios 5 and 6 the coverage is too large for the 
two-step model (greater than 97%), whilst the one-step accounting for clustering (model 8) 
performs best with little bias and suitable coverage.  
Simulation Results for Large Sample Size (30 to 1000) 
Table 5.10 gives the simulation results for scenarios 1 to 6, for n=5 studies and now a sample 
size of 30 to 1000. The findings are as above, but the two-step now performs adequately in all 
scenarios; i.e. the coverage is much closer to 95% (as it falls between 0.936 and 0.964), even 
in scenario 4 to 6. The one-step accounting for clustering is consistently good again, but the 
one-step ignoring clustering still performs poorly in scenarios 4 and 5 (i.e. when the standard 
deviation of ∝ is large and there is a true PF effects > 0). 
5.4.2 Simulation Results for the Number of Studies n=10 
The simulation results for n=10 studies are shown in Appendix D. The results are the same as 
discussed for n=5, whether the sample size for each IPD study lies between 30 to 100 or 30 to 
1000. In particular, the one-step accounting for clustering is consistently a good model, whilst 
in some situations the two-step and one-step ignoring clustering perform poorly.
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Table 5. 9: Simulation results for the pooled effect size,{, for three models of IPD meta-analysis, (two-step, one-step ignoring clustering and 
one-step including indicator variable), mean age is 4 with standard deviation 1.5 and the sample size with-in each study is between 30 to 100 
observations, with the number of studies n=5 and 1000 simulations, the true values of the pooled effect size,, is shown in the table; the 
standard error for ∝ is 0.2 and 1.5. 
 
Scenarios No. of 
studies(n) 
Model Meta-analysis model ∝ 
(s. e. of ∝) 
 
 Mean  of 
{  
 
Bias percentage 
bias* 
 
MSE of  Percentage 
coverage 
Mean 
s.e. of 
{  
1 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.30 
0.30 
0.30 
0.30 
0.30 
0.31 
0.00 
0.00 
0.01 
-0.44 
1.41 
3.57 
 
0.01 
0.01 
0.01 
96.85 
96.29 
96.36 
0.09 
0.09 
0.09 
2 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.10 
0.10 
0.10 
0.09 
0.09 
0.10 
-0.01 
-0.01 
0.00 
-8.24 
-5.95 
-3.67 
0.01 
0.01 
0.01 
97.57 
96.58 
96.58 
0.11 
0.11 
0.11 
3 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0 
0 
0 
0  
0 
0 
0 
0 
0 
NA 
NA 
NA 
0.01 
0.02 
0.02 
96.10 
95.10 
94.90 
0.13 
0.12 
0.12 
4 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.30 
0.30 
0.30 
0.30 
0.23 
0.31 
0.00 
-0.07 
0.01 
-0.95 
-22.13 
3.53 
0.01 
0.01 
0.01 
95.40 
84.10 
94.80 
0.10 
0.09 
0.10 
5 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.10 
0.10 
0.10 
0.10 
0.08 
0.10 
0.00 
-0.02 
0.01 
0.35 
-15.53 
5.45 
0.01 
0.01 
0.01 
97.70 
95.30 
96.10 
0.11 
0.10 
0.11 
6 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0 
0 
0 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
NA 
NA 
NA 
0.01 
0.01 
0.02 
97.00 
95.40 
95.60 
0.12 
0.11 
0.12 
* Note that all the results are shown to two decimal places but the calculations such as bias, percentage bias, ... etc are based on full results (more than two 
decimal places). 
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Table 5. 10: Simulation results for the pooled effect size,{, for three models of IPD meta-analysis, (two-step, one-step ignoring clustering and 
one-step including indicator variable), mean age is 4 with standard deviation 1.5 and the sample size with-in each study is between 30 to 1000 
observations, with the number of studies n=5 and 1000 simulations, the true values of the pooled effect size,, is shown in the table; the 
standard error for ∝ is 0.2 and 1.5. 
Scenarios No. of 
studies(n) 
Model Meta-analysis model ∝ 
(s. e. of ∝) 
 
 Mean  of 
{  
 
Bias percentage 
bias* 
 
MSE of  Percentage 
coverage 
Mean 
s.e. of 
{  
1 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.30 
0.30 
0.30 
0.30 
0.30 
0.30 
0.00 
0.00 
0.00 
-0.08 
-0.39 
0.41 
0.00 
0.00 
0.00 
96.57 
96.36 
96.36 
0.03 
0.03 
0.03 
2 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.10 
0.10 
0.10 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
1.68 
1.72 
2.26 
0.00 
0.00 
0.00 
95.59 
95.68 
95.41 
0.04 
0.04 
0.04 
3 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.00 
0.00 
0.00 
0.04 
0.04 
0.04 
0.04 
0.04 
0.04 
NA 
NA 
NA 
0.04 
0.04 
0.04 
94.90 
95.30 
94.80 
0.04 
0.04 
0.04 
4 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.30 
0.30 
0.30 
0.30 
0.24 
0.30 
0.00 
-0.06 
0.00 
0.22 
-21.64 
0.74 
0.00 
0.01 
0.00 
95.40 
48.00 
95.30 
0.04 
0.03 
0.04 
5 5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.10 
0.10 
0.10 
0.10 
0.08 
0.10 
0.00 
-0.02 
0.00 
-1.09 
-19.03 
-0.60 
0.00 
0.00 
0.00 
95.70 
88.90 
95.50 
0.04 
0.04 
0.04 
6 
 
5 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
NA 
NA 
NA 
0.00 
0.00 
0.00 
95.80 
94.90 
95.60 
0.04 
0.04 
0.04 
* Note that all the results are shown to two decimal places but the calculations such as bias, percentage bias, ... etc are based on full results (more than two 
decimal places). 
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5.5 The Impact of the Prevelance across Studies 
In this simulation study, I did not examine the impact of the prevalence; that is the simulation 
design assumed the same prevalence of the PF in each study, and so relaxing this assumption 
may also effect on the models performance.  
Altman et al.136 states if there is variation in the prevalence across studies, then ignoring the 
clustering of patients across studies (and assuming the data as it came from one study) give 
an incorrect answer. They also stated that “compared to standard meta-analysis, the treat-as-
one-trial method gives greater weight to large trials and will tend to give narrower 
confidence interval”.  
To briefly look at how changes in prevalence in the PF across studies are creating differences 
in the models, I now present three datasets from my simulations where there are reasonable 
differences in the three model results. For dataset 3 (Table 5.11), the one-step ignoring 
clustering gets a smaller standard error and smaller effect size, as seen in the simulations. 
However the prevalence in each study is very similar, thus this shows that there can be 
differences in the model results even when the prevalence is the same in each study, the 
reason being that  ∝< can still vary considerably which causes differences in model results. 
Similarly in dataset 2, the prevalence is similar but the standard error of ;i  is much smaller in 
the one-step ignoring clustering. 
In future work I will consider the additional impact of varying the prevalence on the IPD 
meta-analysis models. This may even increase the bias in the one-step model that ignores the 
clustering of patients across studies. In dataset 1, the prevalence are more different across 
studies, but the ∝< are also different, so it is difficult to tell if the prevalence is having an 
effect or not. 
 
[148] 
 
Table 5.11: Testing the impact of the prevalence on the pooled effect size of the PF. 
 Meta-analysis models ;i  (s.e) Study Event/total Prevalence ∝< 
IPD  
Dataset 1 
Two-step 0.56 (0.21)    1 52/254 0.20 -1.25 
One-step accounting for clustering 0.54(0.20)    2 57/354 0.16 -1.16 
One-step ignoring clustering 0.49(0.19)    3 19/113 0.17 -4.53 
     4 56/306 0.18 -2.68 
     5 12/44 0.27 -2.71 
IPD  
Dataset 2 
Two-step 0.02(0.15)    1 102/575 0.18   2.93 
One-step accounting for clustering -0.02(0.15)    2 141/755 0.19 -1.74 
One-step ignoring clustering -0.12(0.10)    3 122/598 0.20 -1.94 
     4 100/477 0.21 -2.16 
     5 206/999 0.21 -3.51 
IPD Two-step 0.13(0.17)    1 91/433 0.21 -.564 
Dataset 3 One-step accounting for clustering 0.16(0.16)    2 26/122 0.21 -1.54 
 One-step ignoring clustering 0.03(0.09)    3 89/426 0.21 2.94 
      4 168/883 0.19 2.61 
      5 184/925 0.20 -2.98 
5.6 The Impact of the Correlation between ∝ and 	Across Studies 
Recall in chapter 4, I assessed whether the correlation between ∝ and ; in IPD meta-analysis 
models will effect on the pooled effect size of the PF, by using the BFMA models. I showed 
mathematically and by empirical example that the correlation between ∝ and ; has no impact 
on the pooled effect size of the PF, under a certain conditions: (i) the outcome and the PF are 
binary data; (ii)   CÉÃ∝<, ;i<Ä = 	−ÉNM(∝<); (iii) and there is no heterogeneity across 
studies(°Ëp = 0).   But, this arise a question; if there is heterogeneity across studies(°Ëp ≠ 0), 
does the correlation between  ∝ and ; effect on the pooled effect size of the PF? To briefly 
look at this, I select one dataset from my simulation (dataset3, Table 5.11) to investigate. This 
dataset has a substantial variation for	∝ ′L, with	¹∝p = 99.5%. I found the results from the 
BFMA model are exactly the same as two-step model (Table 5.11), that ignores the 
correlation. This indicates that there is still no impact for the correlation between ∝ and		;, 
even when there is heterogeneity across studies. But this is just one example. In the future 
work, I will undertake a simulation study to examine the impact of the correlation between ∝ 
and ; on the IPD meta-analysis model results more fully. 
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5.7 Limitation of My Work  
This simulation study has limitations; firstly I only considered one variable (binary or 
continuous), i.e. a univariate model and I did not consider if there is a variation of the 
prevalence across studies, as discussed. Also, I specified a linearity assumption for the 
continuous variable. I focused on two-step approach (model 2) and one-step approach (model 
6 and 8). Other models are available such as those described in Chapter 4, such as a bivariate 
model in the second stage of the two-stage method, and the models accounting for residual 
variation. Also, I specified no heterogeneity on the PF effect across studies, as in TBI data. 
But often heterogeneity will exist. Further simulations are required to see if my findings hold 
in situations with heterogeneity, and to evaluate the performance of the other models in 
Chapter 4, and to examine the impact of any variation of the prevalence across studies. Also, 
as in any simulation study, other parameter values could have been chosen.  I based mine on 
the TBI dataset, but other values for the number of studies, E, ;, prevalence, sample size etc 
are possible and may (or may not) reveal further findings. Also I have considered a binary 
outcome and fitted logistic regression models, the findings may (or may not) change if 
survival model were considered. 
5.8 Discussion 
In this chapter I have undertaken a simulation study to investigate the impact of ignoring the 
clustering of patients within studies and to compare one-step versus two-step models in IPD 
meta-analysis of PFs. I have undertaken the simulation study for small (30 to 100) and large 
(30 to 1000) sample size respectively, and for 5 or 10 studies in the meta-analysis of either a 
binary or a continuous PF with a binary outcome. 
For many of the scenarios I assessed, the two-step approach, the one-step approach 
accounting for clustering, and even the one-step ignoring clustering give unbiased pooled 
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effect size estimates of the PF, and suitable coverage around 95%. However, the one-step 
ignoring clustering generates downward biased pooled effect size estimates of the PF when 
the standard deviation of ∝ is large (1.5), with a poor coverage less that 95% due to standard 
errors that are too small. When the number of studies in the meta-analysis was small (5), and 
the number of patients was small, the simulation results also show the two-step approach 
gives upward bias in some scenarios for the binary PF analysis, and gave coverage too large 
(>95%), due to large standard errors. However, the one-step model that accounts for 
clustering   performed well in all scenarios considered.  
Also, I selected three datasets from my simulation for the binary PF with reasonable 
difference in the three model results; to examine the impact of the prevalence and the 
correlation between parameters across studies.  I found that when prevalence was similar, 
large differences can still exist due to the variability in∝. Variability in the prevalence may 
increase model differences, but this is for further work.  
Based on my results, I conclude that ignoring the clustering of patients within studies is not to 
be generally recommended, as it can cause too low a coverage and too small standard error 
(i.e. it is anti-conservative). My findings are echoed in non-meta-analysis settings too, and so 
this is my recommended model choice for IMPF projects. Peters et al.137 undertook a 
comparison of methods for analysing cluster randomized trials, the authors concludes that 
ignoring the clustering for standard logistic regression model was highly anti-conservative.  
Bland138 concludes that ‘The effects of clustering can be large, inflating Type I errors’, which 
is exactly the same as my findings here. Clark .139 the author stated that ‘standard errors are 
biased downwards when using single-level models even when there are as few as two 
observations per group on average’. Hogan et al.131 stated that ‘Ignoring important sources 
of variation in any analysis can lead to incorrect confidence intervals and P values’. Also, 
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Hetdker et al. 140 stated that ‘traditional regression models can lead to biased estimates of 
uncertainty and different conclusions’ when clustering is ignored. 
The results of one-step accounting for clustering and two-step approach are often very 
similar, only in a few situations with a binary PF did the two-step methods perform worst.   
This may be because the two-step model did not account for the correlation between 
parameters (∝< and	;<) in the second step.   Jones et al.99 stated that ‘Ignoring correlation can 
lead to different pooled estimates of the treatment difference and their standard errors’. 
Mathew et al.130 stated that ‘We therefore re-iterate that our result is a theoretical result 
giving a complete description of the linear models under which the one-step and two-step 
IPD meta-analysis estimators coincide, assuming that the covariance matrices are known’ 
which suggest further that one-step and two-step meta-analysis approach may be coincide if 
we account for the correlation between parameters in the two-step, as then the whole 
covariance matrix of estimates is used (future work). Another key problem could be that the 
;i<  estimates are assumed normally distributed in the second step, which may not be 
appropriate in situations where the sample size is small and the odds ratio is large. Other 
methods for dealing with pooling odds ratios may also overcome this issue as the one-step 
does141 142. 
Given this and that in more complex scenarios multiple PFs may be of interest in the same 
model, it seems sensible that the one-step method is the general choice for an IMPF. In 
chapter 6, I now consider application to the TBI data again and investigate non-linear trend in 
a PF effect. 
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CHAPTER 6 
POSSIBLE IPD META-ANALYSIS MODELS OF 
CONTINUOUS PROGNOSTIC FACTORS BY 
USING FRACTIONAL POLYNOMIAL 
6.1 Introduction 
There are many issues for the analysis of continuous PFs, and a key one arises when the 
assumption of linearity is found to be untenable. Through my reviewing for the 20 IMPF 
articles ( see chapter 2), only 6 articles considered a non-linear trend of the continuous PF; in 
particular, 4 of them used spline functions75 77 76 78 and the other 2 used polynomial terms72 80.  
Though polynomial models are easy to fit, they may fit the data badly and give misleading 
inferences143 144. Fractional polynomials (FP) are a more flexible set of parametric models 
that can overcome the problems of polynomial models145-147.   
In this chapter, I develop meta-analysis models when the research interest is an estimate of 
the pooled effect of a continuous PF across studies, with potential non-linearity. In particular, 
the focus is on considering the possible two-step and one-step models for synthesising IPD 
studies that account for the clustering of patients across studies, whilst using first and second 
order FP terms within a logistic regression model. The TBI dataset again is used as an 
illustration to compare between one-step and two-step meta-analysis.  
6.2 Fractional Polynomial Modelling on a Single Study 
Regression models based on FP functions of a continuous covariate are described by Royston 
and Altman143.  A FP function can be applied in various regression models such as simple 
and multivariable linear regression, logistic regression, and Cox proportional hazard models. 
In this chapter the focus is on using FP function within the context of IPD meta-analysis of a 
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PF, using logistic regression. Let us first consider how to apply FP in a single study using 
logistic regression.  
 
The general m-degree FP function of a logistic regression model for a continuous variable, J 
(e.g. age), is given by 
														|C¼AB()) = ;\ + ;#		J(G5) + ;p	J(G¬) +⋯… . . +;ã		J(Gä)																								(6.1) 
 Where 8#	,8p	,……8ã,  denote fractional powers,  refers to the degree of the FP model, (the 
focus here is on   ≤ 2 only),J > 0, and the round bracket notation denotes the Box- 
Tidwell transformation as follows: 
                                                  J(G) = åJG																		AÐ	8 ≠ 0log(J) 										AÐ	8 = 0æ 
At first glance, it seems that FP model is similar to the family of conventional polynomial 
models; however it is more flexible as the powers,	8,	 can be a non-integer values and the best 
fitted powers are to be determined.  The powers,	8, are chosen from a restricted set, S. 
Royston et al.148 suggested S = ç−2,−1,−0.5	, 0, 0.5	, 1, 2, 3è, where J\ denotes	log	(J); 
the set includes many possible transformations such as square root (8 = 0.5), reciprocal 
(8 = −1), logarithmic square transformations	(8 = 0) and include no transformation (i.e. 
linear trend) when  8 = 1.  
In this chapter, the focus is on a two degree  FP function (	 ≤ 2), as Royston et al.148 stated 
that “we have found that models with degree higher than 2 are rarely required in 
multivariable analysis. Fractional polynomials with		 ≤ 2	offer many potential 
improvements in fit compared with conventional polynomials of the same degree”. Also they 
stated that “experience gained since 1994 has confirmed S as an excellent general choice”. In 
this chapter, I will use the same notation used by Royston and Sauerbrei 148; in particular, the 
notation FP1 and FP2  refer to fractional polynomial with one power (8#) and two powers 
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(8#,8p) to represent the first and the second-degree FP models respectively. With the set S of 
powers just given, there are 8 models with FP1, 28 models with FP2 with distinct powers 
(8# ≠ 8p) and 8 models for FP2 with equal powers	(8# = 8p), note that in this case the FP2 
models are in the form |C¼AB()<>) =	∝ +;#JG5 + ;p	JG¬ 	|C¼J	; so a total of 44 possible 
models. 
 6.2.1 Model Selection 
Models with FP functions are generally fitted by using maximum likelihood estimation, 
including logistic regression148. The best-fitting model is the one whose power, 8,  gives the 
highest chi-square statistics or the smallest deviance148 (minus twice the maximized log 
likelihood of a fractional polynomial model with power, 8).  
6.2.2 An Illustrated Example 
I now give a simple example of FP modelling within a logistic regression model by applying 
to the first study of the 4 IPD studies within the TBI dataset that was introduced in chapter 1 
(see Table 1.1), and analysed initially in chapter 4. Recall in chapter 4, I found that age was a 
PF for 6-month mortality but I assumed a linear trend for age. I also found that there was 
residual variation due to age, which suggests that the linear relationship may actually not be 
the most suitable.   
The Best Fitted FP1 Logistic Regression Model 
First I fit all of the possible 8 models with one power and decide the best fitted model by 
selecting the model that has the highest chi-square statistics or the lowest deviance.  
Table 6.1 gives the results of the possible 8 models between age and logit probability of 6 
month mortality. The best fitted model is the cubic model (model 8), as it has the lowest 
deviance (885.763) and the highest chi-square statistics (25.82) with one degree of freedom. 
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Model 8 indicates that there is a significant association between N¼-½ and the probability of 
six month mortality as the P-value < 0.001. 
Table 6. 1: The results of possible logistic regression models for FP1, for the association 
between age (per 10 years) and the probability of six month mortality for the first study 
of TBI dataset 
Model Power 
() 
Deviance é { S.e ({) chi 
square 
statistic 
p-value 
of { 
1 -2 901.167 -0.755 -3.020 0.968 10.41 <0.001 
2 -1 896.350 -0.237 -2.691 0.706 15.23 <0.001 
3 -0.5 893.936 0.773 -3.357 0.813 17.65 <0.001 
4 0 891.693 -2.299  1.000 0.227 19.89 <0.001 
5 0.5 889.742 -3.209  1.139 0.245 21.84 <0.001 
6 1 888.169 -2.200  0.311 0.064 23.41 <0.001 
7 2 886.257 -1.684  0.041 0.008 25.32 <0.001 
8 3 885.763 -1.506  0.007 0.001 25.82 <0.001 
 
The model can be written as: 
 																																																						|C¼AB()) =	∝+ ;i	N¼-½																																																															(6.1) 
 
Where ∝ refers to the log-odds of the event (e.g. six month mortality rate) when	N¼-½ = 0, 
N¼-½ is the cubic value of a patient age divided by 10, and ;i  is the change in the log-odds of 
the event for one unit increase in	N¼-½. There is, however, very little difference in the chi-
square statistics value of the models with	8 = 1,2, CM	3, suggesting little difference between a 
linear, quadratic and cubic.  Note that the second best model is model 7, when 8 = 2 and the 
model is given as: 
																																																						|C¼AB()) =	∝+ ;i	N¼-p																																																															(6.2) 
This model has the same interpretation as model 8, except that N¼-p is the square value of the 
covariate (i.e. age); it has the second highest value of the chi-square statistics after model 8. 
Figure 6.1 shows the results of FP1 analysis of age, and the log-odds of mortality. In 
particular, the graph depicts the relationship between N¼-(G) and log-odds of mortality based  
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Figure 6.1: All of the possible logistic regression models for FP1 logistic regression models to assess whether there is an association between 
age and in-odds of six month mortality for study one in the TBI dataset- the best model is 	
 (Figure 6-1h) 
Figure(6-1a): 8 = −2 
 
 
 
Figure(6-1b):	8 = −1 
 
 
Figure(6-1c):		8 = −0.5 
 
 
Figure(6-1d):	8 = 0	
 
Figure (6-1e):	8 = 0.5 
 
 
Figure(6-1f):	8 = 1 
 
 
Figure(6-1g):	8 = 2 
 
 
Figure(6-1h):	8 = 3 
 
 
Note that STATA software is used to estimate these graphs; in particular “fracplot “ module 
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on the logarithmic relationship fitted by logistic regression; shaded area denotes the 95% 
confidence interval around the line. 
The Best Fitted FP2 Logistic Regression Model  
 
FP2 is now applied to the first study in the TBI dataset, and thus 36 models fitted. Table 6.2 
gives the results of the 36 models, the best model has powers	(8# = −2	, 8p = −1), which 
has the lowest deviance and the highest chi-square statistics. The model is given as: 
																																			|C¼AB(8) =	∝+ ;i#N¼-(p + ;ipN¼-(#																																																							(6.3) 
Here ∝ refers to the log-odds of the event (e.g. six month mortality) when	N¼-(p =	N¼-(# =
0, N¼-(p is the inverse of the square value of the age, N¼-(#		is the inverse value of age; 
;i#	NK	;ip	 are the change in the log-odds of the event for one unit increase in  
N¼-(p	NK	N¼-(#		 respectively. Figure 6.2 shows the estimated relationship between age 
with power	(8# = −2	, 8p = −1), and log-odds of mortality.  
Figure 6.2: The best fitted logistic model by using FP2 , to 
investigate whether there is an association between age and log-
odds of six month mortality, the best fitted model with powers  = −			 = −, for study 1.	
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Table 6. 2: All of the possible logistic regression models by using FP2 to assess whether there is an association between age and ln-odds of six 
month mortality for one study of TBI dataset. 
Power Beta 1 
 
Beta2 Beta1 
s.e 
Beta2 
s.e. 
chi 
square 
statistics 
p-value 1 p-value 
2 
Power beta1 beta2 Beta1 
s.e 
Beta2 s.e. chi 
square 
p-value 
1 
p-value 
2 
(-2,-1) 17.68 -15.56 4.94 3.70 27.33 0.00 0.00 (-1,2) 1.12 0.05 1.32 0.02 26.03 0.40 0.00 
(-2,-0.5) 10.51 -12.06 3.29 2.88 27.27 0.00 0.00 (0,1) -1.93 0.86 1.20 0.35 25.98 0.66 0.14 
(-2,-2) 6.25 -21.27 2.30 5.05 27.26 0.01 0.00 (0.5,0.5) -7.42 2.64 4.19 1.29 25.97 0.08 0.04 
(-2,0) 6.90 2.56 2.50 0.62 27.14 0.01 0.00 (-0.5,2) 1.41 0.05 1.82 0.02 25.92 0.44 0.00 
(-1,-1) -2.00 -12.58 0.68 3.58 27.04 0.00 0.00 (-2,3) 0.38 0.01 1.24 0.00 25.91 0.76 0.00 
(-2,0.5) 4.72 2.26 2.04 0.55 26.98 0.02 0.00 (0.5,1) -4.12 1.39 2.62 0.69 25.87 0.12 0.04 
(-1,-0.5) 22.08 -28.89 7.13 8.33 26.85 0.00 0.00 (0,2) -0.46 0.06 0.63 0.02 25.84 0.47 0.02 
(-2,1) 3.26 0.51 1.75 0.12 26.78 0.06 0.00 (-1,3) 0.10 0.01 1.09 0.00 25.83 0.93 0.00 
(-1,0) 9.49 4.05 3.58 1.18 26.66 0.01 0.00 (0.5,3) 0.05 0.01 0.60 0.00 25.83 0.93 0.05 
(-0.5,-0.5) -14.45 -12.60 3.76 4.13 26.64 0.00 0.00 (1,3) 0.02 0.01 0.20 0.00 25.83 0.91 0.12 
(-1,0.5) 5.29 2.95 2.42 0.87 26.48 0.03 0.03 (2,3) 0.01 0.01 0.05 0.01 25.83 0.92 0.48 
(-0.5,0) 21.49 7.02 8.28 2.34 26.45 0.01 0.00 (-0.5,3) 0.02 0.01 1.41 0.00 25.82 0.99 0.01 
(-2,2) 1.45 0.05 1.41 0.01 26.35 0.31 0.00 (0,3) 0.02 0.01 0.46 0.00 25.82 0.96 0.02 
(-1,1) 3.20 0.59 1.86 0.18 26.31 0.09 0.00 (3,3) 0.01 0.00 0.02 0.01 25.82 0.66 0.98 
(-0.5,0.5) 8.91 3.82 4.18 1.29 26.27 0.03 0.00 (1,1) -0.94 0.54 0.81 0.35 25.80 0.25 0.12 
(0,0) -2.52 1.49 1.39 0.58 26.26 0.07 0.01 (0.5,2) -0.63 0.06 0.92 0.03 25.79 0.49 0.05 
(-0.5,1) 4.73 0.68 2.85 0.23 26.13 0.10 0.00 (1,2) -0.24 0.07 0.37 0.05 25.76 0.51 0.13 
(0,0.5) -4.89 6.45 2.35 2.57 26.10 0.04 0.01 (2,2) -0.02 0.03 0.09 0.05 25.76 0.83 0.51 
[159] 
 
I now consider how to apply a two-step or a one-step meta-analysis by using FP functions 
restricted to S subset. 
6.3 Two–step IPD Meta-analysis 
Recall that in the 'two-step' approach, the IPD are first analysed separately in each study using 
an appropriate statistical method for the type of data being analysed; for example, for binary 
outcome a logistic regression model might be fitted. This produces aggregate data for each 
study, such as the PF effect estimate and its standard error; these are then synthesized in the 
second step using a suitable model for meta-analysis of aggregate data, such as one weighting 
by the inverse of the variance whilst assuming fixed or random PF effects across studies (see 
chapter 1). Before fitting the  two-step FP  logistic regression model, testing  of the  linearity 
assumption can be considered for the relation between age and mortality rate by using closed 
test in each study.  
Closed Test: 
Closed test is used to choose the best FP function and it is also used to test the linearity 
assumption between the PF and outcome.  In FP modelling the default function is linear 
(8 = 1) . The procedure for closed test is given as follows148-150, in relation to TBI data: 
1. Calculate the deviance difference between the best FP2 model (i.e. the best fitted 
model with the lowest deviance) and null model (i.e. that which excludes the PF and 
has only the ∝ term) and test it at level ∝		on the chi-square distribution with 4 degree 
of freedom, If the p-value is non-significant, then stop and accept the null model, 
which assumes that the PF is not significant at the ∝ level, but if the test is significant, 
then go to the second step. 
2. Calculate the deviance difference between the FP2 model and the linear model 
() = 1) at the ∝ level on the chi-square distribution with 3 degree of freedom. If the 
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p-value is non-significant, then stop and then accept the linear model (so in this case 
the linearity assumption is achieved); but if the p-value is significant this indicates that 
the linearity assumption is not achieved, so, go to the third step. 
3. Calculate the deviance difference between the best FP2 model and the best FP1 and 
test it at the ∝ level on the chi-square distribution with 2 degree of freedom. If the p-
value is non-significant then stop and FP1 is the best function, but if the test is 
significant, then the best function is FP2.  
Note that step 1 tests whether the PF is significant or not; step 2 is used to test whether the 
linearity assumption between the PF and outcome is achieved or not; and step 3 compare 
between the simple and more complex non-linearity model.  
Test of Linearity Assumption and the Best Selected Function 
Table 6.3 gives the test of linearity assumption, and the best selected FP function for age per 
10 years in TBI dataset for each study separately by using closed test. In the 4 studies, the 
linearity assumption is achieved for  ∝ of 0.05, as the P-values for the 4 studies are not 
significant (Table 6.3).  But, if I changed the level of ∝ to be, say, 0.10, then study 3 does not 
achieve the linearity assumption with P-value = 0.087, and the best fitted model is FP1 with  
8Cª-M = 3 for this study. In this situation, I should decide whether I use linear or non-linear 
models for the 4 studies. Thus, the choice of ∝ is clearly important. 
If I ignore the closed test, so the best fitted models are FP1 with powers 3, 1, 3, 2, for study 1, 
2, 3, and 4 respectively. Then by considering the non-linear trend across the 4 studies, there 
are different powers across the 4 studies which make it difficult to apply a two-step model 
meta-analysis here, as it needs the 4 studies to have the same power (i.e. same model terms in 
each study). For example, if study one has ;J½ and study four has ;Jp , the ; term cannot be 
synthesised. In the next section I give a suggestion on how to fit FP1 two-step IPD meta-
[161] 
 
analysis model, by using logistic regression model, and how to decide upon which power to 
use consistently in each study.  
Table 6. 3: Test of linearity and the best selected FP function for each study for TBI dataset 
in one-step IPD meta-analysis  
Study Model Deviance  Power 
() 
Steps of 
closed 
test 
Comparison Dev.diff P-value The best 
fitted model 
Study 
(1) 
FP2 884.246                                                                                                                         - 1 FP2 vs. null 27.335 <0.001 
Linear 888.169    1 2 FP2 vs. linear 3.923 0.270  
FP1 885.763    3 3 FP2 vs. FP1 1.517 0.468 FP1=3  
Null 911.581    -   - - FP2=(-2,-1)* 
Study 
(2) 
FP2 1087.992    - 1 FP2 vs. null 28.844 <0.001  
Linear 1088.920    1 2 FP2 vs. linear 0.928 0.819  
FP1 1088.920    1 3 FP2 vs. FP1 0.928 0.629 FP1=1 
Null 1116.836    -   - - FP2=(3,3)* 
Study 
(3) 
FP2 565.171      - 1 FP2 vs. null 63.350 <0.001  
Linear 571.751    1 2 FP2 vs. linear 6.579 0.087  
FP1 565.492    3 3 FP2 vs. FP1 0.321 0.852 FP1=3 
Null 628.521    -   - - FP2=(0.5,2)* 
Study 
(4) 
FP2 425.401    - 1 FP2 vs. null 15.558 <0.001  
Linear 426.049    1 2 FP2 vs. linear  0.648 0.885  
FP1 425.795    2 3 FP2 vs. FP1 0.394 0.821 FP1=2 
Null 440.959    -   - - FP2=(-2,3)* 
*Fitted FP1 logistic regression model is better than FP2 in each study of TBI dataset. 
6.3.1 First Order Fractional Polynomial  (FP1) 
I now apply FP1 logistic regression models separately for each of the 4 IPD studies in the TBI 
dataset. Table 6.4 shows the chi-square statistics values for all possible 8 models. Figure 6.3 
shows the fitted curve for each study for 8 = 1, 2 and	3. Figure 6.4 shows the comparison 
between FP functions for linear(8 = 1), quadratic (8 = 2), and cubic (8 = 3)  function for 
each study separately for TBI dataset. Based on the closed test and ∝= 0.05 (i.e. significant 
level is 5%), all studies choose the linear trend as the best fitted relationship. In this case, one 
could apply the methods in chapter 4. However if ∝ = 0.1, then study 3 rather chooses a cubic 
trend (Table 6.3) and so, there are different powers for the best fitted model across studies 
which make it difficult to apply a two-step meta-analysis, as mentioned. The difference of the 
‘best’ model could be a reflection of between study heterogeneity in the true FP relationship 
between age and ln-odds of mortality, or it could be a consequence of chance variation. In 
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chapter 1, for the 4 TBI studies, recall that there was no heterogeneity when age was assumed 
to have a linear trend (¹p = 0%).  Further,  though  the best fitted model for one study is 
different from the best fitted model in others, the  visual difference between the fitted models 
with different powers in each study is not substantial (Figure 6.3 and 6.4). In particular, there is 
only a little difference between linear, quadratic and cubic functions for age especially when the 
age of patients is between 20 to 60 years in all studies; though there is a slight difference 
between the three functions when age is less than 20 years and bigger than 60 years respectively 
(i.e. at the extremes of the data with less values, especially for study 3). 
Table 6. 4 The possible FP1 logistic regression models for each of the 4 TBI studies to assess 
the association between age and the probabilty of six month mortality 
                Study 1                 Study 2                  Study 3                Study 4 Total  
Chi-square
for 4 
studies Model Power 
Chi-
square Model Power 
chi -
square Model Power 
Chi-
square Model Power 
Chi-
square 
1 -2 10.41 1 -2 17.68 1 -2 27.07 1 -2 10.8 
  65.96 
2 -1 15.23 2 -1 22.04 2 -1 36.68 2 -1 12.5 
  86.45 
3 -0.5 17.65 3 -0.5 24.17 3 -0.5 42.12 3 -0.5 13.3 
  97.24 
4 0 19.89 4 0 25.98 4 0 47.56 4 0 13.99 
  107.42 
5 0.5 21.84 5 0.5 27.27 5 0.5 52.57 5 0.5 14.53 
  116.21 
6 1 23.41 6 1 27.92 6 1 56.77 6 1 14.91 
  123.01 
7 2 25.32 7 2 27.2 7 2 61.97 7 2 15.16 
  129.65 
8 3 25.82 8 3 24.5 8 3 63.03 8 3 14.89 
  128.24 
One could thus arguably choose either powers 1, 2, or 3. To help to identify the overall best 
model, I added the chi-square value across for all the 4 IPD studies for the same model (i.e. 
same power), to find the model with the overall highest chi-square statistics (Table 6.4). I 
found that the best FP1 model across all 4 IPD studies is model 7 with 2=p  (see Table 6.4), 
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with total chi-square statistics equals 129.65. Thus, I decided to undertake the two-step IPD 
meta-analysis model for 2=p . This model is written as: 
¿AMLB	LB-8:													|C¼AB(8<) =∝<+ ;i<N¼-<>p 																 																											S-CK	LB-8 ∶ 		 	;{ <=; + -<		, -<~	©(0, ­NM(;i<) )                                    (6.4) 
;i = ∑ ª<		;i<><?#∑ ª<><?#  
where ∝< represents the value of the log-odds when	N¼-p = 0, ;i< refers to the change in log-
odds of mortality for one unit change in N¼-p in each IPD study;	A refers to study. This allows 
a different ∝  in each study but assumes a fixed;; random-effects on ; are also possible if 
necessary. The pooled effect size estimate,	;{ ,	 gives the best estimate of the change in log-
odds for one unit increase of	N¼-p. Note that, for simplicity I did not consider the effect of the 
correlation between parameters E and ; in the second step here (see further work, chapter 8). 
Figure 6.5 presents the forest plot for the association between N¼-p and the probability of six 
month mortality. There is no heterogeneity across studies as	¹p = 0%; thus the quadratic trend 
appears consistent in each study as did a linear trend (Chapter 4). 
[164] 
 
Figure 6.3: The fitted cubic, quadratic and linear regression model for 4 IPD studies of the TBI dataset 
Figure(6- a):Study 1, 8 = 3 
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Figure 6.4: FP1 of linear, quadratic and cubic (p=1, 2, 3) models for age, for each study 
separately by applying on TBI dataset 
Figure (6.4a): FP1 for linear, quadratic and 
cubic models for age for study 1, TBI  dataset 
 
Figure (6.4b): FP1 for linear, quadratic and 
cubic models for age for study2, TBI  dataset 
 
Figure (6.4 c): FP1 for linear, quadratic and 
cubic models for age for study 3, TBI  dataset 
 
Figure (6.4d): FP1 for linear, quadratic and 
cubic models for age for study 4, TBI  dataset 
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Figure 6.5: The forest plot for FP1 with power =2 logistic regression model of 
IPD meta-analysis by using fixed effect method- for the 4 IPD studies for TBI 
dataset 
 
The pooled odds ratio for the 4 IPD studies is 1.04 with 95% confidence interval lies between 
1.03 and 1.05; there is a significant relationship between N¼-p and log-odds of mortality as 
one is not included in the confidence interval; the odds ratio (1.04) indicates that a one unit 
increase of N¼-p multiplies odds of mortality by 4%.  
Note that although FP2 function has the lowest deviance across the 4 studies, the closed test 
yielded that FP1 is better than FP2 as the reduction in deviance is not statistically significant 
at either the 5% or 10 % level. Thus, I will not consider FP2 two-step meta-analysis here. In 
situation where FP2 are required, it may be even more difficult to choose the same powers for 
all of the 4 studies in the meta-analysis, given there are 36 FP2 models possible in each study.  
6.4 One-step Meta-analysis  
Recall in the 'one-step' approach, the IPD from all studies are modeled simultaneously whilst 
accounting for the clustering of patients within studies. In this section I consider one-step 
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logistic regression meta-analysis models that uses the FP approach and account for the 
clustering of patients within studies. TBI is again used as an application. Models that ignore 
clustering are clearly not considered given the findings of Chapter 5. In the next sections, FP1 
and FP2 models are fitted to select the best one-step IPD meta-analysis model.  
6.4.1 First Order FP One-step Meta-analysis Model 
In a one-step FP meta-analysis to adjust for clustering of patients within studies, I include 
study indicator as in chapter 4 (i.e. a separate intercept term); the choice of the first and 
second order FP model for the covariate of interest is then decided simultaneously across all 
studies (i.e. a separate FP model is not fitted per study).		The FP1 one-step IPD meta-analysis 
logistic regression model which can be written as:	 
 
																																						|C¼AB()<>) =	∝<+ ;i	N¼-<>(G5)																																																																		(6.5) 
Where ∝<  is  the log-odds of event in study i  when 	N¼-<>(G5) = 0,  β   indicates the change in  
log odds  for one-unit increase in  N¼-<>G5, with  assumed fixed across studies, 8# is the first 
order FP selected from the restricted S set (with 8 possible numbers). 
One could also allow  ;
 
to vary across studies, i.e. place a random-effects around it , either 
way, one is still forcing each study to have the same FP power terms, even if ;	varies. That is 
the choice of 8	 is forced to be the same in every study. This is similar to the second step 
approach I used in section 6.3.1, where I forced the choice of p=2 in each study as my ‘best’ 
model.  
  
β
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6.4.2 Second Order FP for One-step IPD Meta-analysis 
The FP2 one-step IPD meta-analysis logistic regression model is given as 
																																		|C¼AB	()<>) =	∝<+ ;#N¼-<>G5 + ;p		N¼-<>G¬ 																																																(6.6) 
Where iα   is   the  log odds of event in study i  when N¼-<>G5 = N¼-<>G¬ 	= 0,  ;#		NK	;p  
indicate the change in log-odds of the event for one-unit increase in N¼-G5 and 
N¼-G¬ 		respectively; N¼-<>G5 	and N¼-<>G¬ 		are the fractional transformation of the covariate; 
again 8#	NK	8p refer to the power of the continuous covariate and are selected from 
restricted S set for the best fitted model that has the highest chi-square statistics or the lowest 
deviance. Again the choice of 8# and 8p are forced to be the same in each study, even if the 
model is extended to allow heterogeneity in ;# and;p. 
6.4.3 Application to the TBI Data 
Test of Linearity Assumption and the Best Selected Function 
 By applying the closed test on TBI dataset using the one-step approach, the linearity 
assumption is not achieved as the P-value for comparing FP2 versus linearity is significant 
(8 = 0.043), which indicates that I go to step three to compare between FP2 and FP1 
function. FP1 function is recommended over FP2 as the P-value for FP2 to FP1 is non-
significant (8 = 0.793), see Table 6.5. 
Table 6. 5: Test of linearity and the best selected FP function for each study for TBI dataset 
in one-step IPD meta-analysis 
Study Model Deviance  Power () Step Comparison Dev.diff P-value The best fitted 
model 
Study 
(1) 
FP2 2969.194    - 1 FP2 vs. null 128.702 <0.001  
Linear 2977.319    1 2 FP2 vs. linear 8.125 0.043  
FP1 2969.657    2 3 FP2 vs. FP1 0.463 0.793 FP1=2 
Null 3097.897      FP2=(-2,2)* 
*Fitted FP1 logistic regression model is better than FP2 in each study of TBI dataset.
[169] 
 
Table  6.6: The results of two-step and one-step IPD meta-analysis models for TBI dataset by using FP1 and FP2 
Model Description 
of the 
Model 
FP 
function 
Chi^
2 
Deviance   Odds 
ratio		  
Odds 
ratio		 
95% 
confidence 
interval for 
Odds ratio 			 
95% 
confidence 
interval for 
Odds ratio  
Ln 
(odds 
ratio)  
Ln 
(odds 
ratio)  
95%  
confidence 
interval for Ln 
Odds ratio	 
95%  
confidence 
interval for Ln 
Odds ratio	 
P-value 
for x  P-value for x  
Model1 Two-step FP1   2 
 
- 
 
1.04 
 
- 
 
1.03 to 1.05 
 
- 
 
0.04 
 
- 
 
0.03 to 0.05 
 
- 
 
<0.00 1 
 
- 
Model 2 One-step 
Account 
clustering  
FP1 585.
99 
2969.6 2 - 1.04 - 1.03 to 1.05
 
-  0.04 - 0.032 to 0.05 - <0.001 - 
Model 3  FP2 588.
20 
2969.2 -2 2 1.55		 
 
1.04 0 .44 to 5.42 1.03 to 1.05 0	.44	 
 
0.04  -0.82 to 1.7 0.03 to 0.05 
 
 0.495 < 0.001 
N.B. all of results in this Table have been estimated by using STATA software, and the STATA code to fit the two-step and one-step models by using fractional polynomial are 
logit, fracpoly and metan, for more details see Appendix E. 
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I now apply the one-step FP models to TBI dataset and compare them to the second- step FP 
results. Recall that in two-step IPD meta-analysis models, I decided the best fitted model for 
FP1 was for  	N¼-p (i.e. power = 2) based on the total highest chi-square statistics sum across 
studies; the odds ratio for a one-unit increase in N¼-p  was 1.04 with 95% confidence interval 
between 1.03  to 1.05. Using the closed test approach, for the one-step FP2 model, the best 
fitted model for FP1 is again N¼-p (i.e. power = 2) (Table 6.5); and the estimates from one-
step FP1 model are approximately the same as the two-step FP1 model (Table 6.6), and it has 
the same interpretation. In one-step FP2 model, the best fitted model for FP2 
was	N¼-p	NK		N¼-(p, (i.e. powers 2, -2). However, the P-values were <0.001and <0.50 for 
N¼-p	NK		N¼-(p respectively. The insignificant P-value for 	N¼-(p suggest that 8Cª-M =
−2 can be dropped from the model. Thus, the FP1 IPD meta-analysis model with N¼-p again 
appears the most suitable model across all 44 choices.  
6.5 Discussion 
In this chapter I have proposed and illustrated statistical models for meta-analysis of binary 
outcome data in the presence of the one potential continuous PF with a potential non-linear 
trend, using two-step and one-step IPD meta-analysis models with first and second order FP 
function, whilst accounting for the clustering of patients within studies. Application was 
made to 4 IPD studies of TBI in relation to six month mortality. I found that it was more 
difficult to apply two-step methods, especially using FP2, as it is not straightforward to 
choose a single model with the same powers values in all studies. In contrast this problem 
does not arise when using one-step models as the powers in the model are selected using all 
studies simultaneously, forcing the same powers in each study, to automatically give an 
average trend.  
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The closed test for the same TBI dataset yielded different results when it is applied for the 
two-step or one-step method. For example, by assuming the level of ∝  is 0.05, the two-step 
method yielded that linear trend is achieved for the 4 IPD studies; when the level of ∝ was 
0.10, it yielded that the linearity assumption is not achieved in study 3 of the TBI dataset. 
This makes it difficult to decide whether I consider linear or non-linear trend across studies in 
the meta-analysis. In contrast, in one-step approach, the closed test yielded nonlinear trend 
whether the level of ∝ is 0.05 or 0.10. Thus, this shows that one-step and two-step meta-
analyses can differ in their conclusion, as shown in some simulations in Chapter 5. 
Heterogeneity in the ;  terms can also be considered though I have not done that here. Thus I 
recommend one-step IPD meta-analysis approach for FP modelling as it is simpler and more 
coherent. Recall also from chapter 4 and 5 that the one-step also is unbiased, has suitable 
coverage and accounts for the correlation between parameters. In contrast, the two-step 
approach is occasionally biased with too high coverage and does not account for correlation 
unless the multivariate model is used.  
Others have used FP functions in meta-analysis. In Rota et al.151  the authors present a two-
step meta-analysis using FPs. First, they examined how the risk of disease varies across 
different levels of a given exposure; they considered within studies variability, between 
studies heterogeneity, and nonlinear trend components; the second order fractional 
polynomial (FP2) generalised linear model is fitted for each study. Second, the pooled FP 
terms are estimated by using bivariate random-effects meta-analysis to consider also the 
heterogeneity across studies. They stated that “The best fitting model, denoted by the optimal 
power transformations (8#∗, 8p∗)  is defined as the one minimizing Akaike’s Information 
Criterion (AIC)”. So they decided the best fitted model in the second stage after they obtained 
the AIC for all 36 possible FP2 models that fitted for each study.  It is not clear how they did 
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this, however, as I have shown in this chapter that the powers of the FP models might be 
different from study to study, making it difficult to choose the best FP model that have the 
same power in each study; Recall that I applied FP model for 4 IPD studies only. However, in 
Rota et al.151  14 case–control studies and one cohort study were included for the IPD studies; 
so I would imagine it was even more difficult to find the best fitted FP2 model in their 
example. 
In Fedirko et al.152  the authors aim to investigate whether alcohol consumption is related to 
colorectal cancer (CRC); Twenty-seven cohort and 34 case–control studies were used for 
investigate whether the dose-risk of alcohol increase the risk of colorectal cancer, the authors 
stated that “Thirty-six second-order fractional polynomial random effects models and linear 
random effect models were tested. And they also stated that “The best-fitting model, defined 
as the one with the lowest Akaike’s information criterion”. Again they did not mention how 
they select the best fitted FP2 (with the same powers for all IPD studies included in the 
analysis). However, they state that “A random effects model was used to estimate pooled RRs 
in order to take into account the heterogeneity of the risk estimates and to provide more 
conservative estimates compared with the fixed effects model”. Greater clarity on how FPs is 
used in meta-analyses is needed in published articles.  
FP modelling is also being used in meta-analysis when only aggregated data are available. In 
Bagnardi et al.153 the authors synthesized the aggregated data (i.e. relative risk) for the second 
order fractional polynomials (FP2). In particular, those papers that investigate the association 
between alcohol intake and relative risk of all-cause mortality reported from 29 cohort 
studies. The FP powers are different from study to study; and the authors did not say how 
they overcome this problem and how they select the best fitted fractional polynomial with the 
same powers from the 36 models across 29 articles, they only stated that “The best-fitting 
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model (81	 = 	82	 = 	0.5)	offers a gain in deviance of 138.36 with respect to the reference 
model across the 29 cohort studies”.  
In conclusion, further research into fitting FP models within IPD meta-analysis is needed to 
consider one-step and two-step FP models, and how to select the best fitted model. But, based 
on my findings of this chapter and chapter 5, I would suggest a one-step meta-analysis 
framework for FP modelling should be preferred, which also accounts for the clustering of 
patients within studies.  However a limitation is that it forces the same shape in each study. If 
this seems unrealistic, then it may not be sensible to do meta-analysis or then a two-step 
approach of FP is about to be suggested by Sauerbrei et al. that allows for different powers 
across studies (personal communications) followed by a synthesis.  
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CHAPTER 7 
SMALL-STUDY EFFECTS IN IPD META-
ANALYSIS OF PROGNOSTIC FACTOR STUDIES 
7.1 Small-study Effects and publication related biases 
Meta-analysis of PF studies that use aggregated data are known to be highly subject to 
publication bias and selective reporting biases7 22. Though meta-analyses of individual patient 
data (IPD) are often considered as the “gold standard” method in medical research for 
summarizing quantitative evidence, there has been little research into whether they too are 
affected by bias7 22. This is particularly important for IMPF as primary PF studies are prone to 
selective and biased reporting, and IPD may only available from published PF studies7 (see 
chapter 2). In this chapter I perform an empirical assessment of whether there is potential bias 
within existing IMPF projects; in particular whether smaller studies have the tendency to 
produce more favourable PF results (small-study effects).  
7.1.1 Publication Bias  
Publication bias occurs when studies with statistically significant results are more likely to be 
published compared to studies with non-significant results; if IPD are only obtained from 
published studies, then publication bias remains a concern from IPD meta-analysis just as for 
an aggregated data meta-analysis104 154. Publication bias may arise from the design of the 
studies. For example, studies with inadequate sample sizes are unlikely to demonstrate 
statistical significance for clinically important effects, and may lead to publication bias if the 
results from small studies are unlikely to be published unless significant. This is referred to as 
‘small-study effects’, the tendency for smaller studies to be missing or only published when 
they show significant results. 
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In addition, some editors and reviewers tend to dislike negative studies104 155 156. The British 
Medical Journal stated that “negative results have never made riveting reading.”, as they 
would like articles to be published that affect clinical practice or improve prognosis; as a result 
of that the researchers may decide not to submit their negative findings, or hide negative 
findings and submit only the positive findings in their research154.  
7.1.2 Availability Bias  
In an IPD meta-analysis, another related problem is availability bias, when not all known 
studies provide their IPD; this potentially leads to biased set of studies being included in the 
IPD meta-analysis. For example, in Trivella et al.72 the authors asked for IPD from 38 studies 
but only 18 studies gave their IPD; the remaining 20 IPD studies that did not provide their IPD 
may cause availability bias if their results systematically differ. There are many potential 
causes for unavailable IPD53 55 60; such as there being no access to the data;  authors being 
worried to give their data because they are not convinced about their statistical analysis or  
results; others may not like to share their data if the result is statistically non-significant; others 
may not provide their IPD if they do not have the complete data for particular confounding 
factors  that were asked for or a lack of availability of information on desired outcomes; and 
others may have destroyed the data or refuse to provide it because they spent a lot of money on 
their research53 55 157. Availability bias can be investigated by combining the aggregated data 
from the IPD studies with that extractable from other non-IPD studies, to understand the 
possible  impact of non-IPD studies on the results and conclusion55 60 154.  
7.1.3 Aims of the Chapter 
Publication bias and availability bias are particular concerns for an IMPF articles; recall that in 
chapter 2 I reviewed 20 IMPF articles, and only 2 articles72 93 included unpublished studies 
(which raises the threat of publication bias),  and only 2 articles80 88 obtained IPD from all 
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studies that they asked for (which raises the threat of availability bias). Further, only 2 articles83 
92
 considered the issue of publication bias by using funnel plot or Egger’s test, and only one 
article81 considered the problem of availability bias by examining whether including non-IPD 
studies will potentially affect on the IPD meta-analysis results.  Thus the question arises: are 
IMPF articles subject to publication and other biases that may cause small-study effects? 
This chapter aims to assess small-study effects in the 20 IMPF articles considered in detail in 
chapter 2, by using visual and statistical tools such as funnel plot158, trim and fill method159,  
cumulative meta-analysis45 and tests for  small-study effects (e.g. Egger regression test)159. 
These methods are now introduced.  
7.2 Methods to Assess Small-study Effects 
Checking for evidence of small-study effects should be undertaken routinely in a meta-analysis 
whenever possible20. In this section, four existing methods are described for detecting small-
study effects: funnel plot, cumulative meta-analysis, trim and fill, and regression methods. 
They are applied again to the IPD from Look et al. 14 for illustration. Recall the Look data was 
introduced in section 1.4.2 and first analysed in chapter 2. A general rule of thumb is for at 
least 10 studies to be available in order to reliably use these methods160. 
 7.2.1 Funnel Plot and Contour-enhanced Funnel Plot 
A funnel plot is the most common method for detecting small-study effects and potentially 
publication bias161.  A funnel plot displays the effect estimates (x-axis) against the standard 
error (y-axis)158, and it places the most powerful studies in the top of the graph20 160. In the 
absence of publication bias, the plot is expected to be symmetric (PF effect estimates are 
scattered around the true effect size of the PF in both directions with increasing variability as 
the standard error increases). However, if small-study effects exist this changes the shape of the 
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plot and asymmetry will occur as some small studies will be missing in one direction154; in 
particular  when there is potentially publication bias only those small-studies yielding a large 
effect size of the PF will be included. This indicates that there is an association between the 
sample size and the available PF effect estimates. 
Note that there are many factors that may cause asymmetry in a funnel plot, not just publication 
bias, but also poor methodological quality (e.g. poor methodological design and inadequate 
analysis in small studies), and between-study heterogeneity in the true PF effect. Recent 
recommendations160 note that to test the asymmetry by using funnel plot the number of the 
studies should be at least 10, with a substantial difference for the standard errors of the effect 
size estimates of the PF across studies (i.e. if the standard errors of the effect size estimates of 
the PF are similar, the funnel plot should not be used) as ‘small’ studies cannot be 
distinguished from other studies. Funnel plot can show whether there is asymmetry across 
studies or not, but it cannot show the reasons for this asymmetry158 162.  
A contour enhanced funnel plot is a funnel plot that include contour lines corresponding to 
perceived ‘milestones’ of statistical significance ( p = 0.01, 0.05, 0.1 etc)163-164.  This allows the 
statistical significance of the PF effect size of the PF in the seemingly missing studies to be 
considered; also, it may help to identify whether the asymmetry is due to publication bias or 
from other factors. For example, if the ‘missing’ studies are seemingly in the non-significant 
area (P > 0.05) of the contour-enhanced funnel plot, this possibly indicates that the asymmetry 
is due to publication bias. In contrast, if the missing studies are in the significant area of the 
plot (i.e. P < 0.05), this may indicate that the asymmetry comes from other factors (e.g. 
heterogeneity, poor study design, etc). 
Figure 7.1 shows the contour funnel plot for the Look et al.14 database, relating to the log 
hazard ratio and its standard error for uPA as a PF for relapse-free survival for breast cancer. 
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Note that uPA was measured as a continuous variable.  It can be seen from the graph that most 
of the studies provide log hazard ratio estimate greater than zero, but the larger studies are 
those with a log hazard closest to zero. There is visual asymmetry, with small studies with 
results close to or less than zero potentially missing, broadly in the non-significance area (in 
particular in the white area where p > 0.1). This makes small-study effects a concern here, 
though heterogeneity for uPA (	¹p = 83.4	%), or other factors may also be the cause of 
asymmetry here (e.g. it may also come from the overestimation of PF effect in small IPD 
studies of inadequate methodological quality). 
Figure 7.1: Contour funnel plot for log hazard ratio of  uPA and 
its standard error for relapse-free survival (RFS) as outcome 
with 15 IPD studies from Look et al.14 
 
                               Black line is the meta-analysis pooled result. 
 
7.2.2 Cumulative Meta-analysis 
A cumulative meta-analysis is a method to assess the impact of additional studies to the meta-
analysis. Essentially, it starts with the estimate of the effect size of the first study, then does a 
meta-analysis to estimate the pooled effect size for the first two studies, then repeats this  for 
the first three studies, and so on113. The same thing will appear in the cumulative funnel plot, 
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the first line shows the effect size and the confidence interval  for the first study, the second 
line shows the  meta-analysis  effect size  estimate and the confidence interval for the first two 
studies together, and so on113. The method was originally developed to look at the impact of 
new studies over time, but I will use it here to examine the impact of smaller studies on the IPD 
meta-analysis. The studies can be sorted by the sample size (from high to low) or by the 
standard error (from low to high) 113.  I will sort the IPD studies according to their standard 
errors (from low to high). First, I start with the estimate of the PF effect size for the lowest 
standard error followed by a meta-analysis estimate of the two lowest standard errors and so 
on.  If the cumulative meta-analysis effect size has stabilized with the inclusion of the lowest 
standard error and does not substantially drift with the addition of the smaller studies, this 
indicates that the smaller studies have only a little impact on the pooled effect results and thus 
small-study effects are not a big concern. In contrast, if the cumulative effect size of the PF 
drifts after adding the largest standard errors, this indicates that the smaller studies do effect on 
the meta-analysis effect size for the PF and suggests small-studies effects and potential 
publication bias.  
Figure 7.2 Cumulative meta-analysis plot based on log 
hazard ratio and its standard error for uPA and relapse-
free survival by using the random- effects method. 
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Figure 7.2 shows the cumulative forest plot for the log hazard ratio of uPA for the 15 IPD 
studies from Look et al.14 In particular, the graph shows that the IPD studies were sorted 
according to standard error (from low to high); the effect size of the PF drifted slightly to the 
right hand side of the graph. This shift, however, is not substantial as the pooled effect size is 
changed slightly from 0.05 to 0.06 when the standard error was 0.013 to 0.65 respectively.  
This indicates that there is a slight concern for the small-study effects in uPA, but it is 
potentially not substantial.  
Note that as contour funnel and cumulative meta-analysis plots are visual tools, they may be 
considered as subjective methods, so statistical tests for funnel plot asymmetry can be helpful 
to quantify asymmetry as now discussed.   
7.2.3 Egger’s test for asymmetry 
Recently, regression based adjustment methods have been used to assess the effect of 
publication bias on the pooled effect165. Such regression methods are used to detect small-
study effects and adjust the pooled effect size of the original meta-analysis estimate of the PF 
according to that potential bias; these methods are now explained. 
Eggers Methods  
Egger et al.106 proposed a regression test for funnel asymmetry that is widely used.  There are 
two methods of Egger test. The first method is original Egger test and the second one is called 
Egger D-var method. These two methods are explained as follows:  
(1). Original Egger Method 
This method is equivalent to a variance-weighted meta-regression model 165. This is given as 
	;{ < =∝ +; × L-< +	Á< 		ª-A¼ℎB-K	Òë	 1L-<p 	ªABℎ	Á<~	©(0, L-<p × ∅)																	(7.1) 
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where 	;{ <
  
is the effect estimate of the PF for each study A	(i.e. log odds ratio or log hazard 
ratio from study i ), and ise   is the standard error for  	;{ < ;  α  and  β  represent the adjusted 
pooled effect of the PF (intercept) and the slope associated with funnel plot asymmetry 
respectively. The regression is weighted by the inverse variance for each study i .  ∅  refers to 
an unknown multiplicative dispersion parameter that allows for possible heterogeneity.  Two 
key results from this model are  ∝  which is the pooled effect size having adjusted for 
asymmetry165, and the P-value associated with ;i  , which gives Egger’s test for asymmetry106.  
 (2). Egger D-var method 
This method is similar to the original Egger method except that it replaces the standard error 
for the effect size of the PF  for each study A (L-<), with the corresponding variance. This 
indicates that the relationship between the effect size of the PF and its variance is linear. Note 
that Egger D-var model is identified by Moreno et al.165  as the method with potentially most 
appealing statistical properties for small-study effects adjustment165. 
	;{ < =∝ +; × L-<p +	Á< 		ª-A¼ℎB-K	Òë	 1L-<p 	ªABℎ	Á<~	©(0, L-<p × ∅)																	(7.2) 
The parameters here have the same interpretation in equation (7.1), except that 
	
L-<p is the variance for each study A.  
Moreno et al.165 have undertaken a simulation study for the Egger’s method in relation to 
obtain adjusted estimates (i.e. the adjusted estimates of the effect size of the PF).  The authors 
found that if there is small number of studies in the meta-analysis and (or) heterogeneity 
across studies,  original Egger’s methods yielded too  high coverage, low residual bias and 
high MSE values (due to large variance), while Egger’s D-var method yielded lower, more 
suitable coverage and lower MSE. Based on this the authors conclude that “we recommend 
Egger’s D-var method which perform very similarly throughout the simulations; at least in 
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terms of coverage, MSE and variance”. So, I will consider the Egger D-var method for the 
adjusted pooled effect size of the PF in this chapter.  
Applying to Look et al14. 
I applied the Egger’s regression methods to the Look et al.14  data. Egger’s test for asymmetry 
gave P-value =0.002 so there is evidence of small-study effects. The original meta-analysis 
for the hazard ratio of the PF was 1.22 with 95% confidence interval (1.15 to 1.31).  As there 
is heterogeneity (¹p =87.4%), I applied Egger’s D-var method and the adjusted pooled effect 
size of uPA is 1.06 with 95% confidence interval (1.02 to 1.11). This still indicates that uPA 
is a PF (same as the original data results); although the pooled result is clearly much close to 
1. Thus even though small-study effects are a slight concern given the significant asymmetry, 
uPA appears to still be prognostic even after adjusting for this asymmetry.   
7.2.4 Trim and Fill Method 
The trim and fill method is another method to assess publication bias and small-study effects. 
Peters et al.166 state that  “the trim and fill method is an iterative non-parametric method based 
on the asymmetry of a funnel plot to estimate an adjusted pooled effect size; and it is 
recommended to be used as a form of sensitivity analysis of the pooled effect size”. The trim 
and fill method aims both to identify and correct for funnel plot asymmetry arising from small-
study effects20.  The main idea of the trim and fill method is; (i) to trim the small studies 
(usually on the right hand side for PF studies) that potentially have an extreme effect size of the 
PF which caused asymmetry159 (ii) after omitting the small studies (which might lead to 
overestimated of the pooled effect size), the pooled effect size of the PF is re-estimated 
again106; (iii) estimate the missing studies on the left-hand side that reflects the omitted studies 
on the right-hand side of the funnel plot based on symmetry about the pooled effect from (ii); 
(iv) the adjusted pooled effect size estimate of the PF is calculated by performing a meta-
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analysis including these ‘filled’ studies159 166. This process is repeated until estimates of the 
number of missing studies and pooled effect size of the PF are stable166.   
 Estimators of the number of missing studies 
When there is no publication bias, the number of the individual studies equals 	(i.e. the 
number of studies in the original meta-analysis). For each A = 1	to  study, study A produces an 
effect size ;<	which estimates	; (the average PF effect), and an estimated within-study 
variance113,  Â<p . If the problem of publication bias exists, the true  number of the individual 
studies  is  n+ k0 ;  k0 refers to the missing studies that should also be included in the estimation 
of ;113. Three estimators for k0  are described by Duvel and Tweedie159 166: L0, R0, and Q0, but 
they conclude that
 
L0 and R0 perform better than Q0 and so are the preferred estimators. 
In this chapter the focus is on L0 estimator; for more details about the other estimators, see 
Duvel and Tweedie.104 159 167
   
the
   
L0 estimator is given as: 
                                               	\ = í	«îïð3(	((#)p(#                                                             (7.5) 
where n
 
is the original number of the studies in meta-analysis, rankS  is the Wilcoxon statistic 
(see Rothstein et al.104 for how to calculate rankS ). Note that at each iteration 0L  is rounded up 
to the nearest integer and provides estimates of 0k . After estimating the number of missing 
studies, the meta-analysis is repeated on the filled dataset to get “trim and fill” estimate (i.e. the 
adjusted pooled effect size). Each filled study is assigned the same standard error as the 
trimmed study it reflects in order to maintain symmetry within the filled dataset. 
Note that  Peters et al.166 conclude that if there is evidence of publication bias in the effect 
size with large between study heterogeneity, the fixed-random trim and fill method 
performing better than fixed-fixed and random-random trim and fill method. They state that 
“the fixed–fixed effects trim and fill models give estimates with very narrow 95 percent CIs. 
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Given that between-study heterogeneity is present, these 95 percent CIs are likely to be too 
precise as they do not account for this between-study heterogeneity. The fixed–random effects 
trim and fill models give wider CIs than the fixed–fixed effects model, since a random effects 
model is used to synthesize the filled data set, but the random–random effects model gives the 
most conservative CIs”. Thus, in this chapter, the fixed-random trim and fill method is 
performed to estimate the number of missing studies.  
 
Figure 7.3: Trim and fill plot based on the log hazard ratio and its standard error 
for the association between RFS and increase of uPA in Look et al.14 after filled by 
the effect size of the missing studies by using fixed- random method 
 
I applied the fixed-random  trim and fill method to the Look et al.14 dataset. Figure 7.3 shows 
the trim and fill plot for the log hazard ratio and its standard error for the uPA. As can be seen 
from the graph, there are seven missing studies imputed indicated by a square around the data 
symbol. Again, the original random-effects meta-analysis is 1.22 with 95% confidence interval 
(1.15 to 1.31).  The adjusted pooled effect size from fixed-random trim and fill method after 
imputing the 7 missing studies is 1.10 with 95% confidence interval (1.03 to 1.17). This leads 
to the same conclusion as the adjusted result when using Egger D-var; that is although there is 
some potential evidence of small-study effects, uPA is still a PF.  
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7.2.5 Summary for small-study effects in Look et al.14 
In this section, I summarize the findings results for uPA for the Look et al.14. The original 
meta-analysis of the PF was 1.22 with 95% confidence interval (1.15 to 1.31). The contour 
funnel plot shows asymmetry, and potentially missing studies appear to lie in the white area 
of the graph (insignificant area). This indicates that small-study effects are a potential threat, 
and publication bias may be operating.  There is also a slight shift to the right hand side of the 
cumulative forest plot as small-studies are introduced. The Egger’s P-value is 0.002, and thus 
significant. The trim and fill method yielded 7 missing studies. So it is of interest to use 
Egger’s D-var method to obtain an adjusted estimate of uPA. It yielded a change in their 
pooled estimate value compared to the original meta-analysis method (see section 7.3.3). 
However, uPA is still a PF, and this does not change the clinical conclusion of the original 
results that uPA is prognostic.   
7.3 In-depth Assessment of Small-study Effect in the 20 IMPF 
Articles  
As mentioned, small-study effects were rarely assessed in the 20 IMPF articles examined in 
Chapter 2, so I now do this using the methods introduced in section 7.3. 
7.3.1 Obtaining Suitable Data from 20 IMPF Articles 
To examine small-study effects, I needed to obtain the PF effect estimate and its standard 
error for each IPD study in each IMPF article. Unfortunately, I only found one article that 
reported the PF effect size and its standard error (or the confidence interval that I then used to 
calculate the standard error) for each IPD study, this was Trivella et al.72  
In the other IMPF articles, the authors gave the pooled effect size of the PF and its standard 
error, but without study specific estimates; for example the forest plot visually showed the 
effect size of the PF and its confidence interval for each IPD study but without their exact 
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values given. This did not enable me to extract the data required, unless potentially inaccurate 
extrapolation was made from the forest plot.   
To help overcome this, I e-mailed the authors of the other 19 IMPF articles to ask them for 
the aggregated data for their PF studies; in particular, the effect size of the PF and its standard 
error (or its confidence interval) for each IPD study. I also asked for the IPD itself (if it was 
available). The authors of the IMPACT study kindly agreed to give me their IPD data. Of the 
13 other studies, only five authors replied, and only the 2 MeRGE  articles92 93 provided their  
aggregated data. Thus, in the next section I examine whether small-study effects appear to 
exist and their impact in the Trivella.72 data,  the MeRGE datasets92 93,  and the IMPACT 
database74 76 79. 
7.3.2  Description of the 6 articles and my analysis of  IPD available. 
The IPD and summary data obtained related to six articles; Trivella et al.72,  the two  MeRGE 
datasets92 93,  and three IMPACT articles74 76 79.  These are summarized in Table 7.1 which 
shows for each IMPF article the PF and outcome, whether there is potentially availability 
bias, whether the authors originally examine small-study effects or publication bias, and what 
methods are used to analyse the IPD. None of these 6 articles had considered small-study 
effects previously.   
The IPD for the IMPACT dataset contained all PFs and the outcomes they considered; PF 
values with and without missing data imputed, and an extended set of 15 studies (compared 
to studies in their original analyses) were available; so there was a wide range of potential 
analyses I could undertake. I decided to focus on the PF variables considered in McHugh et 
al.79, Beek et al.76, and Murray et al.74 in relation to 6 month mortality. Further, I considered 
small-study effects in the original set of 7 studies and then again in the update set of 15 
studies.  
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In Trivella et al.72 the authors investigate whether microvessel density count after adjusting 
by age and stage is still a PF. Two sets of data available (all vessel method and Chalkely 
method), as there are two different methods of measurement.  So I assessed small-study 
effects for each group.  
 In MeRGE192, the authors investigate whether there is an association between Restrictive 
Filling Pattern (RFP) and mortality rate for Acute Myocardial infarction disease; in particular 
they assess whether RFP is a PF before and after adjusting by Killip I, II and III/V; so I 
examined the small-study effects for unadjusted and adjusted results. 
 In MeRGE293, the authors examine whether there is an association between RFP and 
mortality rate for the patients with heart failure and whether RFP is a PF after adjusting by 
LV ejection fraction (LVEF) and age.  Thus, again I examined small-study effects for both 
unadjusted and adjusted results.  
7.3.3 My strategy for examining small-study effects 
Following my experience of analysis the Look et al.14 data (section 7.4), I decided upon a 
strategy in the 6 articles.  
1. Assess small-study effects visually by using ‘contour funnel plot’ and ‘cumulative 
forest plot’. 
2. Estimate the number of missing studies by using fixed random trim and fill method.  
3. Obtain P-value for Egger’s test of asymmetry. 
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Table 7. 1: The brief summary for the 6 IMPF articles for which I could assess small-study effects 
Study  PF of interest Disease area Outcome No. of 
studies 
available 
to me  
Percentage 
of IPD 
obtained  
Was there 
potentially 
availability bias (i.e. 
studies for which IPD 
not obtained 
originally) 
Stated the methods I used to 
obtain PF estimate and its s.e. 
In each study 
Did the 
original article 
exam the 
small-study 
effects 
Trivella et 
al
72
. 
Microvessel-density counts Non-metastatic 
surgically treated 
non-small-cell 
lung carcinoma 
Overall 
Survival 
13 3  34% Yes, because they did 
not provide  all IPD 
studies that they 
asked for 
Cox PH model No, but they 
included 2 
unpublished 
studies 
MeRGE 1
92
 Restrictive Filling Pattern 
(RFP) was the key interest; 
they also want to adjust for 
the other factors  such as 
Killip class 
Acute Myocardial 
infraction 
Mortality 18      56% Yes, because they did 
not provide  all IPD 
studies that they 
asked for 
Cox PH model No 
MeRGE2
93
 Restrictive Filling Pattern 
(RFP) was the key interest; 
and they also adjusted by 
LVEF and age 
Heart Failure  Mortality 6      35% Yes, because they did 
not provide  all IPD 
studies that they 
asked for 
Cox PH model No 
Beek et al.
76
 Laboratory parameter 
(glucose, Prothrombin (Ph), 
haemoglobin (Hb)) 
Traumatic brain 
injury 
Six month 
Glasgow 
outcome 
scale 
15 N  NA Not relevant, as it is 
collaboration for 11 
studies.  
logistic regression * No 
Mchugh et 
al.
79
 
Secondary insult (e.g. 
hypoxia, hypotension, and 
hyotheria) 
Traumatic brain 
injury 
Six month 
Glasgow 
outcome 
scale 
15      NA Not relevant, as it is 
collaboration for 11 
studies. 
logistic regression* No 
Murray el 
al.
74
 
Age, Glasgow coma scale 
(GCS),  motor scale, pupil 
response, computerized 
tomography (CT), 
prothrombin time, 
hypotension, hypoxia, and 
glucose 
Traumatic brain 
injury 
Six month 
Glasgow 
outcome 
scale 
15      NA Not relevant, as it is 
collaboration for 11 
studies. 
logistic regression* No 
*All continuous PFs were analysed on their continuous scale and a linear trend assumed for simplicity.  NA refers to not applicable  
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Then, if trim and fill method yielded 2 or more missing studies, or Egger’s P-value was less than 
0.10, or if visually I was concerned about small-study effects, I proceeded to 
4. Use Egger’s D-var method to estimate the adjusted pooled effect size of the PF. 
 Note that (2) to (4) were only considered if the number of studies was greater than 10. 
7.3.4 The assessment of  the small-study effects in the  six IMPF articles 
In this section, I assess small-study effects in the 6 IMPF articles outlined in section 7.3.2. First, 
I assess the three articles that used a literature reviews to identify relevant studies (Trivella et 
al.14, MeRGE192 and MeRGE293). Recall that literature review articles sought IPD by first 
identifying relevant studies using a literature review( e.g. using Medline, Embase), and then 
contacting authors of all identified articles to ask for their IPD (Chapter 2). In contrast,  the three 
IMPACT articles (Beek et al.76, Mchugh et al.79, and Murray et al.74) use IPD from an existing 
dataset. Table 7.2 and 7.3 summarize the results found using my strategy outlined in 7.3.3. 
7.3.4.1 The assessment of the small-study effects for the Literature review articles 
For Trivella et al.72 I assess small-study effects in the analysis of whether microvessel count in a 
PF after adjusting by age and cancer stage, first  for all vessel method and then Chalkely method. 
Figure 7.4 shows the contour funnel plots and cumulative forest plots for the two- measurement 
methods. The contour plot, for all vessel method with 13 studies, shows no evidence of 
asymmetry (Figure 7.4). In Chalkely method, there are only small differences between the 
standard error values across the  6 studies, and so it is not appropriate or sensible to examine  
small-study effects for this method as no smaller study exist160.  For all vessel method the 
cumulative forest plots show barely any shift as smaller studies are included (Figure 7.4). There 
are no missing studies estimated by using trim and fill method, and Egger’s P-values were 
greater than 0.10 (see Table 7.2). Thus, I conclude there is no concern for the small-study effects 
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for either measurement method, and this strengthens the original conclusions from Trivella et 
al.72 
Figure 7.4: Funnel and cumulative funnel meta-analysis plot based on the log hazard ratio 
and its standard error for the first and second group association between risk of death and 
increase of microvessel count, as measured by chalkely and all vessel methods respectively 
adjusted for age and cancer stage in Trivella et al.72 study. 
Figure (7.4a): Contour funnel plot for microvessel 
count  adjusted by age and cancer stage measured by 
all Chalkely method –for  6 studies 
 
Figure(7.4 b): Cumulative funnel plot for microvessel 
count  adjusted by age and cancer stage measured by 
Chalkely  method –for 13 studies 
 
Figure (7.4c): Contour funnel plot for microvessel 
count  adjusted by age and cancer stage measured by 
all vessel method –for  13studies 
 
Figure (7.4d): Cumulative funnel plot for microvessel 
count  adjusted by age and cancer stage measured by 
all vessel method –for 13 studies  
 
          Blue line is the meta-analysis pooled result. 
In MeRGE192, I assessed the small-study effects for unadjusted RFP results and then after 
adjusting by LVEF and age. Figure 7.5 shows that for unadjusted and adjusted RFP, the contour 
funnel plots show no clear asymmetry and cumulative forest plots show no considerable shift as 
smaller studies are included. Trim and fill methods yielded 2 missing studies for the adjusted 
RFP, and Egger’s P-value was 0.49.  Based on my strategy in section 7.3, I was now only 
concerned about small-study effects in the analysis of adjusted results. The pooled effect size of 
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the original meta-analysis of the PF was 2.28 with 95% confidence interval (1.90 to 2.09), this 
indicates that RFP is a PF even after adjusting by LVEF and age; the adjusted pooled effect size 
from D-var method was 1.90 with 95% confidence interval (1.06 to 2.09), this indicates that 
although there is slight concern for small study effects, RFP (after adjusted by LVEF and age) 
still appear to be a PF even when adjusting for any funnel plot asymmetry. This again 
strengthens and enhances the original conclusion that RFP is prognostic.  
Figure 7.5: The contour funnel plot for the log hazard ratio of RFP itself and after adjusted by 
LVEF and age, for the MeRGE1 study92  
Figure 7.5a: The contour funnel plot for the log 
hazard ratio of  unadjusted RFP, for18 IPD studies 
in MeRGE1 
 
Figure 7.5b: The contour funnel plot for the log 
hazard ratio of  unadjusted RFP for 18 IPD studies in 
MeRGE1 
 
Figure 7.5c: The contour funnel plot for the log 
hazard ratio of  RFP after adjusting by LVEF and 
age, for18 IPD studies in MeRGE1 
 
Figure 7.5d: The cumulative forest plot for the Hazard 
ratio of  RFP after adjusting by LVEF and age , for18 IPD 
studies in MeRGE1 
 
 
     Black line is the meta-analysis pooled result. 
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Table 7. 2 : The assessment for the small-study effects and publication bias for the Trivella, MeRGE1 and MeRGE2, by using contour funnel 
plot, cumulative meta-analysis, Egger’s methods and trim and fill method 
Article PF Number 
of 
studies 
Visual 
asymmetry 
Cumulative meta-
analysis shift 
Egger’s 
P-value 
Trim and 
fill, 
number 
of 
missing 
studies 
Original 
meta-
analysis, 
with 95% CI 
Original 
Egger’s  
method, 
with 95% CI 
Egger’s D-var 
method, 
with 95% CI 
Overall 
concerned 
about small-
study effects 
Trivella  
et al. 
(Hazard 
ratio) 
Microvessel count 
adjusted for age , and 
cancer stage for All 
vessel method 
13 No Minor shift  0.68 0 ------ ------ ------ No concern* 
Microvessel count 
adjusted for age , and 
cancer stage, for 
Chalkely method 
6 No Minor shift  ------ ------ ------ ------ ------ No concern* 
MeRGE1 
Hazard 
ratio 
RFP, whole dataset With 
18 IPD studies  
 
18 Tentative yes Minor shift  0.90 1 ------ ------ ------ No concern 
RFP after adjusted by 
LVEF and age , With 18 
IPD studies  
 
18 Tentative yes Slight shift  0.49 2 2.28 
(1.91 to 2.73) 
2.06 
(1.53 to 2.77) 
1.90 
(1.06 to 3.40) 
There is a slight 
concern*, but 
conclusion 
does not 
change 
MeRGE2 
Hazard 
ratio 
(Hazard 
ratio) 
RFP 6 No Minor shift  ------ ------ ------ ------ ------ No concern* 
RFP With info on Killip 
class 
 
6 No Minor  shift  ------ ------ ------ ------ ------ No concern* 
Killip Class II 6 No Minor shift  ------ ------ ------ ------ ------ No concern* 
Killip III/IV 5 Tentative yes Minor  shift  ------ ------ ------ ------ ------ No concern* 
*The number of the studies is not enough as it is less than 10 studies, e.g. this causes Egger D-var to have very wide confidence interval.
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Figure 7.6: The cumulative forest plot and contour funnel plot for RFP itself and after adjusting by killip and grouped by killip II and III/IV, for 
MeRGE2 study 
Figure 7.6a :The cumulative forest plot 
for RFP itself 
 
Figure 7.6b:The cumulative forest plot for 
RFP after adjusted by Killip 
 
Figure 7.6c: The cumulative forest plot for 
RFP for Killip II 
 
Figure 7.6d:The cumulative forest plot 
for RFP for Killip III/IV 
Figure 7.6e :The contour funnel plot for 
RFP itself 
 
 
Figure 7.6f :The contour funnel plot for 
RFP after adjusted by Killip 
 
 
Figure 7.6g :The contour funnel  plot for 
RFP for Killip II 
 
 
Figure 7.6h :The contour funnel plot 
for RFP for Killip III/IV 
 
Black line is the meta-analysis pooled result. 
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In MeRGE293, I assessed the small-study effects for RFP as an independent PF, and after 
adjusting by Killip, and grouped by Killip II, and III/IV. Note that as the number of studies is 
less than 10 studies, I do not apply trim and fill method or Egger’s test etc. Visually, there is no 
concern for small-study effects (Figure 7.6). 
7.3.4.2 The assessment of the IMPACT articles  
Table 7.3 summarizes my investigation of small-study effects for the three IMPACT studies. 
Figures 7.7 to 7.12 show the contour funnel plots and cumulative forest plots for the three 
IMPACT studies. Generally, there is no evidence that small study effects are a concern. Even 
when Egger P-value is less than 0.10 or trim and fill suggest greater than two-missing studies, 
the asymmetry is in the opposite direction to a publication bias mechanism. For example, in 
i_hyypoxia results for 14 IPD studies for Mchugh the original meta-analysis of the PF was 1.76 
with 95% confidence interval 1.45 to 2.14, whilst using Egger’s D-var adjust for asymmetry 
gives an adjusted pooled effect size of i_hypoxia was 2.28 with 95% confidence interval 1.94 to 
2.67. The only slight cause for concern is for age with original 11 studies, as there is asymmetry 
with missing studies potentially in the white area of the graph closer to the null value, which may 
suggest the problem of publication bias. Also, there is a gradual shift to the right hand side of the 
cumulative forest plot. Trim and fill method yielded 5 missing studies. Whilst the original meta-
analysis results of the PF was 2.09 with 95% confidence interval (1.79 to 2.45),  the adjusted 
pooled effect size estimate from  Egger’s D-var  method was 1.82  with 95% confidence interval 
between (1.61 and 2.06). However, this suggests age is still a PF and so-despite the asymmetry-
the conclusion does not change.   
To sum up, for all variables, there is barely any concern for small-study effects and  there is no 
evidence that small-study effects would change the conclusion of the original data, in other 
words, the variables of interest are all PFs and the investigation of small-study effects has 
strengthened this conclusion.  
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Figure 7.7: The contour funnel plot for  the original IPD studies that included in the original article and  the 15 recent IPD studies for Beek et al.76 
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Figure 7. 8: The cumulative funnel plot for  the original IPD studies that included in the original article and  the 15 recent IPD studies for Beek et 
al.76 
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Table 7. 3 : The assessment for the small-study effects and publication bias for the three  IMPACT studies (Beek et al.76, McHugh et al.79 and 
Murray et al.74), by using contour funnel plot, cumulative meta-analysis, Egger’s methods and trim and fill method 
Article Analysis PF No. of 
studies 
Visual 
asymmetry 
Cumulative 
meta-analysis 
shift 
Egger’s 
P-value 
Trim and fill, 
number of 
missing 
studies 
Original meta-
analysis, with 
95% CI 
Egger’s D-var 
method, with 95% 
CI 
Overall 
concerned about 
small-study 
effects 
Beek et 
al.  
Original IPD 
studies  
i_hb for 6 IPD 
studies 
6 Tentative 
yes 
No shift ------ ------ ------ ------ slight concern 
The recent IPD 
studies  
i_hb for the 
recent 15 studies 
15 Tentative 
yes 
Slight right 
shift  
0.05 4 0.68 
(0.64 to 0.72) 
0.62 
(0.56 to 0.69) 
Slight concern  
Original IPD 
studies 
i_ph for 7 IPD 
studies 
7 Tentative 
yes 
No shift ------ ------ ------ ------ No concern 
The recent IPD 
studies  
i_ph for 15 IPD 
studies 
15 No Slight right 
shift 
0.56 2 0.80 
(0.76 to 0.85) 
0.79 
(0.72 to 0.87) 
Slight concern 
Original IPD 
studies  
i_glucose for 7 
IPD studies 
7 Tentative 
yes 
Slight left  
shift  
------ ------ ------ ------ No concern 
The recent IPD 
studies  
i-glucose for 15 
IPD studies 
15 No Slight left 
shift   
0.53 0 ------ ------ No concern 
Mchugh 
et al., 
IMPACT 
article. 
Odds 
ratio 
Original IPD 
studies 
i_Hypoxia for the 
8IPD studies 
8 Tentative 
yes 
Slight left 
shift   
0.12 0 ------ ------ No concern 
The recent IPD 
studies  
i_Hypoxia for the 
14 IPD studies 
14 Tentative 
yes 
Slight shift  to 
the left 
0.06 0 1.76 
(1.45 to 2.14) 
2.28 
(1.94 to 2.67) 
Slight concern 
Original IPD 
studies  
Hypoxia for the 
8IPD studies 
8 Tentative 
yes 
Slight left 
shift 
0.21 0 ------ ------ No concern 
The recent IPD 
studies  
Hypoxia for the 
14 IPD studies 
11 Tentative 
yes 
Slight left 
shift   
0.26 0 ------ ------ No concern 
Original IPD 
studies  
i_Hypotension for 
the 10 IPD studies 
10 Tentative 
yes 
Slight shift  to 
the left 
0.21 0 ------ ------ No concern 
The recent IPD 
studies  
i_Hypotension for 
the 14  IPD 
studies 
14 Tentative 
yes 
Slight shift  to 
the left 
0.20 0 ------ ------ No concern 
Original IPD 
studies  
i_Hypotension for 
the 9 IPD studies 
9 Tentative 
yes 
No shift ------ ------ ------ ------ No concern 
The recent IPD 
studies  
i_Hypotension for 
the 13  IPD 
studies 
13 Yes No shift 0.18 0 ------ ------ No concern 
Note that i_hb: is the haemoglobin with imputed the missing data, i_pH is the Prothrombin with imputed the missing data, i_glucose: is the glucose after imputed the 
missing data, etc. 
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Article Analysis PF No. of 
studies 
Visual 
asymmetry 
Cumulative 
meta-analysis 
shift 
Egger’s 
P-
value 
Trim and 
fill, 
number 
of missing 
studies 
Original meta-
analysis, with 
95% CI 
Egger’s D-var 
method, with 
95% CI 
Overall 
concerned 
about small-
study effects 
Murray 
et al. 
 
Original IPD 
studies 
Pupil for the  11 IPD studies 
 
11 Tentative yes Slight right shift 0.94 0 ------ ------ No concern 
 The recent 
IPD studies  
Pupil for the  14 IPD studies 15 Tentative yes Slight right shift 0.88 0 ------ ------ No concern 
 Original IPD 
studies 
Age for 11 studies 11  Tentative yes Slight right shift 0.21 5 2.09 
(1.79 to 2.45) 
1.82 
(1.38 to 2.44) 
Slight concern 
 The recent 
IPD studies  
Age for 15 studies 15 Tentative yes Slight right shift 0.19 0 ------ ------ No concern 
 Original IPD 
studies  
Adjusted Hypoxia for 11 
studies* 
11 Tentative yes Slight right shift 0.09 0 1.57 
(1.32 to1.85) 
1.86 
(1.46 to 2.36) 
Slight concern 
 The recent 
IPD studies  
Adjusted hypoxia for the  
15 studies* 
15 Yes Slight right shift 0.07 0 1.52 
(1.32 to 1.76) 
1.86 
(1.46 to 2.29) 
Slight concern 
 Original IPD 
studies  
Adjusted Hypotension, for 
11 studies* 
11 Yes Slight right shift 0.22 0 ------ ------ No concern 
 The recent 
IPD studies  
Adjusted Hypotension, for 
15 studies* 
15 Yes Slight right shift 0.16 0 ------ ------ No concern 
 Original IPD 
studies  
Adjusted i_glucose, for 11 
studies * 
 
11 Tentative yes Slight right shift 0.96 1 ------ ------ No concern 
 The recent 
IPD studies  
Adjusted i_glucose , for 15 
studies* 
15 Yes Slight right shift 0.71 0 ------ ------ No concern 
 Original IPD 
studies  
Adjusted pH, for 11 
studies*  
11 Tentative yes Slight right shift 0.14 1 ------ ------ No concern 
 The recent 
IPD studies  
Adjusted pH, for 15 
studies*  
 
15 Yes Slight right shift 0.02 5        0.73 
(0.64 to0.78) 
0.66 
(0.59 to 0.74) 
Slight concern 
* Note that Hypoxia, Hypotension, i_glucose, and pH are adjusting by age d_motor, and pupils, for original studies included and the 15 recent IPD studies 
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Figure 7.9: The contour funnel plot for i_hypoxia, hypoxia, hypotension and i_hypotension for the included studies in the original Mchugh et al.79, 
and the recent IPD IMPACT studies. 
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Figure 7.10: The cumulative forest plot for i_hypoxia, hypoxia, hypotension and i_hypotension for the included studies in the original Mchugh et 
al.79,  and the recent IPD IMPACT studies. 
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Figure 7.11: The contour funnel plot for pupil, age, hypoxia, hypotension, i_glucose and pH after adjusted by age, d_motor, and pupils for 
the included studies in the original Murray et al.74, and the recent IPD IMPACT studies. 
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Figure 7.12: The contour funnel plot for pupil, age, hypoxia, hypotension, i_glucose and pH after adjusted by age, d_motor, and pupils for the 
included studies in the original Murray et al.74, and the recent IPD IMPACT studies. 
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7.4 Conclusion 
In this chapter, I undertook an assessment of publication bias for 6 articles14 72 74 76 79 92 93by 
using contour funnel plot, cumulative funnel plot, trim and fill method and Egger’s test.  I   e-
mailed the authors of  19 IMPF articles ( as there is one article72 reported their aggregated 
data in the article) asking them whether it is possible to provide the aggregated data  (effect 
size of the PF and its standard error) or their IPD, but only 2 articles provide the aggregated 
data, and the 6 IMPACT articles provide the IPD data.  
The results for these articles generally give a little evidence of small-study effects; this 
indicates that the IMPF articles may have less concern for small-study effects or publication 
bias than meta-analysis of PFs using aggregated data. 
The limitation here is that the assessment of small-study effects has been undertaken for only 
a sample IMPF projects that actually gave me data. Thus, my research could also be affected 
by bias; that study results were not obtained from most IMPF articles is very poor practice, 
and shows reporting of IPD meta-analysis most improve. Also, for simplicity I assumed 
linear trends for all continuous PFs. I also recognise that assessment of funnel plot 
asymmetry is notoriously subjective, and others may interpret results differently. However, I 
have used a clear strategy that only if there was clear visual asymmetry, a significant Egger’s 
test results, or two or more missing studies estimated by trim and fill method would I be 
concerned about small-study effects. Only then did I use Egger’s D-var regression method to 
obtain adjusted pooled estimates.  
I undertook the empirical study to assess the small-study effects and publication bias in the 
IMPF articles. However, there are other empirical studies that assess the small-study effects 
in meta-analysis and clinical trials.  For example, Palma et al.168 undertook a systematic 
review of 225 meta-analyses, to examine the assessment for publication bias with meta-
analysis on cardiovascular diseases. They stated that ‘The frequency of assessment of 
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publication bias in meta-analysis is still very low, although it has improved with time. It is 
more frequent in meta-analyses on observational studies and it is related to other 
methodological characteristics of reviews’. Sutton et al.169 took 48 reviews in Cochrane 
Database to assess the effect of publication bias on the results of these articles. The authors 
stated “Publication or related biases were common within the sample of meta-analyses 
assessed. In most cases these biases did not affect the conclusions. Nevertheless, researchers 
should check routinely whether conclusions of systematic reviews are robust to possible non-
random selection mechanisms.” 
There are also empirical studies to assess the small-study effects and publication bias for the 
prognosis research.  For example, Kyzas et al.170 found that most of the articles on cancer PF 
studies yielded significant results. This perhaps indicates to a major problem of publication 
bias, and Hemingway et al. undertook a systematic review for the prognostic effects of 
circulating biomarkers in stable coronary disease; they include 390 reports of biomarker 
effects, and state that “The quality of individual study reports was variable, with evidence of 
small study (publication) bias and incomplete adjustment for simple clinical information such 
as age, sex, smoking, diabetes and obesity”. This highlights that there is an evidence for 
small-study effects in prognosis research. 
In conclusion, although most of the 20 IMPF studies do not assess the small-study effects or 
publication bias in their analysis, after assessing whether there is evidence of small-study 
effects, I found that there is very little evidence of small-study effects to cause concern here 
(based on the 6 IMPF studies). Even, in Look et al. where small-study effects were found, 
adjusting for it did not change clinical conclusion, although the PF effect was smaller. I 
recommend all IMPF projects should assess small-study effects and potential  publication 
bias in the future , as Hemingway et al.2 state that “A prudent default position would be to 
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assume that prognosis research is seriously afflicted by publication bias, until there is 
evidence to the contrary”. 
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CHAPTER 8 
DISCUSSION AND CONCLUSION  
8.1  Introduction 
Prognostic factors (PFs) are patient characteristics (e.g. age, biomarker levels) that are 
associated with future clinical outcomes in patients with existing disease. PFs are 
important clinical tools because they help to identify patients with different risks of outcome 
(e.g. recurrence of disease) and thereby facilitate the most appropriate treatment strategies 
and aid patient counselling3, they are also used in the design and analysis of trials, and act as 
confounding factors in observational studies4. Evidence-based results regarding PFs are 
therefore very important to both clinicians and their patients. However, primary PF studies 
have numerous problems such as poor reporting, analysis and design5-7. PF studies are 
subject to numerous biases, such as selective reporting7  and “optimal” choice of cut-points8. 
These severely limit meta-analysis of PF studies using aggregated data, where summary of 
results are combined across PF studies. Individual Patient Data Meta-analysis of PF studies 
(IMPF) have been proposed as the gold-standard approach9-11, because it utilises the raw 
patient data and thus does not rely on reported results. 
In this thesis I have formally demonstrated the challenges and the pitfalls of IPD meta-
analysis of prognostic factor (IMPF) studies through a literature review of IMPF articles 
(Chapter 2). I have also performed a comparison study between the aggregated data and IPD 
approach by using an empirical example in breast cancer to show up which approach is more 
flexible and more reliable for statistical analysis. I found that IPD approach is better than 
aggregated data (Chapter 3) because it allows to adjust the PF by other confounding factors, 
assess the interaction between two PFs as an additional PF, and examine PFs in subgroup of 
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patients. But it still has challenges such as missing data, different methods of measurement, 
and potentially publication bias. 
I have also demonstrated a wide range of possible one-step and two-step for IPD meta-
analysis of PFs (11 models developed); which differed according to whether they account for 
the clustering of patients across studies, whether they accounts for the residual variation for 
the same values of the PF, and whether they account for the correlation of parameter 
estimates (Chapter 4).  TBI dataset was used as an applied example to show how the effect 
size of the PF and its standard error changed accordingly for the eleven one-step and two-step 
models. Surprisingly, these were little difference between the models. But I recognized this 
was just one dataset for which the baseline risk was remarkably similar across studies.  
So in chapter 5 a simulation study was undertaken to assess three key models from the 11 
possible one-step and two-step models; in particular the standard two-step model (which 
account for the clustering of patients across studies); the one-step model that ignores the 
clustering of patients across studies and assumes that the whole IPD comes from one study; 
and the one-step model that accounts for the clustering of patients across studies by using an 
indicator variable. The simulation study was undertaken for a single binary or continuous PF 
in relation to a binary outcome, and I assumed the PF effect was fixed across studies and only 
a simple univariate logistic regression model was fitted. I found that one-step meta-analysis 
that account for the clustering across studies is the best fitted model, as it consistently 
produces unbiased estimates with suitable coverage.  
Previous chapters assumed linear trends for continuous PFs. In chapter 6 I demonstrated all 
of the first and second order possible IPD logistic regression fractional polynomial models 
that can be used, if the linearity assumption of the PF does not hold. Again the TBI dataset 
was used as an applied example to show and highlight the accuracy for each model according 
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to chi-square statistics and deviance; in particular to indicate to the best model that has less 
deviance. I found one-step FP model is the easiest to fit and that a quadratic trend between 
age and the logit risk of 6 month mortality was appropriate.  
Finally, in chapter 7 I examined the problem of small-study effects in IMPF articles. I was 
able to consider - through obtaining IPD and extracting aggregated data- statistical methods 
for detecting small-study effects and their potential impact on IMPF results. I found that there 
is very little evidence of small-study effects in IMPF articles. Even when small-study effects 
were a concern (e.g. in the best cancer data), adjusting for funnel plot asymmetry did not alter 
clinical conclusion. 
Now, in this concluding chapter I will summarize and discuss the most important findings  
and issues that have arisen during the thesis, and will particularly emphasise why the research 
undertaken benefits future evidence syntheses of  PF studies. I will also consider the 
numerous challenges that remain unaddressed by the research in this thesis, and will identify 
the main further research priorities that have specifically developed out of the work I have 
presented. 
8.2  Key Findings and Recommendations for my Thesis 
 8.2.1 Benefits of IPD over aggregate data for meta-analysis of PF 
studies.  
Individual Patient Data (IPD) is considered as a gold standard method for producing reliable 
PF meta-analysis results107.  I have demonstrated some of these advantages , which include 
fitting one-step models, modelling non-linear trends, reducing the threat of small-study 
effects, and adjustment for other variables171. It also allows an evaluation of combinations of 
PFs, which may produce more specific and accurate prognostic assessments (Chapter 3).  
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IPD meta-analysis of PF is more preferable to using aggregated data. In particular, there are  
several limitations for meta-analysis of aggregated data57 such as the variables included in the 
multivariable model are different from study to study, which is likely to cause heterogeneity 
in the multivariate PF results across studies; there is no same strategy for the choice of cut-off 
level among studies (different cut-off points across studies); there are missing values for the  
aggregated data ( e.g. hazard ratio) in some studies; it also limits the ability to check the 
assumptions of the statistical model in each study, as well as the ability to look at the PF after 
adjusting or grouping by other variables. In contrast, IPD  meta-analysis has many 
advantages over aggregated data56 99 and  Figure 8.1 lists some findings of the benefit of IPD 
approach60, However this does not mean that IPD meta-analysis is without its challenges and 
pitfalls. In section 8.2.2 I tackled some of these challenges, and I highlighted some challenges 
that need to be considered in future research. 
8.2.2 The Challenges Facing IMPF Projects 
There are numerous methodological, statistical and practical problems facing IMPF projects 
(Chapter 2). Firstly, IPD does not solve the problem of poor primary studies. Riley et al.22 
stated that ‘Prognostic markers are important tools in the management of patients with 
cancer and many other diseases, and as such primary studies of prognostic markers are 
essential. However, the design and evaluation of such studies can be greatly improved’. 
Alongside, poor quality of primary studies there are challenges in statistical analysis such as 
how to tackle missing data and different methods of measurement; which method of meta-
analysis is recommended (one-step or two-step); also whether accounting for the clustering of 
patients within studies is considered; how we handle continuous variables when the linearity 
assumption fails; publication bias and availability bias; checking the assumption of the 
statistical analysis in each study and what to do when it fails; also handling some other issues 
such as the problem of skewness in some continuous variables and dealing with outlier 
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values. In this thesis, I considered some of these challenges, but there are still some 
challenges need to be considered (See Chapter 2 Figure 2.8), and section 2.8. 
  Figure 8.1: Some advantages of using individual patient data for a meta-analysis 
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8.2.3  How IMPF Projects can be Improved 
Many aspects of the conduct and reporting of IMPF projects are done well. For example, all 
of the 20 articles I assessed provided a statistical methods section in their methods; all 20 
reported the total number of participants within their IPD; 15 of the 20 accounted for 
heterogeneity in prognostic factor effects or justified why not; and 16 of the 20 considered 
the independent prognostic importance using a multivariable model. However, the available 
data from individual studies impose several challenges to derive a sensible summary estimate 
from an IMPF (see Chapter 2 Figure 2.8) and I also identified a number of ways IMPF 
projects can be improved (Figure 8.2).  In particular, it was a surprise that protocols and 
ethics approval for IMPF projects were rarely mentioned. Protocols are essential components 
of any research project and enhance its credibility, so they should be made and referred to. In 
terms of ethics, researchers may have not considered this to be relevant if IPD was being used 
for the same objectives as in the original studies, for which ethical approval may exist.  
Reporting standards in general must be improved within IMPF. Basic information was often 
missing, such the number of participants and events within each study providing IPD, and the 
keywords used to search for relevant studies. Researchers are encouraged to consider recent 
guidelines for reporting an IPD meta-analysis60, which supplement existing reporting 
guidelines for meta-analysis of a non-IPD approach70 172. Of course, an improved reporting of 
primary studies according to the REMARK guidelines23 is also needed, and this would be 
most helpful for several steps toward the IMPF project (e.g. examining study relevance 
according to inclusion/exclusion criteria; identifying outcomes considered and their specific 
definition; details about available variables and measurement techniques). 
  
[214] 
 
Figure 8.2: How can IMPF be improved 
Rationale & Initiation 
• Produce a protocol for the IMPF project prior to its initiation (detailing all aspects of rationale, 
conduct and statistical analysis) and reference this upon publication of the IMPF 
• Consider whether ethics approval is necessary for the IMPF project, and report this upon 
publication 
Process of obtaining IPD  
• Report how primary study authors were approached to obtain their IPD  
• Report the strategy used for searching the literature for relevant studies (if relevant), including 
keywords used and databases searched. 
• Provide a flowchart showing the search strategy, classification of identified articles, and 
retrieval of IPD from relevant studies (where relevant) 
• Consider how to improve retrieval of IPD from unpublished studies 
Details of IPD obtained 
• Report number of patients and events for each included study 
• Report a summary of the missing data for each study 
• Report the reasons why IPD was unavailable for some studies (if relevant), and report the 
number of patients, number of events and summary prognostic factor results in such studies 
Type and quality of IPD obtained 
• Consider and report the quality of studies for which IPD were obtained; in particular, are they 
all of comparable quality? 
Statistical methods used 
• Check and report the assumptions of the statistical models used; in particular, do model 
assumptions appear valid in each study separately? 
• Where possible, analyse continuous factors on their continuous scale and consider non-linear 
trends 
• In multivariable analyses, define the criteria used to decide whether a factor has independent 
prognostic value over other factors; also potentially consider whether the interaction between 
two (or more) prognostic factors is important 
• In the meta-analysis, account for clustering of patients within studies (and do not merge IPD 
and analyse as if IPD all came from a single study) and report how this was done. 
• Measure and, if necessary, account for between study heterogeneity in the prognostic factor 
effect(s) of interest when undertaking meta-analysis 
• Where sufficient studies are available (e.g. 10 per covariate of interest) and heterogeneity 
exists, examine the potential causes of such heterogeneity. 
• Consider whether meta-analysis conclusions change when restricting to IPD from the higher 
quality studies (if relevant) 
Assessment of publication bias and availability bias 
• Consider the potential impact of publication bias and availability bias on IPD meta-analysis 
results; in particular, are studies providing IPD comparable to those studies not providing IPD 
(if relevant)? 
Reporting guidelines 
• Utilize reporting guidelines for meta-analysis, such as those for MOOSE70 and IPD meta-
analysis60 
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In terms of statistical analysis, some IMPF projects chose to analyse continuous factors on a 
categorised scale without good reason. This approach has severe disadvantages as it loses 
statistical power and weakens the ability to assess non-linear prognostic factors effects173. 
When continuous factors are presented categorised within the available IPD itself, it  is 
questionable whether a summary meta-analysis result is even sensible if different cut points 
are used across studies.174  Another issue is that in five articles the meta-analysis method did 
not appear to account for clustering of participants within studies, and thus treated the IPD as 
if all coming from a single study, which is not appropriate. Further, four articles did not 
consider potential between-study heterogeneity in prognostic factor effects, even though 
heterogeneity is one of the most pertinent considerations in any meta-analysis. Also, missing 
data is considered as one of the substantial challenges. Among all of the 20 IMPF articles, 
each article considers at least one of the missing data problems such as missing data, missing 
variables and missing outcomes.  
Another critical issue is properly acknowledging the heterogeneity of patient populations, 
treatment of the patients, and the available ‘standard’ prognostic variables used to adjust the 
effect of the factor of interest in each study. Issues of the heterogeneity concerning patient 
populations and treatment may be tackled by excluding subgroups of the patients from some 
of the single studies, by stratifying analyses or by restricting analyses to more homogeneous 
subgroups. Ideally the same adjustment variables should be used in each study, but one will 
be restricted by those available in the IPD provided and sometimes relevant factors may be 
missing, which should be clearly noted. For example, Thakkinstian et al81. note that they 
‘could adjust for only a few clinical factors. Other factors (e.g. immunosuppressive drugs and 
dosage, viral hepatitis infection, duration of dialysis, etc.) that were previously associated 
with poor outcomes after renal transplantation were not available in the datasets obtained.’ 
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Perhaps most importantly, publication bias and availability bias were rarely considered in the 
20 IMPF articles examined. These problems are crucial to consider, as they may cause the 
IPD available to be a biased (non-random) portion of a potential prognostic factor’s evidence 
base55. Publication bias is a well-known concern in meta-analysis, and having IPD from 
studies does not negate the fact that additional unknown, unpublished studies may also 
exist157. Funnel plots and tests for asymmetry (‘small-study effects’) are useful tools for 
identifying potential publication bias, but these were only used in two of the 20 articles. 
Availability bias is an added concern for IPD meta-analysis, and relates to when not all 
known studies provide their IPD. For example, IPD may be less obtainable from smaller 
studies and/or studies with non-significant findings as they are more likely to have lost or 
destroyed their IPD. In such situations, comparison of the summary results in IPD and non- 
IPD studies is useful to see if they are similar, as done by Rovers et al.97 and Thakkinstian et 
al81.  
8.2.4 Should a Meta-analysis Account for the Clustering of Patients 
within-studies and is a One-step or Two- step more Appropriate? 
One of the key challenges for IMPF articles was how meta-analysis should account for the 
clustering of patients within studies and whether one-step or two-step approach was more 
appropriate; in the reviewing for IMPF articles in chapter 2 there was only 14 out of 20 
articles that accounted for the clustering of patients within studies. Further, it was clear that 
the statistical differences (if any)  between one-step and two-step methods were not 
understood, as there is not a common used approach, and even accounting for clustering was 
not always considered important.  
In chapter 4, I developed 11 IPD meta-analysis models for examining a single PF with a 
binary outcome; The difference in the model structure arise from using a one-step or two-step 
approach; accounting for the clustering of patients within studies by using two-step model or 
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one-step model66 94 100 124; whether one-step including indicator variable that reflect the 
impact of the clustering of patients across studies or ignoring the clustering of patients across 
studies by assuming  the IPD studies as it came from one study; whether we account for the 
correlation between parameters in the second step of meta-analysis or not; also whether we 
account for the residual variation for the same values of the PF in each study (see Table 4-1).    
The 4 IPD studies of the TBI dataset that investigate whether there is an association between 
age as a PF and probability of death by 6 months (see Table 1-2) was used to illustrate the 
methods. The results yielded no important difference across the 10 estimable models (recall 
that it was difficult to estimate the pooled effect size of the PF from model 1 as it is very 
difficult to estimate the residual variation, 2iσ ); in particular all of the 10 models have 
approximately the same pooled odds ratio and the same confidence interval, and all of the 
models yielded a P-value <0.05. This confirmed that there is a positive  association between 
age and six month mortality rate ( if age increase the probability of death increase) and age is 
still a PF. Initial conclusions suggested standard errors were smallest when correlation was 
accounted for, when residual variation was ignored, and when clustering was ignored. 
However smallest standard error does not necessary mean the best model. Indeed, the results 
did not help to identify the best meta-analysis model. Thus a simulation study was required to 
examine the effect of ignoring the clustering of patients across studies and whether one-step 
or two-step model more appropriate. 
In chapter 5, I undertook a simulation study for  three  out of the eleven IPD meta-analyses 
models from chapter 4  to assess whether  the clustering within studies can be ignored, and 
whether one-step or two-step approach is performed better. I considered these are the key 
questions to answer.  In particular, I selected standard two-step model that account for the 
clustering of patients accross studies; one-step account for the clustering of patients across 
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studies by adding an indicator variable; and one-step ignoring clustering by assuming the IPD 
studies as it came from one study. I undertook my simulation for a single binary PF, and then 
a single continuous PF. 
The simulation studies was undertaken for small and large number of IPD studies ; 5 and 10 
studies repectively; also I assumed that the sample size in each IPD study could be small (30 
to 100 patient) or large (30 to 1000) patients. The simulation study was repeated when the PF 
was continuous ( by assuming normal distribution)  and binary (by assuming Bernoulli 
distribution) .  The outcome was  binary ( 0 for alive and 1 for death) and it was generated for 
each patient according to a specified relationship between the outcome and the PF.  
Bias, percentage bias, MSE, and coverage (95%) were recorded to assess the performance for 
the three IPD meta-analysis models. The findings were similar whether the PF was binary or 
continuous.  The results of the simulation studies yielded that: 
• There is no difference between the three IPD meta-analysis models when the Standard 
deviation for  ∝  ( the baseline risk) was 0 or 0.25. 
• When the standard deviation for  ∝ was large 1.5. 
- This produces inaccurate results for one-step model that ignore the clustering 
across studies (i.e. the coverage of the pooled estimate was considerably less than 
95%, and it was downwardly biased). 
- An accurate result was seen for one-step model that account for the clustering of 
patients across studies (the coverage was around 95%, and there was no bias). 
- The results of two-step model yielded a too wide confidence interval with coverage 
above 95%  when the PF effect was also large.  
To sum up, ignoring clustering across studies is not recommended131 138 139, and the 
results of one-step accounting for clustering and two-step approach are often very 
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similar, only in a few situations with a binary PF did the two-step methods perform 
worst. This may be because the two-step model did not account for the correlation 
between parameters (∝< and	;<) in the second step, and that the normality assumption 
in the second step fails. However, I would recommend one-step meta-analysis that 
account for the clustering across studies as  it was consistently the best model across all 
simulation scenarios considered.  
8.2.5 Benefit for Applying Fractional Polynomial Approach for 
Developing One-step and Two-step Models. 
There are many issues for the analysis of continuous PFs; one of these issues arises when the 
assumption of linearity is found to be untenable, and I consider a fractional polynomial (FP) 
approach to address this problem144 145 148. Note that residual variation in models in chapter 4 
highlight that a non-linear relationship in age is potentially more sensible for the TBI dataset. 
In chapter 6, the focus was on considering the possible two-step and one-step models for IPD 
studies that account for the clustering of patients across studies; in particular by using first 
and second FP order for IPD meta-analyses logistic regression models.  The closed test was 
used to test the linearity assumption between the PF and the outcome, and it was also used to 
decide the best FP function (FP1 or FP2). TBI dataset was again used to estimate the pooled 
effect size of the PF for possible two-step and one-step models.  
Two-step Approach 
In two-step approach, I only fitted   FP1 logistic regression model (p=1). However, it was 
difficult to decide the best fitted model that has the highest chi-square statistics (as there are 8 
possible FP1 models), as there were different best powers for the 4 TBI trials when a 10 % 
significance level was used in the closed test. I handled this problem by adding up the 4 chi-
square statistics for each model and I selected the model that has the highest sum chi-square 
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statistics (this occurred for	N¼-p). Interestingly, however the closed test approach with 5% 
significance level gave age as a linear trend to be most appropriate.  
One-step Approach 
In one-step approach, two-models have been fitted; the first one was one-step FP1 IPD meta-
analysis logistic regression model and it produced N¼-p as the best fitted model. The second 
model was one-step FP2 IPD meta-analysis logistic regression model and it produced N¼-p 
and	N¼-(p, but the ;i#of N¼-(p was insignificant; thus the best model just includeN¼-p. The 
closed test approach gave N¼-p  as the best model regardless of the 5% or 10% significance 
level. Thus, at the 10 % level, it gives different conclusions to the two-step approach.  
In conclusion, I would recommend one-step FP model over two-step FP model, as it is easier 
to apply and it forces the model to have the same power in each study, without need to all of 
the procedures that I considered in the two-step approach. Also closed test was a helpful tool 
to test the linearity assumption and help to choose between the simple and complex FP 
functions. 
8.2.6 Assess the Impact of Small-study Effect on IMPF Articles. 
Small-study effects may arise in IPD meta-analysis projects if only IPD from significant 
small-studies are available104. A contour funnel plot, cumulative funnel plot, trim and fill 
method and Egger’s test were used to assess the small-study effect106 158 166 in 6 IMPF 
articles; these articles were mainly selected according to the availability of their data 
(aggregated data or IPD studies). In particular, aggregated data were provided for 3 articles 
and the IPD were provided for the IMPACT project (relating to 3 articles specifically).  
Generally, despite of array of many analyses, these was very little evidence for small-study 
effects; indeed  in the IMPACT data, most small-study effects suggest that the PF effects will 
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be larger than those originally estimated (i.e. the opposite of a publication bias mechanism). 
In Look et al., however, there is a significant evidence for the small-study effects, but this 
was found unlikely to change the original conclusion for the PF (i.e. uPA), even though the 
pooled results was potentially smaller than thought. 
The limitation here was that the assessment for small-study effects was only taken for 7 
IMPF articles; this is mainly due to the difficulty to obtain suitable aggregated data or IPD for 
examining small-study effects. This is due to different reasons such as some studies provides 
the forest plot without writing the effect size and its confidence interval for each study, and I 
e-mailed the authors to ask them about the aggregated data or IPD data, but many of them did 
not respond of to my request.  To sum up, there is very little evidence for the problem of 
publication bias or small-study effect in IMPF articles according to my limited review; even 
when small-study effects were a concern, the original conclusions were unlikely to change. 
This is encouraging. 
8.3 Future Work 
In Chapter 3 to 7 I examined some of the challenges listed in Figure 2.8. However, I have 
clearly not addressed all of them such as different methods of measurement and missing data.  
For example, in Trivella et al.72 the authors mention that there is different methods of 
measurement for microvessel density; they overcome this problem by dividing the data into 
two groups (each group has the same method of measurement). In Look et al.14  the authors 
also  found different methods of measurement as they state that “Levels of  uPA and PAI-1 in 
tumour tissue extracts were determined by different immunoassays; values were ranked 
within each dataset and divided by the number of patients in that dataset to produce 
fractional ranks that could be compared directly across datasets”. In the future work, I will 
consider the problem of missing data by using one of the statistical models such as 
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imputation analysis175 176 and also I will try to examine the problem of different methods of 
measurement and generate some suggestions. 
In Chapter 3, I compared between IPD and aggregated data meta-analysis approach, and I 
have shown by an empirical example that IPD meta-analysis is more favourable over 
aggregated data approach. However, I recognise that IPD is not always available. In the 
future work, I will examine the impact of combining aggregated data and IPD when some 
IPD are not available.  
In Chapter 4, there are a number of  limitations of the 11 IPD meta-analysis models such as 
the statistical analysis is applied to just a single PF (univariate analysis) and I assumed fixed-
effect method across studies as that there was no heterogeneity across the TBI (¹p = 0%). In 
the future work, I will consider model extension for accounting for the heterogeneity across 
studies. Also, I will consider the multivariable analysis by adjusting the PF of interest by 
other Prognostic factors177.  
In Chapter 5, there are some limitations for the simulation studies. First, I applied the 
simulation on a single variable only (continuous or binary PF); and I did not consider the 
multivariable model. Second, I assumed the linearity assumption for the continuous variable. 
Finally, I applied the simulation study only on three possible models for IPD meta-analysis 
and I assumed fixed effect across studies. In my future research, I will consider the following 
points: (i) the multivariable IPD meta-analysis models; (ii) random-effects to account for 
heterogeneity across studies (iii) and methods to account for the correlation between 
parameters by using multivariable random-effects two-steps meta-analysis models.  
In Chapter 6, generally, two-step FP IPD meta-analysis models, in the first step, allows a 
different FP model in each study but this makes it difficult to synthesize in the second step. 
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On the other hand, one-step model forces each study to have the same FP model (through 
estimates could be different, they all have same shape, e.g. all quadratic or all cubic etc.). 
Saurberi et al., (personal communication) suggest a new approach for FP two-step models, 
which allow a different FP model in each study and then averages these across studies using a 
two-step approach. Also random- effects approach it would be interesting to compare their 
approach to my one-step approach in the future work.  
In Chapter 7, I assessed the small-study effects for 6 IPD studies, and I found that there is 
very little concern for the small-study effects in IMPF. In the future work, more IMPF 
articles need to be assessed, especially in situations where IPD are unavailable for some 
studies. Then, I need to examine aggregated data and IPD. More simulations looking at the 
performance of Eggers D-var method for PF meta-analysis is also needed.   
8.4 Conclusion 
Although IPD offer many advantages over aggregated data. It still presents many challenges 
for meta-analysis of PFs. In this thesis, I have tackled some of these issues, but much 
research is needed in the coming years to help ensure IPD meta-analysis produces reliable 
evidence-based PF results. My key conclusion are shown in Figure 8.3 
In this thesis, I only used and studied retrospective IPD meta-analysis of PFs, due to the 
ease and quickness of using existing data. However they are restricted by the data already 
collected by primary study (e.g. certain variables and outcomes may be missing)1. 
Prospective IPD meta-analysis of PFs may reduce many of the pitfalls that I found for the 
retrospective IPD meta-analysis, as in prospective studies, patients are recruited at the 
current date and followed for an adequate length of time to identify what outcomes are 
achieved in all studies simultaneously.  This allows the same PFs ,  baseline characteristics 
and outcomes to be recorded by the researcher, and to ensure similar methods of 
[224] 
 
measurement, data coding, and variable inclusion from study to study. Thus, ultimately the 
gold standard IPD approach may actually be a prospective meta-analysis.  
Figure 8. 3: Key Conclusions from this thesis 
• IPD meta-analysis hugely beneficial for meta-analysis of PF studies especially 
compared to aggregated data approach.  
• Yet IPD still presents many methodological, statistical and practical challenges.  
• Often there is very little difference between one-step, two-step and even models that 
ignore clustering.  
• But when there is large variation in baseline risk, one-step IPD meta-analysis models 
that account for clustering are preferred; ignoring clustering leads to a low coverage, 
and the two-step (occasionally) leads to too high a coverage. Thus one-step accounting 
for clustering in my recommended best model. 
• When modeling a continuous PF and assuming a linear trend, examining the residual 
variation due to this factor helps decide whether as non-linear trend is sensible.  
• FP modeling allows non-linear PF trends; again the one-step framework is preferred 
because it forces each study to have the same FP terms. 
• Small-study effects may arise for IMPF but there was little evidence of this when 
examined. Only in one dataset (Look et al.) was it a major concern, but even then 
clinical conclusion is unlikely to alter after adjusting for funnel plot asymmetry.  
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APPENDIX 
Appendix A 
Appendix A1: Review of IPD meta-analyses of prognostic factor 
studies 
Aim: To critically examine published IPD meta-analyses of PF studies (in relation to any 
outcome) and ascertain: 
• their objectives and rationale 
• how and why they were conducted 
• the process used to obtain IPD and the success/problems therein 
• how the quality of primary studies was assessed 
• what statistical methods were used and the problems therein; in particular how het- 
erogeneity was examined, how many adjustment factors were used and how they were 
modelled, and how continuous factors were assessed 
• how publication bias related issues were examined 
• what the limitations and successes of the IPD project were, and the benefits/differences 
over aggregate data meta-analysis 
 
 We call a PF study one that looks to see if one or more factor is associated with an 
outcome in patients with existing disease at baseline. 
 We are NOT looking at predictive markers (i.e. those predicting response to 
treatment) and NOT prognostic models (i.e. those developing a risk score to 
predict outcome in future individuals). But of course the papers may have assessed 
the PFs alongside or enroute to a prognostic model or treatment predictions 
 In our review, all the questions relate to the prognostic factor assessments. Other 
parts of the paper (e.g. treatment effect, prognostic models etc) are not of interest at 
all. 
 
 
Below is a list of questions we will ask of a sample of the IPD meta-analyses identified 
 
A.1.1 General questions 
• What country is the corresponding author located in? (i.e. what is the central 
location for the IPD project?) 
• is there reference to a protocol for the IPD project, and, if so, were details given as 
to where it can be found? 
• Was ethics approval granted for the IPD project? If not, were reasons given as to 
why ethics approval was not necessary and, if so, what were the reasons? 
• What were the key prognostic factor research aims of the paper? In particular, are 
they looking to see if a prognostic factor is important on its own, or whether it is 
important after adjusting for existing PFs? 
• What was the main motivation to start the IPD project? (e.g. is it to resolve 
current disagreements; or to look at a new novel marker; is it connected to 
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financial support from a funder or a company or an HTA assessment?) 
• At baseline what was the condition of the patients being assessed (e.g. what 
disease 
• did they have, or what operation had they just had etc) 
• What PFs were of key interest? 
• What outcomes were of interest? 
 
A.1.2 Process of obtaining IPD 
• What were the stated reasons given for taking the IPD approach, rather than a meta- 
analysis of aggregate data? 
• Was another meta-analysis approach tried before and, if so, why was this IPD project 
needed in addition to this previous meta-analysis 
• If a meta-analysis of aggregate data had been done before, what were the stated 
conclusions and limitations of the research? 
• What was the process used to identify relevant studies for the IPD meta-analysis? (e.g. 
literature review, or collaborative group). 
• If literatures review, then what search strategy was used (e.g. search of Medline, 
Embase using keywords)? 
• If collaborative group, how were studies chosen to be included in the collaborative 
group (e.g. uPA is based on projects funded from an EU grant, so all EU studies 
included)? 
• What were the inclusion / exclusion criteria for deciding from which studies IPD 
would be sought? 
• For those studies for which IPD was desired, were there any requirements on the 
information needed within the IPD? In particular, were there any requirements on 
studies providing a certain set of ’adjustment factors’? (e.g. did they say that tumour 
size or stage of disease had to be available in the IPD for the study to be worth 
providing the IPD?) 
• How were authors of relevant studies approached for IPD (e.g.  e-mail, letter, 
phone etc.)? How many authors replied on first or second request? 
• Are there any details on the cost and time required to obtain and ’clean’ the IPD 
provided? 
• How many studies (or collaborating groups) were ultimately approached for IPD, and 
what proportion of these studies/groups actually provided IPD? 
• (If appropriate) what were the reasons given as to why some studies refused to provide 
IPD? 
A.1.3 Details of the IPD obtained 
• Did those studies that provided IPD give all their IPD or only a proportion? 
 
- If only a proportion, then what was omitted (e.g. certain patients, certain 
variables etc) and why? 
• Were details given of any differences in the IPD provided to that used in one or more 
previous publications? If yes, what were they (e.g. IPD has a longer follow-up time 
etc) 
• How many studies ultimately provided IPD? 
• Was the number of patients within each of the IPD studies given 
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• Was the number of events given for each outcome within each of the IPD studies? 
• Were details of any missing individual-level data within the available IPD given for 
each study, and, if so, what were they? 
• How many variables were considered as adjustment factors in the original studies (i.e. 
aside from the prognostic factor(s) of interest, how many other patient-level variables 
were available in each study)? 
• Did all studies have all variables, or was there missing variable information across 
studies? 
A.1.4 Quality of included primary studies 
• Did the inclusion / exclusion criteria for an IPD study include an assessment of study 
quality? 
- If yes, what quality criteria were used to decide inclusion or exclusion (or ’low’ 
quality and ’high’ quality)? 
- Were IPD still sought from low quality studies? 
• If the inclusion / exclusion criteria did not involve an assessment of study quality, was 
a quality assessment done at some other stage (e.g. for those studies actually providing 
IPD)? 
- If yes, describe when the assessment took a ’low quality study’ and a ’high 
quality study’ 
• How were ’low quality studies’ dealt with? In particular, was IPD sought from these 
studies and, if so, how were they included in the meta-analysis (if at all)? 
 
A.1.5 Statistical methods for an IPD meta-analysis 
• Was a statistical analysis plan given or mentioned in the Methods section? 
 
Meta-analysis approach 
• Were the data meta-analysed by: 
 
(a) Lumping all the data together into one big dataset, and ignoring clustering by trial 
or collaborative group; or 
(b) A one-step analysis, where the data from all studies/collaborative groups are 
analysed together but with clustering by study/group accounted for; or 
(c) A two-step approach, where the data are first analysed separately in each study, and 
then their model estimates are pooled together in second-step. 
 
• What type of statistical models was used? In the two-step approach, details are needed 
here of how individual studies were analysed, and then how the model estimates were 
pooled using meta-analysis.  In the one-step approach, again details are need here of 
the one-step model itself (Cox regression, logistic regression) and the meta-analysis 
assumptions therein (e.g. fixed or random-effects on the prognostic factor effect) 
 
Heterogeneity 
 
• Was the presence of between-study heterogeneity assessed and, if so, how? (e.g. I2 
statistic) 
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• Did the meta-analyses account for between-study heterogeneity? If so, how? (e.g. use 
place, and the quality criteria used to define of random-effects) 
• Were the factors causing between-study heterogeneity investigated? If so, how? (e.g. 
including study-level covariates in the model, or performing meta-regression) 
 
Continuous factors 
 
• How were continuous PFs analysed, on a continuous scale or categorized? If 
categorised 
• Were reasons given as to why this was done? 
• How many cut-points were used, and how were they chosen? If on a continuous 
scale 
• Were non-linear trends assessed and, if so, how were they modelled? (e.g. 
spines, fractional polynomials) 
• Was the continuous factor analysed on its original scale, or was it on a 
transformed scale? 
• If a one-step meta-analysis was used, was the continuous factor cantered about 
the mean value in each study? 
 
Clinical factors 
• Were clinical factors adjusted for in the model; if so, what were they? 
• For the prognostic factor(s) of primary interest were different methods of 
measurement used across studies. If so, how did the authors address in their 
analyses (if at all)? 
• Did each patient receive the same treatment? If not, how was treatment received 
ac- counted for in the analyses (if at all)? (NB again potential distinction needed 
here of how individual study analyses accounted for treatment, and then at the 
meta-analysis level how treatment was accounted for) - essentially look for any 
details of how and when treatment was incorporated into the analyses that are 
described. 
A.1.6 Analyses of multiple PFs together  and adjustment factors 
• Was the prognostic factor assessment adjusted for other variables (e.g.  other PFs or 
adjustment variables)? If so: 
• What method was used (e.g. Cox regression)? - Were combinations of PFs assessed 
(i.e. was the interaction between two or more PFs modelled). If so, how? 
 
 
• If multivariable models were fitted (i.e. models that included multiple variables) 
 
- What criteria were used to decide inclusion in the model?  (e.g.  statistical 
criteria, such as p < 0.1, or clinical criteria such as a hazard ratio > 2 or 
inclusion of ’smoking’ variable regardless). 
- Were results for non-significant presented in full (i.e. an effect estimate and its 
confidence interval, or p-value). - How were continuous factors analysed in the 
model. 
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A.1.7 Missing data  and check of assumptions 
• how were missing data handled at the study-level (e.g. missing treatment information) 
and/or at the patient-level (e.g. missing prognostic factor values) 
• Were the assumptions of the statistical models validated (e.g?  proportional hazards) 
within each study 
• What problems limited the statistical analysis (e.g. different method of measurements, 
different set of adjustment factors available etc) and how did the authors attempt to 
overcome these problems? 
A.1.8 Bias in the  set of IPD  available  / differences  between IPD and 
non-IPD studies 
• Was there an assessment or discussion of whether the IPD studies were a biased set of 
all studies (akin to the problem of publication bias), e.g. using a funnel plot? If yes, 
describe the assessment and what was found. 
• (if appropriate) for studies not providing IPD, were details given as to the number of 
patients and events in these studies 
• (If appropriate) were there any other details provided on the qualitative or quantitative 
differences between those studies providing IPD and those studies not providing IPD? 
If so, what were these differences? 
• (If appropriate) were details given regarding the robustness of meta-analysis results to 
the inclusion/exclusion of non-IPD studies? If so, what were these differences? 
• (If appropriate) were IPD and non-IPD studies meta-analysed together?  If so, what 
methods were used to do so? 
A.1.9  Reporting and Discussion 
• In terms of reporting, was it stated anywhere that the reporting guidelines of QUO- 
RUM or MOOSE were used, or was reference given to the QUOROM or MOOSE 
articles? (see refs below) 
• What were the main conclusions of the IPD project in the Discussion? 
• How do the conclusions differ (if at all) to any previous meta-analyses that have been 
done on the topic? 
• What strengths of the IPD project were noted in the Discussion? 
• What limitations and problems of the IPD project were noted in the Discussion? 
• What is the key further research? 
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Appendix B 
Appendix B1: The proof of ñòó({ô, {)= - var ({ô),  by using 
logistic regression model is explained as follows: 
Note that ;i\ = E , and ;i = ;i#. Let Y be a dichotomous random variable denoting the 
outcome of the PFs, and let 121 ,..........,, −= pxxxX  be a collection of PFs (for simplicity, I 
assume that there is only one PF); the conditional probability of the outcome is presented by
)()/1( xxYP pi== , where )(xpi  has the form  
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The logistic regression problem is then to obtain an estimate of the vector: 
),(ˆ 10 βββ =  
As with logistic regression, the matrix X for one PF and the intercept can be written as: 
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This matrix is called the regression matrix, where 1’s denoted to the intercept, and  ijx  refer 
to the PF. 
Maximum likelihood method is used to estimate the vector βˆ , and the likelihood function 
given as: 
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Estimates for the variances and covariances of the estimated parameters jβ are computed 
using the following equations.  Let VXXI ′=)ˆ(ˆ β , where X  is the pn×  
Matrix called regression matrix, and V  is a nn×  diagonal matrix with thi  diagonal term
)1( ii pipi − . That is, the matrix X is: 
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The matrix X ′  is  
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Now I will multiply the first two matrixes  VX ′  and the result will be  
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The inverse of the VXX ′  matrix can be calculated as follows: 
First, the determine of VXX ′   denote by )(det VXX ′ , and is given as 
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Second, the inverse of VXX ′  is called the variance covariance matrix of the estimated 
parameters 0ˆβ  and 1ˆβ , this is given as:  
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Appendix B2: Special case: Bivariate Random Meta-Analysis (BRMA) revert to 
Univariate Fixed effect Meta-Analysis  (UFMA) for αˆ    when both of outcomes and PF 
are binary data, the correlation within study does not effect on the estimated value of 
αˆ
 
Note that, let  ÉNM	Ã;i<#Ä = 	S<#p  and 	Ã;i<pÄ = 	S<pp  ,V< = CÉ	(E<, ;i<), ∝<=	Ô<#, and ;i< = Ô<p 
BRMA is a statistical model that can be utilised to estimate  jβˆ  ; it also  includes  the effect 
of the within and between studies correlation ; again assume that each study summary 
statistic  ijY (where  i=1 to n and j=1 to 2 outcomes)  is assumed an estimate of a different 
underlying true value ijθ  in each study; each ijθ  is assumed to be drawn from a distribution 
with mean value jβ  and between study variance jτˆ ; then the BRMA model can be written 
mathematically as follows: 
 
 
 
 
Where iδ  and Ω  are the within-study and between-study covariance matrices 
respectively; iλ  is the within-study covariance, 12τ  is the between-study covariance. As can 
be seen in equation (6), the BRMA consider the correlation within study and between 
studies. The covariance within-studies assume to be known. On the other hand, the UFMA 
does not account for the within and between studies correlation.  
BRMA model revert to UFMA model when  0ˆˆˆ 212
2
2
2
1 === τττ   (i.e. there is no 
heterogeneity across studies and no correlation across studies), and 21ii s−=λ  
(i.e. the covariance within studies equal negative the variance of the αˆ  when the outcome 
and the PF are binary data by using BRMA of logistic regression model). Note that the 
prove of 21ii s−=λ  is explained in appendix B1. Also, there is only one case when  BRMA 
revert to UFMA model for αˆ  only, when 21
2
12
2
2
2
1 ,0ˆˆˆ ii s−==== λτττ   and when the 
outcome is binary and the PF is binary. However, if the PF is continuous then the estimated 
value for   αˆ  by using UFMA model does not equal the estimated value for αˆ   when the PF 
is continuous. Note that the focus here is on the estimated value for βˆ (not onαˆ ).   
First,   the pooled estimate of the PF effect size of the BRMA can be estimated by using 
restricted iterative generalized least square method (RIGLS) as: 
 
 (5) 
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, where  nk ,.....,1=  representing the n  studies, and k  is used to distinguish the summation 
from 1 to n within the summation for ni ,......,1= .  
Second, by substituting in equation (5) when 212122221 ,0ˆˆˆ ii s−==== λτττ , then 1ˆβ  can be 
written as: 
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Third, by cancelling 21is   out from the denominator (in the very down line), equation 6 
reduce to: 
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Fourth, by taking 21ks  as a factor from the numerator and ∑
=
−
n
i ii ss1
2
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   as a factor from the 
denominator, equation 7 can be written as: 
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Fifth, by cancelling 21ks  and 
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2 ii ss −   out from the top numerator, and cancel ∑
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out, then equation 8 is given as: 
(6) 
(7) 
(8) 
   (9) 
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This can be written as:  
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As we can see from the equation (9) that the BRMA revert to UFMA 
Note that, this prove only for the case that the outcome and the PF are binary; an applied 
example will be given later.  However, this can be extended to the continuous case; in 
particular when the PF is continuous (e.g. age), but I will show that by applying on the TBI 
data set later.  
 
 
  
(10) 
(11) 
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Appendix C 
Appendix C1: STATA codes for possible two-step IPD meta-analysis models 
\\ Model 2 accounts for the clustering across studies and did not account for within-study 
variation for the patients who have the same age;  the pooled estimate of the PF is estimated  
through two  steps\\  
The first code: 
 by studyid: logit dead age10 
The second code: 
metan   beta s.e. of beta, fixedi  
\\Model 3: This model account for the clustering across studies and the variation within-
studies for   the patients who have the same age value in each IPD study. The pooled 
estimate effect size of the PF is estimated through two steps\\ 
The first code: 
by studyid: xtmelogit dead age10, || age10: cov(indep) intp (1) var 
The second code: 
 metan beta s.e of beta, fixedi 
the explanation here is the same as in the model 2 except that   this code ’ ||  age10: , 
cov(indep) intp(1) var’  is allowed  the  PF (age ) to vary across patients with different 
value of age and cov(indep) means one variance parameter per random effect.  The second 
step estimates the pooled effect size of meta-analysis by using ‘metan’. The interpretation 
here is similar to model 2.  
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Appendix C2: STATA codes for possible one-step IPD meta-analysis 
models 
\\ Model 6 ignores the clustering across studies and within study variation (assume that all 
of the data came from one study)\\  
  logit dead age10 
\\ Model7 ignores the clustering across studies by including the indicator variables and 
accounting for the variation within patients who have the same age value\\ 
Xtmelogit dead age10 || age10:, cov (indep) intp (1) var 
\\ Model 8 accounts for the clustering across studies and ignoring the variation within-
studies for the patients who have the same value of the PF in each study\\ 
 logit dead f11 f12 f13 f14 age10, nocons  
\\Model 9 accounts for the clustering across studies by including indicator variables and 
account for the variation within-study for the patients who have the same value of the PF\\  
xtmelogit dead age10 f11 f12 f13 f14, nocons || age10:, cov (indep) intp(1) var 
\\ Model 11 accounts for the clustering across studies and ignoring the variation within-
studies for the patients who have the same value of age in each study and assign a normal 
distribution for  α  to allow  for different values for alpha in each IPD study\\   
xtmelogit dead age10 || studyid: ,  cov(indep) intp(1) var 
\\Model 11 accounts for the clustering across studies and account for  the variation within-
studies for the patients who have the same value of age in each study and assign a normal 
distribution for  α  to allow  for different values for alpha in each IPD study\\ 
xtmelogit dead  age10 || studyid: , ||  age10: f11 f12 f13 f14, nocons cov(indep) intp(1) 
var 
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Appendix C3: SAS code for bivariate fixed-effect (Model 4 and 5) 
SAS code to fit a bivariate fixed-effect model in the second step and allowing a different alpha in 
each study, for the continuous age and after accounting for residual variation in the first step 
data tbi; 
input id estimate alpha beta study1 study2 study3
 study4 var; 
cards; 
1 -2.199809 1 0 1 0 0 0 0.057277796 
1 0.3105692 0 1 1 0 0 0 0.004113465 
2 -1.928625 1 0 0 1 0 0 0.043479673 
2 0.2672432 0 1 0 1 1 0 0.002791823 
3 -1.956439 1 0 0 0 1 0 0.067149704 
3 0.376585 0 1 0 0 0 0 0.003082048 
4 -2.323136 1 0 0 0 0 1 0.122192753 
4 0.3283813 0 1 0 0 0 1 0.007850244 
; 
run; 
/* Bivariate meta-analysis allowing alpha to be different in each study 
(and not estimated) but allowing beta to be the same in each study and 
estimated */ 
proc mixed cl method=reml data=tbi ; 
class id ; 
model estimate = alpha beta / noint s cl ddf=10000 10000; 
random alpha beta / subject=id g type=arh(1); 
repeated / type=un subject=id group=id ; 
parms   
0.1 
0 
0 
0.057277796 
-0.01440608 
0.004113465 
0.043479673 
-0.01018656 
0.002791823 
0.067149704 
-0.01320622 
0.003082048 
0.122192753 
-0.02883057 
0.007850244 
/ eqcons = 2 to 15; 
 
run; 
 
  
[239] 
 
Appendix D 
Appendix D1: The simulation STATA code program for binary PF. 
** parameter setting from here 
clear 
clear matrix 
set memory 1000m 
set more off 
set seed 12345678 
cd "C:\my thesis" tempname simparm   /*record all parameter and population value for each senario*/ 
postfile `simparm' senario inercept_m inercept_v slope lymphnod n_studies using C:\my thesis\senario_monitor_cat.dta, 
replace 
*****set different parameter here, following are Ghada's code 
local a_m "-1.27"       /*intercept mean for control,you can set value list here, e.g. -1 0 +1*/ 
local a_v "0.25 "       /*intercept SD for control,you can set value list here, e.g. -1 0 +1*/ 
local b "0.1 0"   /*treatment effect, you can set value list here, e.g. -1 0 +1*/ 
local p_lym "0.2" /* prevenlance lymphnode positive, you can set value list here, e.g. 0.1 0.2 0.3*/ 
local n_studies "5 10" /* number of IPD_j in each meta analysis, you can set value list here, e.g. 5 10 20 30 */global repl = 
1000   /*decide how many replication used*/ 
****** DO not change following code****** 
local senario = 1     
foreach intpt_m in `a_m' { 
 foreach intpt_v in `a_v' { 
  foreach slp in `b' { 
   foreach lymph in `p_lym' { 
    foreach n_meta in `n_studies' { 
          
    quietly replic `intpt_m' `intpt_v' `slp' `lymph' `n_meta'  `senario'  /*simulate 
data*/ 
         
    post `simparm' (`senario') (`intpt_m') (`intpt_v') (`slp') (`lymph') (`n_meta') /*save 
parameter setting for each senario*/ 
     
    *Analysis data here or seperately? 
    use "C:\my thesis\data\senario_`senario'", clear 
    two_step `intpt_m' `intpt_v' `slp' `lymph' `n_meta'  `senario' /*runing two_step 
analysis*/ 
     
    use "C:\my thesis\data\senario_`senario'", clear 
    step_cluster `intpt_m' `intpt_v' `slp' `lymph' `n_meta'  `senario' /*runing one_step 
cluster*/ 
     
    use "C:\my thesis\data\senario_`senario'", clear 
    step_dummy `intpt_m' `intpt_v' `slp' `lymph' `n_meta'  `senario' /*runing 
one_step dummy*/ 
     
     conbin_result `intpt_m' `intpt_v' `slp' `lymph' `n_meta'  `senario' /*combine 3 
kind of result together for same senario*/ 
   
    local ++senario 
     }/*end of study number loop*/ 
 
    }/*end of lymphnode prevelence loop*/ 
   }/*end of slope loop*/ 
  }/*end of  alpha variance loop*/ 
 } /*end of  intercept loop*/ 
 postclose `simparm'  /*close to save senario parameter*/ 
  
 ************ 
*JAN-21-2011 
* programe here are called by file My thesis_leices 
* programm are  
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*IPD_j 
*replic 
*two_step 
*step_cluster 
*step_dummy 
*binary covariate 
********************** 
capture program drop IPD_j 
capture program drop replic 
capture program drop two_step 
capture program drop step_cluster 
capture program drop step_dummy 
capture program drop conbin_result 
program define IPD_j 
 local alpha_m `1' 
 local alpha_v `2' 
   local beta `3' 
 local p_x `4' 
  
 clear /*clear the file in memory for new simulation*/ 
 local alpha= (rnormal(`alpha_m', `alpha_v')) /* alpha is normal dist value*/ 
  
 local n_ipd_j = int(30+(runiform()*(100-30))) /*30~100, Gadha subjects for each primary study_j*/ 
 quietly set obs `n_ipd_j' /*how many people in each IPD study*/ 
  
 gen x = rbinomial(1, `p_x')  /*x is bianry treatment variable, p_x is the percentage of X=1*/ 
   
 gen y = runiform() < invlogit(`alpha'+ `beta'*x) /*Thompson code*/  
end 
program define replic   /*more work needed!!*/ 
 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local prevelence_x `4' 
 local nstudies  `5' 
 local senario `6' 
forvalues replic=1(1)$repl { /* replication loop start from here*/ 
  
 forvalues j= 1(1)`nstudies' {      /*how mnay simulated IPD_i in each meta analysis*/ 
  *call onestudy for IPD 
  IPD_j `intercept_m' `intercept_v' `slope' `prevelence_x'  /*code to simulate the Y and X using program 
IPD_j*/ 
   
  gen study_id= `j'  /*ID for each IPD_J data within one replication*/ 
     
  tempfile ipd_`replic'_`j'      /*create a temporary file and save for each IPD_j in each replication*/ 
      
   if `j'>1 {  
     local j_former =`j'-1 
     append using "C:\my thesis\middata\senario_`senario'ipd_`j_former'"  
/*append last saved file from study_2 within same replication*/      
         erase  
"C:\my thesis\middata\senario_`senario'ipd_`j_former'.dta" /*remove the appended file*/ 
      }/*for the */  
    
   *save "C:\my thesis\middata\senario_`senario'ipd_`replic'_`j'", replace /*save all data, 
removed*/ 
    
   save "C:\my thesis\middata\senario_`senario'ipd_`j'", replace 
 
   }   /*end of loop for each meta analysis*   
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   *****keep data for checking purpose***** 
   erase "C:\my thesis\middata\senario_`senario'ipd_`nstudies'.dta" 
    
  gen replic_id = `replic' /*create ID variable for each replication*/ 
   
  tempfile repl_`replic' 
  if `replic'>1 {  
     local repl_former =`replic'-1 
     append using  
"C:\my thesis\middata\senario_`senario'repl_`repl_former'"  /*append last saved file*/ 
         erase  
"C:\my thesis\middata\senario_`senario'repl_`repl_former'.dta" 
      }/*for the */  
   save "C:\my thesis\middata\senario_`senario'repl_`replic'" , replace 
   *save replic_`replic', replace   
   /*for code checking*/   
   if `replic'==$repl {   
    save "C:\my thesis\data\senario_`senario'", replace    
      } /*save the last file for permernant: senario 1 all replication*/
       
     } /* end replication*/ 
   
    
     *****keep data for checking purpose*****  
      
  *erase "C:\my thesis\middata\senario_`senario'repl_$repl.dta"  /*remove the last repl file*/  
end 
program two_step 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local prevelence_x `4' 
 local nstudies `5' 
 local senario `6' 
 capture log close 
 capture log using "C:\my thesis\two_step\cat_twostp_senario_`senario'", replace 
 tempname step2_result  /*record all parameter and beta, se_beta value for each senario of each primary 
study*/ 
 capture postfile `step2_result' senario intercept_m intercept_v slope lymphnod n_studies  beta se_beta  study 
replic using "C:\my thesis\two_step\two_step_result_senario`senario'", replace 
 forvalues replic = 1(1)$repl {    /*must change replic*/ 
  forvalues ipd_j = 1(1) `nstudies' {  
   capture quietly logit y x if replic_id == `replic'& study_id == `ipd_j' 
     
   if _rc==0 { 
     local b_x = _b[x] 
     local se_x = _se[x]    
       } 
   if _rc>0 { 
    di "problemb data for 2stp is scenerio= " `senario' "   replication= " `replic' " 
studyID= " `ipd_j' 
     local b_x = . 
     local se_x = . 
      }     
 capture post `step2_result' (`senario') (`intercept_m') (`intercept_v') (`slope') (`prevelence_x') (`nstudies') 
(`b_x') (`se_x') (`ipd_j') (`replic')  /*save parameter setting for each senario*/  
     }   /*each meta-analysis loop*/ 
   } /*replication loop*/   
 capture postclose `step2_result'  /*close to save senario parameter*/ 
  *** starting meta analysis beta for each senario*** 
 *reading two-step results for each senario 
 use "C:\my thesis\two_step\two_step_result_senario`senario'" , clear 
 drop if se_beta==0 |se_beta==. /*remove no variance data in Logit model*/ 
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 tempname step2_meta  /*record all parameter and beta, se_beta value for each senario of each primary 
study*/ 
  postfile `step2_meta' senario intercept_m intercept_v slope lymphnod n_studies  beta_mt se_mt replic using 
"C:\my thesis\two_step\two_step_meta_senario`senario'", replace 
   
  for values replication = 1(1)$repl {  
  capture quietly metan  beta se_beta if replic==`replication', nograph notable 
   capture post `step2_meta' (`senario') (`intercept_m') (`intercept_v') (`slope') 
(`prevelence_x') (`nstudies')  (`r(ES)') (`r(seES)') (`replication') 
     } 
 postclose `step2_meta' 
 *** finish meta anlysis for senario and save file in two_step_meta_`senario'*** 
  capture log close 
                 end 
program step_cluster 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local prevelence_x `4' 
 local nstudies  `5' 
 local senario `6' 
  
 capture log close 
 capture log using "C:\my thesis\step_cluster\cat_cluster_senario_`senario'", replace 
 tempname cluster_result  /*record all parameter and beta, se_beta value for each senario of each primary 
study*/ 
 postfile `cluster_result' senario intercept_m intercept_v slope lymphnod n_studies  beta_cls se_cls replic using 
"C:\my thesis\step_cluster\cluster_result_senario`senario'", replace 
 
 forvalues replic = 1(1)$repl {    /*must change replic*/ 
     
  capture quietly logit y x if replic_id == `replic' 
   if _rc==0 { 
     local b_x = _b[x] 
     local se_x = _se[x]    
    } 
     
   if _rc>0 { 
    di "problemb data for cluster is scenerio= " `senario' "   replication= " `replic' 
     local b_x = . 
     local se_x = . 
      } 
 capture post `cluster_result' (`senario') (`intercept_m') (`intercept_v') (`slope') (`prevelence_x') (`nstudies') 
(`b_x') (`se_x') (`replic') /*save parameter setting for each senario*/  
     }   /*each meta-analysis loop*/ 
 capture postclose `cluster_result'  /*close to save senario parameter*/ 
 capture log close 
end 
program step_dummy 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local prevelence_x `4' 
 local nstudies  `5' 
 local senario `6'  
 capture log close 
 capture log using "C:\my thesis\step_dummy\cat_dummy_senario_`senario'", replace 
 tempname dummy_result  /*record all parameter and beta, se_beta value for each senario of each primary 
study*/ 
 postfile `dummy_result' senario intercept_m intercept_v slope lymphnod n_studies  beta_dmy se_dmy replic 
using "C:\my thesis\step_dummy\dummy_result_senario`senario'", replace 
 
 forvalues replic = 1(1)$repl {    /*must change replic*/ 
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  capture quietly xi: logit y x i.study_id if replic_id == `replic' 
    if _rc==0 { 
     local b_x = _b[x] 
     local se_x = _se[x]    
    } 
   if _rc>0 { 
    di "problemb data for DUMMY  is scenerio= " `senario' "   replication= " `replic' 
     local b_x = . 
     local se_x = . 
     } 
 capture post `dummy_result' (`senario') (`intercept_m') (`intercept_v') (`slope') (`prevelence_x') (`nstudies') 
(`b_x') (`se_x') (`replic') /*save parameter setting for each senario*/  
     }   /*each meta-analysis loop*/ 
 capture postclose `dummy_result'  /*close to save senario parameter*/ 
 capture log close  
end 
 
*** conbine 3 results from one senario data 
program conbin_result 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local prevelence_x `4' 
 local nstudies  `5' 
 local senario `6' 
  
use "C:\my thesis\two_step\two_step_meta_senario`senario'", clear 
merge 1:1  senario intercept_m intercept_v slope lymphnod n_studies replic using "C:\my 
thesis\step_cluster\cluster_result_senario`senario'", generate(frm_cls)  
merge 1:1  senario intercept_m intercept_v slope lymphnod n_studies replic using "C:\my 
thesis\step_dummy\dummy_result_senario`senario'",  
save  "C:\my thesis\result\cat_result_senario_`senario'", replace   /*file name as categorical x*/ 
end 
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Appendix D2: The simulation STATA code program for continuous 
PF. 
* Jan-21-2011 
*C:\my thesis 
*need cal macro in file gadasim first 
*continous covariate code 
do C:\my thesis\code\Ghada_sim_cont 
** parameter seting from here 
clear 
clear matrix 
set memory 1000m 
set more off 
set seed 12345678 
cd "C:\my thesis" 
tempname simparm   /*record all parameter and population value for each senario*/ 
postfile `simparm' senario inercept_m inercept_v slope age_m age_sd n_studies using C:\my thesis\senario_monitor.dta, 
replace 
*****set different parameter here, following are Gadha's code 
local a_m  "-2.10"       /*intercept mean*/ 
local a_v  "1.5"       /*intercept SD*/ 
local b  "0.30 0.1 0"   /*treatment*/ 
local m_age  "4"  /* prevenlance*/ 
local sd_age "1.5"  
local n_studies "5" /* number of IPD_j in each meta analysis */ 
 
global repl = 1000   /*decide how many replication used*/ 
****** DO not change following code****** 
local senario = 1   
foreach intpt_m in `a_m' {  
 foreach intpt_v in `a_v'  {  
  foreach slp in `b'   {    
   foreach age_m in `m_age' {     
    foreach age_sd in `sd_age' {      
     foreach n_meta in `n_studies' {    
  
    quietly replic `intpt_m' `intpt_v' `slp' `age_m' `age_sd' `n_meta'  `senario'  
/*simulate data*/ 
         
    post `simparm' (`senario') (`intpt_m') (`intpt_v') (`slp') (`age_m') (`age_sd') 
(`n_meta') /*save parameter setting for each senario*/  
    *Analysis data here or seperately? 
    use "C:\my thesis\data\senario_`senario'", clear 
    two_step `intpt_m' `intpt_v' `slp' `age_m' `age_sd' `n_meta'  `senario' /*runing 
two_step analysis*/  
    use "C:\my thesis\data\senario_`senario'", clear 
    step_cluster `intpt_m' `intpt_v' `slp' `age_m' `age_sd' `n_meta'  `senario' /*runing 
one_step cluster*/ 
    use "C:\my thesis\data\senario_`senario'", clear 
    step_dummy `intpt_m' `intpt_v' `slp' `age_m' `age_sd' `n_meta'  `senario' 
/*runing one_step dummy*/ 
    conbin_result `intpt_m' `intpt_v' `slp' `age_m' `age_sd' `n_meta'  `senario' 
/*combine 3 kind of result together for same senario*/ 
    local ++senario 
      } /*end of study number loop*/ 
     } /*end of age sd loop*/ 
    } /*end of age mean loop*/ 
   } /*end of slope loop*/ 
  } /*end of  alpha variance loop*/ 
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 } /*end of  intercept loop*/ 
  
 postclose `simparm'  /*close to save senario parameter*/ 
  
 ************ 
**Jan21-2011 
* programe here are called by file My thesis_cont 
* programm are  
*IPD_j 
*replic 
*two_step 
*step_cluster 
*step_dummy 
*continous covriate 
********************** 
capture program drop IPD_j 
capture program drop replic 
capture program drop two_step 
capture program drop step_cluster 
capture program drop step_dummy 
capture program drop conbin_result 
 
program define IPD_j 
 
 local alpha_m `1' 
 local alpha_v `2' 
   local beta `3' 
 local p_x `4' 
 local p_xsd `5' 
  clear /*clear the file in memory for new simulation*/ 
 local alpha= (rnormal(`alpha_m', `alpha_v'))  
  local n_ipd_j = int(30+(runiform()*(1000-30))) /*30~100 subjects for each primary study_j gadha*/ 
 quietly set obs `n_ipd_j' /*how many people in each IPD study*/ 
  
 gen x = (rnormal(`p_x', `p_xsd')) /*x is age, centered X, doesn't affect beta and intercept is alpha!!*/ 
 gen y = runiform() < invlogit(`alpha'+ `beta'*x) /*Thompson code*/ 
end 
program define replic   /*more work needed!!*/ 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local age_m `4' 
 local age_sd `5' 
 local nstudies  `6' 
 local senario `7' 
 forvalues replic=1(1)$repl { /* replication loop start from here*/ 
 forvalues j= 1(1)`nstudies' {      /*how mnay simulated IPD_i in each meta analysis*/ 
  *call onestudy for IPD 
  IPD_j `intercept_m' `intercept_v' `slope' `age_m' `age_sd'  /*code to simulate the Y and X using 
program IPD_j*/ 
   
  gen study_id= `j'  /*ID for each IPD_J data within one replication*/ 
     
  tempfile ipd_`replic'_`j'      /*create a temporary file and save for each IPD_j in each replication*/ 
       
   if `j'>1 {  
     local j_former =`j'-1 
     append using "C:\my thesis\middata\senario_`senario'ipd_`j_former'"  
/*append last saved file from study_2 within same replication*/ 
      
         erase  
"C:\my thesis\middata\senario_`senario'ipd_`j_former'.dta" /*remove the appended file*/ 
      }/*for the */  
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   *save "C:\my thesis\middata\senario_`senario'ipd_`replic'_`j'", replace /*save all data, 
removed*/ 
    
   save "C:\my thesis\middata\senario_`senario'ipd_`j'", replace 
 
   }   /*end of loop for each meta analysis*/ 
    
      ****keep data for checking purpose 
   erase "C:\my thesis\middata\senario_`senario'ipd_`nstudies'.dta" 
    
  gen replic_id = `replic' /*create ID variable for each replication*/ 
   
  tempfile repl_`replic' 
  if `replic'>1 {  
     local repl_former =`replic'-1 
     append using  
"C:\my thesis\middata\senario_`senario'repl_`repl_former'"  /*append last saved file*/ 
         erase  
"C:\my thesis\middata\senario_`senario'repl_`repl_former'.dta" 
      }/*for the */  
   save "C:\my thesis\middata\senario_`senario'repl_`replic'" , replace 
   *save replic_`replic', replace   
   /*for code checking*/ 
    
   if `replic'==$repl { 
    
    save "C:\my thesis\data\senario_`senario'", replace 
      
      } /*save the last file for permernant: senario 1 all replication*/ 
            
      
     } /* end replication*/ 
    
  ****keep data for checking purpose 
  *erase "C:\my thesis\middata\senario_`senario'repl_$repl.dta"  /*remove the last repl file*/  
   
end   
program two_step 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local age_m `4' 
 local age_sd `5' 
 local nstudies  `6' 
 local senario `7' 
  
 capture log close 
 capture log using "C:\my thesis\two_step\twostp_senario_`senario'", replace 
  
 tempname step2_result  /*record all parameter and beta, se_beta value for each senario of each primary 
study*/ 
 capture postfile `step2_result' senario intercept_m intercept_v slope age_m age_sd n_studies  beta se_beta  
study replic using "C:\my thesis\two_step\two_step_result_senario`senario'", replace 
  
 forvalues replic = 1(1)$repl {    /*must change replic*/ 
  forvalues ipd_j = 1(1) `nstudies' { 
   
   capture quietly logit y x if replic_id == `replic'& study_id == `ipd_j' 
    
    if _rc==0 { 
    
     local b_x = _b[x] 
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     local se_x = _se[x] 
         } 
    /*report problem dataset*/ 
    if _rc>0 { 
      di "problem data for 2stp is scenerio= " `senario' "   
replication= " `replic' " studyID= " `ipd_j' 
     local b_x = . 
     local se_x = . 
     } 
    
   capture post `step2_result' (`senario') (`intercept_m') (`intercept_v') (`slope') (`age_m') 
(`age_sd') (`nstudies') (`b_x') (`se_x') (`ipd_j') (`replic')  /*save parameter setting for each senario*/  
     }   /*each meta-analysis loop*/ 
   } /*replication loop*/ 
    
 capture postclose `step2_result'  /*close to save senario parameter*/ 
  
 *** starting meta analysis beta for each senario*** 
 *reading two-step results for each senario 
 use "C:\my thesis\two_step\two_step_result_senario`senario'" , clear 
 drop if se_beta==0 |se_beta==. /*remove no variance data in Logit model*/ 
 tempname step2_meta  /*record all parameter and beta, se_beta value for each senario of each primary 
study*/ 
 capture postfile `step2_meta' senario intercept_m intercept_v slope age_m age_sd n_studies  beta_mt se_mt 
replic using "C:\my thesis\two_step\two_step_meta_senario`senario'", replace 
   
  forvalues replication = 1(1)$repl {  
   capture quietly metan  beta se_beta if replic==`replication', nograph notable 
    
   capture post `step2_meta' (`senario') (`intercept_m') (`intercept_v') (`slope') (`age_m') 
(`age_sd') (`nstudies')  (`r(ES)') (`r(seES)') (`replication') 
    } 
 postclose `step2_meta' 
 *** finish meta anlysis for senario and save file in two_step_meta_`senario'*** 
   
 capture log close 
end 
 
program step_cluster 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local age_m `4' 
 local age_sd `5' 
 local nstudies  `6' 
 local senario `7' 
  
 capture log close 
 capture log using "C:\my thesis\step_cluster\cluster_senario_`senario'", replace 
  
 tempname cluster_result  /*record all parameter and beta, se_beta value for each senario of each primary 
study*/ 
 capture postfile `cluster_result' senario intercept_m intercept_v slope age_m age_sd n_studies  beta_cls se_cls 
replic using "C:\my thesis\step_cluster\cluster_result_senario`senario'", replace 
 
 forvalues replic = 1(1)$repl {    /*must change replic*/ 
     
  capture quietly logit y x if replic_id == `replic' 
    if _rc==0 { 
    
     local b_x = _b[x] 
     local se_x = _se[x] 
    
[248] 
 
      } 
  /*report problem dataset*/ 
    if _rc>0 { 
     di "problem data for CLUSTER is scenerio= " `senario' "   replication= " 
`replic' 
     local b_x = . 
     local se_x = . 
     } 
  
  capture post `cluster_result' (`senario') (`intercept_m') (`intercept_v') (`slope') (`age_m') (`age_sd') 
(`nstudies') (`b_x') (`se_x') (`replic') /*save parameter setting for each senario*/  
     }   /*each meta-analysis loop*/ 
 capture postclose `cluster_result'  /*close to save senario parameter*/ 
 capture log close 
 
end 
program step_dummy 
 local intercept_m `1' 
 local intercept_v `2' 
   local slope `3' 
 local age_m `4' 
 local age_sd `5' 
 local nstudies  `6' 
 local senario `7' 
  
 capture log close 
 capture log using "C:\my thesis\step_dummy\dummy_senario_`senario'", replace 
  
 tempname dummy_result  /*record all parameter and beta, se_beta value for each senario of each primary 
study*/ 
 capture postfile `dummy_result' senario intercept_m intercept_v slope age_m age_sd n_studies  beta_dmy 
se_dmy replic using "C:\my thesis\step_dummy\dummy_result_senario`senario'", replace 
 
 forvalues replic = 1(1)$repl {    /*must change replic*/ 
     
  capture quietly xi: logit y x i.study_id if replic_id == `replic' 
   
     if _rc==0 { 
    
     local b_x = _b[x] 
     local se_x = _se[x] 
    
      } 
  /*report problem dataset*/ 
    if _rc>0 { 
     di "problem data for DUMMY is scenerio= " `senario' "   replication= " 
`replic' 
     local b_x = . 
     local se_x = . 
     } 
  
  post `dummy_result' (`senario') (`intercept_m') (`intercept_v') (`slope') (`age_m') (`age_sd') 
(`nstudies') (`b_x') (`se_x') (`replic') /*save parameter setting for each senario*/  
     }   /*each meta-analysis loop*/ 
  postclose `dummy_result'  /*close to save senario parameter*/ 
  
 capture log close 
 end 
 
*** conbine 3 results from one senario data 
rogram conbin_result 
 local intercept_m `1' 
 local intercept_v `2' 
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   local slope `3' 
 local age_m `4' 
 local age_sd `5' 
 local nstudies  `6' 
 local senario `7' 
use "C:\my thesis\two_step\two_step_meta_senario`senario'", clear 
merge 1:1  senario intercept_m intercept_v slope age_m age_sd n_studies replic using "C:\my 
thesis\step_cluster\cluster_result_senario`senario'", generate(frm_cls)  
merge 1:1  senario intercept_m intercept_v slope age_m age_sd n_studies replic using "C:\my 
thesis\step_dummy\dummy_result_senario`senario'",  
save  "C:\my thesis\result\result_senario_`senario'", replace 
/*remove mid-process files*/  
 End 
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Appendix D3: Create 95% CIs and  how many of the 1000 simulations 
give a CI containing true value	 
gen lower_mt = beta_mt - (1.96*se_mt) 
gen upper_mt = beta_mt + (1.96*se_mt) 
gen included_mt = 0 
replace included_mt = 1 if  lower_mt <=  & upper_mt >=	  
gen lower_cls = beta_cls - (1.96*se_cls) 
gen upper_cls = beta_cls + (1.96*se_cls) 
gen included_cls = 0 
replace included_cls = 1 if  lower_cls <=  & upper_cls >=  
gen lower_dmy = beta_dmy - (1.96*se_dmy) 
gen upper_dmy = beta_dmy + (1.96*se_dmy) 
gen included_dmy = 0 
replace included_dmy = 1 if  lower_dmy <= 0 & upper_dmy >= 0 
total included_mt included_cls included_dmy 
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Appendix D4: Simulation results for n=10 studies for binary PF 
Table D4.1:  Simulation results for the pooled effect size,{, for three models of IPD meta-analysis,( two-step, one-step ignoring clustering and 
one-step including indicator variable), with prevalence =0.5and the sample size with-in each study is between 30 to 1000 observations, with 
the number of studies n=10 and 1000 simulations, the true values of the pooled effect size,, is shown in the table; the standard error for ∝ is 0 
and 0.25. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(s. e. of ∝) 
 
prevalence True  Mean  
of {  
 
Bias percentage 
bias 
 
MSE of 
 
Percentage 
coverage 
Mean 
s.e. of 
{  
1 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.9 
0.9 
0.9 
0.90 
0.89 
0.90 
0.00 
-0.01 
0.00 
-0.49 
-1.48 
-0.14 
0.01 
0.01 
0.01 
95.00 
94.30 
94.90 
 
0.06 
0.06 
0.06 
2 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.1 
0.1 
0.1 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
1.28 
0.62 
1.80 
0.01 
0.01 
0.01 
95.00 
94.70 
94.70 
 
0.10 
0.10 
0.10 
3 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0 
0 
0 
0 
0 
0 
 
0.00 
0.00 
0.00 
NA 
NA 
NA 
 
0.01 
0.01 
0.01 
95.10 
94.70 
94.90 
0.07 
0.07 
0.07 
4 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0.9 
0.9 
0.9 
0.90 
0.90 
0.90 
0.00 
0.00 
0.00 
-0.17 
-0.11 
0.07 
0.01 
0.01 
0.01 
95.10 
95.20 
95.40 
0.09 
0.09 
0.09 
5 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0.1 
0.1 
0.1 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
-2.65 
-2.63 
-2.48 
0.01 
0.01 
0.01 
95.40 
95.50 
95.30 
0.06 
0.06 
0.06 
6 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0 
0 
0 
0 
0 
0 
0.00 
0.00 
0.00 
NA 
NA 
NA 
 
0.01 
0.01 
0.01 
95.50 
95.50 
95.40 
0.06 
0.06 
0.06 
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Table D4.2: Simulation results for the pooled effect size,	;i , for three models of IPD meta-analyses (two-step, one-step ignoring clustering and 
one-step including indicator variable), with prevalence=0.2 and the sample size with-in each study is between 30 to 1000 observations, with the 
number of studies n=10 and 1000 simulations, the true values of the pooled effect size,;, is shown in the table; the standard error for ∝ is 0 and 
0.25. 
 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(s. e of ∝) 
 
Prevalence 
 
True 		 Mean  of {  
 
Bias percentage 
bias 
 
MSE 
of  Percentage coverage Mean s.e. of {  
7 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2  
0.9 
0.9 
0.9 
0.89 
0.90 
0.90 
-0.01 
0.00 
0.00 
-0.63 
0.12 
0.29 
0.01 
0.01 
0.01 
94.80 
94.30 
94.40 
0.08 
0.08 
0.08 
8 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2 
0.1 
0.1 
0.1 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
-2.52 
-1.87 
-1.76 
0.01 
0.01 
0.01 
95.90 
95.60 
95.60 
0.07 
0.07 
0.07 
9 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2 
0 
0 
0 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
NA 
NA 
NA 
 
0.01 
0.01 
0.01 
95.00 
94.80 
94.80 
0.07 
0.07 
0.07 
10 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0.9 
0.9 
0.9 
0.90 
0.90 
0.90 
0.00 
0.00 
0.00 
0.30 
-1.18 
0.11 
0.01 
0.01 
0.01 
95.20 
94.20 
94.90 
0.08 
0.08 
0.08 
11 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0.1 
0.1 
0.1 
0.11 
0.10 
0.10 
0.01 
0.00 
0.00 
10.45 
-0.52 
0.39 
0.01 
0.01 
0.01 
95.30 
95.20 
95.40 
0.11 
0.10 
0.10 
10 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0 
0 
0 
0.01 
0.00 
0.00 
0.01 
0.00 
0.00 
NA 
NA 
NA 
 
0.01 
0.01 
0.01 
95.50 
94.70 
95.20 
0.09 
0.09 
0.09 
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Table D4.3: Simulation results for the pooled effect size,	 ,  for three models of IPD meta-analyses (two-step, one-step ignoring clustering and 
one-step including indicator variable, with prevalence =0.2 and the sample size with-in each study is between 30 to 1000 observations, with the 
number of studies n=10 and 1000 simulations, the standard error for ∝ is 1.5. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(s.e. of ∝) 
 
Prevalence 
 
True 		 Mean  of 	{  
 
Bias percentage 
bias 
 
MSE of  Percentage coverage Mean s.e. of {  
13 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2  
0.9 
0.9 
0.9 
0.90 
0.67 
0.90 
0.00 
-0.23 
0.00 
-0.33 
-25.57 
-0.23 
0.01 
0.07 
0.01 
95.90 
23.50 
96.10 
0.09 
0.07 
0.09 
14 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2 
0.1 
0.1 
0.1 
0.11 
0.08 
0.10 
0.01 
-0.02 
0.00 
10.39 
-23.89 
0.29 
0.01 
0.01 
0.01 
94.50 
93.70 
94.00 
0.09 
0.08 
0.09 
15 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2 
0 
0 
0 
0.01 
0.00 
-0.01 
0.01 
0.00 
-0.01 
 
NA 
NA 
NA 
 
0.02 
0.02 
0.02 
94.70 
94.40 
94.20 
0.09 
0.08 
0.09 
16 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5  
0.9 
0.9 
0.9 
0.86 
0.67 
0.91 
-0.04 
-0.23 
0.01 
-4.44 
-25.56 
1.11 
0.04 
0.09 
0.04 
96.70 
71.80 
96.10 
0.21 
0.17 
0.21 
17 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
0.1 
0.1 
0.1 
0.10 
0.08 
0.11 
0.00 
-0.02 
0.01 
0.00 
-20.00 
10.00 
0.04 
0.03 
0.04 
96.3 
95.6 
94.7 
0.22 
0.18 
0.21 
18 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
0 
0 
0 
-0.01 
0.00 
-0.01 
-0.01 
0.00 
-0.01 
NA 
NA 
NA 
 
0.04 
0.03 
0.04 
96.50 
95.70 
95.20 
0.22 
0.18 
0.21 
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Table D4.4: Simulation results for the pooled effect size,{, for three models of IPD meta-analysis, two-step, one-step ignoring clustering and 
one-step including indicator variable, with prevalence =0.5and the sample size with-in each study is between 30 to 100 observations, with the 
number of studies n=10 and 1000 simulations, the true values of the pooled effect size,, is shown in the table; the standard error for ∝ is 0 
and 0.25. 
Scenarios No. of 
studies(
n) 
Model Meta-analysis 
model 
∝ 
(s. e. of ∝) 
 
prevalence Mean  
of {  
 
 Bias percentage 
bias 
 
MSE of 
 
Percentage 
coverage 
Mean 
s.e. of 
{  
1 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.90 
0.91 
0.92 
0.9 
0.9 
0.9 
0.00 
0.01 
0.02 
-0.18 
0.50 
1.97 
0.03 
0.03 
0.03 
95.90 
95.90 
95.00 
0.17 
0.17 
0.17 
2 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.10 
0.11 
0.11 
0.10 
0.10 
0.10 
0.00 
0.01 
0.01 
3.73 
4.95 
5.90 
0.03 
0.03 
0.03 
95.9 
95.7 
95.5 
0.16 
0.16 
0.16 
3 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
0.5 
0.5 
0.5 
0.00 
0.00 
0.00 
0 
0 
0 
0.00 
0.00 
0.00 
NA 
NA 
NA 
 
0.03 
0.03 
0.03 
96.50 
96.70 
95.80 
0.16 
0.16 
0.16 
4 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0.88 
0.89  
0.91 
0.9 
0.9 
0.9 
-0.03 
-0.01 
0.01 
-2.77 
-1.57 
0.85 
0.03 
0.03 
0.03 
 
96.30 
95.50 
95.30 
0.17 
0.18 
0.18 
5 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
0.10 
0.10 
0.10 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
-2.45 
1.25 
3.19 
0.04 
0.04 
0.04 
 
95.90 
95.10 
94.50 
0.20 
0.19 
0.19 
6 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
0.5 
0.5 
0.5 
-0.01 
-0.01 
 0.01 
0 
0 
0 
-0.01 
-0.01 
 0.01 
NA 
NA 
NA 
 
0.04 
0.04 
0.04 
96.70 
94.90 
95.20 
0.20 
0.19 
0.20 
 
 
Table D4.5: Simulation results for the pooled effect size,	{, for three models of IPD meta-analyses (two-step, one-step ignoring clustering and 
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one-step including indicator variable, with prevalence=0.2 and the sample size with-in each study is between 30 to 100 observations, with the 
number of studies n=10 and 1000 simulations, the true values of the pooled effect size,, is shown in the table; the standard error for ∝ is 0 
and 0.25. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(s.e of ∝) 
 
Prevalence 
 
Mean  
of {  
 
True 		 Bias percentage bias 
 
MSE 
of  Percentage coverage Mean s.e. of {  
7 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2  
0.89 
0.90 
   0.90 
  0.9 
  0.9 
  0.9 
-0.01 
0.00 
0.00 
-0.63 
0.12 
0.29 
-7.15 
1.36 
3.24 
94.80 
94.30 
94.40 
0.08 
0.08 
0.08 
8 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2 
0.10 
0.10 
   0.10 
  0.10 
  0.10 
  0.10 
0.00 
0.00 
0.00 
-2.52 
-1.87 
-1.76 
-3.63 
-2.68 
-2.52 
95.90 
95.60 
95.60 
0.07 
0.07 
0.07 
9 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0) 
-1.27(0) 
-1.27(0) 
     0.2 
     0.2 
     0.2 
0.00 
0.00 
   0.00 
   0 
   0 
   0 
0.00 
0.00 
0.00 
NA 
NA 
NA 
 
-0.52 
-0.26 
-3.17 
95.00 
94.80 
94.80 
0.07 
0.07 
0.07 
10 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0.90 
0.90 
   0.90 
  0.9 
  0.9 
  0.9 
0.00 
0.00 
0.00 
0.30 
-1.18 
0.11 
0.01 
0.01 
0.01 
95.20 
94.20 
94.90 
0.08 
0.08 
0.08 
11 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0.11 
0.10 
0.10 
  0.1 
  0.1 
  0.1 
0.01 
0.00 
0.00 
10.45 
-0.52 
0.39 
0.01 
0.01 
0.01 
95.30 
95.20 
95.40 
0.11 
0.10 
0.10 
10 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(0.25) 
-1.27(0.25) 
-1.27(0.25) 
     0.2 
     0.2 
     0.2 
0.01 
0.00 
0.00 
   0 
   0 
   0 
0.01 
0.00 
0.00 
NA 
NA 
NA 
 
0.01 
0.01 
0.01 
95.50 
94.70 
95.20 
0.09 
0.09 
0.09 
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Table D4.6: Simulation results for the pooled effect size, for three models of IPD meta-analyses (two-step, one-step ignoring clustering and one-
step including indicator variable, with prevalence =0.2 and the sample size with-in each study is between 30 to 100 observations, with the 
number of studies n=10 and 1000 simulations, the standard error for ∝ is 1.5. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(s.e. of ∝) 
 
Prevalence 
 
Mean  
of {  
 
True 		 Bias percentage bias 
 
MSE of  Percentage coverage Mean s.e. of {  
13 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2  
0.91 
0.67 
 0.92 
  0.9 
  0.9 
  0.9 
0.01 
-0.23 
0.02 
0.88 
-25.65 
2.06 
0.06 
0.10 
0.06 
97.20 
78.50 
95.10 
0.26 
0.21 
0.25 
14 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2 
0.19 
0.08 
0.10 
  0.1 
  0.1 
  0.1 
0.09 
-0.02 
0.00 
91.34 
-22.30 
3.29 
0.07 
0.05 
0.07 
95.80 
95.60 
95.20 
0.28 
0.22 
0.26 
15 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.2 
     0.2 
     0.2 
0.10 
0.00 
0.00 
   0 
   0 
   0 
0.10 
0.00 
0.00 
NA 
NA 
NA 
 
0.08 
0.05 
0.07 
95.60 
95.00 
95.10 
0.28 
0.23 
0.27 
16 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
0.89 
0.67 
0.90 
  0.9 
  0.9 
  0.9 
-0.01 
-0.23 
0.00 
1.11 
-25.56 
0.00 
0.01 
0.06 
0.00 
94.00 
14.80 
93.90 
0.07 
0.06 
0.07 
17 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
0.10 
0.07 
0.10 
  0.1 
  0.1 
  0.1 
0.00 
-0.03 
0.00 
0.00 
-30.00 
0.00 
0.00 
0.01 
0.01 
96.00 
93.00 
95.90 
0.07 
0.06 
0.07 
18 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-1.27(1.5) 
-1.27(1.5) 
-1.27(1.5) 
     0.5 
     0.5 
     0.5 
0.00 
0.00 
0.00 
   0 
   0 
   0 
0.00 
0.00 
0.00 
NA 
NA 
NA 
0.01 
0.00 
0.01 
94.10 
94.70 
94.00 
0.07 
0.06 
0.07 
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Appendix D5: Simulation results for n=10 studies for continuous  PF 
Table D5.1: Simulation results for the pooled effect size,{, for three models of IPD meta-analysis, two-step, one-step ignoring clustering and 
one-step including indicator variable, mean age is 4 with standard deviation 1.5 and the sample size with-in each study is between 30 to 100 
observations, with the number of studies n=10 and 100 simulations, the true values of the pooled effect size,, is shown in the table; the 
standard error for ∝ is 0.2 and 1.5. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(s. e. of ∝) 
 
Mean  
of {  
 
 Bias percentage 
bias 
 
MSE of 
 
Percentage 
coverage 
Mean 
s.e. of 
{  
1 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.29 
0.30 
0.31 
0.30 
0.30 
0.30 
-0.006 
0.000 
0.007 
-2.16 
-0.05 
2.25 
0.00 
0.00 
0.00 
97.27 
96.71 
96.85 
0.06 
0.06 
0.06 
2 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.10 
0.10 
0.10 
0.10 
0.10 
0.10 
0.002 
0.002 
0.002 
1.68 
1.72 
2.26 
0.00 
0.00 
0.00 
95.59 
95.68 
95.41 
0.04 
0.04 
0.04 
3 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
NA 
NA 
NA 
0.01 
0.01 
0.01 
96.60 
95.40 
95.30 
0.09 
0.09 
0.09 
4 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.29 
0.22 
0.30 
0.30 
0.30 
0.30 
-0.01 
-0.08 
0.00 
-3.38 
-25.57 
1.42 
0.00 
0.01 
0.01 
96.50 
72.10 
94.90 
0.07 
0.06 
0.07 
5 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.09 
0.08 
0.10 
0.10 
0.10 
0.10 
-0.01 
-0.02 
0.00 
-5.50 
-24.37 
-0.53 
0.01 
0.00 
0.01 
97.40 
94.80 
95.70 
0.08 
0.07 
0.08 
6 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.00 
0.00 
0.00 
0 
0 
0 
0.00 
0.00 
0.00 
NA 
NA 
NA 
0.01 
0.01 
0.01 
97.40 
94.90 
96.70 
0.08 
0.07 
0.08 
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Table D5.2: Simulation results for the pooled effect size,{, for three models of IPD meta-analysis, two-step, one-step ignoring clustering and 
one-step including indicator variable, mean age is 4 with standard deviation 1.5 and the sample size with-in each study is between 30 to 100 
observations, with the number of studies n=10 and 1000 simulations, the true values of the pooled effect size,, is shown in the table; the 
standard error for ∝ is 0.2 and 1.5. 
Scenarios No. of 
studies(n) 
Model Meta-analysis 
model 
∝ 
(s. e. of ∝) 
 
Mean  
of {  
 
 Bias percentage 
bias 
 
MSE of 
 
Percentage 
coverage 
Mean 
s.e. of 
{  
1 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.30 
0.30 
0.30 
0.30 
0.30 
0.30 
0.00 
0.00 
0.00 
0.02 
-0.36 
0.56 
0.00 
0.00 
0.00 
94.8 
94.7 
94.4 
0.02 
0.02 
0.02 
2 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.10 
0.10 
0.10 
0.10 
0.10 
0.10 
0.00 
0.00 
0.00 
0.77 
0.67 
1.36 
0.00 
0.00 
0.00 
95.8 
95.9 
95.8 
0.03 
0.03 
0.03 
3 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(0.2) 
-2.1(0.2) 
-2.1(0.2) 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
NA 
NA 
NA 
0.00 
0.00 
0.00 
95.6 
95.3 
95.5 
0.03 
0.03 
0.03 
4 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.30 
0.23 
0.30 
0.30 
0.30 
0.30 
0.00 
-0.07 
0.00 
-0.28 
-24.97 
0.27 
0.00 
0.01 
0.00 
94.10 
18.60 
93.30 
0.02 
0.02 
0.02 
5 10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.10 
0.08 
0.10 
0.10 
0.10 
0.10 
0.00 
-0.02 
0.00 
-2.76 
-23.75 
-2.18 
0.00 
0.00 
0.00 
95.20 
79.10 
95.20 
0.03 
0.02 
0.03 
6 
 
10 Model 2 
Model 6 
Model 8 
Two-step 
Ignoring clustering 
One-step including 
indicator variable. 
-2.1(1.5) 
-2.1(1.5) 
-2.1(1.5) 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
NA 
NA 
NA 
0.00 
0.00 
0.00 
94.70 
94.60 
94.50 
0.03 
0.03 
0.03 
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Appendix E 
Appendix E1: STATA code for possible FP IPD meta-analysis models 
Two-step model  
FP1 IPD meta-analysis of logistic regression model 
fracgen age -2 -1 -0.5 0 0.5 1 2 3 
 
logit dead age10_1 
logit dead age10_2 
logit dead age10_3 
logit dead age10_4 
logit dead age10_5 
logit dead age10_6 
logit dead age10_7 
logit dead age10_8 
 
Then I selected the best model that has the highest sum Chi-square statistics for the 4 IPD 
meta-analysis and I applied the second step of meta-analysis by using fixed effect methods to 
estimate the pooled effect size of the PF(age), gives as 
.metan beta s.e. (beta) 
One-step model 
\\Accounting for the clustering of patients within-studies by using indicator variables for the 
studies with Fractional polynomial model with power=1\\ 
fracpoly logit dead age10 f11 f12 f13 f14 , nocons degree(1) log center(no) noscaling 
compare 
\\Accounting for the clustering of patients within-studies by using indicator variables for the 
studies with Fractional polynomial model with power=2\\ 
fracpoly logit dead f11 f12 f13 f14 age10, nocons degree(2) compare 
fracplot age, msize(small) 
  
[260] 
 
Appendix F 
Appendix F1: STATA code for possible FP IPD meta-analysis models 
Contour funnel plot 
 confunnel coef se, legend(pos(6)) 
Cumulative meta-analysis forest plot 
metacum coef se,lcols(samplesize cumulative standard error)   
Egger’s test: Small –study effect  
metabias coef  lose, egger 
or, 
regress coef se, [aweight=1/var] 
 
Orginal Egger test: 
regress  coef var[aweight=1/var] 
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